#BEGIN_DRUGCARD DB04395

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C10H17N6O12P3

# Chemical_IUPAC_Name:
({[({[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}amino)phosphonic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
5&#39;-Adenylic acid, monoanhydride with imidodiphosphoric acid. An analog of ATP, in which the oxygen atom bridging the beta to the gamma phosphate is replaced by a nitrogen atom. It is a potent competitive inhibitor of soluble and membrane-bound mitochondrial ATPase and also inhibits ATP-dependent reactions of oxidative phosphorylation. [PubChem]

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Phosphoaminophosphonic Acid-Adenylate Ester

# HET_ID:
ANP

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C10H17N6O12P3/c11-8-5-9(13-2-12-8)16(3-14-5)10-7(18)6(17)4(27-10)1-26-31(24,25)28-30(22,23)15-29(19,20)21/h2-4,6-7,10,17-18H,1H2,(H,24,25)(H2,11,12,13)(H4,15,19,20,21,22,23)/t4-,6-,7+,10+/m0/s1

# InChI_Key:
InChIKey=PVKSNHVPLWYQGJ-FCIPNVEPSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
4395

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
506.1963

# Molecular_Weight_Mono:
506.011729574

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1TQM

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.99

# Predicted_LogS:
-2.1

# Predicted_Water_Solubility:
4.17e+00 g/l

# Primary_Accession_No:
DB04395

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
44462678

# PubChem_Substance_ID:
46507028

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT00524

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
NC1=NC=NC2=C1N=CN2[C@@H]1O[C@@H](CO[P@](O)(=O)O[P@@](O)(=O)NP(O)(O)=O)[C@H](O)[C@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:23:17 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_10_Cellular_Location:
Not Available

# Drug_Target_10_Chromosome_Location:
Not Available

# Drug_Target_10_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_10_Essentiality:
Non-Essential

# Drug_Target_10_GenAtlas_ID:
Not Available

# Drug_Target_10_GenBank_ID_Gene:
Not Available

# Drug_Target_10_GenBank_ID_Protein:
Not Available

# Drug_Target_10_GeneCard_ID:
Not Available

# Drug_Target_10_Gene_Name:
CCT3

# Drug_Target_10_Gene_Sequence:
Not Available

# Drug_Target_10_General_Function:
Not Available

# Drug_Target_10_General_References:
Not Available

# Drug_Target_10_HGNC_ID:
Not Available

# Drug_Target_10_HPRD_ID:
Not Available

# Drug_Target_10_ID:
7064

# Drug_Target_10_Locus:
Not Available

# Drug_Target_10_Molecular_Weight:
Not Available

# Drug_Target_10_Name:
T-complex protein 1 subunit gamma

# Drug_Target_10_Number_of_Residues:
0

# Drug_Target_10_PDB_ID:
Not Available

# Drug_Target_10_Pathway:
Not Available

# Drug_Target_10_Pfam_Domain_Function:
Not Available

# Drug_Target_10_Protein_Sequence:
Not Available

# Drug_Target_10_Reaction:
Not Available

# Drug_Target_10_Signals:
Not Available

# Drug_Target_10_Specific_Function:
Not Available

# Drug_Target_10_SwissProt_ID:
P49368

# Drug_Target_10_SwissProt_Name:
TCPG_HUMAN

# Drug_Target_10_Synonyms:
Not Available

# Drug_Target_10_Theoretical_pI:
Not Available

# Drug_Target_10_Transmembrane_Regions:
Not Available

# Drug_Target_11_Cellular_Location:
Not Available

# Drug_Target_11_Chromosome_Location:
Not Available

# Drug_Target_11_Drug_References:
Not Available

# Drug_Target_11_Essentiality:
Non-Essential

# Drug_Target_11_GenAtlas_ID:
Not Available

# Drug_Target_11_GenBank_ID_Gene:
AE000512

# Drug_Target_11_GenBank_ID_Protein:
Not Available

# Drug_Target_11_GeneCard_ID:
Not Available

# Drug_Target_11_Gene_Name:
TM_0588

# Drug_Target_11_Gene_Sequence:
>1011 bp
GTGTTGAGAAAAGACATAGGAATAGATCTCGGTACGGCAAACACCCTCGTCTTTCTCAGA
GGGAAAGGCATCGTGGTGAATGAACCATCGGTGATAGCGATAGATTCGACCACAGGTGAG
ATACTGAAGGTCGGTCTCGAAGCGAAAAACATGATAGGAAAAACTCCCGCCACGATCAAG
GCCATAAGGCCCATGAGGGATGGCGTTATAGCGGACTACACCGTGGCCCTTGTGATGCTC
AGGTATTTCATAAACAAAGCCAAGGGCGGAATGAATCTGTTCAAACCTCGTGTGGTTATA
GGAGTTCCCATAGGAATAACGGATGTGGAAAGGAGAGCCATTCTCGATGCTGGGCTCGAG
GCGGGTGCCAGTAAGGTCTTTCTCATAGAAGAGCCCATGGCGGCTGCTATAGGCTCAAAT
CTCAACGTCGAAGAGCCCTCCGGGAACATGGTGGTGGACATCGGTGGAGGAACGACGGAG
GTCGCCGTCATCTCCCTTGGAAGCATTGTCACGTGGGAGTCGATACGTATCGCTGGAGAC
GAGATGGATGAAGCCATAGTTCAGTACGTGAGGGAGACCTACCGGGTGGCGATCGGTGAG
AGAACGGCCGAACGGGTGAAGATAGAGATAGGGAACGTCTTCCCATCCAAAGAAAACGAT
GAGCTCGAAACGACGGTTTCCGGGATAGACCTTTCCACTGGACTGCCCAGAAAACTCACT
CTGAAAGGAGGAGAGGTGAGGGAAGCCCTCAGGAGTGTGGTGGTAGCCATAGTGGAGAGC
GTGAGAACCACTCTGGAAAAAACGCCTCCCGAGCTCGTTTCCGACATCATAGAACGCGGA
ATTTTCCTCACCGGCGGCGGGTCTCTTCTAAGAGGGCTCGACACTCTGCTTCAGAAAGAA
ACGGGGATCAGTGTCATCAGGTCCGAAGAGCCGCTCACCGCTGTGGCTAAAGGAGCGGGA
ATGGTTCTGGACAAGGTGAACATTCTGAAGAAGCTTCAGGGTGCCGGGTGA

# Drug_Target_11_General_Function:
Involved in ATP binding

# Drug_Target_11_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.
11544518	van den Ent F, Amos LA, Lowe J: Prokaryotic origin of the actin cytoskeleton. Nature. 2001 Sep 6;413(6851):39-44.

# Drug_Target_11_HGNC_ID:
Not Available

# Drug_Target_11_HPRD_ID:
Not Available

# Drug_Target_11_ID:
5641

# Drug_Target_11_Locus:
Not Available

# Drug_Target_11_Molecular_Weight:
35787

# Drug_Target_11_Name:
Rod shape-determining protein MreB

# Drug_Target_11_Number_of_Residues:
336

# Drug_Target_11_PDB_ID:
1JCG

# Drug_Target_11_Pathway:
Not Available

# Drug_Target_11_Pfam_Domain_Function:
PF06723	MreB_Mbl

# Drug_Target_11_Protein_Sequence:
>Rod shape-determining protein MreB
MLRKDIGIDLGTANTLVFLRGKGIVVNEPSVIAIDSTTGEILKVGLEAKNMIGKTPATIK
AIRPMRDGVIADYTVALVMLRYFINKAKGGMNLFKPRVVIGVPIGITDVERRAILDAGLE
AGASKVFLIEEPMAAAIGSNLNVEEPSGNMVVDIGGGTTEVAVISLGSIVTWESIRIAGD
EMDEAIVQYVRETYRVAIGERTAERVKIEIGNVFPSKENDELETTVSGIDLSTGLPRKLT
LKGGEVREALRSVVVAIVESVRTTLEKTPPELVSDIIERGIFLTGGGSLLRGLDTLLQKE
TGISVIRSEEPLTAVAKGAGMVLDKVNILKKLQGAG

# Drug_Target_11_Reaction:
Not Available

# Drug_Target_11_Signals:
None

# Drug_Target_11_Specific_Function:
Acts as a chaperone (By similarity)

# Drug_Target_11_SwissProt_ID:
Q9WZ57

# Drug_Target_11_SwissProt_Name:
Q9WZ57_THEMA

# Drug_Target_11_Synonyms:
Not Available

# Drug_Target_11_Theoretical_pI:
5.04

# Drug_Target_11_Transmembrane_Regions:
None

# Drug_Target_12_Cellular_Location:
Cytoplasm. Nucleus

# Drug_Target_12_Chromosome_Location:
7

# Drug_Target_12_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_12_Essentiality:
Non-Essential

# Drug_Target_12_GenAtlas_ID:
Not Available

# Drug_Target_12_GenBank_ID_Gene:
U88666

# Drug_Target_12_GenBank_ID_Protein:
1857944

# Drug_Target_12_GeneCard_ID:
SRPK2

# Drug_Target_12_Gene_Name:
SRPK2

# Drug_Target_12_Gene_Sequence:
>2061 bp
ATGTCAGTTAACTCTGAGAAGTCGTCCTCTTCAGAAAGGCCGGAGCCTCAACAGAAAGCT
CCTTTAGTTCCTCCTCCTCCACCGCCACCACCACCACCACCGCCACCTTTGCCAGACCCC
ACACCCCCGGAGCCAGAGGAGGAGATCCTGGGATCAGATGATGAGGAGCAAGAGGACCCT
GCGGACTACTGCAAAGGTGGATATCATCCAGTGAAAATTGGAGACCTCTTCAATGGCCGG
TATCATGTTATTAGAAAGCTTGGATGGGGGCACTTCTCTACTGTCTGGCTGTGCTGGGAT
ATGCAGGGGAAAAGATTTGTTGCAATGAAAGTTGTAAAAAGTGCCCAGCATTATACGGAG
ACAGCCTTGGATGAAATAAAATTGCTCAAATGTGTTCGAGAAAGTGATCCCAGTGACCCA
AACAAAGACATGGTGGTCCAGCTCATTGACGACTTCAAGATTTCAGGCATGAATGGGATA
CATGTCTGCATGGTCTTCGAAGTACTTGGCCACCATCTCCTCAAGTGGATCATCAAATCC
AACTATCAAGGCCTCCCAGTACGTTGTGTGAAGAGTATCATTCGACAGGTCCTTCAAGGG
TTAGATTACTTACACAGTAAGTGCAAGATCATTCATACTGACATAAAGCCGGAAAATATC
TTGATGTGTGTGGATGATGCATATGTGAGAAGAATGGCAGCTGAGCCTGAGTGGCAGAAA
GCAGGTGCTCCTCCTCCTTCAGGGTCTGCAGTGAGTACGGCTCCACAGCAGAAACCTATA
GGAAAAATATCTAAAAACAAAAAGAAAAAACTGAAAAAGAAACAGAAGAGGCAGGCTGAG
TTATTGGAGAAGCGCCTGCAGGAGATAGAAGAATTGGAGCGAGAAGCTGAAAGGAAAATA
ATAGAAGAAAACATCACCTCAGCTGCACCTTCCAATGACCAGGATGGCGAATACTGCCCA
GAGGTGAAACTAAAAACAACAGGATTAGAGGAGGCGGCTGAGGCAGAGACTGCAAAGGAC
AATGGTGAAGCTGAGGACCAGGAAGAGAAAGAAGATGCTGAGAAAGAAAACATTGAAAAA
GATGAAGATGATGTAGATCAGGAACTTGCGAACATAGACCCTACGTGGATAGAATCACCT
AAAACCAATGGCCATATTGAGAATGGCCCATTCTCACTGGAGCAGCAACTGGACGATGAA
GATGATGATGAAGAAGACTGCCCAAATCCTGAGGAATATAATCTTGATGAGCCAAATGCA
GAAAGTGATTACACATATAGCAGCTCCTATGAACAATTCAATGGTGAATTGCCAAATGGA
CGACATAAAATTCCCGAGTCACAGTTCCCAGAGTTTTCCACCTCGTTGTTCTCTGGATCC
TTAGAACCTGTGGCCTGCGGCTCTGTGCTTTCTGAGGGATCACCACTTACTGAGCAAGAG
GAGAGCAGTCCATCCCATGACAGAAGCAGAACGGTTTCAGCCTCCAGTACTGGGGATTTG
CCAAAAGCAAAAACCCGGGCAGCTGACTTGTTGGTGAATCCCCTGGATCCGCGGAATCGA
GATAAAATTAGAGTAAAAATTGCTGACCTGGGAAATGCTTGTTGGGTGCATAAACACTTC
ACGGAAGACATCCAGACGCGTCAGTACCGCTCCATAGAGGTTTTAATAGGAGCGGGGTAC
AGCACCCCTGCGGACATCTGGAGCACGGCGTGTATGGCATTTGAGCTGGCAACGGGAGAT
TATTTGTTTGAACCACATTCTGGGGAAGACTATTCCAGAGACGAAGACCACATAGCCCAC
ATCATAGAGCTGCTAGGCAGTATTCCAAGGCACTTTGCTCTATCTGGAAAATATTCTCGG
GAATTCTTCAATCGCAGAGGAGAACTGCGACACATCACCAAGCTGAAGCCCTGGAGCCTC
TTTGATGTACTTGTGGAAAAGTATGGCTGGCCCCATGAAGATGCTGCACAGTTTACAGAT
TTCCTGATCCCGATGTTAGAAATGGTTCCAGAAAAACGAGCCTCAGCTGGCGAATGTCGG
CATCCTTGGTTGAATTCTTAG

# Drug_Target_12_General_Function:
Involved in ATP binding

# Drug_Target_12_General_References:
12134018	Daub H, Blencke S, Habenberger P, Kurtenbach A, Dennenmoser J, Wissing J, Ullrich A, Cotten M: Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein. J Virol. 2002 Aug;76(16):8124-37.
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
15592455	Rush J, Moritz A, Lee KA, Guo A, Goss VL, Spek EJ, Zhang H, Zha XM, Polakiewicz RD, Comb MJ: Immunoaffinity profiling of tyrosine phosphorylation in cancer cells. Nat Biotechnol. 2005 Jan;23(1):94-101. Epub 2004 Dec 12.
17344846	Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C, Edkins S, O'Meara S, Vastrik I, Schmidt EE, Avis T, Barthorpe S, Bhamra G, Buck G, Choudhury B, Clements J, Cole J, Dicks E, Forbes S, Gray K, Halliday K, Harrison R, Hills K, Hinton J, Jenkinson A, Jones D, Menzies A, Mironenko T, Perry J, Raine K, Richardson D, Shepherd R, Small A, Tofts C, Varian J, Webb T, West S, Widaa S, Yates A, Cahill DP, Louis DN, Goldstraw P, Nicholson AG, Brasseur F, Looijenga L, Weber BL, Chiew YE, DeFazio A, Greaves MF, Green AR, Campbell P, Birney E, Easton DF, Chenevix-Trench G, Tan MH, Khoo SK, Teh BT, Yuen ST, Leung SY, Wooster R, Futreal PA, Stratton MR: Patterns of somatic mutation in human cancer genomes. Nature. 2007 Mar 8;446(7132):153-8.
18669648	Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP: A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7. Epub 2008 Jul 31.
18691976	Daub H, Olsen JV, Bairlein M, Gnad F, Oppermann FS, Korner R, Greff Z, Keri G, Stemmann O, Mann M: Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell. 2008 Aug 8;31(3):438-48.
9472028	Wang HY, Lin W, Dyck JA, Yeakley JM, Songyang Z, Cantley LC, Fu XD: SRPK2: a differentially expressed SR protein-specific kinase involved in mediating the interaction and localization of pre-mRNA splicing factors in mammalian cells. J Cell Biol. 1998 Feb 23;140(4):737-50.

# Drug_Target_12_HGNC_ID:
GNC:11306

# Drug_Target_12_HPRD_ID:
Not Available

# Drug_Target_12_ID:
6832

# Drug_Target_12_Locus:
7q22-q31.1

# Drug_Target_12_Molecular_Weight:
77542.1

# Drug_Target_12_Name:
Serine/threonine-protein kinase SRPK2

# Drug_Target_12_Number_of_Residues:
688

# Drug_Target_12_PDB_ID:
Not Available

# Drug_Target_12_Pathway:
Not Available

# Drug_Target_12_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_12_Protein_Sequence:
>Serine/threonine-protein kinase SRPK2
MSVNSEKSSSSERPEPQQKAPLVPPPPPPPPPPPPPLPDPTPPEPEEEILGSDDEEQEDP
ADYCKGGYHPVKIGDLFNGRYHVIRKLGWGHFSTVWLCWDMQGKRFVAMKVVKSAQHYTE
TALDEIKLLKCVRESDPSDPNKDMVVQLIDDFKISGMNGIHVCMVFEVLGHHLLKWIIKS
NYQGLPVRCVKSIIRQVLQGLDYLHSKCKIIHTDIKPENILMCVDDAYVRRMAAEATEWQ
KAGAPPPSGSAVSTAPQQKPIGKISKNKKKKLKKKQKRQAELLEKRLQEIEELEREAERK
IIEENITSAAPSNDQDGEYCPEVKLKTTGLEEAAEAETAKDNGEAEDQEEKEDAEKENIE
KDEDDVDQELANIDPTWIESPKTNGHIENGPFSLEQQLDDEDDDEEDCPNPEEYNLDEPN
AESDYTYSSSYEQFNGELPNGRHKIPESQFPEFSTSLFSGSLEPVACGSVLSEGSPLTEQ
EESSPSHDRSRTVSASSTGDLPKAKTRAADLLVNPLDPRARDKIRVKIADLGNACWVHKH
FTEDIQTRQYRSIEVLIGAGYSTPADIWSTACMAFELATGDYLFEPHSGEDYSRDEDHIA
HIIELLGSIPRHFALSGKYSREFFNRRGELRHITKLKPWSLFDVLVEKYGWPHEDAAQFT
DFLIPMLEMVPEKRASAGCLCRHPWLNS

# Drug_Target_12_Reaction:
Not Available

# Drug_Target_12_Signals:
None

# Drug_Target_12_Specific_Function:
Phosphorylates RS domain-containing proteins, such as SFRS1 and SFRS2 on serine residues. Role in spliceosome assembly and in mediating the trafficking of splicing factors. Appears to mediate HBV core protein phosphorylation which is a prerequisite for pregenomic RNA encapsidation into viral capsids

# Drug_Target_12_SwissProt_ID:
P78362

# Drug_Target_12_SwissProt_Name:
SRPK2_HUMAN

# Drug_Target_12_Synonyms:
SFRS protein kinase 2
SR-protein-specific kinase 2
Serine/arginine-rich protein-specific kinase 2

# Drug_Target_12_Theoretical_pI:
4.65

# Drug_Target_12_Transmembrane_Regions:
None

# Drug_Target_13_Cellular_Location:
Cytoplasm. Mitochondrion

# Drug_Target_13_Chromosome_Location:
Not Available

# Drug_Target_13_Drug_References:
Not Available

# Drug_Target_13_Essentiality:
Non-Essential

# Drug_Target_13_GenAtlas_ID:
MAPK12

# Drug_Target_13_GenBank_ID_Gene:
X79483

# Drug_Target_13_GenBank_ID_Protein:
Not Available

# Drug_Target_13_GeneCard_ID:
Not Available

# Drug_Target_13_Gene_Name:
MAPK12

# Drug_Target_13_Gene_Sequence:
>1104 bp
ATGAGCTCTCCGCCGCCCACCCGCAGTGGCTTTTACCGCCAGGAGGTGACCAAGACGGCC
TGGGAGGTGCGCGCCGTGTACCGGGACCTGCAGCCCGTGGGCTCGGGCGCCTACGGCGCG
GTGTGCTCGGCCGTGGACGGCCGCACCGGCGCTAAGGTTGCCATCAAGAAGCTGTATCGG
CCCTTCCAGTCCGAGCTGTTCGCCAAGCTCGCCTACCGCGAGCTGCGCCTGCTCAAGCAC
ATGCGCCACGAGAACGTGATCGGGCTGCTGGACGTATTCACTCCTGATGAGACCCTGGAT
GACTTCACGGACTTTTACCTGGTGATGCCGTTCATGGGCACCGACCTGGGCAAGCTCATG
AAACATGAGAAGCTAGGCGAGGACCGGATCCAGTTCCTCGTGTACCAGATGATGAAGGGG
CTGAGGTATATCCACGCTGCCGGCATCATCCACAGAGACCTGAAGCCCGGCAACCTGGCT
GTGAACGAAGACTGTGAGCTGAAGATCCTGGACTTCGGCCTGGCCAGGCAGGCAGACAGT
GAGATGACTGGGTACGTGGTGACCCGGTGGTACCGGGCTCCCGAGGTCATCTTGAATTGG
ATCGCGTACACGCAGACGGTGGACATCTGGTCTGTGGGCTGCATCATGGCGGAGATGATC
ACAGGCAAGACGCTGTTCAAGGGCAGCGACCACCTGGACCAGCTGAAGGAGATCATGAAG
GTGACGGGGACGCCTCCGGCTGAGTTTGTGCAGCGGCTGCAGAGCGATGAGGCCAAGAAC
TACATGAAGGGCCTCCCCGAATTGGAGAAGAAGGATTTTGCCTCTATCCTGACCAATGCA
AGCCCTCTGGCTGTGAACCTCCTGGAGAAGATGCTGGTGCTGGACGCGGACATCAGGTTG
ACTGCAGGCGAGTTTCTTTCCCATCCCTACTTCGAGTCCCTGCACGACACGGAAGATGAG
CCCCAGGTCCAGAAGTATGATGACTCCTTTGACTACTTTGACCGCACACTGGATGAATGG
AAGCGTGTTACTTACAAAGAGGTGCTCAGCTTCAAGCCTCCCCGGCAGCTGGGGGCCAGG
GTCTCCAAGGAGACGCCTCTGTGA

# Drug_Target_13_General_Function:
Involved in MAP kinase activity

# Drug_Target_13_General_References:
10212242	Hasegawa M, Cuenda A, Spillantini MG, Thomas GM, Buee-Scherrer V, Cohen P, Goedert M: Stress-activated protein kinase-3 interacts with the PDZ domain of alpha1-syntrophin. A mechanism for specific substrate recognition. J Biol Chem. 1999 Apr 30;274(18):12626-31.
10591208	Dunham I, Shimizu N, Roe BA, Chissoe S, Hunt AR, Collins JE, Bruskiewich R, Beare DM, Clamp M, Smink LJ, Ainscough R, Almeida JP, Babbage A, Bagguley C, Bailey J, Barlow K, Bates KN, Beasley O, Bird CP, Blakey S, Bridgeman AM, Buck D, Burgess J, Burrill WD, O'Brien KP, et al.: The DNA sequence of human chromosome 22. Nature. 1999 Dec 2;402(6761):489-95.
11991731	Court NW, dos Remedios CG, Cordell J, Bogoyevitch MA: Cardiac expression and subcellular localization of the p38 mitogen-activated protein kinase member, stress-activated protein kinase-3 (SAPK3). J Mol Cell Cardiol. 2002 Apr;34(4):413-26.
12167088	Wiltshire C, Matsushita M, Tsukada S, Gillespie DA, May GH: A new c-Jun N-terminal kinase (JNK)-interacting protein, Sab (SH3BP5), associates with mitochondria. Biochem J. 2002 Nov 1;367(Pt 3):577-85.
8633070	Lechner C, Zahalka MA, Giot JF, Moller NP, Ullrich A: ERK6, a mitogen-activated protein kinase involved in C2C12 myoblast differentiation. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4355-9.
8920915	Li Z, Jiang Y, Ulevitch RJ, Han J: The primary structure of p38 gamma: a new member of p38 group of MAP kinases. Biochem Biophys Res Commun. 1996 Nov 12;228(2):334-40.
9169156	Goedert M, Hasegawa J, Craxton M, Leversha MA, Clegg S: Assignment of the human stress-activated protein kinase-3 gene (SAPK3) to chromosome 22q13.3 by fluorescence in situ hybridization. Genomics. 1997 May 1;41(3):501-2.

# Drug_Target_13_HGNC_ID:
HGNC:6874

# Drug_Target_13_HPRD_ID:
Not Available

# Drug_Target_13_ID:
4751

# Drug_Target_13_Locus:
22q13.33

# Drug_Target_13_Molecular_Weight:
41941

# Drug_Target_13_Name:
Mitogen-activated protein kinase 12

# Drug_Target_13_Number_of_Residues:
367

# Drug_Target_13_PDB_ID:
1CM8

# Drug_Target_13_Pathway:
Not Available

# Drug_Target_13_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_13_Protein_Sequence:
>Mitogen-activated protein kinase 12
MSSPPPARSGFYRQEVTKTAWEVRAVYRDLQPVGSGAYGAVCSAVDGRTGAKVAIKKLYR
PFQSELFAKRAYRELRLLKHMRHENVIGLLDVFTPDETLDDFTDFYLVMPFMGTDLGKLM
KHEKLGEDRIQFLVYQMLKGLRYIHAAGIIHRDLKPGNLAVNEDCELKILDFGLARQADS
EMTGYVVTRWYRAPEVILNWMRYTQTVDIWSVGCIMAEMITGKTLFKGSDHLDQLKEIMK
VTGTPPAEFVQRLQSDEAKNYMKGLPELEKKDFASILTNASPLAVNLLEKMLVLDAEQRV
TAGEALAHPYFESLHDTEDEPQVQKYDDSFDDVDRTLDEWKRVTYKEVLSFKPPRQLGAR
VSKETPL

# Drug_Target_13_Reaction:
Not Available

# Drug_Target_13_Signals:
None

# Drug_Target_13_Specific_Function:
Responds to activation by environmental stress and pro- inflammatory cytokines by phosphorylating downstream targets. Plays a role in myoblast differentiation and also in the down- regulation of cyclin D1 in response to hypoxia in adrenal cells suggesting MAPK12 may inhibit cell proliferation while promoting differentiation

# Drug_Target_13_SwissProt_ID:
P53778

# Drug_Target_13_SwissProt_Name:
MK12_HUMAN

# Drug_Target_13_Synonyms:
EC 2.7.11.24
ERK-6
ERK5
Extracellular signal-regulated kinase 6
MAP kinase p38 gamma
Mitogen-activated protein kinase p38 gamma
Stress-activated protein kinase 3

# Drug_Target_13_Theoretical_pI:
6.33

# Drug_Target_13_Transmembrane_Regions:
None

# Drug_Target_14_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_14_Chromosome_Location:
Not Available

# Drug_Target_14_Drug_References:
Not Available

# Drug_Target_14_Essentiality:
Non-Essential

# Drug_Target_14_GenAtlas_ID:
Not Available

# Drug_Target_14_GenBank_ID_Gene:
AB012390

# Drug_Target_14_GenBank_ID_Protein:
Not Available

# Drug_Target_14_GeneCard_ID:
Not Available

# Drug_Target_14_Gene_Name:
clpB

# Drug_Target_14_Gene_Sequence:
>2565 bp
ATGAACCTGGAACGCTGGACCCAAGCCGCCCGCGAAGCCCTGGCCCAGGCGCAGGTCCTG
GCGCAAAGGATGAAGCACCAGGCCATAGACCTGCCCCACCTCTGGGCTGTCCTCCTGAAG
GACGAGAGAAGCCTCGCCTGGCGCCTCTTGGAGAAGGCGGGGGCCGACCCCAAGGCCCTT
AAAGAGCTCCAGGAGCGGGAGCTTGCCCGCCTGCCCAAGGTGGAAGGGGCCGAGGTGGGC
CAGTACCTCACGAGCCGCCTCTCCGGGGCCTTGAACCGGGCCGAGGGCCTGATGGAGGAG
CTCAAGGACCGCTACGTGGCGGTGGACACCCTGGTCCTGGCCTTGGCGGAGGCCACGCCG
GGGCTTCCGGGCCTGGAGGCCCTGAAGGGGGCGCTCAAGGAACTGAGGGGAGGGAGAACC
GTGCAGACGGAACACGCGGAAAGCACCTACAACGCTTTGGAGCAGTACGGCATTGACCTC
ACGCGGCTTGCCGCCGAGGGGAAGCTGGACCCCGTGATCGGCCGGGACGAGGAGATCCGG
CGGGTGATCCAGATCCTCCTCCGGCGCACCAAGAACAACCCGGTGCTCATCGGCGAGCCC
GGCGTGGGGAAGACGGCCATCGTGGAGGGCCTGGCCCAGCGCATCGTCAAGGGGGACGTG
CCCGAAGGCCTCAAGGGCAAGCGGATCGTCTCCTTGCAGATGGGCTCCCTCCTCGCCGGG
GCCAAGTACCGGGGCGAGTTTGAGGAGCGCTTGAAGGCGGTGATCCAGGAGGTGGTCCAG
TCCCAAGGGGAAGTCATCCTCTTCATTGACGAGCTCCACACCGTGGTGGGGGCAGGCAAG
GCCGAGGGCGCCGTGGACGCGGGCAACATGCTGAAGCCCGCCCTGGCCCGGGGGGAGCTC
AGGCTCATCGGGGCCACCACCCTGGACGAGTACCGGGAGATTGAGAAGGACCCCGCCCTG
GAGCGCCGCTTCCAGCCCGTGTACGTGGACGAGCCCACGGTGGAGGAGACCATCTCCATC
CTCCGGGGCCTCAAGGAGAAGTACGAGGTCCACCACGGGGTGCGCATCTCCGACAGCGCC
ATCATCGCCGCCGCCACCCTCTCCCACCGGTACATCACGGAAAGGCGCCTTCCCGACAAG
GCCATTGACCTCATTGACGAGGCGGCGGCCCGCCTGCGCATGGCCCTGGAGAGCGCTCCC
GAGGAGATTGACGCCCTGGAGCGCAAGAAGCTCCAGCTGGAGATTGAGCGGGAGGCCCTG
AAGAAGGAGAAGGACCCGGACTCCCAGGAGCGCCTCAAGGCCATTGAGGCCGAGATCGCC
AAGCTCACGGAGGAGATCGCCAAGCTCCGGGCCGAGTGGGAGAGGGAGCGGGAGATCCTG
AGGAAGCTCCGCGAGGCCCAGCACCGCCTGGACGAGGTCAGGCGGGAGATTGAGCTCGCC
GAGCGGCAGTACGACCTGAACCGGGCCGCCGAGCTCCGCTACGGGGAGCTTCCCAAGCTG
GAGGCCGAGGTGGAGGCCCTTTCGGAAAAGCTCCGGGGCGCCCGCTTCGTCCGCCTCGAG
GTCACCGAGGAGGACATCGCCGAGATCGTCTCCCGCTGGACCGGGATCCCTGTGTCCAAG
CTCCTGGAAGGGGAGAGGGAGAAGCTTTTGAGGCTTGAGGAGGAGCTCCACAAGCGGGTG
GTGGGGCAGGACGAGGCCATAAGGGCCGTGGCCGACGCCATCCGCCGGGCGAGGGCCGGC
CTAAAGGACCCGAACCGGCCCATCGGAAGCTTCCTCTTCCTCGGGCCCACGGGGGTGGGG
AAGACGGAGCTCGCCAAGACCCTGGCCGCCACCCTCTTTGACACCGAGGAGGCCATGATC
CGCATTGACATGACGGAGTACATGGAGAAGCACGCCGTCTCCCGCCTCATCGGGGCCCCG
CCCGGCTACGTGGGCTACGAGGAGGGGGGGCAGCTCACCGAGGCGGTGCGGAGGAGGCCC
TACTCGGTCATCCTCTTTGACGAGATTGAGAAGGCCCACCCCGACGTCTTCAACATCCTC
CTCCAGATCCTGGACGACGGCCGCCTCACCGACAGCCACGGCCGCACCGTGGACTTCCGC
AACACCGTCATCATCCTCACCTCCAACCTGGGGAGCCCCTTGATCCTCGAGGGCCTCCAG
AAGGGCTGGCCCTACGAGAGGATCCGGGACGAGGTCTTTAAGGTCTTGCAGCAGCACTTC
CGCCCCGAGTTCCTGAACCGCCTGGACGAGATCGTGGTCTTCCGGCCCCTCACCAAGGAG
CAGATCCGCCAGATCGTGGAGATCCAGCTCTCCTACCTCCGGGCCCGCCTCGCCGAGAAG
CGCATCTCCCTGGAGCTCACCGAGGCCGCCAAGGACTTCCTGGCGGAAAGGGGCTACGAC
CCCGTCTTCGGGGCAAGGCCCTTGCGGCGGGTCATCCAGCGGGAGCTGGAGACGCCCCTC
GCCCAGAAGATCCTGGCCGGCGAGGTCAAGGAGGGGGACCGCGTGCAGGTGGACGTGGGG
CCCGCGGGCCTCGTGTTTGCCGTCCCCGCCCGGGTGGAGGCCTGA

# Drug_Target_14_General_Function:
Involved in nucleotide binding

# Drug_Target_14_General_References:
10092456	Klostermeier D, Seidel R, Reinstein J: The functional cycle and regulation of the Thermus thermophilus DnaK chaperone system. J Mol Biol. 1999 Apr 2;287(3):511-25.
10377389	Motohashi K, Watanabe Y, Yohda M, Yoshida M: Heat-inactivated proteins are rescued by the DnaK.J-GrpE set and ClpB chaperones. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7184-9.

# Drug_Target_14_HGNC_ID:
Not Available

# Drug_Target_14_HPRD_ID:
Not Available

# Drug_Target_14_ID:
5642

# Drug_Target_14_Locus:
Not Available

# Drug_Target_14_Molecular_Weight:
96255

# Drug_Target_14_Name:
Chaperone clpB

# Drug_Target_14_Number_of_Residues:
854

# Drug_Target_14_PDB_ID:
1QVR

# Drug_Target_14_Pathway:
Not Available

# Drug_Target_14_Pfam_Domain_Function:
PF00004	AAA
PF02861	Clp_N
PF07724	AAA_2

# Drug_Target_14_Protein_Sequence:
>Chaperone clpB
MNLERWTQAAREALAQAQVLAQRMKHQAIDLPHLWAVLLKDERSLAWRLLEKAGADPKAL
KELQERELARLPKVEGAEVGQYLTSRLSGALNRAEALMEELKDRYVAVDTLVLALAEATP
GLPGLEALKGALKELRGGRTVQTEHAESTYNALEQYGIDLTRLAAEGKLDPVIGRDEEIR
RVIQILLRRTKNNPVLIGEPGVGKTAIVEGLAQRIVKGDVPEGLKGKRIVSLQMGSLLAG
AKYRGEFEERLKAVIQEVVQSQGEVILFIDELHTVVGAGKAEGAVDAGNMLKPALARGEL
RLIGATTLDEYREIEKDPALERRFQPVYVDEPTVEETISILRGLKEKYEVHHGVRISDSA
IIAAATLSHRYITERRLPDKAIDLIDEAAARLRMALESAPEEIDALERKKLQLEIEREAL
KKEKDPDSQERLKAIEAEIAKLTEEIAKLRAEWEREREILRKLREAQHRLDEVRREIELA
ERQYDLNRAAELRYGELPKLEAEVEALSEKLRGARFVRLEVTEEDIAEIVSRWTGIPVSK
LLEGEREKLLRLEEELHKRVVGQDEAIRAVADAIRRARAGLKDPNRPIGSFLFLGPTGVG
KTELAKTLAATLFDTEEAMIRIDMTEYMEKHAVSRLIGAPPGYVGYEEGGQLTEAVRRRP
YSVILFDEIEKAHPDVFNILLQILDDGRLTDSHGRTVDFRNTVIILTSNLGSPLILEGLQ
KGWPYERIRDEVFKVLQQHFRPEFLNRLDEIVVFRPLTKEQIRQIVEIQLSYLRARLAEK
RISLELTEAAKDFLAERGYDPVFGARPLRRVIQRELETPLAQKILAGEVKEGDRVQVDVG
PAGLVFAVPARVEA

# Drug_Target_14_Reaction:
Not Available

# Drug_Target_14_Signals:
None

# Drug_Target_14_Specific_Function:
Part of a stress-induced multi-chaperone system, it is involved in the recovery of the cell from heat-induced damage, in cooperation with dnaK, dnaJ and grpE. Acts before dnaK, in the processing of protein aggregates. Protein binding stimulates the ATPase activity; ATP hydrolysis unfolds the denatured protein aggregates, which probably helps expose new hydrophobic binding sites on the surface of clpB-bound aggregates, contributing to the solubilization and refolding of denatured protein aggregates by dnaK

# Drug_Target_14_SwissProt_ID:
Q9RA63

# Drug_Target_14_SwissProt_Name:
CLPB_THET8

# Drug_Target_14_Synonyms:
Not Available

# Drug_Target_14_Theoretical_pI:
5.57

# Drug_Target_14_Transmembrane_Regions:
None

# Drug_Target_15_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_15_Chromosome_Location:
Not Available

# Drug_Target_15_Drug_References:
Not Available

# Drug_Target_15_Essentiality:
Non-Essential

# Drug_Target_15_GenAtlas_ID:
Not Available

# Drug_Target_15_GenBank_ID_Gene:
M96172

# Drug_Target_15_GenBank_ID_Protein:
Not Available

# Drug_Target_15_GeneCard_ID:
Not Available

# Drug_Target_15_Gene_Name:
epsE

# Drug_Target_15_Gene_Sequence:
>1512 bp
ATGACCGAAATGGTGATCTCTCCAGCTGAGCGACAGTCGATTCGTCGTCTGCCCTTTAGC
TTCGCCAATCGCTTTAAGTTGGTGCTGGATTGGAATGAGGATTTCTCCCAAGCCAGCATT
TATTACTTAGCCCCGTTGTCGATGGAGGCGCTCGTCGAAACCAAGCGGGTGGTCAAGCAC
GCTTTCCAACTGATTGAGCTCTCTCAAGCGGAGTTTGAAAGCAAGCTAACCCAAGTCTAT
CAGCGTGATTCTTCAGAAGCGCGTCAATTGATGGAAGACATTGGTGCCGACAGTGATGAC
TTCTTCTCACTGGCGGAAGAGCTGCCTCAAAACGAAGATTTGCTAGAAAGTGAAGATGAT
GCGCCGATCATCAAACTGATCAACGCCATGTTGGGCGAAGCGATCAAAGAAGGCGCGTCA
GATATTCACATTGAAACTTTTGAAAAAACACTGTCGATCCGTTTTCGAGTCGATGGCGTG
CTGCGCGAAGTACTGGCACCCAGCCGCAAACTCTCATCGCTGCTCGTTTCACGGGTCAAA
GTGATGGCCAAGCTCGACATTGCCGAAAAACGTGTGCCGCAAGATGGCCGTATTTCGCTG
CGTATCGGTGGCCGCGCGGTCGATGTGCGGGTTTCAACCATGCCTTCATCACATGGTGAG
CGAGTGGTAATGCGTTTGCTGGATAAAAACGCGACGCGCCTTGATCTGCACAGTTTGGGT
ATGACGGCGCATAACCATGATAATTTCCGCCGTTTGATTAAGCGGCCGCATGGGATCATT
CTGGTGACTGGCCCAACCGGCTCGGGTAAATCGACCACCTTGTACGCGGGTTTGCAAGAG
CTCAACAGCAGCGAGCGCAACATTTTAACCGTAGAAGATCCGATCGAATTTGATATTGAT
GGTATCGGTCAGACCCAAGTCAACCCAAGGGTAGACATGACCTTCGCACGGGGGCTACGC
GCTATTTTGCGTCAAGACCCCGATGTGGTGATGGTGGGGGAAATTCGTGATTTGGAAACG
GCGCAAATTGCAGTGCAAGCCTCGCTGACTGGTCACTTAGTGATGTCGACTCTGCACACC
AACACGGCCGTTGGGGCGGTGACTCGGCTGCGCGATATGGGCATCGAGCCTTTTTTGATC
TCCTCTTCACTGCTCGGTGTTCTGGCTCAGCGCTTGGTGCGCACCTTATGCCCAGATTGC
AAAGAGCCTTACGAGGCGGACAAAGAGCAGCGCAAACTGTTTGATAGCAAGAAAAAAGAA
CCGCTGATCCTTTATCGTGCAACGGGCTGCCCTAAATGTAACCACAAAGGTTACCGTGGC
CGAACCGGTATCCACGAGCTGCTGCTGGTGGATGACGCGTTGCAGGAGCTGATCCATAGC
GAGGCGGGCGAACAGGCGATGGAGAAACACATTCGCGCGACCACGCCGAGCATTCGTGAT
GATGGTCTAGATAAGGTGCGCCAAGGCATTACTTCGCTAGAAGAAGTGATGCGGGTGACT
AAGGAGTCCTAA

# Drug_Target_15_General_Function:
Involved in nucleotide binding

# Drug_Target_15_General_References:
10952301	Heidelberg JF, Eisen JA, Nelson WC, Clayton RA, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Umayam L, Gill SR, Nelson KE, Read TD, Tettelin H, Richardson D, Ermolaeva MD, Vamathevan J, Bass S, Qin H, Dragoi I, Sellers P, McDonald L, Utterback T, Fleishmann RD, Nierman WC, White O, Salzberg SL, Smith HO, Colwell RR, Mekalanos JJ, Venter JC, Fraser CM: DNA sequence of both chromosomes of the cholera pathogen Vibrio cholerae. Nature. 2000 Aug 3;406(6795):477-83.
8423007	Sandkvist M, Morales V, Bagdasarian M: A protein required for secretion of cholera toxin through the outer membrane of Vibrio cholerae. Gene. 1993 Jan 15;123(1):81-6.

# Drug_Target_15_HGNC_ID:
Not Available

# Drug_Target_15_HPRD_ID:
Not Available

# Drug_Target_15_ID:
5643

# Drug_Target_15_Locus:
Not Available

# Drug_Target_15_Molecular_Weight:
56359

# Drug_Target_15_Name:
General secretion pathway protein E

# Drug_Target_15_Number_of_Residues:
503

# Drug_Target_15_PDB_ID:
1P9W

# Drug_Target_15_Pathway:
Not Available

# Drug_Target_15_Pfam_Domain_Function:
PF00437	GSPII_E

# Drug_Target_15_Protein_Sequence:
>General secretion pathway protein E
MTEMVISPAERQSIRRLPFSFANRFKLVLDWNEDFSQASIYYLAPLSMEALVETKRVVKH
AFQLIELSQAEFESKLTQVYQRDSSEARQLMEDIGADSDDFFSLAEELPQNEDLLESEDD
APIIKLINAMLGEAIKEGASDIHIETFEKTLSIRFRVDGVLREVLAPSRKLSSLLVSRVK
VMAKLDIAEKRVPQDGRISLRIGGRAVDVRVSTMPSSHGERVVMRLLDKNATRLDLHSLG
MTAHNHDNFRRLIKRPHGIILVTGPTGSGKSTTLYAGLQELNSSERNILTVEDPIEFDID
GIGQTQVNPRVDMTFARGLRAILRQDPDVVMVGEIRDLETAQIAVQASLTGHLVMSTLHT
NTAVGAVTRLRDMGIEPFLISSSLLGVLAQRLVRTLCPDCKEPYEADKEQRKLFDSKKKE
PLILYRATGCPKCNHKGYRGRTGIHELLLVDDALQELIHSEAGEQAMEKHIRATTPSIRD
DGLDKVRQGITSLEEVMRVTKES

# Drug_Target_15_Reaction:
Not Available

# Drug_Target_15_Signals:
None

# Drug_Target_15_Specific_Function:
Required for secretion of cholera toxin through the outer membrane

# Drug_Target_15_SwissProt_ID:
P37093

# Drug_Target_15_SwissProt_Name:
GSPE_VIBCH

# Drug_Target_15_Synonyms:
Cholera toxin secretion protein epsE
Type II traffic warden ATPase

# Drug_Target_15_Theoretical_pI:
6.22

# Drug_Target_15_Transmembrane_Regions:
None

# Drug_Target_16_Cellular_Location:
Cell inner membrane

# Drug_Target_16_Chromosome_Location:
Not Available

# Drug_Target_16_Drug_References:
Not Available

# Drug_Target_16_Essentiality:
Non-Essential

# Drug_Target_16_GenAtlas_ID:
Not Available

# Drug_Target_16_GenBank_ID_Gene:
D90393

# Drug_Target_16_GenBank_ID_Protein:
Not Available

# Drug_Target_16_GeneCard_ID:
Not Available

# Drug_Target_16_Gene_Name:
phoQ

# Drug_Target_16_Gene_Sequence:
>1461 bp
ATGAAAAAATTACTGCGTCTTTTTTTCCCGCTCTCGCTGCGGGTACGTTTTCTGTTGGCA
ACGGCAGCGGTAGTACTGGTGCTTTCGCTTGCCTACGGAATGGTCGCGCTGATCGGTTAT
AGCGTCAGTTTCGATAAAACTACGTTTCGGCTGTTACGTGGCGAGAGCAATCTGTTCTAT
ACCCTTGCGAAGTGGGAAAACAATAAGTTGCATGTCGAGTTACCCGAAAATATCGACAAG
CAAAGCCCCACCATGACGCTAATTTATGATGAGAACGGGCAGCTTTTATGGGCGCAACGT
GACGTGCCCTGGCTGATGAAGATGATCCAGCCTGACTGGCTGAAATCGAATGGTTTTCAT
GAAATTGAAGCGGATGTTAACGATACCAGCCTCTTGCTGAGTGGAGATCATTCGATACAG
CAACAGTTGCAGGAAGTGCGGGAAGATGATGACGACGCGGAGATGACCCACTCGGTGGCA
GTAAACGTCTACCCGGCAACATCGCGGATGCCAAAATTAACCATTGTGGTGGTGGATACC
ATTCCGGTGGAGCTAAAAAGTTCCTATATGGTCTGGAGCTGGTTTATCTATGTGCTCTCA
GCCAATCTGCTGTTAGTGATCCCGCTGCTGTGGGTCGCCGCCTGGTGGAGTTTACGCCCC
ATCGAAGCCCTGGCAAAAGAAGTCCGCGAACTGGAAGAACATAACCGCGAATTGCTCAAT
CCAGCCACAACGCGAGAACTGACCAGTCTGGTACGAAACCTGAACCGATTGTTAAAAAGT
GAACGCGAACGTTACGACAAATACCGTACGACGCTCACCGACCTGACCCATAGTCTGAAA
ACGCCACTGGCGGTGCTGCAAAGTACGCTGCGTTCTCTGCGTAGTGAAAAGATGAGCGTC
AGTGATGCTGAGCCGGTAATGCTGGAGCAAATCAGCCGCATTTCACAGCAAATTGGCTAC
TACCTGCATCGTGCCAGTATGCGCGGCGGGACATTGCTCAGCCGCGAGCTGCATCCGGTC
GCCCCACTGCTGGACAATCTCACCTCAGCGCTGAACAAAGTGTATCAACGCAAAGGGGTC
AATATCTCTCTCGATATTTCGCCAGAGATCAGCTTTGTCGGTGAGCAGAACGATTTTGTC
GAGGTGATGGGCAACGTGCTGGATAATGCCTGTAAATATTGCCTCGAGTTTGTCGAAATT
TCTGCAAGGCAAACCGACGAGCATCTCTATATTGTGGTCGAGGATGATGGCCCCGGTATT
CCATTAAGCAAGCGAGAGGTCATTTTCGACCGTGGTCAACGGGTTGATACTTTACGCCCT
GGGCAAGGTGTAGGGCTGGCGGTAGCCCGCGAAATCACCGAGCAATATGAGGGTAAAATC
GTCGCCGGAGAGAGCATGCTGGGCGGTGCGCGGATGGAGGTGATTTTTGGTCGCCAGCAT
TCTGCGCCGAAAGATGAATAA

# Drug_Target_16_General_Function:
Involved in ATP binding

# Drug_Target_16_General_References:
1530848	Groisman EA, Heffron F, Solomon F: Molecular genetic analysis of the Escherichia coli phoP locus. J Bacteriol. 1992 Jan;174(2):486-91.
1729240	Kasahara M, Nakata A, Shinagawa H: Molecular analysis of the Escherichia coli phoP-phoQ operon. J Bacteriol. 1992 Jan;174(2):492-8.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_16_HGNC_ID:
Not Available

# Drug_Target_16_HPRD_ID:
Not Available

# Drug_Target_16_ID:
5644

# Drug_Target_16_Locus:
Not Available

# Drug_Target_16_Molecular_Weight:
55300

# Drug_Target_16_Name:
Sensor protein phoQ

# Drug_Target_16_Number_of_Residues:
486

# Drug_Target_16_PDB_ID:
1ID0

# Drug_Target_16_Pathway:
Not Available

# Drug_Target_16_Pfam_Domain_Function:
PF00512	HisKA
PF00672	HAMP
PF02518	HATPase_c
PF08918	PhoQ_Sensor

# Drug_Target_16_Protein_Sequence:
>Sensor protein phoQ
MKKLLRLFFPLSLRVRFLLATAAVVLVLSLAYGMVALIGYSVSFDKTTFRLLRGESNLFY
TLAKWENNKLHVELPENIDKQSPTMTLIYDENGQLLWAQRDVPWLMKMIQPDWLKSNGFH
EIEADVNDTSLLLSGDHSIQQQLQEVREDDDDAEMTHSVAVNVYPATSRMPKLTIVVVDT
IPVELKSSYMVWSWFIYVLSANLLLVIPLLWVAAWWSLRPIEALAKEVRELEEHNRELLN
PATTRELTSLVRNLNRLLKSERERYDKYRTTLTDLTHSLKTPLAVLQSTLRSLRSEKMSV
SDAEPVMLEQISRISQQIGYYLHRASMRGGTLLSRELHPVAPLLDNLTSALNKVYQRKGV
NISLDISPEISFVGEQNDFVEVMGNVLDNACKYCLEFVEISARQTDEHLYIVVEDDGPGI
PLSKREVIFDRGQRVDTLRPGQGVGLAVAREITEQYEGKIVAGESMLGGARMEVIFGRQH
SAPKDE

# Drug_Target_16_Reaction:
Not Available

# Drug_Target_16_Signals:
None

# Drug_Target_16_Specific_Function:
Member of the two-component regulatory system phoQ/phoP involved in adaptation to low Mg(2+) environments and the control of acid resistance genes. In presence of low periplasmic Mg(2+) concentrations, phoQ functions as a membrane-associated protein kinase that undergoes autophosphorylation and subsequently transfers the phosphate to phoP, which results in the expression of phoP-activated genes (PAG) and repression of phoP-repressed genes (PRG). In presence of high periplasmic Mg(2+) concentrations, acts as a protein phosphatase that dephosphorylates phospho-phoP, which results in the repression of phoP-activated genes and may lead to expression of some phoP- repressed genes (By similarity). Mediates magnesium influx to the cytosol by activation of mgtA. Promotes expression of the two- component regulatory system rstA/rstB and transcription of the hemL, mgrB, nagA, slyB, vboR and yrbL genes

# Drug_Target_16_SwissProt_ID:
P23837

# Drug_Target_16_SwissProt_Name:
PHOQ_ECOLI

# Drug_Target_16_Synonyms:
EC 2.7.13.3

# Drug_Target_16_Theoretical_pI:
5.53

# Drug_Target_16_Transmembrane_Regions:
17-37
195-215

# Drug_Target_17_Cellular_Location:
Cytoplasmic

# Drug_Target_17_Chromosome_Location:
Not Available

# Drug_Target_17_Drug_References:
Not Available

# Drug_Target_17_Essentiality:
Non-Essential

# Drug_Target_17_GenAtlas_ID:
Not Available

# Drug_Target_17_GenBank_ID_Gene:
U28377

# Drug_Target_17_GenBank_ID_Protein:
Not Available

# Drug_Target_17_GeneCard_ID:
Not Available

# Drug_Target_17_Gene_Name:
parE

# Drug_Target_17_Gene_Sequence:
>1893 bp
TTAAACCTCAATCTCCGCCATGTCGCCTTTCTCTTGCAACCAGTTGCGGCGATCTTCCGA
GCGTTTCTTCGCCAGCAGCATATCCATCATCGCGTCAGTACGCTGATCGTCTTCATCATC
GATAGTCAACTGCACCAGACGGCGAGTGTTCGGATCAAGCGTGGTTTCGCGCAATTGCAT
CGGGTTCATTTCCCCCAGACCTTTAAAACGCTGGACGTTCGGCTTGCCTTTCTTGCGTTT
TAATTGCTCAAGTACGCCCTCTTTCTCTTCTTCCGTCAGCGCGTAATAAACCTCTTTCCC
GAGATCAATACGGTAGAGCGGTGGCAGTGCGACGTAAACGTGACCGTGTTTCACCAACGC
GCGGAAATGTTTTACGAACAAAGCGCAGAGCAGCGTGGCAATGTGCAGACCATCAGAGTC
CGCATCCGCGAGGATACAGATTTTGCCATAACGAAGCTGGCTCAGATCGTCGCTGTCAGG
ATCGATACCGATCGCTACCGAAATATCGTGCACTTCCTGCGAAGCCAGCACTTCGTCGGA
AGAGACTTCCCAGGTGTTAAGGATCTTACCTTTCAGTGGCATGATCGCCTGATATTCGCG
ATCGCGCGCCTGCTTGGCAGATCCGCCTGCGGAGTCACCTTCCACAAGGAACAGCTCGGT
ACGGTTAAGGTCCTGCGCGGTACAATCAGCCAGTTTGCCAGGCAACGCCGGGCCGCTGGT
CAGCTTTTTACGCACCACTTTTTTGGCCGCACGCATACGGCGCTGGGCGCTGGAAATCGC
CATCTCCGCCAGCAGTTCAGCCGCCTGAACGTTCTGGTTCAGCCACAGGATAAAGGCATC
TTTCACCACGCCAGAAACGAATGCCGCGCATTGACGCGAAGAGAGACGCTCTTTCGTCTG
CCCGGCAAACTGCGGATCCTGCATTTTTACTGACAGCACATAGGCGCAGCGATCCCAGAT
ATCTTCCGCCGACAGCTTTACACCGCGCGGCAGAATATTGCGGTATTCACAGAACTCACG
CATCGCGTCCAACAGGCCCTGACGCAGACCATTAACATGGGTACCGCCCTGCATCGTTGG
GATAAGGTTGACGTAGCTTTCGGTCAGCAGTTCACCGCCTTCCGGCAGCCACAGTAGCGC
CCAGTCCACAGCTTCAGTATCACCAGCGAAATTACCGATAAACGGTTTTTCCGGCAGCGT
CGGCAGACCATTTACCGCTTCCGCCAGGTAATCATTCAGACCGTCCTGATAGCACCAGCG
TTGTTCGGTATTGTTGATCTCATCTTTAAAAGTGATCTCAACGCCAGGGCACAATACCGC
TTTGGCTTTCAGCACATGCGTCAGGCGTGAAACAGAAAATCGCGGGCTGTCAAAGAAGGT
TTCATCCGGCCAGAAGTGCACACTGGTACCAGTATTGCGTTTACCGCAAGTGCCGACAAC
CTGTAAATCCTGCACCTTTTCGCCATTTTCAAAGGCGATGTTATAAACCTGACCATCGCG
GCGCACGTTAACTTCTACGCGCTTCGACAGGGCGTTAACCACCGAAATCCCCACGCCATG
CAGGCCGCCAGAGAACTGGTAATTTTTGTTAGAGAATTTACCGCCTGCATGCAGACGGCA
AAGAATCAGTTCAACCGCCGGTACACCCTCTTCCGGGTGAATATCCACCGGCATCCCGCG
CCCATCGTCAATAACTTCTAACGACTGGTCAGCATGTAAAATAACGTCCACGCGTTTTGC
GTGACCCGCCAGTGCTTCATCCACACTGTTATCAATGACTTCTTGCCCCAAATGGTTAGG
GCGAGTGGTATCGGTATACATCCCCGGACGGCGGCGAACCGGCTCAAGCCCGGTGAGTAC
CTCAATGGCATCAGCGTTATAAGTTTGCGTCAT

# Drug_Target_17_General_Function:
Involved in ATP binding

# Drug_Target_17_General_References:
2170028	Kato J, Nishimura Y, Imamura R, Niki H, Hiraga S, Suzuki H: New topoisomerase essential for chromosome segregation in E. coli. Cell. 1990 Oct 19;63(2):393-404.
8227000	Peng H, Marians KJ: Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions. J Biol Chem. 1993 Nov 15;268(32):24481-90.
8388096	Springer AL, Schmid MB: Molecular characterization of the Salmonella typhimurium parE gene. Nucleic Acids Res. 1993 Apr 25;21(8):1805-9.
8980775	Breines DM, Ouabdesselam S, Ng EY, Tankovic J, Shah S, Soussy CJ, Hooper DC: Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob Agents Chemother. 1997 Jan;41(1):175-9.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_17_HGNC_ID:
Not Available

# Drug_Target_17_HPRD_ID:
Not Available

# Drug_Target_17_ID:
5645

# Drug_Target_17_Locus:
Not Available

# Drug_Target_17_Molecular_Weight:
70245

# Drug_Target_17_Name:
DNA topoisomerase 4 subunit B

# Drug_Target_17_Number_of_Residues:
630

# Drug_Target_17_PDB_ID:
1S16

# Drug_Target_17_Pathway:
Not Available

# Drug_Target_17_Pfam_Domain_Function:
PF00204	DNA_gyraseB
PF00986	DNA_gyraseB_C
PF02518	HATPase_c

# Drug_Target_17_Protein_Sequence:
>DNA topoisomerase 4 subunit B
MTQTYNADAIEVLTGLEPVRRRPGMYTDTTRPNHLGQEVIDNSVDEALAGHAKRVDVILH
ADQSLEVIDDGRGMPVDIHPEEGVPAVELILCRLHAGGKFSNKNYQFSGGLHGVGISVVN
ALSKRVEVNVRRDGQVYNIAFENGEKVQDLQVVGTCGKRNTGTSVHFWPDETFFDSPRFS
VSRLTHVLKAKAVLCPGVEITFKDEINNTEQRWCYQDGLNDYLAEAVNGLPTLPEKPFIG
NFAGDTEAVDWALLWLPEGGELLTESYVNLIPTMQGGTHVNGLRQGLLDAMREFCEYRNI
LPRGVKLSAEDIWDRCAYVLSVKMQDPQFAGQTKERLSSRQCAAFVSGVVKDAFILWLNQ
NVQAAELLAEMAISSAQRRMRAAKKVVRKKLTSGPALPGKLADCTAQDLNRTELFLVEGD
SAGGSAKQARDREYQAIMPLKGKILNTWEVSSDEVLASQEVHDISVAIGIDPDSDDLSQL
RYGKICILADADSDGLHIATLLCALFVKHFRALVKHGHVYVALPPLYRIDLGKEVYYALT
EEEKEGVLEQLKRKKGKPNVQRFKGLGEMNPMQLRETTLDPNTRRLVQLTIDDEDDQRTD
AMMDMLLAKKRSEDRRNWLQEKGDMAEIEV

# Drug_Target_17_Reaction:
Not Available

# Drug_Target_17_Signals:
None

# Drug_Target_17_Specific_Function:
Topoisomerase IV is essential for chromosome segregation. It has relaxation of supercoiled DNA activity. Performs the decatenation events required during the replication of a circular DNA molecule

# Drug_Target_17_SwissProt_ID:
P20083

# Drug_Target_17_SwissProt_Name:
PARE_ECOLI

# Drug_Target_17_Synonyms:
EC 5.99.1.-
Topoisomerase IV subunit B

# Drug_Target_17_Theoretical_pI:
5.36

# Drug_Target_17_Transmembrane_Regions:
None

# Drug_Target_18_Cellular_Location:
Not Available

# Drug_Target_18_Chromosome_Location:
Not Available

# Drug_Target_18_Drug_References:
Not Available

# Drug_Target_18_Essentiality:
Non-Essential

# Drug_Target_18_GenAtlas_ID:
GALK1

# Drug_Target_18_GenBank_ID_Gene:
U26401

# Drug_Target_18_GenBank_ID_Protein:
Not Available

# Drug_Target_18_GeneCard_ID:
Not Available

# Drug_Target_18_Gene_Name:
GALK1

# Drug_Target_18_Gene_Sequence:
>1179 bp
ATGGCTGCTTTGAGACAGCCCCAGGTCGCGGAGCTGCTGGCCGAGGCCCGGCGAGCCTTC
CGGGAGGAGTTCGGGGCCGAGCCCGAGCTGGCCGTGTCAGCGCCGGGCCGCGTCAACCTC
ATCGGGGAACACACGGACTACAACCAGGGCCTGGTGCTGCCTATGGCTCTGGAGCTCATG
ACGGTGCTGGTGGGCAGCCCCCGCAAGGATGGGCTGGTGTCTCTCCTCACCACCTCTGAG
GGTGCCGATGAGCCCCAGCGGCTGCAGTTTCCACTGCCCACAGCCCAGCGCTCGCTGGAG
CCTGGGACTCCTCGGTGGGCCAACTATGTCAAGGGAGTGATTCAGTACTACCCAGCTGCC
CCCCTCCCTGGCTTCAGTGCAGTGGTGGTCAGCTCAGTGCCCCTGGGGGGTGGCCTGTCC
AGCTCAGCATCCTTGGAAGTGGCCACGTACACCTTCCTCCAGCAGCTCTGTCCAGACTCG
GGCACAATAGCTGCCCGCGCCCAGGTGTGTCAGCAGGCCGAGCACAGCTTCGCAGGGATG
CCCTGTGGCATCATGGACCAGTTCATCTCACTTATGGGACAGAAAGGCCACGCGCTGCTC
ATTGACTGCAGGTCCTTGGAGACCAGCCTGGTGCCACTCTCGGACCCCAAGCTGGCCGTG
CTCATCACCAACTCTAATGTCCGCCACTCCCTGGCCTCCAGCGAGTACCCTGTGCGGCGG
CGCCAATGTGAAGAAGTGGCCCGGGCGCTGGGCAAGGAAAGCCTCCGGGAGGTACAACTG
GAAGAGCTAGAGGCTGCCAGGGACCTGGTGAGCAAAGAGGGCTTCCGGCGGGCCCGGCAC
GTGGTGGGGGAGATTCGGCGCACGGCCCAGGCAGCGGCCGCCCTGAGACGTGGCGACTAC
AGAGCCTTTGGCCGCCTCATGGTGGAGAGCCACCGCTCACTCAGAGACGACTATGAGGTG
AGCTGCCCAGAGCTGGACCAGCTGGTGGAGGCTGCGCTTGCTGTGCCTGGGGTTTATGGC
AGCCGCATGACGGGCGGTGGCTTCGGTGGCTGCACGGTGACACTGCTGGAGGCCTCCGCT
GCTCCCCACGCCATGCGGCACATCCAGGAGCACTACGGCGGGACTGCCACCTTCTACCTC
TCTCAAGCAGCCGATGGAGCCAAGGTGCTGTGCTTGTGA

# Drug_Target_18_General_Function:
Involved in galactokinase activity

# Drug_Target_18_General_References:
10521295	Kalaydjieva L, Perez-Lezaun A, Angelicheva D, Onengut S, Dye D, Bosshard NU, Jordanova A, Savov A, Yanakiev P, Kremensky I, Radeva B, Hallmayer J, Markov A, Nedkova V, Tournev I, Aneva L, Gitzelmann R: A founder mutation in the GK1 gene is responsible for galactokinase deficiency in Roma (Gypsies). Am J Hum Genet. 1999 Nov;65(5):1299-307.
11231902	Okano Y, Asada M, Fujimoto A, Ohtake A, Murayama K, Hsiao KJ, Choeh K, Yang Y, Cao Q, Reichardt JK, Niihira S, Imamura T, Yamano T: A genetic factor for age-related cataract: identification and characterization of a novel galactokinase variant, "Osaka," in Asians. Am J Hum Genet. 2001 Apr;68(4):1036-42. Epub 2001 Feb 23.
7542884	Ai Y, Basu M, Bergsma DJ, Stambolian D: Comparison of the enzymatic activities of human galactokinase GALK1 and a related human galactokinase protein GK2. Biochem Biophys Res Commun. 1995 Jul 17;212(2):687-91.
7670469	Stambolian D, Ai Y, Sidjanin D, Nesburn K, Sathe G, Rosenberg M, Bergsma DJ: Cloning of the galactokinase cDNA and identification of mutations in two families with cataracts. Nat Genet. 1995 Jul;10(3):307-12.
8908517	Bergsma DJ, Ai Y, Skach WR, Nesburn K, Anoia E, Van Horn S, Stambolian D: Fine structure of the human galactokinase GALK1 gene. Genome Res. 1996 Oct;6(10):980-5.

# Drug_Target_18_HGNC_ID:
HGNC:4118

# Drug_Target_18_HPRD_ID:
Not Available

# Drug_Target_18_ID:
5646

# Drug_Target_18_Locus:
17q24

# Drug_Target_18_Molecular_Weight:
42273

# Drug_Target_18_Name:
Galactokinase

# Drug_Target_18_Number_of_Residues:
392

# Drug_Target_18_PDB_ID:
1WUU

# Drug_Target_18_Pathway:
Not Available

# Drug_Target_18_Pfam_Domain_Function:
PF00288	GHMP_kinases_N
PF08544	GHMP_kinases_C

# Drug_Target_18_Protein_Sequence:
>Galactokinase
MAALRQPQVAELLAEARRAFREEFGAEPELAVSAPGRVNLIGEHTDYNQGLVLPMALELM
TVLVGSPRKDGLVSLLTTSEGADEPQRLQFPLPTAQRSLEPGTPRWANYVKGVIQYYPAA
PLPGFSAVVVSSVPLGGGLSSSASLEVATYTFLQQLCPDSGTIAARAQVCQQAEHSFAGM
PCGIMDQFISLMGQKGHALLIDCRSLETSLVPLSDPKLAVLITNSNVRHSLASSEYPVRR
RQCEEVARALGKESLREVQLEELEAARDLVSKEGFRRARHVVGEIRRTAQAAAALRRGDY
RAFGRLMVESHRSLRDDYEVSCPELDQLVEAALAVPGVYGSRMTGGGFGGCTVTLLEASA
APHAMRHIQEHYGGTATFYLSQAADGAKVLCL

# Drug_Target_18_Reaction:
Not Available

# Drug_Target_18_Signals:
None

# Drug_Target_18_Specific_Function:
Major enzyme for galactose metabolism

# Drug_Target_18_SwissProt_ID:
P51570

# Drug_Target_18_SwissProt_Name:
GALK1_HUMAN

# Drug_Target_18_Synonyms:
EC 2.7.1.6
Galactose kinase

# Drug_Target_18_Theoretical_pI:
6.42

# Drug_Target_18_Transmembrane_Regions:
None

# Drug_Target_19_Cellular_Location:
Cytoplasm (By similarity)

# Drug_Target_19_Chromosome_Location:
Not Available

# Drug_Target_19_Drug_References:
Not Available

# Drug_Target_19_Essentiality:
Non-Essential

# Drug_Target_19_GenAtlas_ID:
Not Available

# Drug_Target_19_GenBank_ID_Gene:
X55553

# Drug_Target_19_GenBank_ID_Protein:
Not Available

# Drug_Target_19_GeneCard_ID:
Not Available

# Drug_Target_19_Gene_Name:
recA

# Drug_Target_19_Gene_Sequence:
>1062 bp
ATGGCTATCGACGAAAACAAACAGAAAGCGTTGGCGGCAGCACTGGGCCAGATTGAGAAA
CAATTTGGTAAAGGCTCCATCATGCGCCTGGGTGAAGACCGTTCCATGGATGTGGAAACC
ATCTCTACCGGTTCGCTTTCACTGGATATCGCGCTTGGGGCAGGTGGTCTGCCGATGGGC
CGTATCGTCGAAATCTACGGACCGGAATCTTCCGGTAAAACCACGCTGACGCTGCAGGTG
ATCGCCGCAGCGCAGCGTGAAGGTAAAACCTGTGCGTTTATCGATGCTGAACACGCGCTG
GACCCAATCTACGCACGTAAACTGGGCGTCGATATCGATAACCTGCTGTGCTCCCAGCCG
GATACCGGCGAGCAGGCACTGGAAATCTGTGACGCCCTGGCGCGTTCTGGCGCAGTAGAC
GTTATCGTCGTTGACTCCGTGGCGGCACTGACGCCGAAAGCGGAAATCGAAGGCGAAATC
GGCGACTCTCACATGGGCCTTGCGGCACGTATGATGAGCCAGGCGATGCGTAAGCTGGCG
GGTAACCTGAAGCAGTCCAACACGCTGCTGATCTTCATCAACCAGATCCGTATGAAAATT
GGTGTGATGTTCGGTAACCCGGAAACCACTACCGGTGGTAACGCGCTGAAATTCTACGCC
TCTGTTCGTCTCGACATCCGTCGTATCGGCGCGGTGAAAGAGGGCGAAAACGTGGTGGGT
AGCGAAACCCGCGTGAAAGTGGTGAAGAACAAAATCGCTGCACCGTTTAAACAGGCTGAA
TTTCAGATCCTCTACGGCGAAGGTATCAACTTCTACGGCGAACTGGTTGACCTGGGCGTA
AAAGAGAAGCTGATCGAGAAAGCAGGCGCGTGGTACAGCTACAAAGGTGAGAAGATCGGT
CAGGGTAAAGCGAATGCAACTGCCTGGCTGAAAGATAACCCGGAAACCGCGAAAGAGATC
GAGAAGAAAGTACGTGAGTTGCTGCTGAGCAACCCGAACTCAACGCCGGATTTCTCTGTA
GATGACAGCGAAGGAGTAGCAGAAACTAACGAAGATTTTTAA

# Drug_Target_19_General_Function:
Involved in nucleotide binding

# Drug_Target_19_General_References:
12384590	Jin Q, Yuan Z, Xu J, Wang Y, Shen Y, Lu W, Wang J, Liu H, Yang J, Yang F, Zhang X, Zhang J, Yang G, Wu H, Qu D, Dong J, Sun L, Xue Y, Zhao A, Gao Y, Zhu J, Kan B, Ding K, Chen S, Cheng H, Yao Z, He B, Chen R, Ma D, Qiang B, Wen Y, Hou Y, Yu J: Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res. 2002 Oct 15;30(20):4432-41.
12704152	Wei J, Goldberg MB, Burland V, Venkatesan MM, Deng W, Fournier G, Mayhew GF, Plunkett G 3rd, Rose DJ, Darling A, Mau B, Perna NT, Payne SM, Runyen-Janecky LJ, Zhou S, Schwartz DC, Blattner FR: Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun. 2003 May;71(5):2775-86.
2274037	Zhao XJ, McEntee K: DNA sequence analysis of the recA genes from Proteus vulgaris, Erwinia carotovora, Shigella flexneri and Escherichia coli B/r. Mol Gen Genet. 1990 Jul;222(2-3):369-76.

# Drug_Target_19_HGNC_ID:
Not Available

# Drug_Target_19_HPRD_ID:
Not Available

# Drug_Target_19_ID:
5263

# Drug_Target_19_Locus:
Not Available

# Drug_Target_19_Molecular_Weight:
37974

# Drug_Target_19_Name:
Protein recA

# Drug_Target_19_Number_of_Residues:
353

# Drug_Target_19_PDB_ID:
2REC

# Drug_Target_19_Pathway:
Not Available

# Drug_Target_19_Pfam_Domain_Function:
PF00154	RecA

# Drug_Target_19_Protein_Sequence:
>Protein recA
MAIDENKQKALAAALGQIEKQFGKGSIMRLGEDRSMDVETISTGSLSLDIALGAGGLPMG
RIVEIYGPESSGKTTLTLQVIAAAQREGKTCAFIDAEHALDPIYARKLGVDIDNLLCSQP
DTGEQALEICDALARSGAVDVIVVDSVAALTPKAEIEGEIGDSHMGLAARMMSQAMRKLA
GNLKQSNTLLIFINQIRMKIGVMFGNPETTTGGNALKFYASVRLDIRRIGAVKEGENVVG
SETRVKVVKNKIAAPFKQAEFQILYGEGINFYGELVDLGVKEKLIEKAGAWYSYKGEKIG
QGKANATAWLKDNPETAKEIEKKVRELLLSNPNSTPDFSVDDSEGVAETNEDF

# Drug_Target_19_Reaction:
Not Available

# Drug_Target_19_Signals:
None

# Drug_Target_19_Specific_Function:
Can catalyze the hydrolysis of ATP in the presence of single-stranded DNA, the ATP-dependent uptake of single-stranded DNA by duplex DNA, and the ATP-dependent hybridization of homologous single-stranded DNAs. It interacts with lexA causing its activation and leading to its autocatalytic cleavage (By similarity)

# Drug_Target_19_SwissProt_ID:
P0A7G9

# Drug_Target_19_SwissProt_Name:
RECA_SHIFL

# Drug_Target_19_Synonyms:
Recombinase A

# Drug_Target_19_Theoretical_pI:
4.82

# Drug_Target_19_Transmembrane_Regions:
None

# Drug_Target_1_Cellular_Location:
Cytoplasm (By similarity)

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
Not Available

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AE005674

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
hslU

# Drug_Target_1_Gene_Sequence:
>1332 bp
TTATAGGATAAAACGGCTCAGATCTTCATCTGCCACCAACGCATCCAGATGTTTGCTCAC
ATAATCTGCGTCAATAGTGATATTTTGACCGCTTAAATCGCTGGCGTCGTAGGAAATCTC
TTCCATTAAACGCTCCAGAACAGTGTGTAAACGACGAGCACCGATGTTTTCGGTAGATTC
GTTCACCTGCCATGCCGCTTCCGCGATGCGTTTAATACCGGAGTCGGTAAACTCGATATT
TACGCCTTCAGTCGCCATCAGTGCTTTGTACTGCACGGTGATAGAGGCATTCGGCTCGGT
CAGAATACGCTCGAAGTCGCTGGTGGTCAGTGCCTGCAGTTCAACGCGGATTGGCAGCCG
ACCTTGCAGTTCCGGGATCAGGTCAGACGGTTTCGCAATCTGGAACGCGCCAGAAGCGAT
AAACAGAATGTGGTCAGTTTTGACCATCCCGTGTTTGGTGGAAACGGTGCAACCTTCTAC
CAGCGGCAGCAGGTCACGCTGAACGCCTTCACGAGAAACATCCGGACCGGAAGACTCGCC
GCGCTTACAGATTTTGTCGATTTCGTCGATAAACACGATCCCGTGCTGCTCAACAGCGTC
GATAGCGTCTTGCTTCAGCTCTTCCGGGTTCACCAGTTTCGCCGCTTCTTCTTCAATCAG
CAGCTTCATGGCGTCTTTGATTTTCAGCTTACGCGCTTTTTGCTTCTGGCCGCCCAGGTT
CTGGAACATGGACTGCAGCTGGCTGGTCATCTCTTCCATGCCCGGAGGAGCCATAATTTC
AACGCCCATCGGTGCTGCGGCAAGATCGATCTCGATTTCTTTGTCATCAAGCTGGCCTTC
ACGCAGTTTTTTGCGGAATGCCTGACGAGCAGCGGAAGGTTCCTGCTGCTGTTCAGTCTG
TCCCCAGTTGTTTTTAGCAGGTGGGATCAGCACGTCGAGAATACGTTCTTCTGCCAGTTC
TTCAGCGCGATAACGGTTTTTCTCGATAGCCTGGACGCGTACCATTTTCACGGCGGCATC
GGTCAGATCGCGAATAATAGAATCAACTTCCTTACCGACGTAGCCCACTTCGGTAAATTT
GGTCGCTTCAACTTTGATGAACGGCGCATTCGCCAGCTTAGCCAGACGACGGGCGATTTC
AGTTTTACCGACACCGGTCGGGCCGATCATCAGGATATTTTTCGGGGTCACTTCATGGCG
CAGCTCTTCGTTGAGCTGCATGCGACGCCAGCGGTTACGCAGAGCAATCGCCACAGAACG
CTTGGCGTTGTCCTGGCCGATGATGTGCTTATCCAGTTCGCTGACGATTTCGCGTGGGGT
CATTTCAGACAT

# Drug_Target_1_General_Function:
Involved in nucleotide binding

# Drug_Target_1_General_References:
12384590	Jin Q, Yuan Z, Xu J, Wang Y, Shen Y, Lu W, Wang J, Liu H, Yang J, Yang F, Zhang X, Zhang J, Yang G, Wu H, Qu D, Dong J, Sun L, Xue Y, Zhao A, Gao Y, Zhu J, Kan B, Ding K, Chen S, Cheng H, Yao Z, He B, Chen R, Ma D, Qiang B, Wen Y, Hou Y, Yu J: Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res. 2002 Oct 15;30(20):4432-41.
12704152	Wei J, Goldberg MB, Burland V, Venkatesan MM, Deng W, Fournier G, Mayhew GF, Plunkett G 3rd, Rose DJ, Darling A, Mau B, Perna NT, Payne SM, Runyen-Janecky LJ, Zhou S, Schwartz DC, Blattner FR: Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun. 2003 May;71(5):2775-86.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
5638

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
49595

# Drug_Target_1_Name:
ATP-dependent hsl protease ATP-binding subunit hslU

# Drug_Target_1_Number_of_Residues:
443

# Drug_Target_1_PDB_ID:
1G4B

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF07724	AAA_2

# Drug_Target_1_Protein_Sequence:
>ATP-dependent hsl protease ATP-binding subunit hslU
MSEMTPREIVSELDKHIIGQDNAKRSVAIALRNRWRRMQLNEELRHEVTPKNILMIGPTG
VGKTEIARRLAKLANAPFIKVEATKFTEVGYVGKEVDSIIRDLTDAAVKMVRVQAIEKNR
YRAEELAEERILDVLIPPAKNNWGQTEQQQEPSAARQAFRKKLREGQLDDKEIEIDLAAA
PMGVEIMAPPGMEEMTSQLQSMFQNLGGQKQKARKLKIKDAMKLLIEEEAAKLVNPEELK
QDAIDAVEQHGIVFIDEIDKICKRGESSGPDVSREGVQRDLLPLVEGCTVSTKHGMVKTD
HILFIASGAFQIAKPSDLIPELQGRLPIRVELQALTTSDFERILTEPNASITVQYKALMA
TEGVNIEFTDSGIKRIAEAAWQVNESTENIGARRLHTVLERLMEEISYDASDLSGQNITI
DADYVSKHLDALVADEDLSRFIL

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Chaperone subunit of a proteasome-like degradation complex

# Drug_Target_1_SwissProt_ID:
P0A6H7

# Drug_Target_1_SwissProt_Name:
HSLU_SHIFL

# Drug_Target_1_Synonyms:
Heat shock protein hslU

# Drug_Target_1_Theoretical_pI:
5.00

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_20_Cellular_Location:
Nucleus

# Drug_Target_20_Chromosome_Location:
Not Available

# Drug_Target_20_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_20_Essentiality:
Non-Essential

# Drug_Target_20_GenAtlas_ID:
RAD51

# Drug_Target_20_GenBank_ID_Gene:
D13804

# Drug_Target_20_GenBank_ID_Protein:
Not Available

# Drug_Target_20_GeneCard_ID:
Not Available

# Drug_Target_20_Gene_Name:
RAD51

# Drug_Target_20_Gene_Sequence:
>1020 bp
ATGGCAATGCAGATGCAGCTTGAAGCAAATGCAGATACTTCAGTGGAAGAAGAAAGCTTT
GGCCCACAACCCATTTCACGGTTAGAGCAGTGTGGCATAAATGCCAACGATGTGAAGAAA
TTGGAAGAAGCTGGATTCCATACTGTGGAGGCTGTTGCCTATGCGCCAAAGAAGGAGCTA
ATAAATATTAAGGGAATTAGTGAAGCCAAAGCTGATAAAATTCTGGCTGAGGCAGCTAAA
TTAGTTCCAATGGGTTTCACCACTGCAACTGAATTCCACCAAAGGCGGTCAGAGATCATA
CAGATTACTACTGGCTCCAAAGAGCTTGACAAACTACTTCAAGGTGGAATTGAGACTGGA
TCTATCACAGAAATGTTTGGAGAATTCCGAACTGGGAAGACCCAGATCTGTCATACGCTA
GCTGTCACCTGCCAGCTTCCCATTGACCGGGGTGGAGGTGAAGGAAAGGCCATGTACATT
GACACTGAGGGTACCTTTAGGCCAGAACGGCTGCTGGCAGTGGCTGAGAGGTATGGTCTC
TCTGGCAGTGATGTCCTGGATAATGTAGCATATGCTCGAGCGTTCAACACAGACCACCAG
ACCCAGCTCCTTTATCAAGCATCAGCCATGATGGTAGAATCTAGGTATGCACTGCTTATT
GTAGACAGTGCCACCGCCCTTTACAGAACAGACTACTCGGGTCGAGGTGAGCTTTCAGCC
AGGCAGATGCACTTGGCCAGGTTTCTGCGGATGCTTCTGCGACTCGCTGATGAGTTTGGT
GTAGCAGTGGTAATCACTAATCAGGTGGTAGCTCAAGTGGATGGAGCAGCGATGTTTGCT
GCTGATCCCAAAAAACCTATTGGAGGAAATATCATCGCCCATGCATCAACAACCAGATTG
TATCTGAGGAAAGGAAGAGGGGAAACCAGAATCTGCCAAATCTACGACTCTCCCTGTCTT
CCTGAAGCTGAAGCTATGTTCGCCATTAATGCAGATGGAGTGGGAGATGCCAAAGACTGA

# Drug_Target_20_General_Function:
Involved in nucleotide binding

# Drug_Target_20_General_References:
10493508	Schmutte C, Tombline G, Rhiem K, Sadoff MM, Schmutzler R, von Deimling A, Fishel R: Characterization of the human Rad51 genomic locus and examination of tumors with 15q14-15 loss of heterozygosity (LOH). Cancer Res. 1999 Sep 15;59(18):4564-9.
7988572	Benson FE, Stasiak A, West SC: Purification and characterization of the human Rad51 protein, an analogue of E. coli RecA. EMBO J. 1994 Dec 1;13(23):5764-71.
8358431	Shinohara A, Ogawa H, Matsuda Y, Ushio N, Ikeo K, Ogawa T: Cloning of human, mouse and fission yeast recombination genes homologous to RAD51 and recA. Nat Genet. 1993 Jul;4(3):239-43.
8479919	Yoshimura Y, Morita T, Yamamoto A, Matsushiro A: Cloning and sequence of the human RecA-like gene cDNA. Nucleic Acids Res. 1993 Apr 11;21(7):1665.
9396801	Kovalenko OV, Golub EI, Bray-Ward P, Ward DC, Radding CM: A novel nucleic acid-binding protein that interacts with human rad51 recombinase. Nucleic Acids Res. 1997 Dec 15;25(24):4946-53.

# Drug_Target_20_HGNC_ID:
HGNC:9817

# Drug_Target_20_HPRD_ID:
Not Available

# Drug_Target_20_ID:
4178

# Drug_Target_20_Locus:
15q15.1

# Drug_Target_20_Molecular_Weight:
36967

# Drug_Target_20_Name:
DNA repair protein RAD51 homolog 1

# Drug_Target_20_Number_of_Residues:
339

# Drug_Target_20_PDB_ID:
1N0W

# Drug_Target_20_Pathway:
Not Available

# Drug_Target_20_Pfam_Domain_Function:
PF08423	Rad51

# Drug_Target_20_Protein_Sequence:
>DNA repair protein RAD51 homolog 1
MAMQMQLEANADTSVEEESFGPQPISRLEQCGINANDVKKLEEAGFHTVEAVAYAPKKEL
INIKGISEAKADKILAEAAKLVPMGFTTATEFHQRRSEIIQITTGSKELDKLLQGGIETG
SITEMFGEFRTGKTQICHTLAVTCQLPIDRGGGEGKAMYIDTEGTFRPERLLAVAERYGL
SGSDVLDNVAYARAFNTDHQTQLLYQASAMMVESRYALLIVDSATALYRTDYSGRGELSA
RQMHLARFLRMLLRLADEFGVAVVITNQVVAQVDGAAMFAADPKKPIGGNIIAHASTTRL
YLRKGRGETRICKIYDSPCLPEAEAMFAINADGVGDAKD

# Drug_Target_20_Reaction:
Not Available

# Drug_Target_20_Signals:
None

# Drug_Target_20_Specific_Function:
May participate in a common DNA damage response pathway associated with the activation of homologous recombination and double-strand break repair. Binds to single and double stranded DNA and exhibits DNA-dependent ATPase activity. Underwinds duplex DNA and forms helical nucleoprotein filaments

# Drug_Target_20_SwissProt_ID:
Q06609

# Drug_Target_20_SwissProt_Name:
RAD51_HUMAN

# Drug_Target_20_Synonyms:
HsRAD51
hRAD51

# Drug_Target_20_Theoretical_pI:
5.29

# Drug_Target_20_Transmembrane_Regions:
None

# Drug_Target_21_Cellular_Location:
Cell inner membrane

# Drug_Target_21_Chromosome_Location:
Not Available

# Drug_Target_21_Drug_References:
Not Available

# Drug_Target_21_Essentiality:
Non-Essential

# Drug_Target_21_GenAtlas_ID:
Not Available

# Drug_Target_21_GenBank_ID_Gene:
K02670

# Drug_Target_21_GenBank_ID_Protein:
Not Available

# Drug_Target_21_GeneCard_ID:
Not Available

# Drug_Target_21_Gene_Name:
kdpB

# Drug_Target_21_Gene_Sequence:
>2049 bp
ATGAGTCGTAAACAACTGGCGCTATTCGAACCAACACTTGTCGTTCAGGCGCTGAAAGAA
GCGGTGAAAAAATTAAACCCGCAGGCGCAATGGCGCAATCCGGTGATGTTTATCGTCTGG
ATCGGCAGTCTGCTGACCACCTGTATTAGCATCGCGATGGCAAGCGGTGCGATGCCCGGC
AATGCGCTGTTTAGCGCGGCCATTAGCGGTTGGCTGTGGATCACCGTACTGTTCGCTAAT
TTCGCCGAGGCCCTGGCAGAAGGCCGCAGTAAAGCGCAGGCCAACAGTCTGAAAGGGGTG
AAAAAAACTGCCTTTGCCCGCAAGCTGCGTGACGCGAAATATGGCGCTGCGGCGGACAAA
GTTCCTGCCGACCAACTTCGTAAAGGCGATATCGTACTGGTAGAAGCTGGCGATATTATC
CCCTGCGATGGTGAAGTTATTGAAGGGGGTGCATCGGTCGATGAAAGCGCCATCACCGGG
GAATCGGCACCGGTGATCCGTGAATCCGGCGGCGATTTTGCCTCCGTCACCGGCGGCACG
CGTATTCTTTCTGACTGGCTGGTGATTGAGTGTAGCGTTAACCCCGGCGAGACATTTCTG
GATCGGATGATCGCGATGGTGGAAGGCGCACAGCGACGCAAAACGCCGAACGAAATTGCC
CTGACCATTCTGCTGATTGCCCTGACTATCGTCTTTTTACTGGCAACCGCCACGCTGTGG
CCGTTTTCCGCGTGGGGCGGTAATGCAGTCAGCGTAACGGTACTGGTGGCGCTGCTGGTC
TGTCTGATCCCAACCACTATTGGCGGCCTGTTGTCAGCGATCGGCGTCGCCGGGATGAGC
CGGATGCTAGGCGCGAATGTGATTGCCACCAGCGGACGTGCAGTTGAAGCGGCAGGTGAC
GTTGACGTTCTGCTACTGGATAAAACCGGCACCATCACACTCGGTAACCGTCAGGCGTCG
GAGTTTATCCCCGCGCAGGGCGTGGATGAAAAAACGCTGGCTGACGCCGCACAACTGGCT
TCGCTGGCTGATGAAACGCCGGAAGGCCGCAGTATTGTGATCCTCGCCAAGCAGCGTTTT
AACCTGCGCGAGCGCGATGTGCAGTCGCTCCATGCCACCTTTGTACCGTTTACTGCGCAA
AGCCGGATGAGCGGGATCAACATCGACAACCGCATGATCCGTAAAGGTTCTGTCGATGCC
ATTCGTCGCCATGTTGAGGCTAACGGTGGTCACTTCCCTACCGATGTTGATCAAAAAGTC
GATCAGGTTGCGCGTCAGGGAGCCACGCCGCTGGTGGTGGTGGAAGGTTCTCGTGTGCTG
GGCGTTATTGCGCTGAAAGATATCGTCAAAGGCGGTATTAAAGAGCGCTTCGCCCAGCTG
CGCAAAATGGGCATTAAAACGGTGATGATTACCGGCGATAACCGTCTGACTGCCGCCGCG
ATTGCTGCGGAAGCGGGTGTCGATGATTTTCTCGCCGAAGCGACACCGGAGGCCAAGCTG
GCATTGATCCGTCAGTATCAGGCGGAAGGTCGTTTGGTAGCGATGACCGGCGACGGCACC
AACGATGCTCCGGCGCTGGCGCAGGCAGATGTCGCGGTGGCGATGAACTCCGGCACCCAG
GCGGCGAAAGAGGCGGGCAATATGGTCGATCTCGACTCTAACCCGACCAAGTTGATCGAG
GTGGTGCACATTGGCAAACAGATGCTGATGACCCGTGGCTCGCTGACCACCTTCAGCATT
GCCAACGATGTGGCGAAATACTTCGCCATTATTCCGGCGGCATTCGCGGCAACGTATCCG
CAGTTAAATGCGCTGAACATCATGTGCCTGCATTCGCCCGACTCCGCAATCCTCAGTGCG
GTGATTTTCAACGCCTTGATTATCGTCTTTTTGATTCCCCTGGCGTTAAAAGGCGTGAGT
TATAAACCGCTTACCGCTTCTGCCATGTTGCGCCGTAACTTATGGATTTACGGTCTGGGT
GGGCTGCTGGTGCCGTTTATCGGTATCAAAGTCATTGATTTACTGCTGACCGTTTGCGGT
CTGGTGTGA

# Drug_Target_21_General_Function:
Involved in potassium-transporting ATPase activity

# Drug_Target_21_General_References:
6146979	Hesse JE, Wieczorek L, Altendorf K, Reicin AS, Dorus E, Epstein W: Sequence homology between two membrane transport ATPases, the Kdp-ATPase of Escherichia coli and the Ca2+-ATPase of sarcoplasmic reticulum. Proc Natl Acad Sci U S A. 1984 Aug;81(15):4746-50.
8905232	Oshima T, Aiba H, Baba T, Fujita K, Hayashi K, Honjo A, Ikemoto K, Inada T, Itoh T, Kajihara M, Kanai K, Kashimoto K, Kimura S, Kitagawa M, Makino K, Masuda S, Miki T, Mizobuchi K, Mori H, Motomura K, Nakamura Y, Nashimoto H, Nishio Y, Saito N, Horiuchi T, et al.: A 718-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 12.7-28.0 min region on the linkage map. DNA Res. 1996 Jun 30;3(3):137-55.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_21_HGNC_ID:
Not Available

# Drug_Target_21_HPRD_ID:
Not Available

# Drug_Target_21_ID:
5649

# Drug_Target_21_Locus:
Not Available

# Drug_Target_21_Molecular_Weight:
72200

# Drug_Target_21_Name:
Potassium-transporting ATPase B chain

# Drug_Target_21_Number_of_Residues:
682

# Drug_Target_21_PDB_ID:
1X6K

# Drug_Target_21_Pathway:
Not Available

# Drug_Target_21_Pfam_Domain_Function:
PF00122	E1-E2_ATPase
PF00702	Hydrolase

# Drug_Target_21_Protein_Sequence:
>Potassium-transporting ATPase B chain
MSRKQLALFEPTLVVQALKEAVKKLNPQAQWRNPVMFIVWIGSLLTTCISIAMASGAMPG
NALFSAAISGWLWITVLFANFAEALAEGRSKAQANSLKGVKKTAFARKLREPKYGAAADK
VPADQLRKGDIVLVEAGDIIPCDGEVIEGGASVDESAITGESAPVIRESGGDFASVTGGT
RILSDWLVIECSVNPGETFLDRMIAMVEGAQRRKTPNEIALTILLIALTIVFLLATATLW
PFSAWGGNAVSVTVLVALLVCLIPTTIGGLLSAIGVAGMSRMLGANVIATSGRAVEAAGD
VDVLLLDKTGTITLGNRQASEFIPAQGVDEKTLADAAQLASLADETPEGRSIVILAKQRF
NLRERDVQSLHATFVPFTAQSRMSGINIDNRMIRKGSVDAIRRHVEANGGHFPTDVDQKV
DQVARQGATPLVVVEGSRVLGVIALKDIVKGGIKERFAQLRKMGIKTVMITGDNRLTAAA
IAAEAGVDDFLAEATPEAKLALIRQYQAEGRLVAMTGDGTNDAPALAQADVAVAMNSGTQ
AAKEAGNMVDLDSNPTKLIEVVHIGKQMLMTRGSLTTFSIANDVAKYFAIIPAAFAATYP
QLNALNIMCLHSPDSAILSAVIFNALIIVFLIPLALKGVSYKPLTASAMLRRNLWIYGLG
GLLVPFIGIKVIDLLLTVCGLV

# Drug_Target_21_Reaction:
Not Available

# Drug_Target_21_Signals:
None

# Drug_Target_21_Specific_Function:
One of the components of the high-affinity ATP-driven potassium transport (or KDP) system, which catalyzes the hydrolysis of ATP coupled with the exchange of hydrogen and potassium ions

# Drug_Target_21_SwissProt_ID:
P03960

# Drug_Target_21_SwissProt_Name:
ATKB_ECOLI

# Drug_Target_21_Synonyms:
ATP phosphohydrolase [potassium- transporting] B chain
EC 3.6.3.12
Potassium- translocating ATPase B chain
Potassium-binding and translocating subunit B

# Drug_Target_21_Theoretical_pI:
7.82

# Drug_Target_21_Transmembrane_Regions:
36-58
63-85
220-242
252-274
578-600
615-634
654-676

# Drug_Target_22_Cellular_Location:
Not Available

# Drug_Target_22_Chromosome_Location:
Not Available

# Drug_Target_22_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_22_Essentiality:
Non-Essential

# Drug_Target_22_GenAtlas_ID:
GSK3B

# Drug_Target_22_GenBank_ID_Gene:
L33801

# Drug_Target_22_GenBank_ID_Protein:
529237

# Drug_Target_22_GeneCard_ID:
GSK3B

# Drug_Target_22_Gene_Name:
GSK3B

# Drug_Target_22_Gene_Sequence:
>1263 bp
ATGTCAGGGCGGCCCAGAACCACCTCCTTTGCGGAGAGCTGCAAGCCGGTGCAGCAGCCT
TCAGCTTTTGGCAGCATGAAAGTTAGCAGAGACAAGGACGGCAGCAAGGTGACAACAGTG
GTGGCAACTCCTGGGCAGGGTCCAGACAGGCCACAAGAAGTCAGCTATACAGACACTAAA
GTGATTGGAAATGGATCATTTGGTGTGGTATATCAAGCCAAACTTTGTGATTCAGGAGAA
CTGGTCGCCATCAAGAAAGTATTGCAGGACAAGAGATTTAAGAATCGAGAGCTCCAGATC
ATGAGAAAGCTAGATCACTGTAACATAGTCCGATTGCGTTATTTCTTCTACTCCAGTGGT
GAGAAGAAAGATGAGGTCTATCTTAATCTGGTGCTGGACTATGTTCCGGAAACAGTATAC
AGAGTTGCCAGACACTATAGTCGAGCCAAACAGACGCTCCCTGTGATTTATGTCAAGTTG
TATATGTATCAGCTGTTCCGAAGTTTAGCCTATATCCATTCCTTTGGAATCTGCCATCGG
GATATTAAACCGCAGAACCTCTTGTTGGATCCTGATACTGCTGTATTAAAACTCTGTGAC
TTTGGAAGTGCAAAGCAGCTGGTCCGAGGAGAACCCAATGTTTCGTATATCTGTTCTCGG
TACTATAGGGCACCAGAGTTGATCTTTGGAGCCACTGATTATACCTCTAGTATAGATGTA
TGGTCTGCTGGCTGTGTGTTGGCTGAGCTGTTACTAGGACAACCAATATTTCCAGGGGAT
AGTGGTGTGGATCAGTTGGTAGAAATAATCAAGGTCCTGGGAACTCCAACAAGGGAGCAA
ATCAGAGAAATGAACCCAAACTACACAGAATTTAAATTCCCTCAAATTAAGGCACATCCT
TGGACTAAGGTCTTCCGACCCCGAACTCCACCGGAGGCAATTGCACTGTGTAGCCGTCTG
CTGGAGTATACACCAACTGCCCGACTAACACCACTGGAAGCTTGTGCACATTCATTTTTT
GATGAATTACGGGACCCAAATGTCAAACATCCAAATGGGCGAGACACACCTGCACTCTTC
AACTTCACCACTCAAGAACTGTCAAGTAATCCACCTCTGGCTACCATCCTTATTCCTCCT
CATGCTCGGATTCAAGCAGCTGCTTCAACCCCCACAAATGCCACAGCAGCGTCAGATGCT
AATACTGGAGACCGTGGACAGACCAATAATGCTGCTTCTGCATCAGCTTCCAACTCCACC
TGA

# Drug_Target_22_General_Function:
Involved in protein kinase activity

# Drug_Target_22_General_References:
10486203	Lau KF, Miller CC, Anderton BH, Shaw PC: Molecular cloning and characterization of the human glycogen synthase kinase-3beta promoter. Genomics. 1999 Sep 1;60(2):121-8.
10523816	Rhoads AR, Karkera JD, Detera-Wadleigh SD: Radiation hybrid mapping of genes in the lithium-sensitive wnt signaling pathway. Mol Psychiatry. 1999 Sep;4(5):437-42.
11004522	Hong YR, Chen CH, Chang JH, Wang S, Sy WD, Chou CK, Howng SL: Cloning and characterization of a novel human ninein protein that interacts with the glycogen synthase kinase 3beta. Biochim Biophys Acta. 2000 Jul 24;1492(2-3):513-6.
11440715	Dajani R, Fraser E, Roe SM, Young N, Good V, Dale TC, Pearl LH: Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell. 2001 Jun 15;105(6):721-32.
11738041	Bax B, Carter PS, Lewis C, Guy AR, Bridges A, Tanner R, Pettman G, Mannix C, Culbert AA, Brown MJ, Smith DG, Reith AD: The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation. Structure. 2001 Dec;9(12):1143-52.
7980435	Stambolic V, Woodgett JR: Mitogen inactivation of glycogen synthase kinase-3 beta in intact cells via serine 9 phosphorylation. Biochem J. 1994 Nov 1;303 ( Pt 3):701-4.
9736715	Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S: Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11211-6.

# Drug_Target_22_HGNC_ID:
HGNC:4617

# Drug_Target_22_HPRD_ID:
05418

# Drug_Target_22_ID:
1721

# Drug_Target_22_Locus:
3q13.3

# Drug_Target_22_Molecular_Weight:
46745

# Drug_Target_22_Name:
Glycogen synthase kinase-3 beta

# Drug_Target_22_Number_of_Residues:
420

# Drug_Target_22_PDB_ID:
1J1C

# Drug_Target_22_Pathway:
Not Available

# Drug_Target_22_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_22_Protein_Sequence:
>Glycogen synthase kinase-3 beta
MSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTK
VIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSG
EKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHR
DIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDV
WSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHP
WTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALF
NFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST

# Drug_Target_22_Reaction:
ATP + [tau-protein] = ADP + O-phospho-[tau-protein] ALL_REAC (other) R03744

# Drug_Target_22_Signals:
None

# Drug_Target_22_Specific_Function:
Participates in the Wnt signaling pathway. Implicated in the hormonal control of several regulatory proteins including glycogen synthase, MYB and the transcription factor JUN. Phosphorylates JUN at sites proximal to its DNA-binding domain, thereby reducing its affinity for DNA

# Drug_Target_22_SwissProt_ID:
P49841

# Drug_Target_22_SwissProt_Name:
GSK3B_HUMAN

# Drug_Target_22_Synonyms:
EC 2.7.11.26
GSK-3 beta

# Drug_Target_22_Theoretical_pI:
8.97

# Drug_Target_22_Transmembrane_Regions:
None

# Drug_Target_23_Cellular_Location:
Not Available

# Drug_Target_23_Chromosome_Location:
Not Available

# Drug_Target_23_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_23_Essentiality:
Non-Essential

# Drug_Target_23_GenAtlas_ID:
DTYMK

# Drug_Target_23_GenBank_ID_Gene:
X54729

# Drug_Target_23_GenBank_ID_Protein:
37206

# Drug_Target_23_GeneCard_ID:
DTYMK

# Drug_Target_23_Gene_Name:
DTYMK

# Drug_Target_23_Gene_Sequence:
>636 bp
ATGGCGGCCCGGCGCGGGGCTCTCATAGTGCTGGAGGGCGTGGACCGCGCCGGGAAGAGC
ACGCAGAGCCGCAAGCTGGTGGAAGCGCTGTCGCGCGGGCCACCGCCCGAACTGCTCCGG
TTCCCGGAAAGATCAACTGAAATCGGCAAACTTCTGAGTTCCTACTTGCAAAAGAAAAGT
GACGTGGAGGATCACTCGGTGCACCTGCTTTTTTCTGCAAATCGCTGGGAACAAGTGCCG
TTAATTAAGGAAAAGTTGAGCCAGGGCGTGACCCTCGTCGTGGACAGATACGCATTTTCT
GGTGTGGCCTTCACCGGTGCCAAGGAGAATTTTTCCCTAGACTGGTGTAAACAGCCAGAC
GTGGGCCTTCCCAAACCCGACCTGGTCCTGTTCCTCCAGTTACAGCTGGCGGATGCTGCC
AAGCGGGGAGCGTTTGGCCATGAGCGCTATGAGAACGGGGCTTTCCAGGAGCGGGCGCTC
CGGTGTTTCCACCAGCTCATGAAAGACACGACTTTGAACTGGAAGATGGTGGATGCTTCC
AAAAGACTCGAAGCTGTCCATGAGGAACTCCGCGTGCTCTCTGAGGACGCCATCCGCACT
GCCACAGAGAAGCCGCTGGGGGAGCTATGGAAGTGA

# Drug_Target_23_General_Function:
Nucleotide transport and metabolism

# Drug_Target_23_General_References:
2017365	Su JY, Sclafani RA: Molecular cloning and expression of the human deoxythymidylate kinase gene in yeast. Nucleic Acids Res. 1991 Feb 25;19(4):823-7.
8024690	Huang SH, Tang A, Drisco B, Zhang SQ, Seeger R, Li C, Jong A: Human dTMP kinase: gene expression and enzymatic activity coinciding with cell cycle progression and cell growth. DNA Cell Biol. 1994 May;13(5):461-71.

# Drug_Target_23_HGNC_ID:
HGNC:3061

# Drug_Target_23_HPRD_ID:
01773

# Drug_Target_23_ID:
2254

# Drug_Target_23_Locus:
2q37.3

# Drug_Target_23_Molecular_Weight:
23820

# Drug_Target_23_Name:
Thymidylate kinase

# Drug_Target_23_Number_of_Residues:
212

# Drug_Target_23_PDB_ID:
1E9A

# Drug_Target_23_Pathway:
Methotrexate Pathway	SMP00432

# Drug_Target_23_Pfam_Domain_Function:
PF02223	Thymidylate_kin

# Drug_Target_23_Protein_Sequence:
>Thymidylate kinase
MAARRGALIVLEGVDRAGKSTQSRKLVEALCAAGHRAELLRFPERSTEIGKLLSSYLQKK
SDVEDHSVHLLFSANRWEQVPLIKEKLSQGVTLVVDRYAFSGVAFTGAKENFSLDWCKQP
DVGLPKPDLVLFLQLQLADAAKRGAFGHERYENGAFQERALRCFHQLMKDTTLNWKMVDA
SKSIEAVHEDIRVLSEDAIRTATEKPLGELWK

# Drug_Target_23_Reaction:
ATP + dTMP = ADP + dTDP

# Drug_Target_23_Signals:
None

# Drug_Target_23_Specific_Function:
Catalyzes the conversion of dTMP to dTDP

# Drug_Target_23_SwissProt_ID:
P23919

# Drug_Target_23_SwissProt_Name:
KTHY_HUMAN

# Drug_Target_23_Synonyms:
EC 2.7.4.9
dTMP kinase

# Drug_Target_23_Theoretical_pI:
8.49

# Drug_Target_23_Transmembrane_Regions:
None

# Drug_Target_24_Cellular_Location:
Cytoplasm (Potential)

# Drug_Target_24_Chromosome_Location:
Not Available

# Drug_Target_24_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_24_Essentiality:
Non-Essential

# Drug_Target_24_GenAtlas_ID:
Not Available

# Drug_Target_24_GenBank_ID_Gene:
U30501

# Drug_Target_24_GenBank_ID_Protein:
940146

# Drug_Target_24_GeneCard_ID:
Not Available

# Drug_Target_24_Gene_Name:
cheA

# Drug_Target_24_Gene_Sequence:
>2016 bp
ATGATGGAAGAATATCTCGGAGTGTTTGTCGATGAGACAAAAGAATACCTTCAAAATCTG
AACGATACCCTCCTCGAATTGGAGAAAAATCCCGAAGATATGGAACTCATAAACGAAGCG
TTCAGGGCTCTTCATACCCTGAAAGGAATGGCAGGTACAATGGGGTTTTCCAGTATGGCG
AAGCTCTGCCATACCTTAGAAAACATCCTCGATAAAGCCAGAAACAGCGAGATAAAGATA
ACTTCCGATCTCCTCGATAAGATCTTCGCGGGGGTCGATATGATAACCAGAATGGTTGAT
AAGATCGTCTCCGAGGGAAGTGACGACATCGGAGAAAACATAGACGTGTTCTCCGACACC
ATAAAAAGCTTTGCATCATCGGGAAAAGAGAAGCCTTCAGAAATCAAAAATGAAACGGAA
ACAAAGGGTGAGGAAGAACACAAAGGAGAATCAACAAGCAATGAAGAAGTCGTAGTTCTT
CCTGAAGAAGTTGCCCACGTTCTTCAGGAAGCGAGAAACAAGGGTTTCAAAACGTTTTAT
ATTAAAGTGATTCTCAAAGAAGGAACGCAGTTGAAATCCGCCAGGATTTACCTCGTTTTC
CACAAGCTTGAAGAACTGAAGTGTGAAGTTGTGAGAACGATTCCTTCGGTTGAAGAGATA
GAAGAAGAGAAATTCGAAAACGAAGTGGAACTCTTCGTAATCTCCCCTGTGGATCTGGAG
AAACTCTCTGAAGCTCTGTCAAGCATCGCCGATATAGAGAGGGTAATAATAAAAGAAGTA
ACCGCCGTCACCGAAGAATCAGGGGCTGAGAAAAGAACCGAGAAAGAAGAGAAAACTGAA
AAAACTGAGGAAAAGGCCGAAAGAAAAAAGGTTATTTCGCAAACAGTCAGGGTAGATATA
GAGAAACTGGGCAATTTGATGGATTTGATGGGAGAACTGGTCATCGCAAGGAGCAGAATA
CTGGAAACGCTCAAGAAATACAACATAAAAGAACTGGATGAGAGTTTGTCTCATCTCAGC
AGGATCACCTTAGACCTTCAGAATGTTGTGATGAAGATCAGAATGGTTCCCATCTCCTTT
GTTTTCAACAGATTCCCTCGAATGGTGAGAGACCTTGCCAAAAAGATGAACAAAGAAGTG
AATTTCATCATGAGAGGAGAAGACACAGAGCTCGACAGAACGTTCGTTGAAGAAATTGGC
GAACCCCTGCTCCATCTCCTGAGAAACGCCATCGACCACGGTATAGAACCCAAAGAAGAA
CGAATAGCCAAAGGAAAACCCCCCATTGGAACACTCATTCTCTCGGCACGTCACGAGGGA
AACAACGTGGTAATAGAAGTCGAAGATGACGGAAGGGGTATAGACAAGGAAAAGATCATC
AGAAAAGCCATAGAAAAGGGACTCATAGATGAATCAAAGGCCGCTACCCTTTCTGATCAG
GAGATTCTGAACTTCCTCTTCGTTCCGGGATTCTCCACAAAGGAAAAAGTCTCAGAAGTC
TCCGGAAGAGGCGTGGGAATGGATGTCGTGAAAAATGTGGTGGAATCTTTGAATGGTAGC
ATAAGCATAGAAAGCGAGAAAGATAAAGGAACAAAAGTTACGATAAGACTACCGCTCACT
CTGGCCATCATTCAGGCGCTCCTCGTCAAAGTCAACAATCTCGTCTACGCGATTCCGATA
GCGAACATAGACACAATACTCAGCATTTCAAAAGAGGATATTCAAAGAGTTCAGGACAGA
GATGTGATAGTCATAAGAGGAGAAGTGATACCCGTTTACCGTCTGTGGGAAGTGCTTCAA
ATAGAGCACAAAGAAGAACTGGAGGAGATGGAAGCGGTTATTGTGAGGGTAGGAAACAGG
AAGTACGGTATCGTCGTAGACGATCTTCTCGGTCAGGACGATATCGTGATAAAATCTCTT
GGAAAGGTGTTCTCTGAGGTGAAGGAATTCAGCGGAGCAGCTATTCTCGGTGATGGTAGT
ATAGCGCTGATAATCAACGTCTCCGGCATTGTATAA

# Drug_Target_24_General_Function:
Signal transduction mechanisms

# Drug_Target_24_General_References:
10360571	Nelson KE, Clayton RA, Gill SR, Gwinn ML, Dodson RJ, Haft DH, Hickey EK, Peterson JD, Nelson WC, Ketchum KA, McDonald L, Utterback TR, Malek JA, Linher KD, Garrett MM, Stewart AM, Cotton MD, Pratt MS, Phillips CA, Richardson D, Heidelberg J, Sutton GG, Fleischmann RD, Eisen JA, White O, Salzberg SL, Smith HO, Venter JC, Fraser CM: Evidence for lateral gene transfer between Archaea and bacteria from genome sequence of Thermotoga maritima. Nature. 1999 May 27;399(6734):323-9.
8550470	Swanson RV, Sanna MG, Simon MI: Thermostable chemotaxis proteins from the hyperthermophilic bacterium Thermotoga maritima. J Bacteriol. 1996 Jan;178(2):484-9.
9989504	Bilwes AM, Alex LA, Crane BR, Simon MI: Structure of CheA, a signal-transducing histidine kinase. Cell. 1999 Jan 8;96(1):131-41.

# Drug_Target_24_HGNC_ID:
Not Available

# Drug_Target_24_HPRD_ID:
Not Available

# Drug_Target_24_ID:
2615

# Drug_Target_24_Locus:
Not Available

# Drug_Target_24_Molecular_Weight:
75557

# Drug_Target_24_Name:
Chemotaxis protein cheA

# Drug_Target_24_Number_of_Residues:
671

# Drug_Target_24_PDB_ID:
1B3Q

# Drug_Target_24_Pathway:
Not Available

# Drug_Target_24_Pfam_Domain_Function:
PF01584	CheW
PF01627	Hpt
PF02518	HATPase_c
PF02895	H-kinase_dim
PF07194	P2

# Drug_Target_24_Protein_Sequence:
>Chemotaxis protein cheA
MMEEYLGVFVDETKEYLQNLNDTLLELEKNPEDMELINEAFRALHTLKGMAGTMGFSSMA
KLCHTLENILDKARNSEIKITSDLLDKIFAGVDMITRMVDKIVSEGSDDIGENIDVFSDT
IKSFASSGKEKPSEIKNETETKGEEEHKGESTSNEEVVVLPEEVAHVLQEARNKGFKTFY
IKVILKEGTQLKSARIYLVFHKLEELKCEVVRTIPSVEEIEEEKFENEVELFVISPVDLE
KLSEALSSIADIERVIIKEVTAVTEESGAEKRTEKEEKTEKTEEKAERKKVISQTVRVDI
EKLDNLMDLMGELVIARSRILETLKKYNIKELDESLSHLSRITLDLQNVVMKIRMVPISF
VFNRFPRMVRDLAKKMNKEVNFIMRGEDTELDRTFVEEIGEPLLHLLRNAIDHGIEPKEE
RIAKGKPPIGTLILSARHEGNNVVIEVEDDGRGIDKEKIIRKAIEKGLIDESKAATLSDQ
EILNFLFVPGFSTKEKVSEVSGRGVGMDVVKNVVESLNGSISIESEKDKGTKVTIRLPLT
LAIIQALLVKVNNLVYAIPIANIDTILSISKEDIQRVQDRDVIVIRGEVIPVYRLWEVLQ
IEHKEELEEMEAVIVRVGNRKYGIVVDDLLGQDDIVIKSLGKVFSEVKEFSGAAILGDGS
IALIINVSGIV

# Drug_Target_24_Reaction:
ATP + protein L-histidine = ADP + protein N-phospho-L-histidine

# Drug_Target_24_Signals:
None

# Drug_Target_24_Specific_Function:
Involved in the transmission of sensory signals from the chemoreceptors to the flagellar motors. CheA is autophosphorylated; it can transfer its phosphate group to either cheB or cheY

# Drug_Target_24_SwissProt_ID:
Q56310

# Drug_Target_24_SwissProt_Name:
CHEA_THEMA

# Drug_Target_24_Synonyms:
EC 2.7.13.3

# Drug_Target_24_Theoretical_pI:
4.64

# Drug_Target_24_Transmembrane_Regions:
None

# Drug_Target_25_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_25_Chromosome_Location:
Not Available

# Drug_Target_25_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_25_Essentiality:
Non-Essential

# Drug_Target_25_GenAtlas_ID:
IGF1R

# Drug_Target_25_GenBank_ID_Gene:
X04434

# Drug_Target_25_GenBank_ID_Protein:
804990

# Drug_Target_25_GeneCard_ID:
IGF1R

# Drug_Target_25_Gene_Name:
IGF1R

# Drug_Target_25_Gene_Sequence:
>4104 bp
ATGAAGTCTGGCTCCGGAGGAGGGTCCCCGACCTCGCTGTGGGGGCTCCTGTTTCTCTCC
GCCGCGCTCTCGCTCTGGCCGACGAGTGGAGAAATCTGCGGGCCAGGCATCGACATCCGC
AACGACTATCAGCAGCTGAAGCGCCTGGAGAACTGCACGGTGATCGAGGGCTACCTCCAC
ATCCTGCTCATCTCCAAGGCCGAGGACTACCGCAGCTACCGCTTCCCCAAGCTCACGGTC
ATTACCGAGTACTTGCTGCTGTTCCGAGTGGCTGGCCTCGAGAGCCTCGGAGACCTCTTC
CCCAACCTCACGGTCATCCGCGGCTGGAAACTCTTCTACAACTACGCCCTGGTCATCTTC
GAGATGACCAATCTCAAGGATATTGGGCTTTACAACCTGAGGAACATTACTCGGGGGGCC
ATCAGGATTGAGAAAAATGCTGACCTCTGTTACCTCTCCACTGTGGACTGGTCCCTGATC
CTGGATGCGGTGTCCAATAACTACATTGTGGGGAATAAGCCCCCAAAGGAATGTGGGGAC
CTGTGTCCAGGGACCATGGAGGAGAAGCCGATGTGTGAGAAGACCACCATCAACAATGAG
TACAACTACCGCTGCTGGACCACAAACCGCTGCCAGAAAATGTGCCCAAGCACGTGTGGG
AAGCGGGCGTGCACCGAGAACAATGAGTGCTGCCACCCCGAGTGCCTGGGCAGCTGCAGC
GCGCCTGACAACGACACGGCCTGTGTAGCTTGCCGCCACTACTACTATGCCGGTGTCTGT
GTGCCTGCCTGCCCGCCCAACACCTACAGGTTTGAGGGCTGGCGCTGTGTGGACCGTGAC
TTCTGCGCCAACATCCTCAGCGCCGAGAGCAGCGACTCCGAGGGGTTTGTGATCCACGAC
GGCGAGTGCATGCAGGAGTGCCCCTCGGGCTTCATCCGCAACGGCAGCCAGAGCATGTAC
TGCATCCCTTGTGAAGGTCCTTGCCCGAAGGTCTGTGAGGAAGAAAAGAAAACAAAGACC
ATTGATTCTGTTACTTCTGCTCAGATGCTCCAAGGATGCACCATCTTCAAGGGCAATTTG
CTCATTAACATCCGACGGGGGAATAACATTGCTTCAGAGCTGGAGAACTTCATGGGGCTC
ATCGAGGTGGTGACGGGCTACGTGAAGATCCGCCATTCTCATGCCTTGGTCTCCTTGTCC
TTCCTAAAAAACCTTCGCCTCATCCTAGGAGAGGAGCAGCTAGAAGGGAATTACTCCTTC
TACGTCCTCGACAACCAGAACTTGCAGCAACTGTGGGACTGGGACCACCGCAACCTGACC
ATCAAAGCAGGGAAAATGTACTTTGCTTTCAATCCCAAATTATGTGTTTCCGAAATTTAC
CGCATGGAGGAAGTGACGGGGACTAAAGGGCGCCAAAGCAAAGGGGACATAAACACCAGG
AACAACGGGGAGAGAGCCTCCTGTGAAAGTGACGTCCTGCATTTCACCTCCACCACCACG
TCGAAGAATCGCATCATCATAACCTGGCACCGGTACCGGCCCCCTGACTACAGGGATCTC
ATCAGCTTCACCGTTTACTACAAGGAAGCACCCTTTAAGAATGTCACAGAGTATGATGGG
CAGGATGCCTGCGGCTCCAACAGCTGGAACATGGTGGACGTGGACCTCCCGCCCAACAAG
GACGTGGAGCCCGGCATCTTACTACATGGGCTGAAGCCCTGGACTCAGTACGCCGTTTAC
GTCAAGGCTGTGACCCTCACCATGGTGGAGAACGACCATATCCGTGGGGCCAAGAGTGAG
ATCTTGTACATTCGCACCAATGCTTCAGTTCCTTCCATTCCCTTGGACGTTCTTTCAGCA
TCGAACTCCTCTTCTCAGTTAATCGTGAAGTGGAACCCTCCCTCTCTGCCCAACGGCAAC
CTGAGTTACTACATTGTGCGCTGGCAGCGGCAGCCTCAGGACGGCTACCTTTACCGGCAC
AATTACTGCTCCAAAGACAAAATCCCCATCAGGAAGTATGCCGACGGCACCATCGACATT
GAGGAGGTCACAGAGAACCCCAAGACTGAGGTGTGTGGTGGGGAGAAAGGGCCTTGCTGC
GCCTGCCCCAAAACTGAAGCCGAGAAGCAGGCCGAGAAGGAGGAGGCTGAATACCGCAAA
GTCTTTGAGAATTTCCTGCACAACTCCATCTTCGTGCCCAGACCTGAAAGGAAGCGGAGA
GATGTCATGCAAGTGGCCAACACCACCATGTCCAGCCGAAGCAGGAACACCACGGCCGCA
GACACCTACAACATCACCGACCCGGAAGAGCTGGAGACAGAGTACCCTTTCTTTGAGAGC
AGAGTGGATAACAAGGAGAGAACTGTCATTTCTAACCTTCGGCCTTTCACATTGTACCGC
ATCGATATCCACAGCTGCAACCACGAGGCTGAGAAGCTGGGCTGCAGCGCCTCCAACTTC
GTCTTTGCAAGGACTATGCCCGCAGAAGGAGCAGATGACATTCCTGGGCCAGTGACCTGG
GAGCCAAGGCCTGAAAACTCCATCTTTTTAAAGTGGCCGGAACCTGAGAATCCCAATGGA
TTGATTCTAATGTATGAAATAAAATACGGATCACAAGTTGAGGATCAGCGAGAATGTGTG
TCCAGACAGGAATACAGGAAGTATGGAGGGGCCAAGCTAAACCGGCTAAACCCGGGGAAC
TACACAGCCCGGATTCAGGCCACATCTCTCTCTGGGAATGGGTCGTGGACAGATCCTGTG
TTCTTCTATGTCCAGGCCAAAACAGGATATGAAAACTTCATCCATCTGATCATCGCTCTG
CCCGTCGCTGTCCTGTTGATCGTGGGAGGGTTGGTGATTATGCTGTACGTCTTCCATAGA
AAGAGAAATAACAGCAGGCTGGGGAATGGAGTGCTGTATGCCTCTGTGAACCCGGAGTAC
TTCAGCGCTGCTGATGTGTACGTTCCTGATGAGTGGGAGGTGGCTCGGGAGAAGATCACC
ATGAGCCGGGAACTTGGGCAGGGGTCGTTTGGGATGGTCTATGAAGGAGTTGCCAAGGGT
GTGGTGAAAGATGAACCTGAAACCAGAGTGGCCATTAAAACAGTGAACGAGGCCGCAAGC
ATGCGTGAGAGGATTGAGTTTCTCAACGAAGCTTCTGTGATGAAGGAGTTCAATTGTCAC
CATGTGGTGCGATTGCTGGGTGTGGTGTCCCAAGGCCAGCCAACACTGGTCATCATGGAA
CTGATGACACGGGGCGATCTCAAAAGTTATCTCCGGTCTCTGAGGCCAGAAATGGAGAAT
AATCCAGTCCTAGCACCTCCAAGCCTGAGCAAGATGATTCAGATGGCCGGAGAGATTGCA
GACGGCATGGCATACCTCAACGCCAATAAGTTCGTCCACAGAGACCTTGCTGCCCGGAAT
TGCATGGTAGCCGAAGATTTCACAGTCAAAATCGGAGATTTTGGTATGACGCGAGATATC
TATGAGACAGACTATTACCGGAAAGGAGGCAAAGGGCTGCTGCCCGTGCGCTGGATGTCT
CCTGAGTCCCTCAAGGATGGAGTCTTCACCACTTACTCGGACGTCTGGTCCTTCGGGGTC
GTCCTCTGGGAGATCGCCACACTGGCCGAGCAGCCCTACCAGGGCTTGTCCAACGAGCAA
GTCCTTCGCTTCGTCATGGAGGGCGGCCTTCTGGACAAGCCAGACAACTGTCCTGACATG
CTGTTTGAACTGATGCGCATGTGCTGGCAGTATAACCCCAAGATGAGGCCTTCCTTCCTG
GAGATCATCAGCAGCATCAAAGAGGAGATGGAGCCTGGCTTCCGGGAGGTCTCCTTCTAC
TACAGCGAGGAGAACAAGCTGCCCGAGCCGGAGGAGCTGGACCTGGAGCCAGAGAACATG
GAGAGCGTCCCCCTGGACCCCTCGGCCTCCTCGTCCTCCCTGCCACTGCCCGACAGACAC
TCAGGACACAAGGCCGAGAACGGCCCCGGCCCTGGGGTGCTGGTCCTCCGCGCCAGCTTC
GACGAGAGACAGCCTTACGCCCACATGAACGGGGGCCGCAAGAACGAGCGGGCCTTGCCG
CTGCCCCAGTCTTCGACCTGCTGA

# Drug_Target_25_General_Function:
Involved in transmembrane receptor protein tyrosine kinase activity

# Drug_Target_25_General_References:
1316909	Abbott AM, Bueno R, Pedrini MT, Murray JM, Smith RJ: Insulin-like growth factor I receptor gene structure. J Biol Chem. 1992 May 25;267(15):10759-63.
1711844	Cooke DW, Bankert LA, Roberts CT Jr, LeRoith D, Casella SJ: Analysis of the human type I insulin-like growth factor receptor promoter region. Biochem Biophys Res Commun. 1991 Jun 28;177(3):1113-20.
2877871	Ullrich A, Gray A, Tam AW, Yang-Feng T, Tsubokawa M, Collins C, Henzel W, Le Bon T, Kathuria S, Chen E, et al.: Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986 Oct;5(10):2503-12.
7541045	Craparo A, O'Neill TJ, Gustafson TA: Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their phosphotyrosine-dependent interaction with the NPEY motif of the insulin-like growth factor I receptor. J Biol Chem. 1995 Jun 30;270(26):15639-43.
8247543	Lee ST, Strunk KM, Spritz RA: A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes. Oncogene. 1993 Dec;8(12):3403-10.

# Drug_Target_25_HGNC_ID:
HGNC:5465

# Drug_Target_25_HPRD_ID:
00932

# Drug_Target_25_ID:
958

# Drug_Target_25_Locus:
15q26.3

# Drug_Target_25_Molecular_Weight:
154795

# Drug_Target_25_Name:
Insulin-like growth factor 1 receptor

# Drug_Target_25_Number_of_Residues:
1367

# Drug_Target_25_PDB_ID:
1IGR

# Drug_Target_25_Pathway:
Not Available

# Drug_Target_25_Pfam_Domain_Function:
PF00041	fn3
PF00757	Furin-like
PF01030	Recep_L_domain
PF07714	Pkinase_Tyr

# Drug_Target_25_Protein_Sequence:
>Insulin-like growth factor 1 receptor precursor
MKSGSGGGSPTSLWGLLFLSAALSLWPTSGEICGPGIDIRNDYQQLKRLENCTVIEGYLH
ILLISKAEDYRSYRFPKLTVITEYLLLFRVAGLESLGDLFPNLTVIRGWKLFYNYALVIF
EMTNLKDIGLYNLRNITRGAIRIEKNADLCYLSTVDWSLILDAVSNNYIVGNKPPKECGD
LCPGTMEEKPMCEKTTINNEYNYRCWTTNRCQKMCPSTCGKRACTENNECCHPECLGSCS
APDNDTACVACRHYYYAGVCVPACPPNTYRFEGWRCVDRDFCANILSAESSDSEGFVIHD
GECMQECPSGFIRNGSQSMYCIPCEGPCPKVCEEEKKTKTIDSVTSAQMLQGCTIFKGNL
LINIRRGNNIASELENFMGLIEVVTGYVKIRHSHALVSLSFLKNLRLILGEEQLEGNYSF
YVLDNQNLQQLWDWDHRNLTIKAGKMYFAFNPKLCVSEIYRMEEVTGTKGRQSKGDINTR
NNGERASCESDVLHFTSTTTSKNRIIITWHRYRPPDYRDLISFTVYYKEAPFKNVTEYDG
QDACGSNSWNMVDVDLPPNKDVEPGILLHGLKPWTQYAVYVKAVTLTMVENDHIRGAKSE
ILYIRTNASVPSIPLDVLSASNSSSQLIVKWNPPSLPNGNLSYYIVRWQRQPQDGYLYRH
NYCSKDKIPIRKYADGTIDIEEVTENPKTEVCGGEKGPCCACPKTEAEKQAEKEEAEYRK
VFENFLHNSIFVPRPERKRRDVMQVANTTMSSRSRNTTAADTYNITDPEELETEYPFFES
RVDNKERTVISNLRPFTLYRIDIHSCNHEAEKLGCSASNFVFARTMPAEGADDIPGPVTW
EPRPENSIFLKWPEPENPNGLILMYEIKYGSQVEDQRECVSRQEYRKYGGAKLNRLNPGN
YTARIQATSLSGNGSWTDPVFFYVQAKTGYENFIHLIIALPVAVLLIVGGLVIMLYVFHR
KRNNSRLGNGVLYASVNPEYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKG
VVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIME
LMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARN
CMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGV
VLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFL
EIISSIKEEMEPGFREVSFYYSEENKLPEPEELDLEPENMESVPLDPSASSSSLPLPDRH
SGHKAENGPGPGVLVLRASFDERQPYAHMNGGRKNERALPLPQSSTC

# Drug_Target_25_Reaction:
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate

# Drug_Target_25_Signals:
1-30

# Drug_Target_25_Specific_Function:
This receptor binds insulin-like growth factor 1 (IGF1) with a high affinity and IGF2 with a lower affinity. It has a tyrosine-protein kinase activity, which is necessary for the activation of the IGF1-stimulated downstream signaling cascade

# Drug_Target_25_SwissProt_ID:
P08069

# Drug_Target_25_SwissProt_Name:
IGF1R_HUMAN

# Drug_Target_25_Synonyms:
CD221 antigen
EC 2.7.10.1
IGF-I receptor
Insulin-like growth factor 1 receptor precursor
Insulin-like growth factor I receptor

# Drug_Target_25_Theoretical_pI:
5.54

# Drug_Target_25_Transmembrane_Regions:
936-959

# Drug_Target_26_Cellular_Location:
Isoform 2:Cytoplasm. Nucleus. Isoform 1:Cell membrane

# Drug_Target_26_Chromosome_Location:
Not Available

# Drug_Target_26_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_26_Essentiality:
Non-Essential

# Drug_Target_26_GenAtlas_ID:
PIM1

# Drug_Target_26_GenBank_ID_Gene:
M27903

# Drug_Target_26_GenBank_ID_Protein:
387022

# Drug_Target_26_GeneCard_ID:
PIM1

# Drug_Target_26_Gene_Name:
PIM1

# Drug_Target_26_Gene_Sequence:
>1215 bp
CTGCCGCACGAGCCCCACGAGCCGCTCACCCCGCCGTTCTCAGCGCTGCCCGACCCCGCT
GGCGCGCCCTCCCGCCGCCAGTCCCGGCAGCGCCCTCAGTTGTCCTCCGACTCGCCCTCG
GCCTTCCGCGCCAGCCGCAGCCACAGCCGCAACGCCACCCGCAGCCACAGCCACAGCCAC
AGCCCCAGGCATAGCCTTCGGCACAGCCCCGGCTCCGGCTCCTGCGGCAGCTCCTCTGGG
CACCGTCCCTGCGCCGACATCCTGGAGGTTGGGATGCTCTTGTCCAAAATCAACTCGCTT
GCCCACCTGCGCGCCGCGCCCTGCAACGACCTGCACGCCACCAAGCTGGCGCCCGGCAAG
GAGAAGGAGCCCCTGGAGTCGCAGTACCAGGTGGGCCCGCTACTGGGCAGCGGCGGCTTC
GGCTCGGTCTACTCAGGCATCCGCGTCTCCGACAACTTGCCGGTGGCCATCAAACACGTG
GAGAAGGACCGGATTTCCGACTGGGGAGAGCTGCCTAATGGCACTCGAGTGCCCATGGAA
GTGGTCCTGCTGAAGAAGGTGAGCTCGGGTTTCTCCGGCGTCATTAGGCTCCTGGACTGG
TTCGAGAGGCCCGACAGTTTCGTCCTGATCCTGGAGAGGNCCGAGCCGGTGCAAGATCTC
TTCGACTTCATCACGGAAAGGGGAGCCCTGCAAGAGGAGCTGGCCCGCAGCTTCTTCTGG
CAGGTGCTGGAGGCCGTGCGGCACTGCCACAACTGCGGGGTGCTCCACCGCGACATCAAG
GACGAAAACATCCTTATCGACCTCAATCGCGGCGAGCTCAAGCTCATCGACTTCGGGTCG
GGGGCGCTGCTCAAGGACACCGTCTACACGGACTTCGATGGGACCCGAGTGTATAGCCCT
CCAGAGTGGATCCGCTACCATCGCTACCATGGCAGGTCGGCGGCAGTCTGGTCCCTGGGG
ATCCTGCTGTATGATATGGTGTGTGGAGATATTCCTTTCGAGCATGACGAAGAGATCATC
AGGGGCCAGGTTTTCTTCAGGCAGAGGGTCTCTTCAGAATGTCAGCATCTCATTAGATGG
TGCTTGGCCCTGAGACCATCAGATAGGCCAACCTTCGAAGAAATCCAGAACCATCCATGG
ATGCAAGATGTTCTCCTGCCCCAGGAAACTGCTGAGATCCACCTCCACAGCCTGTCGCCG
GGGCCCAGCAAATAG

# Drug_Target_26_General_Function:
Involved in protein kinase activity

# Drug_Target_26_General_References:
10664448	Koike N, Maita H, Taira T, Ariga H, Iguchi-Ariga SM: Identification of heterochromatin protein 1 (HP1) as a phosphorylation target by Pim-1 kinase and the effect of phosphorylation on the transcriptional repression function of HP1(1). FEBS Lett. 2000 Feb 4;467(1):17-21.
11460166	Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, Kuppers R, Dalla-Favera R: Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001 Jul 19;412(6844):341-6.
12680209	Ionov Y, Le X, Tunquist BJ, Sweetenham J, Sachs T, Ryder J, Johnson T, Lilly MB, Kraft AS: Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res. 2003 Jan-Feb;23(1A):167-78.
2205533	Reeves R, Spies GA, Kiefer M, Barr PJ, Power M: Primary structure of the putative human oncogene, pim-1. Gene. 1990 Jun 15;90(2):303-7.
2837645	Telerman A, Amson R, Zakut-Houri R, Givol D: Identification of the human pim-1 gene product as a 33-kilodalton cytoplasmic protein with tyrosine kinase activity. Mol Cell Biol. 1988 Apr;8(4):1498-503.
3329709	Domen J, Von Lindern M, Hermans A, Breuer M, Grosveld G, Berns A: Comparison of the human and mouse PIM-1 cDNAs: nucleotide sequence and immunological identification of the in vitro synthesized PIM-1 protein. Oncogene Res. 1987 Jun;1(1):103-12.
3429489	Meeker TC, Nagarajan L, ar-Rushdi A, Croce CM: Cloning and characterization of the human PIM-1 gene: a putative oncogene related to the protein kinases. J Cell Biochem. 1987 Oct;35(2):105-12.
3475233	Zakut-Houri R, Hazum S, Givol D, Telerman A: The cDNA sequence and gene analysis of the human pim oncogene. Gene. 1987;54(1):105-11.

# Drug_Target_26_HGNC_ID:
HGNC:8986

# Drug_Target_26_HPRD_ID:
01292

# Drug_Target_26_ID:
2347

# Drug_Target_26_Locus:
6p21.2

# Drug_Target_26_Molecular_Weight:
45413

# Drug_Target_26_Name:
Proto-oncogene serine/threonine-protein kinase Pim-1

# Drug_Target_26_Number_of_Residues:
404

# Drug_Target_26_PDB_ID:
1XWS

# Drug_Target_26_Pathway:
Not Available

# Drug_Target_26_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_26_Protein_Sequence:
>Proto-oncogene serine/threonine-protein kinase Pim-1
MPHEPHEPLTPPFSALPDPAGAPSRRQSRQRPQLSSDSPSAFRASRSHSRNATRSHSHSH
SPRHSLRHSPGSGSCGSSSGHRPCADILEVGMLLSKINSLAHLRAAPCNDLHATKLAPGK
EKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPME
VVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFW
QVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSP
PEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRW
CLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSK

# Drug_Target_26_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_26_Signals:
None

# Drug_Target_26_Specific_Function:
Plays a role in signal transduction in blood cells. Contributes to both cell proliferation and survival and thus provide a selective advantage in tumorigenesis. May affect the structure or silencing of chromatin by phosphorylating HP1 gamma/CBX3

# Drug_Target_26_SwissProt_ID:
P11309

# Drug_Target_26_SwissProt_Name:
PIM1_HUMAN

# Drug_Target_26_Synonyms:
EC 2.7.11.1

# Drug_Target_26_Theoretical_pI:
7.01

# Drug_Target_26_Transmembrane_Regions:
None

# Drug_Target_27_Cellular_Location:
Not Available

# Drug_Target_27_Chromosome_Location:
Not Available

# Drug_Target_27_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_27_Essentiality:
Non-Essential

# Drug_Target_27_GenAtlas_ID:
Not Available

# Drug_Target_27_GenBank_ID_Gene:
U09771

# Drug_Target_27_GenBank_ID_Protein:
493083

# Drug_Target_27_GeneCard_ID:
Not Available

# Drug_Target_27_Gene_Name:
dhaK

# Drug_Target_27_Gene_Sequence:
>1659 bp
TTAGCCCAGCTCACTCTCCGCTAGCGCTTTAAACACCATCGCTAGGCGCTGCGCGCCGGG
GTCCATATTTCCGAGCAGGCTTTCGCTGCTCAGATACGATGCGCGACCCGCATTGGCTTT
GCTCGACAAACAGGTTCGTTCGGCTCCCGCTTGCGCGGCGTCGAATGCGGCCTGCAGATT
TTTCGGCTGTGCGAGCAGCGAGGTCAGGGCCGGTTGCAGCGCATCAATCATCGTGCGATC
GCCTTCGTCTGCGCCGCCGTAGAACTTCATCTGCGCCAGCCCCGTATTTAGCGCTTCGAC
AACGTTAGCGCCCTGTTCCAGTTTCTGCCCGGCGGCGGTAAAGAAGATTGACATCAGCAC
ACCGCTGGAACCGCCCATCACCACGGTCAGACGTTCGCCAATCAGCGCGAACAGCGTGGC
AAGGTTATTCAGCGGCAGCTGCTGGCGATGCAGCAGGCTGGCAATTTCACGCGCCGCGGC
GGCAAAGGTCGAACCGGTATCGCCATCGCCGACTTTGGCGTCCAGCGCATTCAGATGAGT
CTCCAGATCGGAAAGGGTTGCGGTGACCAGCTCCACAATCCCGGCCACCAGGGCGTTTGC
CGAAGGCTGGAATTCCACGCGGGCGCTAGCGTGAGATGACACTACGCAGGTGATTTCACG
CGGTGGGACCGGCGTCGGCCAGTTGCTGGTTTCCACTTCGGTGAGCAGTGCTTTTTCGAT
GCTCTCTTCCAGCACGATGGCCGTCAGTGAGAAGCCTTTCATATCCAGCGCGGTGACCAG
CGAGGCCGGGCCAATTAGCCAGTCGATACGCGAGTGCAGCGGGCTGCTGGCGAGTTCGCG
GGTGATGATGGCCATTTCGGCCACGGAAACGCCGCCAAGATTATTAATCATCACCGCCAG
ACGACCGGTTTCAGGCAGGGCGGCCAGCAGTTTATCCACCATCAGGTTTACCACTTGCGC
ACTGTTTTGGGTGTCGATAACCGATGCGCCTGGTTCGCCGTGAATTCCCATACCCAGCTC
CGCATGACCCGGATGATGACGAGGGGCTGCGTCGGTTTCTTGCGGCAGATGACAGCTGGA
AAGCGCTACGCCCAGGCTAAAGGTGTTGCTGGCTGCGTACTGCGCTTCACGCAGGACGGT
GGCGAGGTTATAGCCGCGTTCGGCAAAATAGCCTGCGATTTTATGCACCAGGATAGTTCC
CGCAATGCCACGTGGGTGTTTGTTATCCGGCAGGGAGATGTCGTCGCCGACAATCAGCAT
TTCAACGTTATAGCCAAGGCGACGCGCCTTCTCGGCGGCGAGACCGAAATTAAGACGGTC
ACCGGTGTAGTTTTTCACAATCAACAAACAGCCAGCCTCACCGGTCACCGCCTGAATCGC
GGTCAGTACAGCATCCACGCTCGGGGAGGCGAAAACGTCGCCGCAGACCGCAGCGGTTAG
CATGCCTTTACCGATAAACCCAACGTGCGCGGGTTCGTGTCCCGAACCGCCGCCGGAAAT
GACCGCTACGTTATTTTTATTAAGGTCACGACGGACCACGATGCGAATGGCCGGATCGCT
TTCCAGACGCGCCAGGTTATTCCATGGGCTGGCGATAATCGCCCCGTCGATGACGTCGCT
CACAAGATGGGTGCGTTGGTTAAAAAAGAATTGAGACAT

# Drug_Target_27_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_27_General_References:
Not Available

# Drug_Target_27_HGNC_ID:
Not Available

# Drug_Target_27_HPRD_ID:
Not Available

# Drug_Target_27_ID:
2397

# Drug_Target_27_Locus:
Not Available

# Drug_Target_27_Molecular_Weight:
57941

# Drug_Target_27_Name:
Dihydroxyacetone kinase

# Drug_Target_27_Number_of_Residues:
552

# Drug_Target_27_PDB_ID:
1UN8

# Drug_Target_27_Pathway:
Not Available

# Drug_Target_27_Pfam_Domain_Function:
PF02733	Dak1
PF02734	Dak2

# Drug_Target_27_Protein_Sequence:
>Dihydroxyacetone kinase
MSQFFFNQRTHLVSDVIDGAIIASPWNNLARLESDPAIRIVVRRDLNKNNVAVISGGGSG
HEPAHVGFIGKGMLTAAVCGDVFASPSVDAVLTAIQAVTGEAGCLLIVKNYTGDRLNFGL
AAEKARRLGYNVEMLIVGDDISLPDNKHPRGIAGTILVHKIAGYFAERGYNLATVLREAQ
YAASNTFSLGVALSSCHLPQETDAAPRHHPGHAELGMGIHGEPGASVIDTQNSAQVVNLM
VDKLLAALPETGRLAVMINNLGGVSVAEMAIITRELASSPLHSRIDWLIGPASLVTALDM
KGFSLTAIVLEESIEKALLTEVETSNWPTPVPPREITCVVSSHASARVEFQPSANALVAG
IVELVTATLSDLETHLNALDAKVGDGDTGSTFAAAAREIASLLHRQQLPLNNLATLFALI
GERLTVVMGGSSGVLMSIFFTAAGQKLEQGANVVEALNTGLAQMKFYGGADEGDRTMIDA
LQPALTSLLAQPKNLQAAFDAAQAGAERTCLSSKANAGRASYLSSESLLGNMDPGAQRLA
MVFKALAESELG

# Drug_Target_27_Reaction:
ATP + glycerone = ADP + glycerone phosphate

# Drug_Target_27_Signals:
None

# Drug_Target_27_Specific_Function:
Catalyzes the phosphorylation of dihydroxyacetone

# Drug_Target_27_SwissProt_ID:
P45510

# Drug_Target_27_SwissProt_Name:
DHAK_CITFR

# Drug_Target_27_Synonyms:
DHA kinase
EC 2.7.1.29
Glycerone kinase

# Drug_Target_27_Theoretical_pI:
5.29

# Drug_Target_27_Transmembrane_Regions:
None

# Drug_Target_28_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_28_Chromosome_Location:
Not Available

# Drug_Target_28_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_28_Essentiality:
Non-Essential

# Drug_Target_28_GenAtlas_ID:
Not Available

# Drug_Target_28_GenBank_ID_Gene:
M36321

# Drug_Target_28_GenBank_ID_Protein:
147780

# Drug_Target_28_GeneCard_ID:
Not Available

# Drug_Target_28_Gene_Name:
coaA

# Drug_Target_28_Gene_Sequence:
>1011 bp
GTGACGCGCCATGGCAAATATCGCTTTGCCGATAGAGCTATGACCGCCAGAAACATGCTT
ATGAGTATAAAAGAGCAAACGTTAATGACGCCTTACCTACAGTTTGACCGCAACCAGTGG
GCAGCTCTGCGTGATTCCGTACCTATGACGTTATCGGAAGATGAGATCGCCCGTCTCAAA
GGTATTAATGAAGATCTCTCGTTAGAAGAAGTTGCCGAGATCTATTTACCTTTGTCACGT
TTGCTGAACTTCTATATAAGCTCGAATCTGCGCCGTCAGGCAGTTCTGGAACAGTTTCTT
GGTACCAACGGGCAACGCATTCCTTACATTATCAGTATTGCTGGCAGTGTCGCGGTGGGG
AAAAGTACAACCGCCCGTGTATTGCAGGCGCTATTAAGCCGTTGGCCGGAACATCGTCGT
GTTGAACTGATCACTACAGATGGCTTCCTTCACCCTAATCAGGTTCTGAAAGAACGTGGT
CTGATGAAGAAGAAAGGCTTCCCGGAATCGTATGATATGCATCGCCTGGTGAAGTTTGTT
TCCGATCTCAAATCCGGCGTGCCAAACGTTACAGCACCTGTTTACTCACATCTTATTTAT
GATGTGATCCCGGATGGAGATAAAACGGTTGTTCAGCCTGATATTTTAATTCTTGAAGGG
TTAAATGTCTTACAGAGCGGGATGGATTATCCACACGATCCACATCATGTATTTGTTTCT
GATTTTGTCGATTTTTCGATATATGTTGATGCACCGGAAGACTTACTTCAGACATGGTAT
ATCAACCGTTTTCTGAAATTCCGCGAAGGGGCTTTTACCGACCCGGATTCCTATTTTCAT
AACTACGCGAAATTAACTAAAGAAGAAGCGATTAAGACTGCCATGACATTGTGGAAAGAG
ATCAACTGGCTGAACTTAAAGCAAAATATTCTACCTACTCGTGAGCGCGCCAGTTTAATC
CTGACGAAAAGTGCTAATCATGCGGTAGAAGAGGTCAGACTACGCAAATAA

# Drug_Target_28_General_Function:
Coenzyme transport and metabolism

# Drug_Target_28_General_References:
1311303	Song WJ, Jackowski S: coaA and rts are allelic and located at kilobase 3532 on the Escherichia coli physical map. J Bacteriol. 1992 Mar;174(5):1705-6.
1328157	Song WJ, Jackowski S: Cloning, sequencing, and expression of the pantothenate kinase (coaA) gene of Escherichia coli. J Bacteriol. 1992 Oct;174(20):6411-7.
3073109	Flamm JA, Friesen JD, Otsuka AJ: The nucleotide sequence of the Escherichia coli rts gene. Gene. 1988 Dec 30;74(2):555-8.
8265357	Blattner FR, Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL: Analysis of the Escherichia coli genome. IV. DNA sequence of the region from 89.2 to 92.8 minutes. Nucleic Acids Res. 1993 Nov 25;21(23):5408-17.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_28_HGNC_ID:
Not Available

# Drug_Target_28_HPRD_ID:
Not Available

# Drug_Target_28_ID:
2371

# Drug_Target_28_Locus:
Not Available

# Drug_Target_28_Molecular_Weight:
36360

# Drug_Target_28_Name:
Pantothenate kinase

# Drug_Target_28_Number_of_Residues:
316

# Drug_Target_28_PDB_ID:
1SQ5

# Drug_Target_28_Pathway:
Not Available

# Drug_Target_28_Pfam_Domain_Function:
PF00485	PRK

# Drug_Target_28_Protein_Sequence:
>Pantothenate kinase
MSIKEQTLMTPYLQFDRNQWAALRDSVPMTLSEDEIARLKGINEDLSLEEVAEIYLPLSR
LLNFYISSNLRRQAVLEQFLGTNGQRIPYIISIAGSVAVGKSTTARVLQALLSRWPEHRR
VELITTDGFLHPNQVLKERGLMKKKGFPESYDMHRLVKFVSDLKSGVPNVTAPVYSHLIY
DVIPDGDKTVVQPDILILEGLNVLQSGMDYPHDPHHVFVSDFVDFSIYVDAPEDLLQTWY
INRFLKFREGAFTDPDSYFHNYAKLTKEEAIKTAMTLWKEINWLNLKQNILPTRERASLI
LTKSANHAVEEVRLRK

# Drug_Target_28_Reaction:
ATP + (R)-pantothenate = ADP + (R)-4'-phosphopantothenate

# Drug_Target_28_Signals:
None

# Drug_Target_28_Specific_Function:
ATP + (R)-pantothenate = ADP + (R)-4'- phosphopantothenate

# Drug_Target_28_SwissProt_ID:
P0A6I3

# Drug_Target_28_SwissProt_Name:
COAA_ECOLI

# Drug_Target_28_Synonyms:
EC 2.7.1.33
Pantothenic acid kinase
Rts protein

# Drug_Target_28_Theoretical_pI:
6.81

# Drug_Target_28_Transmembrane_Regions:
None

# Drug_Target_29_Cellular_Location:
Mitochondrion
mitochondrial outer membrane. Note=Its hydrophobic N-terminal sequence may be involve

# Drug_Target_29_Chromosome_Location:
Not Available

# Drug_Target_29_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_29_Essentiality:
Non-Essential

# Drug_Target_29_GenAtlas_ID:
HK1

# Drug_Target_29_GenBank_ID_Gene:
M75126

# Drug_Target_29_GenBank_ID_Protein:
184021

# Drug_Target_29_GeneCard_ID:
HK1

# Drug_Target_29_Gene_Name:
HK1

# Drug_Target_29_Gene_Sequence:
>2754 bp
ATGATCGCCGCGCAGCTCCTGGCCTATTACTTCACGGAGCTGAAGGATGACCAGGTCAAA
AAGATTGACAAGTATCTGTATGCCATGCGGCTCTCCGATGAAACTCTCATAGATATCATG
ACTCGCTTCAGGAAGGAGATGAAGAATGGCCTCTCCCGGGATTTTAATCCAACAGCCACA
GTCAAGATGTTGCCAACATTCGTAAGGTCCATTCCTGATGGCTCTGAAAAGGGAGATTTC
ATTGCCCTGGATCTTGGTGGGTCTTCCTTTCGAATTCTGCGGGTGCAAGTGAATCATGAG
AAAAACCAGAATGTTCACATGGAGTCCGAGGTTTATGACACCCCAGAGAACATCGTGCAC
GGCAGTGGAAGCCAGCTTTTTGATCATGTTGCTGAGTGCCTGGGAGATTTCATGGAGAAA
AGGAAGATCAAGGACAAGAAGTTACCTGTGGGATTCACGTTTTCTTTTCCTTGCCAACAA
TCCAAAATAGATGAGGCCATCCTGATCACCTGGACAAAGCGATTTAAAGCGAGCGGAGTG
GAAGGAGCAGATGTGGTCAAACTGCTTAACAAAGCCATCAAAAAGCGAGGGGACTATGAT
GCCAACATCGTAGCTGTGGTGAATGACACAGTGGGCACCATGATGACCTGTGGCTATGAC
GACCAGCACTGTGAAGTCGGCCTGATCATCGGCACTGGCACCAATGCTTGCTACATGGAG
GAACTGAGGCACATTGATCTGGTGGAAGGAGACGAGGGGAGGATGTGTATCAATACAGAA
TGGGGAGCCTTTGGAGACGATGGATCATTAGAAGACATCCGGACAGAGTTTGACAGGGAG
ATAGACCGGGGATCCCTCAACCCTGGAAAACAGCTGTTTGAGAAGATGGTCAGTGGCATG
TACTTGGGAGAGCTGGTTCGACTGATCCTAGTCAAGATGGCCAAGGAGGGCCTCTTATTT
GAAGGGCGGATCACCCCGGAGCTGCTCACCCGAGGGAAGTTTAACACCAGTGATGTGTCA
GCCATCGAAAAGAATAAGGAAGGCCTCCACAATGCCAAAGAAATCCTGACCCGCCTGGGA
GTGGAGCCGTCCGATGATGACTGTGTCTCAGTCCAGCACGTTTGCACCATTGTCTCATTT
CGCTCAGCCAACTTGGTGGCTGCCACACTGGGCGCCATCTTGAACCGCCTGCGTGATAAC
AAGGGCACACCCAGGCTGCGGACCACGGTTGGTGTCGACGGATCTCTTTACAAGACGCAC
CCACAGTATTCCCGGCGTTTCCACAAGACTCTAAGGCGCTTGGTGCCAGACTCCGATGTG
CGCTTCCTCCTCTCGGAGAGTGGCAGCGGCAAGGGGGCTGCCATGGTGACGGCGGTGGCC
TACCGCTTGGCCGAGCAGCACCGGCAGATAGAGGAGACCCTGGCTCATTTCCACCTCACC
AAAGACATGCTGCTGGAGGTGAAGAAGAGGATGCGGGCCGAGATGGAGCTGGGGCTGAGG
AAGCAGACGCACAACAATGCCGTGGTTAAGATGCTGCCCTCCTTCGTCCGGAGAACTCCC
GACGGGACCGAGAATGGTGACTTCTTGGCCCTGGATCTTGGAGGAACCAATTTCCGTGTG
CTGCTGGTGAAAATCCGTAGTGGGAAAAAGAGAACGGTGGAAATGCACAACAAGATCTAC
GCCATTCCTATTGAAATCATGCAGGGCACTGGGGAAGAGCTGTTTGATCACATTGTCTCC
TGCATCTCTGACTTCTTGGACTACATGGGGATCAAAGGCCCCAGGATGCCTCTGGGCTTC
ACGTTCTCATTTCCCTGCCAGCAGACGAGTCTGGACGCGGGAATCTTGATCACGTGGACA
AAGGGTTTTAAGGCAACAGACTGCGTGGGCCACGATGTAGTCACCTTACTAAGGGATGCG
ATAAAAAGGAGAGAGGAATTTGACCTGGACGTGGTGGCTGTGGTCAACGACACAGTGGGC
ACCATGATGACCTGTGCTTATGAGGAGCCCACCTGTGAGGTTGGACTCATTGTTGGGACC
GGCAGCAATGCCTGCTACATGGAGGAGATGAAGAACGTGGAGATGGTGGAGGGGGACCAG
GGGCAGATGTGCATCAACATGGAGTGGGGGGCCTTTGGGGACAACGGGTGTCTGGATGAT
ATCAGGACACACTACGACAGACTGGTGAACGAATATTCCCTAAATGCTGGGAAACAAAGG
TATGAGAAGATGATCAGTGGTATGTACCTGGGTGAAATCGTCCGCAACATCTTAATCGAC
TTCACCAAGAAGGGATTCCTCTTCCGAGGGCAGATCTCTGAGACGATGAAGACCCGGGGC
ATCTTTGAGACCAAGTTTCTCTCTCAGATCGAGAGTGACCGATTAGCACTGCTCCAGGTC
CGGGCTATCCTCCAGCAGCTAGGTCTGAATAGCACCTGCGATGACAGTATCCTCGTCAAG
ACAGTGTGCGGGGTGGTGTCCAGGAGGGCCGCACAGCTGTGTGGCGCAGGCATGGCTGCG
GTTGTGGATAAGATCCGCGAGAACAGAGGACTGGACCGTCTGAATGTGACTGTGGGAGTG
GACGGGACACTCTACAAGCTTCATCCACACTTCTCCAGAATCATGCACCAGACGGTGAAG
GAACTGTCACCAAAATGTAACGTGTCCTTCCTCCTGTCTGAGGATGGCAGCGGCAAGGGG
GCCGCCCTCATCACGGCCGTGGGCGTGCGGTTACGCACAGAGGCAAGCAGCTAA

# Drug_Target_29_General_Function:
Involved in hexokinase activity

# Drug_Target_29_General_References:
10574795	Rosano C, Sabini E, Rizzi M, Deriu D, Murshudov G, Bianchi M, Serafini G, Magnani M, Bolognesi M: Binding of non-catalytic ATP to human hexokinase I highlights the structural components for enzyme-membrane association control. Structure. 1999 Nov 15;7(11):1427-37.
10686099	Aleshin AE, Kirby C, Liu X, Bourenkov GP, Bartunik HD, Fromm HJ, Honzatko RB: Crystal structures of mutant monomeric hexokinase I reveal multiple ADP binding sites and conformational changes relevant to allosteric regulation. J Mol Biol. 2000 Mar 3;296(4):1001-15.
10978502	Andreoni F, Ruzzo A, Magnani M: Structure of the 5' region of the human hexokinase type I (HKI) gene and identification of an additional testis-specific HKI mRNA. Biochim Biophys Acta. 2000 Sep 7;1493(1-2):19-26.
1637300	Magnani M, Bianchi M, Casabianca A, Stocchi V, Daniele A, Altruda F, Ferrone M, Silengo L: A recombinant human 'mini'-hexokinase is catalytically active and regulated by hexose 6-phosphates. Biochem J. 1992 Jul 1;285 ( Pt 1):193-9.
1985912	Magnani M, Serafini G, Bianchi M, Casabianca A, Stocchi V: Human hexokinase type I microheterogeneity is due to different amino-terminal sequences. J Biol Chem. 1991 Jan 5;266(1):502-5.
3207429	Nishi S, Seino S, Bell GI: Human hexokinase: sequences of amino- and carboxyl-terminal halves are homologous. Biochem Biophys Res Commun. 1988 Dec 30;157(3):937-43.
7655856	Bianchi M, Magnani M: Hexokinase mutations that produce nonspherocytic hemolytic anemia. Blood Cells Mol Dis. 1995;21(1):2-8.
8706938	Aleshin AE, Zeng C, Fromm HJ, Honzatko RB: Crystallization and preliminary X-ray analysis of human brain hexokinase. FEBS Lett. 1996 Aug 5;391(1-2):9-10.
9028305	Murakami K, Piomelli S: Identification of the cDNA for human red blood cell-specific hexokinase isozyme. Blood. 1997 Feb 1;89(3):762-6.
9493266	Aleshin AE, Zeng C, Bourenkov GP, Bartunik HD, Fromm HJ, Honzatko RB: The mechanism of regulation of hexokinase: new insights from the crystal structure of recombinant human brain hexokinase complexed with glucose and glucose-6-phosphate. Structure. 1998 Jan 15;6(1):39-50.
9531504	Ruzzo A, Andreoni F, Magnani M: Structure of the human hexokinase type I gene and nucleotide sequence of the 5' flanking region. Biochem J. 1998 Apr 15;331 ( Pt 2):607-13.
9735292	Aleshin AE, Zeng C, Bartunik HD, Fromm HJ, Honzatko RB: Regulation of hexokinase I: crystal structure of recombinant human brain hexokinase complexed with glucose and phosphate. J Mol Biol. 1998 Sep 18;282(2):345-57.

# Drug_Target_29_HGNC_ID:
HGNC:4922

# Drug_Target_29_HPRD_ID:
00809

# Drug_Target_29_ID:
1881

# Drug_Target_29_Locus:
10q22

# Drug_Target_29_Molecular_Weight:
102487

# Drug_Target_29_Name:
Hexokinase-1

# Drug_Target_29_Number_of_Residues:
917

# Drug_Target_29_PDB_ID:
1HKB

# Drug_Target_29_Pathway:
Not Available

# Drug_Target_29_Pfam_Domain_Function:
PF00349	Hexokinase_1
PF03727	Hexokinase_2

# Drug_Target_29_Protein_Sequence:
>Hexokinase-1
MIAAQLLAYYFTELKDDQVKKIDKYLYAMRLSDETLIDIMTRFRKEMKNGLSRDFNPTAT
VKMLPTFVRSIPDGSEKGDFIALDLGGSSFRILRVQVNHEKNQNVHMESEVYDTPENIVH
GSGSQLFDHVAECLGDFMEKRKIKDKKLPVGFTFSFPCQQSKIDEAILITWTKRFKASGV
EGADVVKLLNKAIKKRGDYDANIVAVVNDTVGTMMTCGYDDQHCEVGLIIGTGTNACYME
ELRHIDLVEGDEGRMCINTEWGAFGDDGSLEDIRTEFDREIDRGSLNPGKQLFEKMVSGM
YLGELVRLILVKMAKEGLLFEGRITPELLTRGKFNTSDVSAIEKNKEGLHNAKEILTRLG
VEPSDDDCVSVQHVCTIVSFRSANLVAATLGAILNRLRDNKGTPRLRTTVGVDGSLYKTH
PQYSRRFHKTLRRLVPDSDVRFLLSESGSGKGAAMVTAVAYRLAEQHRQIEETLAHFHLT
KDMLLEVKKRMRAEMELGLRKQTHNNAVVKMLPSFVRRTPDGTENGDFLALDLGGTNFRV
LLVKIRSGKKRTVEMHNKIYAIPIEIMQGTGEELFDHIVSCISDFLDYMGIKGPRMPLGF
TFSFPCQQTSLDAGILITWTKGFKATDCVGHDVVTLLRDAIKRREEFDLDVVAVVNDTVG
TMMTCAYEEPTCEVGLIVGTGSNACYMEEMKNVEMVEGDQGQMCINMEWGAFGDNGCLDD
IRTHYDRLVDEYSLNAGKQRYEKMISGMYLGEIVRNILIDFTKKGFLFRGQISETLKTRG
IFETKFLSQIESDRLALLQVRAILQQLGLNSTCDDSILVKTVCGVVSRRAAQLCGAGMAA
VVDKIRENRGLDRLNVTVGVDGTLYKLHPHFSRIMHQTVKELSPKCNVSFLLSEDGSGKG
AALITAVGVRLRTEASS

# Drug_Target_29_Reaction:
ATP + D-hexose = ADP + D-hexose 6-phosphate

# Drug_Target_29_Signals:
None

# Drug_Target_29_Specific_Function:
ATP + D-hexose = ADP + D-hexose 6-phosphate

# Drug_Target_29_SwissProt_ID:
P19367

# Drug_Target_29_SwissProt_Name:
HXK1_HUMAN

# Drug_Target_29_Synonyms:
Brain form hexokinase
EC 2.7.1.1
HK I
Hexokinase type I

# Drug_Target_29_Theoretical_pI:
6.78

# Drug_Target_29_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
Not Available

# Drug_Target_2_GenBank_ID_Gene:
Not Available

# Drug_Target_2_GenBank_ID_Protein:
Not Available

# Drug_Target_2_GeneCard_ID:
Not Available

# Drug_Target_2_Gene_Name:
EPHB2

# Drug_Target_2_Gene_Sequence:
Not Available

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
Not Available

# Drug_Target_2_HGNC_ID:
Not Available

# Drug_Target_2_HPRD_ID:
Not Available

# Drug_Target_2_ID:
7059

# Drug_Target_2_Locus:
Not Available

# Drug_Target_2_Molecular_Weight:
Not Available

# Drug_Target_2_Name:
Ephrin type-B receptor 2

# Drug_Target_2_Number_of_Residues:
0

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
Not Available

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
Not Available

# Drug_Target_2_Specific_Function:
Not Available

# Drug_Target_2_SwissProt_ID:
P29323

# Drug_Target_2_SwissProt_Name:
EPHB2_HUMAN

# Drug_Target_2_Synonyms:
Not Available

# Drug_Target_2_Theoretical_pI:
Not Available

# Drug_Target_2_Transmembrane_Regions:
Not Available

# Drug_Target_30_Cellular_Location:
Not Available

# Drug_Target_30_Chromosome_Location:
Not Available

# Drug_Target_30_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_30_Essentiality:
Non-Essential

# Drug_Target_30_GenAtlas_ID:
Not Available

# Drug_Target_30_GenBank_ID_Gene:
L20897

# Drug_Target_30_GenBank_ID_Protein:
304887

# Drug_Target_30_GeneCard_ID:
Not Available

# Drug_Target_30_Gene_Name:
purT

# Drug_Target_30_Gene_Sequence:
>1179 bp
ATGACGTTATTAGGCACTGCGCTGCGTCCGGCAGCAACTCGCGTGATGTTATTAGGCTCC
GGTGAACTGGGTAAAGAAGTGGCAATCGAGTGTCAGCGTCTCGGCGTAGAGGTGATTGCC
GTCGATCGCTATGCCGACGCACCAGCCATGCATGTCGCGCATCGCTCCCATGTCATTAAT
ATGCTTGATGGTGATGCATTACGCCGTGTGGTTGAACTGGAAAAACCACATTATATCGTG
CCGGAGATCGAAGCTATTGCCACCGATATGCTGATCCAACTTGAAGAGGAAGGACTGAAT
GTTGTCCCCTGCGCTCGCGCAACGAAATTAACGATGAATCGCGAGGGTATCCGTCGCCTG
GCGGCAGAAGAGCTGCAGCTGCCCACTTCCACTTATCGTTTTGCCGATAGCGAAAGCCTT
TTCCGCGAGGCGGTTGCTGACATTGGCTATCCCTGCATTGTAAAACCGGTGATGAGCTCT
TCCGGCAAGGGGCAGACGTTTATTCGTTCTGCAGAGCAACTTGCTCAGGCATGGAAGTAC
GCTCAGCAAGGCGGTCGCGCCGGAGCGGGCCGCGTAATTGTTGAAGGCGTCGTTAAGTTT
GACTTCGAAATTACCCTGCTAACCGTCAGCGCGGTGGATGGCGTCCATTTCTGTGCACCA
GTAGGTCATCGCCAGGAAGATGGCGACTACCGTGAATCCTGGCAACCACAGCAAATGAGC
CCGCTTGCCCTTGAACGTGCGCAGGAGATTGCCCGTAAAGTGGTGCTGGCACTGGGCGGT
TATGGGTTGTTTGGTGTCGAGCTATTTGTCTGTGGTGATGAGGTGATTTTCAGTGAGGTC
TCCCCTCGTCCACATGATACCGGGATGGTGACGTTAATTTCTCAAGATCTCTCAGAGTTT
GCCCTGCATGTACGTGCCTTCCTCGGACTTCCGGTTGGCGGGATCCGTCAGTATGGTCCT
GCAGCTTCTGCCGTTATTCTGCCACAACTGACCAGTCAGAATGTCACGTTTGATAATGTG
CAGAATGCCGTAGGCGCAGATTTGCAGATTCGTTTATTTGGTAAGCCGGAAATTGATGGC
AGCCGTCGTCTGGGGGTGGCACTGGCTACTGCAGAGAGTGTTGTTGACGCCATTGAACGC
GCGAAGCACGCCGCCGGACAGGTAAAAGTACAGGGTTAA

# Drug_Target_30_General_Function:
Nucleotide transport and metabolism

# Drug_Target_30_General_References:
10913290	Thoden JB, Firestine S, Nixon A, Benkovic SJ, Holden HM: Molecular structure of Escherichia coli PurT-encoded glycinamide ribonucleotide transformylase. Biochemistry. 2000 Aug 1;39(30):8791-802.
8117714	Marolewski A, Smith JM, Benkovic SJ: Cloning and characterization of a new purine biosynthetic enzyme: a non-folate glycinamide ribonucleotide transformylase from E. coli. Biochemistry. 1994 Mar 8;33(9):2531-7.
9097040	Itoh T, Aiba H, Baba T, Hayashi K, Inada T, Isono K, Kasai H, Kimura S, Kitakawa M, Kitagawa M, Makino K, Miki T, Mizobuchi K, Mori H, Mori T, Motomura K, Nakade S, Nakamura Y, Nashimoto H, Nishio Y, Oshima T, Saito N, Sampei G, Seki Y, Horiuchi T, et al.: A 460-kb DNA sequence of the Escherichia coli K-12 genome corresponding to the 40.1-50.0 min region on the linkage map. DNA Res. 1996 Dec 31;3(6):379-92.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_30_HGNC_ID:
Not Available

# Drug_Target_30_HPRD_ID:
Not Available

# Drug_Target_30_ID:
2817

# Drug_Target_30_Locus:
Not Available

# Drug_Target_30_Molecular_Weight:
42434

# Drug_Target_30_Name:
Phosphoribosylglycinamide formyltransferase 2

# Drug_Target_30_Number_of_Residues:
392

# Drug_Target_30_PDB_ID:
1EZ1

# Drug_Target_30_Pathway:
Not Available

# Drug_Target_30_Pfam_Domain_Function:
PF02222	ATP-grasp

# Drug_Target_30_Protein_Sequence:
>Phosphoribosylglycinamide formyltransferase 2
MTLLGTALRPAATRVMLLGSGELGKEVAIECQRLGVEVIAVDRYADAPAMHVAHRSHVIN
MLDGDALRRVVELEKPHYIVPEIEAIATDMLIQLEEEGLNVVPCARATKLTMNREGIRRL
AAEELQLPTSTYRFADSESLFREAVADIGYPCIVKPVMSSSGKGQTFIRSAEQLAQAWKY
AQQGGRAGAGRVIVEGVVKFDFEITLLTVSAVDGVHFCAPVGHRQEDGDYRESWQPQQMS
PLALERAQEIARKVVLALGGYGLFGVELFVCGDEVIFSEVSPRPHDTGMVTLISQDLSEF
ALHVRAFLGLPVGGIRQYGPAASAVILPQLTSQNVTFDNVQNAVGADLQIRLFGKPEIDG
SRRLGVALATAESVVDAIERAKHAAGQVKVQG

# Drug_Target_30_Reaction:
Not Available

# Drug_Target_30_Signals:
None

# Drug_Target_30_Specific_Function:
Catalyzes two reactions:the first one is the production of beta-formyl glycinamide ribonucleotide (GAR) from formate, ATP and beta GAR; the second, a side reaction, is the production of acetyl phosphate and ADP from acetate and ATP

# Drug_Target_30_SwissProt_ID:
P33221

# Drug_Target_30_SwissProt_Name:
PURT_ECOLI

# Drug_Target_30_Synonyms:
5'-phosphoribosylglycinamide transformylase 2
EC 2.1.2.-
Formate-dependent GAR transformylase
GAR transformylase 2
GART 2

# Drug_Target_30_Theoretical_pI:
5.46

# Drug_Target_30_Transmembrane_Regions:
None

# Drug_Target_31_Cellular_Location:
Cytoplasm. Cell membrane
cytoplasmic side. Present in lipid rafts in an unactive form
lipid-anchor

# Drug_Target_31_Chromosome_Location:
Not Available

# Drug_Target_31_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_31_Essentiality:
Non-Essential

# Drug_Target_31_GenAtlas_ID:
LCK

# Drug_Target_31_GenBank_ID_Gene:
X05027

# Drug_Target_31_GenBank_ID_Protein:
36808

# Drug_Target_31_GeneCard_ID:
LCK

# Drug_Target_31_Gene_Name:
LCK

# Drug_Target_31_Gene_Sequence:
>1524 bp
ATGGGCTGTGGCTGCAGCTCACACCCGGAAGATGACTGGATGGAAAACATCGATGTGTGT
GAGAACTGCCATTATCCCATAGTCCCACTGGATGGCAAGGGCACGCTGCTCATCCGAAAT
GGCTCTGAGGTGCGGGACCCACTGGTTACCTACGAAGGCTCCAATCCGCCGGCTTCCCCA
CTGCAAGACAACCTGGTTATCGCTCTGCACAGCTATGAGCCCTCTCACGACGGAGATCTG
GGCTTTGAGAAGGGGGAACAGCTCCGCATCCTGGAGCAGAGCGGCGAGTGGTGGAAGGCG
CAGTCCCTGACCACGGGCCAGGAAGGCTTCATCCCCTTCAATTTTGTGGCCAAAGCGAAC
AGCCTGGAGCCCGAACCCTGGTTCTTCAAGAACCTGAGCCGCAAGGACGCGGAGCGGCAG
CTCCTGGCGCCCGGGAACACTCACGGCTCCTTCCTCATCCGGGAGAGCGAGAGCACCGCG
GGATCGTTTTCACTGTCGGTCCGGGACTTCGACCAGAACCAGGGAGAGGTGGTGAAACAT
TACAAGATCCGTAATCTGGACAACGGTGGCTTCTACATCTCCCCTCGAATCACTTTTCCC
GGCCTGCATGAACTGGCCTCCGCCATTACACCAATCGCTTCAGATGGGCTGTGCACACGG
TTGAGCCGCCCCTGCCAGACCCAGAAGCCCCAGAAGCCGTGGTGGGAGGACGAGTGGGAG
GTTCCCAGGGAGACGCTGAAGCTGGTGGAGCGGCTGGGGGCTGGACAGTTCGGGAGGTGT
GGATGGGGTACTACAACGGGCACAACGAAGGTGGCGGTGAAGAGCCTGAAGCAGGGCAGC
ATGTCCGCCGGACGCCTTCCTGCCGAGGCCAACCTCATGAAGCAGCTGCAACACCAGCGG
CTGGTTCGGCTCTACGCTGTGGTCACCCAGGAGCCCATCTACATCATCACTGAATACATG
GAGAATGGGAGTCTAGTGGATTTTCTCAAGACCCCTTCAGGCATCAAGTTGACCATCAAC
AAACTCCTGGACATGGCAGCCCAAATTGCAGAAGGCATGGCATTCATTGAAGAGCGGAAT
TATATTCATCGTGACCTTCGGGCTGCCAACATTCTGGTGTCTGACACCCTGAGCTGCAAG
ATTGCAGACTTTGGCCTAGCACGCCTCATTGAGGACAACGAGTACACAGCCAGGGAGGGG
GCCAAGTTTCCCATTAAGTGGACAGCGCCAGAAGCCATTAACTACGGGACATTCACCATC
AAGTCAGATGTGTGGTCTTTTGGGATCCTGCTGACGGAAATTGTCACCCACGGCCGCATC
CCTTACCCAGGGATGACCAACCCGGAGGTGATTCAGAACCTGGAGCGAGGCTACCGCATG
GTGCGCCCTGACAACTGTCCAGAGGAGCTGTACCAACTCATGAGGCTGTGCTGGAAGGAG
CGCCCAGAGGACCGGCCCACCTTTGACTACCTGCGCAGTGTGCTGGAGGACTTCTTCACG
GCCACAGAGGGCAGTACAGCCTAG

# Drug_Target_31_General_Function:
Involved in protein kinase activity

# Drug_Target_31_General_References:
11009097	Boncristiano M, Majolini MB, D'Elios MM, Pacini S, Valensin S, Ulivieri C, Amedei A, Falini B, Del Prete G, Telford JL, Baldari CT: Defective recruitment and activation of ZAP-70 in common variable immunodeficiency patients with T cell defects. Eur J Immunol. 2000 Sep;30(9):2632-8.
11840567	Harris RA, Yang A, Stein RC, Lucy K, Brusten L, Herath A, Parekh R, Waterfield MD, O'Hare MJ, Neville MA, Page MJ, Zvelebil MJ: Cluster analysis of an extensive human breast cancer cell line protein expression map database. Proteomics. 2002 Feb;2(2):212-23.
1639064	Bergman M, Mustelin T, Oetken C, Partanen J, Flint NA, Amrein KE, Autero M, Burn P, Alitalo K: The human p50csk tyrosine kinase phosphorylates p56lck at Tyr-505 and down regulates its catalytic activity. EMBO J. 1992 Aug;11(8):2919-24.
2558056	Rouer E, Van Huynh T, Lavareda de Souza S, Lang MC, Fischer S, Benarous R: Structure of the human lck gene: differences in genomic organisation within src-related genes affect only N-terminal exons. Gene. 1989 Dec 7;84(1):105-13.
2787474	Takadera T, Leung S, Gernone A, Koga Y, Takihara Y, Miyamoto NG, Mak TW: Structure of the two promoters of the human lck gene: differential accumulation of two classes of lck transcripts in T cells. Mol Cell Biol. 1989 May;9(5):2173-80.
2835736	Veillette A, Foss FM, Sausville EA, Bolen JB, Rosen N: Expression of the lck tyrosine kinase gene in human colon carcinoma and other non-lymphoid human tumor cell lines. Oncogene Res. 1987 Sep-Oct;1(4):357-74.
2850479	Garvin AM, Pawar S, Marth JD, Perlmutter RM: Structure of the murine lck gene and its rearrangement in a murine lymphoma cell line. Mol Cell Biol. 1988 Aug;8(8):3058-64.
3265417	Perlmutter RM, Marth JD, Lewis DB, Peet R, Ziegler SF, Wilson CB: Structure and expression of lck transcripts in human lymphoid cells. J Cell Biochem. 1988 Oct;38(2):117-26.
3489486	Trevillyan JM, Lin Y, Chen SJ, Phillips CA, Canna C, Linna TJ: Human T lymphocytes express a protein-tyrosine kinase homologous to p56LSTRA. Biochim Biophys Acta. 1986 Oct 10;888(3):286-95.
3493153	Koga Y, Caccia N, Toyonaga B, Spolski R, Yanagi Y, Yoshikai Y, Mak TW: A human T cell-specific cDNA clone (YT16) encodes a protein with extensive homology to a family of protein-tyrosine kinases. Eur J Immunol. 1986 Dec;16(12):1643-6.
7495859	Vogel LB, Arthur R, Fujita DJ: An aberrant lck mRNA in two human T-cell lines. Biochim Biophys Acta. 1995 Nov 7;1264(2):168-72.
7504174	Vogel LB, Fujita DJ: The SH3 domain of p56lck is involved in binding to phosphatidylinositol 3'-kinase from T lymphocytes. Mol Cell Biol. 1993 Dec;13(12):7408-17.
7512222	Eck MJ, Atwell SK, Shoelson SE, Harrison SC: Structure of the regulatory domains of the Src-family tyrosine kinase Lck. Nature. 1994 Apr 21;368(6473):764-9.
7532720	Mikol V, Baumann G, Keller TH, Manning U, Zurini MG: The crystal structures of the SH2 domain of p56lck complexed with two phosphonopeptides suggest a gated peptide binding site. J Mol Biol. 1995 Feb 17;246(2):344-55.
7852312	Vogel LB, Fujita DJ: p70 phosphorylation and binding to p56lck is an early event in interleukin-2-induced onset of cell cycle progression in T-lymphocytes. J Biol Chem. 1995 Feb 10;270(6):2506-11.
8139546	Wright DD, Sefton BM, Kamps MP: Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia. Mol Cell Biol. 1994 Apr;14(4):2429-37.
8604142	Tong L, Warren TC, King J, Betageri R, Rose J, Jakes S: Crystal structures of the human p56lck SH2 domain in complex with two short phosphotyrosyl peptides at 1.0 A and 1.8 A resolution. J Mol Biol. 1996 Mar 1;256(3):601-10.
8794306	Greenway A, Azad A, Mills J, McPhee D: Human immunodeficiency virus type 1 Nef binds directly to Lck and mitogen-activated protein kinase, inhibiting kinase activity. J Virol. 1996 Oct;70(10):6701-8.
8945479	Yamaguchi H, Hendrickson WA: Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation. Nature. 1996 Dec 5;384(6608):484-9.
9685372	Tong L, Warren TC, Lukas S, Schembri-King J, Betageri R, Proudfoot JR, Jakes S: Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in SH2 domain binding. J Biol Chem. 1998 Aug 7;273(32):20238-42.

# Drug_Target_31_HGNC_ID:
HGNC:6524

# Drug_Target_31_HPRD_ID:
01080

# Drug_Target_31_ID:
937

# Drug_Target_31_Locus:
1p34.3

# Drug_Target_31_Molecular_Weight:
57870

# Drug_Target_31_Name:
Proto-oncogene tyrosine-protein kinase LCK

# Drug_Target_31_Number_of_Residues:
508

# Drug_Target_31_PDB_ID:
Not Available

# Drug_Target_31_Pathway:
Not Available

# Drug_Target_31_Pfam_Domain_Function:
PF00017	SH2
PF00018	SH3_1
PF07714	Pkinase_Tyr

# Drug_Target_31_Protein_Sequence:
>Proto-oncogene tyrosine-protein kinase LCK
GCGCSSHPEDDWMENIDVCENCHYPIVPLDGKGTLLIRNGSEVRDPLVTYEGSNPPASPL
QDNLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKANS
LEPEPWFFKNLSRKDAERQLLAPGNTHGSFLIRESESTAGSFSLSVRDFDQNQGEVVKHY
KIRNLDNGGFYISPRITFPGLHELVRHYTNASDGLCTRLSRPCQTQKPQKPWWEDEWEVP
RETLKLVERLGAGQFGEVWMGYYNGHTKVAVKSLKQGSMSPDAFLAEANLMKQLQHQRLV
RLYAVVTQEPIYIITEYMENGSLVDFLKTPSGIKLTINKLLDMAAQIAEGMAFIEERNYI
HRDLRAANILVSDTLSCKIADFGLARLIEDNEYTAREGAKFPIKWTAPEAINYGTFTIKS
DVWSFGILLTEIVTHGRIPYPGMTNPEVIQNLERGYRMVRPDNCPEELYQLMRLCWKERP
EDRPTFDYLRSVLEDFFTATEGQYQPQP

# Drug_Target_31_Reaction:
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate

# Drug_Target_31_Signals:
None

# Drug_Target_31_Specific_Function:
Tyrosine kinase that plays an essential role for the selection and maturation of developing T-cell in the thymus and in mature T-cell function. Is constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors and plays a key role in T-cell antigen receptor(TCR)-linked signal transduction pathways. Association of the TCR with a peptide antigen-bound MHC complex facilitates the interaction of CD4 and CD8 with MHC class II and class I molecules, respectively, and thereby recruits the associated LCK to the vicinity of the TCR/CD3 complex. LCK then phosphorylates tyrosines residues within the immunoreceptor tyrosines-based activation motifs (ITAMs) in the cytoplasmic tails of the TCRgamma chains and CD3 subunits, initiating the TCR/CD3 signaling pathway. In addition, contributes to signaling by other receptor molecules. Associates directly with the cytoplasmic tail of CD2, and upon engagement of the CD2 molecule, LCK undergoes hyperphosphorylation and activation. Also plays a role in the IL2 receptor-linked signaling pathway that controls T-cell proliferative response. Binding of IL2 to its receptor results in increased activity of LCK. Is expressed at all stages of thymocyte development and is required for the regulation of maturation events that are governed by both pre-TCR and mature alpha beta TCR

# Drug_Target_31_SwissProt_ID:
P06239

# Drug_Target_31_SwissProt_Name:
LCK_HUMAN

# Drug_Target_31_Synonyms:
EC 2.7.10.2
LSK
Lymphocyte cell-specific protein-tyrosine kinase
T cell- specific protein-tyrosine kinase
p56-LCK

# Drug_Target_31_Theoretical_pI:
5.03

# Drug_Target_31_Transmembrane_Regions:
None

# Drug_Target_32_Cellular_Location:
Not Available

# Drug_Target_32_Chromosome_Location:
Not Available

# Drug_Target_32_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_32_Essentiality:
Non-Essential

# Drug_Target_32_GenAtlas_ID:
CSNK2A1

# Drug_Target_32_GenBank_ID_Gene:
J02853

# Drug_Target_32_GenBank_ID_Protein:
598147

# Drug_Target_32_GeneCard_ID:
CSNK2A1

# Drug_Target_32_Gene_Name:
CSNK2A1

# Drug_Target_32_Gene_Sequence:
>1176 bp
ATGTCGGGACCCGTGCCAAGCAGGGCCAGAGTTTACACAGATGTTAATACACACAGACCT
CGAGAATACTGGGATTACGAGTCACATGTGGTGGAATGGGGAAATCAAGATGACTACCAG
CTGGTTCGAAAATTAGGCCGAGGTAAATACAGTGAAGTATTTGAAGCCATCAACATCACA
AATAATGAAAAAGTTGTTGTTAAAATTCTCAAGCCAGTAAAAAAGAAGAAAATTAAGCGT
GAAATAAAGATTTTGGAGAATTTGAGAGGAGGTCCCAACATCATCACACTGGCAGACATT
GTAAAAGACCCTGTGTCACGAACCCCCGCCTTGGTTTTTGAACACGTAAACAACACAGAC
TTCAAGCAATTGTACCAGACGTTAACAGACTATGATATTCGATTTTACATGTATGAGATT
CTGAAGGCCCTGGATTATTGTCACAGCATGGGAATTATGCACAGAGATGTCAAGCCCCAT
AATGTCATGATTGATCATGAGCACAGAAAGCTACGACTAATAGACTGGGGTTTGGCTGAG
TTTTATCATCCTGGCCAAGAATATAATGTCCGAGTTGCTTCCCGATACTTCAAAGGTCCT
GAGCTACTTGTAGACTATCAGATGTACGATTATAGTTTGGATATGTGGAGTTTGGGTTGT
ATGCTGGCAAGTATGATCTTTCGGAAGGAGCCATTTTTCCATGGACATGACAATTATGAT
CAGTTGGTGAGGATAGCCAAGGTTCTGGGGACAGAAGATTTATATGACTATATTGACAAA
TACAACATTGAATTAGATCCACGTTTCAATGATATCTTGGGCAGACACTCTCGAAAGCGA
TGGGAACGCTTTGTCCACAGTGAAAATCAGCACCTTGTCAGCCCTGAGGCCTTGGATTTC
CTGGACAAACTGCTGCGATATGACCACCAGTCACGGCTTACTGCAAGAGAGGCAATGGAG
CACCCCTATTTCTACACTGTTGTGAAGGACCAGGCTCGAATGGGTTCATCTAGCATGCCA
GGGGGCAGTACGCCCGTCAGCAGCGCCAATATGATGTCAGGGATTTCTTCAGTGCCAACC
CCTTCACCCCTTGGACCTCTGGCAGGCTCACCAGTGATTGCTGCTGCCAACCCCCTTGGG
ATGCCTGTTCCAGCTGCCGCTGGCGCTCAGCAGTAA

# Drug_Target_32_General_Function:
Involved in protein kinase activity

# Drug_Target_32_General_References:
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
2174700	Lozeman FJ, Litchfield DW, Piening C, Takio K, Walsh KA, Krebs EG: Isolation and characterization of human cDNA clones encoding the alpha and the alpha' subunits of casein kinase II. Biochemistry. 1990 Sep 11;29(36):8436-47.
2752008	Meisner H, Heller-Harrison R, Buxton J, Czech MP: Molecular cloning of the human casein kinase II alpha subunit. Biochemistry. 1989 May 2;28(9):4072-6.
8420794	Devilat I, Carvallo P: Structure and sequence of an intronless gene for human casein kinase II-alpha subunit. FEBS Lett. 1993 Jan 25;316(2):114-8.

# Drug_Target_32_HGNC_ID:
HGNC:2457

# Drug_Target_32_HPRD_ID:
00277

# Drug_Target_32_ID:
2236

# Drug_Target_32_Locus:
20p13

# Drug_Target_32_Molecular_Weight:
45144

# Drug_Target_32_Name:
Casein kinase II subunit alpha

# Drug_Target_32_Number_of_Residues:
391

# Drug_Target_32_PDB_ID:
1JWH

# Drug_Target_32_Pathway:
Not Available

# Drug_Target_32_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_32_Protein_Sequence:
>Casein kinase II subunit alpha
MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINIT
NNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTD
FKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAE
FYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYD
QLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDF
LDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMGSSSMPGGSTPVSSANMMSGISSVPT
PSPLGPLAGSPVIAAANPLGMPVPAAAGAQQ

# Drug_Target_32_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_32_Signals:
None

# Drug_Target_32_Specific_Function:
Casein kinases are operationally defined by their preferential utilization of acidic proteins such as caseins as substrates. The alpha and alpha' chains contain the catalytic site. Participates in Wnt signaling. CK2 phosphorylates 'Ser-392' of p53/TP53 following UV irradiation

# Drug_Target_32_SwissProt_ID:
P68400

# Drug_Target_32_SwissProt_Name:
CSK21_HUMAN

# Drug_Target_32_Synonyms:
CK II
EC 2.7.11.1

# Drug_Target_32_Theoretical_pI:
7.86

# Drug_Target_32_Transmembrane_Regions:
None

# Drug_Target_33_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_33_Chromosome_Location:
Not Available

# Drug_Target_33_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_33_Essentiality:
Non-Essential

# Drug_Target_33_GenAtlas_ID:
EPHA2

# Drug_Target_33_GenBank_ID_Gene:
M59371

# Drug_Target_33_GenBank_ID_Protein:
181944

# Drug_Target_33_GeneCard_ID:
EPHA2

# Drug_Target_33_Gene_Name:
EPHA2

# Drug_Target_33_Gene_Sequence:
>2931 bp
ATGGAGCTCCAGGCAGCCCGCGCCTGCTTCGCCCTGCTGTGGGGCTGTGCGCTGGCCGCG
GCCGCGGCGGCGCAGGGCAAGGAAGTGGTACTGCTGGACTTTGCTGCAGCTGGAGGGGAG
CTCGGCTGGCTCACACACCCGTATGGCAAAGGGTGGGACCTGATGCAGAACATCATGAAT
GACATGCCGATCTACATGTACTCCGTGTGCAACGTGATGTCTGGCGACCAGGACAACTGG
CTCCGCACCAACTGGGTGTACCGAGGAGAGGCTGAGCGTAACAACTTTGAGCTCAACTTT
ACTGTACGTGACTGCAACAGCTTCCCTGGTGGCGCCAGCTCCTGCAAGGAGACTTTCAAC
CTCTACTATGCCGAGTCGGACCTGGACTACGGCACCAACTTCCAGAAGCGCCTGTTCACC
AAGATTGACACCATTGCGCCCGATGAGATCACCGTCAGCAGCGACTTCGAGGCACGCCAC
GTGAAGCTGAACGTGGAGGAGCGCTCCGTGGGGCCGCTCACCCGCAAAGGCTTCTACCTG
GCCTTCCAGGATATCGGTGCCTGTGTGGCGCTGCTCTCCGTCCGTGTCTACTACAAGAAG
TGCCCCGAGCTGCTGCAGGGCCTGGCCCACTTCCCTGAGACCATCGCCGGCTCTGATGCA
CCTTCCCTGGCCACTGTGGCCGGCACCTGTGTGGACCATGCCGTGGTGCCACCGGGGGGT
GAAGAGCCCCGTATGCACTGTGCAGTGGATGGCGAGTGGCTGGTGCCCATTGGGCAGTGC
CTGTGCCAGGCAGGCTACGAGAAGGTGGAGGATGCCTGCCAGGCCTGCTCGCCTGGATTT
TTTAAGTTTGAGGCATCTGAGAGCCCCTGCTTGGAGTGCCCTGAGCACACGCTGCCATCC
CCTGAGGGTGCCACCTCCTGCGAGTGTGAGGAAGGCTTCTTCCGGGCACCTCAGGACCCA
GCGTCGATGCCTTGCACACGACCCCCTTCCGCCCCACACTACCTCACAGCCGTGGGCATG
GGTGCCAAGGTGGAGCTGCGCTGGACGCCCCCTCAGGACAGCGGGGGCCGCGAGGACATT
GTCTACAGCGTCACCTGCGAACAGTGCTGGCCCGAGTCTGGGGAATGCGGGCCGTGTGAG
GCCAGTGTGCGCTACTCGGAGCCTCCTCACGGACTGACCCGCACCAGTGTGACAGTGAGC
GACCTGGAGCCCCACATGAACTACACCTTCACCGTGGAGGCCCGCAATGGCGTCTCAGGC
CTGGTAACCAGCCGCAGCTTCCGTACTGCCAGTGTCAGCATCAACCAGACAGAGCCCCCC
AAGGTGAGGCTGGAGGGCCGCAGCACCACCTCGCTTAGCGTCTCCTGGAGCATCCCCCCG
CCGCAGCAGAGCCGAGTGTGGAAGTACGAGGTCACTTACCGCAAGAAGGGAGACTCCAAC
AGCTACAATGTGCGCCGCACCGAGGGTTTCTCCGTGACCCTGGACGACCTGGCCCCAGAC
ACCACCTACCTGGTCCAGGTGCAGGCACTGACGCAGGAGGGCCAGGGGGCCGGCAGCAAG
GTGCACGAATTCCAGACGCTGTCCCCGGAGGGATCTGGCAACTTGGCGGTGATTGGCGGC
GTGGCTGTCGGTGTGGTCCTGCTTCTGGTGCTGGCAGGAGTTGGCTTCTTTATCCACCGC
AGGAGGAAGAACCAGCGTGCCCGCCAGTCCCCGGAGGACGTTTACTTCTCCAAGTCAGAA
CAACTGAAGCCCCTGAAGACATACGTGGACCCCCACACATATGAGGACCCCAACCAGGCT
GTGTTGAAGTTCACTACCGAGATCCATCCATCCTGTGTCACTCGGCAGAAGGTGATCGGA
GCAGGAGAGTTTGGGGAGGTGTACAAGGGCATGCTGAAGACATCCTCGGGGAAGAAGGAG
GTGCCGGTGGCCATCAAGACGCTGAAAGCCGGCTACACAGAGAAGCAGCGAGTGGACTTC
CTCGGCGAGGCCGGCATCATGGGCCAGTTCAGCCACCACAACATCATCCGCCTAGAGGGC
GTCATCTCCAAATACAAGCCCATGATGATCATCACTGAGTACATGGAGAATGGGGCCCTG
GACAAGTTCCTTCGGGAGAAGGATGGCGAGTTCAGCGTGCTGCAGCTGGTGGGCATGCTG
CGGGGCATCGCAGCTGGCATGAAGTACCTGGCCAACATGAACTATGTGCACCGTGACCTG
GCTGCCCGCAACATCCTCGTCAACAGCAACCTGGTCTGCAAGGTGTCTGACTTTGGCCTG
TCCCGCGTGCTGGAGGACGACCCCGAGGCCACCTACACCACCAGTGGCGGCAAGATCCCC
ATCCGCTGGACCGCCCCGGAGGCCATTTCCTACCGGAAGTTCACCTCTGCCAGCGACGTG
TGGAGCTTTGGCATTGTCATGTGGGAGGTGATGACCTATGGCGAGCGGCCCTACTGGGAG
TTGTCCAACCACGAGGTGATGAAAGCCATCAATGATGGCTTCCGGCTCCCCACACCCATG
GACTGCCCCTCCGCCATCTACCAGCTCATGATGCAGTGCTGGCAGCAGGAGCGTGCCCGC
CGCCCCAAGTTCGCTGACATCGTCAGCATCCTGGACAAGCTCATTCGTGCCCCTGACTCC
CTCAAGACCCTGGCTGACTTTGACCCCCGCGTGTCTATCCGGCTCCCCAGCACGAGCGGC
TCGGAGGGGGTGCCCTTCCGCACGGTGTCCGAGTGGCTGGAGTCCATCAAGATGCAGCAG
TATACGGAGCACTTCATGGCGGCCGGCTACACTGCCATCGAGAAGGTGGTGCAGATGACC
AACGACGACATCAAGAGGATTGGGGTGCGGCTGCCCGGCCACCAGAAGCGCATCGCCTAC
AGCCTGCTGGGACTCAAGGACCAGGTGAACACTGTGGGGATCCCCATCTGA

# Drug_Target_33_General_Function:
Involved in ephrin receptor activity

# Drug_Target_33_General_References:
12467573	Nowakowski J, Cronin CN, McRee DE, Knuth MW, Nelson CG, Pavletich NP, Rogers J, Sang BC, Scheibe DN, Swanson RV, Thompson DA: Structures of the cancer-related Aurora-A, FAK, and EphA2 protein kinases from nanovolume crystallography. Structure. 2002 Dec;10(12):1659-67.
2174105	Lindberg RA, Hunter T: cDNA cloning and characterization of eck, an epithelial cell receptor protein-tyrosine kinase in the eph/elk family of protein kinases. Mol Cell Biol. 1990 Dec;10(12):6316-24.

# Drug_Target_33_HGNC_ID:
HGNC:3386

# Drug_Target_33_HPRD_ID:
01494

# Drug_Target_33_ID:
936

# Drug_Target_33_Locus:
1p36

# Drug_Target_33_Molecular_Weight:
108255

# Drug_Target_33_Name:
Ephrin type-A receptor 2

# Drug_Target_33_Number_of_Residues:
976

# Drug_Target_33_PDB_ID:
1MQB

# Drug_Target_33_Pathway:
Not Available

# Drug_Target_33_Pfam_Domain_Function:
PF00041	fn3
PF00536	SAM_1
PF01404	Ephrin_lbd
PF07714	Pkinase_Tyr

# Drug_Target_33_Protein_Sequence:
>Ephrin type-A receptor 2 precursor
MELQAARACFALLWGCALAAAAAAQGKEVVLLDFAAAGGELGWLTHPYGKGWDLMQNIMN
DMPIYMYSVCNVMSGDQDNWLRTNWVYRGEAERNNFELNFTVRDCNSFPGGASSCKETFN
LYYAESDLDYGTNFQKRLFTKIDTIAPDEITVSSDFEARHVKLNVEERSVGPLTRKGFYL
AFQDIGACVALLSVRVYYKKCPELLQGLAHFPETIAGSDAPSLATVAGTCVDHAVVPPGG
EEPRMHCAVDGEWLVPIGQCLCQAGYEKVEDACQACSPGFFKFEASESPCLECPEHTLPS
PEGATSCECEEGFFRAPQDPASMPCTRPPSAPHYLTAVGMGAKVELRWTPPQDSGGREDI
VYSVTCEQCWPESGECGPCEASVRYSEPPHGLTRTSVTVSDLEPHMNYTFTVEARNGVSG
LVTSRSFRTASVSINQTEPPKVRLEGRSTTSLSVSWSIPPPQQSRVWKYEVTYRKKGDSN
SYNVRRTEGFSVTLDDLAPDTTYLVQVQALTQEGQGAGSKVHEFQTLSPEGSGNLAVIGG
VAVGVVLLLVLAGVGFFIHRRRKNQRARQSPEDVYFSKSEQLKPLKTYVDPHTYEDPNQA
VLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDF
LGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGML
RGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIP
IRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPM
DCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG
SEGVPFRTVSEWLESIKMQQYTEHFMAAGYTAIEKVVQMTNDDIKRIGVRLPGHQKRIAY
SLLGLKDQVNTVGIPI

# Drug_Target_33_Reaction:
ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate

# Drug_Target_33_Signals:
1-24

# Drug_Target_33_Specific_Function:
Receptor for members of the ephrin-A family. Binds to ephrin-A1, -A3, -A4 and -A5

# Drug_Target_33_SwissProt_ID:
P29317

# Drug_Target_33_SwissProt_Name:
EPHA2_HUMAN

# Drug_Target_33_Synonyms:
EC 2.7.10.1
Ephrin type-A receptor 2 precursor
Epithelial cell kinase
Tyrosine-protein kinase receptor ECK

# Drug_Target_33_Theoretical_pI:
6.05

# Drug_Target_33_Transmembrane_Regions:
535-558

# Drug_Target_34_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_34_Chromosome_Location:
Not Available

# Drug_Target_34_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_34_Essentiality:
Non-Essential

# Drug_Target_34_GenAtlas_ID:
Not Available

# Drug_Target_34_GenBank_ID_Gene:
AP008226

# Drug_Target_34_GenBank_ID_Protein:
55771665

# Drug_Target_34_GeneCard_ID:
Not Available

# Drug_Target_34_Gene_Name:
argG

# Drug_Target_34_Gene_Sequence:
>1203 bp
CTATGCGCCATGGCCCTCCCTCTCCACAAGGGCCCGCACCCGGAGGCGCAGGGCCTGGAT
CTTGATGAAGCCCTCGGCGTCCTTCTGGTCGTAGCCCCCTGCCTCGTCAAAGGAGACCAG
GTCCTGGCGGTAGAGGCTCTTCGGGGCCTTCCTTCCCACCACGTAGACGTTCCCCTTGTA
GAGCTTGAGCCGGGCCACGCCGGTGACGCTTCTCGCCACGTGGTCAAAGTAGGCCTGAAG
GGCCTCCCGCTCCGGGGCGTACCAGAAGCCGTAGTAGACGAGCTCGGCGTACTTGGGGGA
GAGCATGTCCCTTTGGTGGAGGACCTCCCGGTCCAGGGTGAGGCTTTCCACCGCCCGCCT
GGCGTGGTAGAGGATCGTCCCCCCCGGGGTCTCGTAGACCCCCCGGGACTTCATGCCCAC
AAAGCGGTTCTCCACGATGTCCACCCGGCCCACCCCGTGACGCCCCCCGATCTCGTTGAG
CCTCTGCAGAAGGGCCGCCGGGGAAAGCCTCTCCCCGTTCACCGCCACGGGATCGCCCTC
AAAAAACTCCACCTCCACGTACTCCGGGGCGTCGGGAGCCTCCTCGGGGTCTTGGGTCAT
GCGGAACATCCCCTTGGGGGGCTCGGCCCAGGGGTCCTCGAGGACCCCGCCCTCGTAGGA
AATATGCAAGAGGTTGGCGTCCATGGAGTAAGGCTTCTCCTGGGTCACGGGGACGGGAAT
GCCGTGGGCCTCGGCGTAGGCGATCATCTCCTTGCGGCCCTGGAAGCTCCACTCCCGCCA
GGGGGCGATGACCTTGATGTCGGGCTTCAGGGCGTAGGCGGTGAGCTCAAAGCGCACCTG
GTCGTTCCCCTTCCCCGTGGCCCCGTGGGCGATGGCCTCCGCCCCCTCCTCCTCGGCGAT
CCGCACCAGGTGCTTGGCGATCAAAGGCCTCGCGATGGAAGTGCCGAGGAGGTAGTAGCC
CTCGTACACCGCGCCAGCCCGCATCATGGGGAAGACGAAGTCGCGGACGAACTCCTCCTT
GAGGTCCAGGGCGATGGCCTTGGAAGCGCCCGTCCTCAGCGCCTTCTCCCGGGCCTCCTC
CACCTCCTCCCCCTGGCCGATGTCCGCGGTGAAGGCGATGACCTCGGCCCGATAGGTCTC
CTTGAGCCACTTGAGGATGATGCTGGTGTCCAGTCCGCCGGAGTAGGCCAAGACGATCTT
CAT

# Drug_Target_34_General_Function:
Amino acid transport and metabolism

# Drug_Target_34_General_References:
11844799	Goto M, Nakajima Y, Hirotsu K: Crystal structure of argininosuccinate synthetase from Thermus thermophilus HB8. Structural basis for the catalytic action. J Biol Chem. 2002 May 3;277(18):15890-6. Epub 2002 Feb 13.

# Drug_Target_34_HGNC_ID:
Not Available

# Drug_Target_34_HPRD_ID:
Not Available

# Drug_Target_34_ID:
2680

# Drug_Target_34_Locus:
Not Available

# Drug_Target_34_Molecular_Weight:
44817

# Drug_Target_34_Name:
Argininosuccinate synthase

# Drug_Target_34_Number_of_Residues:
400

# Drug_Target_34_PDB_ID:
1KH3

# Drug_Target_34_Pathway:
Not Available

# Drug_Target_34_Pfam_Domain_Function:
PF00764	Arginosuc_synth

# Drug_Target_34_Protein_Sequence:
>Argininosuccinate synthase
MKIVLAYSGGLDTSIILKWLKETYRAEVIAFTADIGQGEEVEEAREKALRTGASKAIALD
LKEEFVRDFVFPMMRAGAVYEGYYLLGTSIARPLIAKHLVRIAEEEGAEAIAHGATGKGN
DQVRFELTAYALKPDIKVIAPWREWSFQGRKEMIAYAEAHGIPVPVTQEKPYSMDANLLH
ISYEGGVLEDPWAEPPKGMFRMTQDPEEAPDAPEYVEVEFFEGDPVAVNGERLSPAALLQ
RLNEIGGRHGVGRVDIVENRFVGMKSRGVYETPGGTILYHARRAVESLTLDREVLHQRDM
LSPKYAELVYYGFWYAPEREALQAYFDHVARSVTGVARLKLYKGNVYVVGRKAPKSLYRQ
DLVSFDEAGGYDQKDAEGFIKIQALRLRVRALVEREGHGA

# Drug_Target_34_Reaction:
ATP + L-citrulline + L-aspartate = AMP + diphosphate + 2-(Nomega-L-arginino)succinate

# Drug_Target_34_Signals:
None

# Drug_Target_34_Specific_Function:
ATP + L-citrulline + L-aspartate = AMP + diphosphate + omega-N-(L-arginino)succinate

# Drug_Target_34_SwissProt_ID:
P59846

# Drug_Target_34_SwissProt_Name:
ASSY_THET8

# Drug_Target_34_Synonyms:
Citrulline--aspartate ligase
EC 6.3.4.5

# Drug_Target_34_Theoretical_pI:
5.71

# Drug_Target_34_Transmembrane_Regions:
None

# Drug_Target_35_Cellular_Location:
Cytoplasm

# Drug_Target_35_Chromosome_Location:
Not Available

# Drug_Target_35_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_35_Essentiality:
Non-Essential

# Drug_Target_35_GenAtlas_ID:
MAPK10

# Drug_Target_35_GenBank_ID_Gene:
U07620

# Drug_Target_35_GenBank_ID_Protein:
468151

# Drug_Target_35_GeneCard_ID:
MAPK10

# Drug_Target_35_Gene_Name:
MAPK10

# Drug_Target_35_Gene_Sequence:
>1395 bp
ATGAGCCTCCATTTCTTATACTACTGCAGTGAACCAACATTGGATGTGAAAATTGCCTTT
TGTCAGGGATTCGATAAACAAGTGGATGTGTCATATATTGCCAAACATTACAACATGAGC
AAAAGCAAAGTTGACAACCAGTTCTACAGTGTGGAAGTGGGAGACTCAACCTTCACAGTT
CTCAAGCGCTACCAGAATCTAAAGCCTATTGGCTCTGGGGCTCAGGGCATAGTTTGTGCC
GCGTATGATGCTGTCCTTGACAGAAATGTGGCCATTAAGAAGCTCAGCAGACCCTTTCAG
AACCAAACACATGCCAAGAGAGCGTACCGGGAGCTGGTCCTCATGAAGTGTGTGAACCAT
AAAAACATTATTAGTTTATTAAATGTCTTCACACCCCAGAAAACGCTGGAGGAGTTCCAA
GATGTTTACTTAGTAATGGAACTGATGGATGCCAACTTATGTCAAGTGATTCAGATGGAA
TTAGACCATGAGCGAATGTCTTACCTGCTGTACCAAATGTTGTGTGGCATTAAGCACCTC
CATTCTGCTGGAATTATTCACAGGGATTTAAAACCAAGTAACATTGTAGTCAAGTCTGAT
TGCACATTGAAAATCCTGGACTTTGGACTGGCCAGGACAGCAGGCACAAGCTTCATGATG
ACTCCATATGTGGTGACACGTTATTACAGAGCCCCTGAGGTCATCCTGGGGATGGGCTAC
AAGGAGAACGTGGATATATGGTCTGTGGGATGCATTATGGGAGAAATGGTTCGCCACAAA
ATCCTCTTTCCAGGAAGGGACTATATTGACCAGTGGAATAAGGTAATTGAACAACTAGGA
ACACCATGTCCAGAATTCATGAAGAAATTGCAACCCACAGTAAGAAACTATGTGGAGAAT
CGGCCCAAGTATGCGGGACTCACCTTCCCCAAACTCTTCCCAGATTCCCTCTTCCCAGCG
GACTCCGAGCACAATAAACTCAAAGCCAGCCAAGCCAGGGACTTGTTGTCAAAGATGCTA
GTGATTGACCCAGCAAAAAGAATATCAGTGGACGACGCCTTACAGCATCCCTACATCAAC
GTCTGGTATGACCCAGCCGAAGTGGAGGCGCCTCCACCTCAGATATATGACAAGCAGTTG
GATGAAAGAGAACACACAATTGAAGAATGGAAAGAACTTATCTACAAGGAAGTAATGAAT
TCAGAAGAAAAGACTAAAAATGGTGTAGTAAAAGGACAGCCTTCTCCTTCAGGTGCAGCA
GTGAACAGCAGTGAGAGTCTCCCTCCATCCTCGTCTGTCAATGACATCTCCTCCATGTCC
ACCGACCAGACCCTGGCATCTGACACTGACAGCAGCCTGGAAGCCTCGGCAGGACCCCTG
GGTTGTTGCAGGTGA

# Drug_Target_35_General_Function:
Involved in MAP kinase activity

# Drug_Target_35_General_References:
10715136	Lisnock J, Griffin P, Calaycay J, Frantz B, Parsons J, O'Keefe SJ, LoGrasso P: Activation of JNK3 alpha 1 requires both MKK4 and MKK7: kinetic characterization of in vitro phosphorylated JNK3 alpha 1. Biochemistry. 2000 Mar 21;39(11):3141-8.
7826642	Mohit AA, Martin JH, Miller CA: p493F12 kinase: a novel MAP kinase expressed in a subset of neurons in the human nervous system. Neuron. 1995 Jan;14(1):67-78.
8654373	Gupta S, Barrett T, Whitmarsh AJ, Cavanagh J, Sluss HK, Derijard B, Davis RJ: Selective interaction of JNK protein kinase isoforms with transcription factors. EMBO J. 1996 Jun 3;15(11):2760-70.
9739089	Xie X, Gu Y, Fox T, Coll JT, Fleming MA, Markland W, Caron PR, Wilson KP, Su MS: Crystal structure of JNK3: a kinase implicated in neuronal apoptosis. Structure. 1998 Aug 15;6(8):983-91.

# Drug_Target_35_HGNC_ID:
HGNC:6872

# Drug_Target_35_HPRD_ID:
04207

# Drug_Target_35_ID:
1836

# Drug_Target_35_Locus:
4q22.1-q23

# Drug_Target_35_Molecular_Weight:
52586

# Drug_Target_35_Name:
Mitogen-activated protein kinase 10

# Drug_Target_35_Number_of_Residues:
464

# Drug_Target_35_PDB_ID:
1JNK

# Drug_Target_35_Pathway:
Not Available

# Drug_Target_35_Pfam_Domain_Function:
PF00069	Pkinase

# Drug_Target_35_Protein_Sequence:
>Mitogen-activated protein kinase 10
MSLHFLYYCSEPTLDVKIAFCQGFDKQVDVSYIAKHYNMSKSKVDNQFYSVEVGDSTFTV
LKRYQNLKPIGSGAQGIVCAAYDAVLDRNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNH
KNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHL
HSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGY
KENVDIWSVGCIMGEMVRHKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRNYVEN
RPKYAGLTFPKLFPDSLFPADSEHNKLKASQARDLLSKMLVIDPAKRISVDDALQHPYIN
VWYDPAEVEAPPPQIYDKQLDEREHTIEEWKELIYKEVMNSEEKTKNGVVKGQPSPSGAA
VNSSESLPPSSSVNDISSMSTDQTLASDTDSSLEASAGPLGCCR

# Drug_Target_35_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_35_Signals:
None

# Drug_Target_35_Specific_Function:
Responds to activation by environmental stress and pro- inflammatory cytokines by phosphorylating a number of transcription factors, primarily components of AP-1 such as c-Jun and ATF2 and thus regulates AP-1 transcriptional activity. Required for stress-induced neuronal apoptosis and the pathogenesis of glutamate excitotoxicity

# Drug_Target_35_SwissProt_ID:
P53779

# Drug_Target_35_SwissProt_Name:
MK10_HUMAN

# Drug_Target_35_Synonyms:
EC 2.7.11.24
MAP kinase p49 3F12
Stress-activated protein kinase JNK3
c-Jun N-terminal kinase 3

# Drug_Target_35_Theoretical_pI:
6.78

# Drug_Target_35_Transmembrane_Regions:
None

# Drug_Target_36_Cellular_Location:
Cytoplasm

# Drug_Target_36_Chromosome_Location:
Not Available

# Drug_Target_36_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_36_Essentiality:
Non-Essential

# Drug_Target_36_GenAtlas_ID:
Not Available

# Drug_Target_36_GenBank_ID_Gene:
AE005674

# Drug_Target_36_GenBank_ID_Protein:
24053342

# Drug_Target_36_GeneCard_ID:
Not Available

# Drug_Target_36_Gene_Name:
metK

# Drug_Target_36_Gene_Sequence:
>1167 bp
GTGATATTAAATATGGCAAAACACCTTTTTACGTCCGAGTCCGTCTCTGAAGGGCATCCT
GACAAAATTGCTGACCAAATCTCTGATGCCGTTTTAGACGCGATCCTCGAACAGGATCCG
AAAGCACGCGTTGCTTGCGAAACCTACGTAAAAACCGGCATGGTTTTAGTTGGCGGCGAA
ATCACCACCAGCGCCTGGGTAGACATCGAAGAGATCACCCGTAACACCGTTCGCGAAATT
GGCTATGTGCATTCCGACATGGGCTTTGACGCTAACTCCTGTGCGGTTCTGAGCGCTATC
GGCAAACAGTCTCCTGACATCAACCAAGGCGTTGACCGTGCCGATCCGCTGGAACAGGGC
GCGGGTGACCAGGGTCTGATGTTTGGCTACGCAACTAATGAAACCGACGTGCTGATGCCA
GCACCTATCACCTATGCACACCGTCTGGTACAGCGTCAGGCTGAAGTGCGTAAAAACGGC
ACTCTGCCGTGGCTGCGCCCGGACGCGAAAAGCCAGGTGACTTTCCAGTATGACGACGGC
AAAATCGTTGGTATTGATGCTGTCGTGCTTTCCACTCAGCACTCTGAAGAGATCGACCAG
AAATCGCTGCAAGAAGCGGTAATGGAAGAGATCATCAAGCCAATTCTGCCCGCTGAATGG
CTGACTTCTGCCACCAAATTCTTCATCAACCCGACCGGTCGTTTCGTTATCGGTGGCCCA
ATGGGTGACTGCGGTCTGACTGGCCGTAAAATTATCGTTGATACCTACGGCGGCATGGCG
CGTCACGGTGGCGGTGCATTCTCTGGTAAAGATCCATCAAAAGTGGACCGTTCCGCAGCC
TACGCAGCACGTTATGTCGCGAAAAACATCGTTGCTGCTGGCCTGGCCGATCGTTGTGAA
ATTCAGGTTTCCTACGCAATCGGCGTGGCTGAACCGACCTCCATCATGGTAGAAACTTTC
GGTACTGAGAAAGTGCCTTCTGAACAACTGACTCTGCTGGTACGTGAGTTCTTCGACCTG
CGCCCATACGGACTGATTCAGATGCTGGATCTGCTGCACCCGATCTACAAAGAAACCGCA
GCATACGGTCACTTTGGTCGTGAACATTTCCCGTGGGAAAAAACCGACAAAGCGCAGCTG
CTGCGCGATGCTGCCGGTCTGAAGTAA

# Drug_Target_36_General_Function:
Coenzyme transport and metabolism

# Drug_Target_36_General_References:
12384590	Jin Q, Yuan Z, Xu J, Wang Y, Shen Y, Lu W, Wang J, Liu H, Yang J, Yang F, Zhang X, Zhang J, Yang G, Wu H, Qu D, Dong J, Sun L, Xue Y, Zhao A, Gao Y, Zhu J, Kan B, Ding K, Chen S, Cheng H, Yao Z, He B, Chen R, Ma D, Qiang B, Wen Y, Hou Y, Yu J: Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res. 2002 Oct 15;30(20):4432-41.
12704152	Wei J, Goldberg MB, Burland V, Venkatesan MM, Deng W, Fournier G, Mayhew GF, Plunkett G 3rd, Rose DJ, Darling A, Mau B, Perna NT, Payne SM, Runyen-Janecky LJ, Zhou S, Schwartz DC, Blattner FR: Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun. 2003 May;71(5):2775-86.

# Drug_Target_36_HGNC_ID:
Not Available

# Drug_Target_36_HPRD_ID:
Not Available

# Drug_Target_36_ID:
2727

# Drug_Target_36_Locus:
Not Available

# Drug_Target_36_Molecular_Weight:
41952

# Drug_Target_36_Name:
S-adenosylmethionine synthetase

# Drug_Target_36_Number_of_Residues:
384

# Drug_Target_36_PDB_ID:
1RG9

# Drug_Target_36_Pathway:
Not Available

# Drug_Target_36_Pfam_Domain_Function:
PF00438	S-AdoMet_synt_N
PF02772	S-AdoMet_synt_M
PF02773	S-AdoMet_synt_C

# Drug_Target_36_Protein_Sequence:
>S-adenosylmethionine synthetase
MAKHLFTSESVSEGHPDKIADQISDAVLDAILEQDPKARVACETYVKTGMVLVGGEITTS
AWVDIEEITRNTVREIGYVHSDMGFDANSCAVLSAIGKQSPDINQGVDRADPLEQGAGDQ
GLMFGYATNETDVLMPAPITYAHRLVQRQAEVRKNGTLPWLRPDAKSQVTFQYDDGKIVG
IDAVVLSTQHSEEIDQKSLQEAVMEEIIKPILPAEWLTSATKFFINPTGRFVIGGPMGDC
GLTGRKIIVDTYGGMARHGGGAFSGKDPSKVDRSAAYAARYVAKNIVAAGLADRCEIQVS
YAIGVAEPTSIMVETFGTEKVPSEQLTLLVREFFDLRPYGLIQMLDLLHPIYKETAAYGH
FGREHFPWEKTDKAQLLRDAAGLK

# Drug_Target_36_Reaction:
ATP + L-methionine + H2O = phosphate + diphosphate + S-adenosyl-L-methionine

# Drug_Target_36_Signals:
None

# Drug_Target_36_Specific_Function:
Catalyzes the formation of S-adenosylmethionine from methionine and ATP. The overall synthetic reaction is composed of two sequential steps, AdoMet formation and the subsequent tripolyphosphate hydrolysis which occurs prior to release of AdoMet from the enzyme

# Drug_Target_36_SwissProt_ID:
P0A820

# Drug_Target_36_SwissProt_Name:
METK_SHIFL

# Drug_Target_36_Synonyms:
AdoMet synthetase
EC 2.5.1.6
MAT
Methionine adenosyltransferase

# Drug_Target_36_Theoretical_pI:
4.89

# Drug_Target_36_Transmembrane_Regions:
None

# Drug_Target_37_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_37_Chromosome_Location:
Not Available

# Drug_Target_37_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_37_Essentiality:
Non-Essential

# Drug_Target_37_GenAtlas_ID:
Not Available

# Drug_Target_37_GenBank_ID_Gene:
L42023

# Drug_Target_37_GenBank_ID_Protein:
1574695

# Drug_Target_37_GeneCard_ID:
Not Available

# Drug_Target_37_Gene_Name:
murC

# Drug_Target_37_Gene_Sequence:
>1428 bp
ATGAAACATTCCCACGAAGAAATTAGAAAAATTATCCCTGAAATGCGCCGTGTACAGCAA
ATTCATTTCATTGGCATTGGTGGTGCGGGAATGAGCGGCATTGCAGAAATTTTATTAAAT
GAAGGTTATCAAATTTCAGGTTCAGATATTGCCGATGGCGTAGTCACTCAACGTTTAGCT
CAAGCTGGGGCAAAAATCTACATTGGTCATGCAGAAGAACATATTGAAGGTGCCAGTGTT
GTTGTTGTGTCTAGTGCGATAAAAGATGATAACCCTGAATTAGTTACATCGAAACAAAAA
CGCATTCCAGTGATTCAACGCGCACAAATGTTGGCGGAGATTATGCGTTTTCGTCACGGT
ATTGCTGTTGCAGGAACACACGGGAAAACGACAACAACAGCAATGATTTCAATGATTTAC
ACCCAAGCTAAACTTGATCCGACTTTTGTAAATGGCGGTTTAGTGAAATCGGCGGGTAAG
AATGCACATTTAGGAGCAAGTCGTTATTTAATTGCCGAAGCCGATGAAAGTGATGCGTCG
TTTTTGCATTTACAGCCAATGGTATCTGTTGTAACTAATATGGAGCCAGACCATATGGAT
ACTTACGAAGGCGATTTTGAAAAAATGAAAGCCACTTATGTGAAATTCCTGCATAATTTA
CCCTTCTATGGTTTAGCCGTGATGTGCGCTGATGATCCTGTTTTAATGGAACTTGTGCCA
AAAGTTGGTCGCCAAGTGATTACATATGGTTTTAGTGAACAGGCAGATTATCGCATTGAA
GATTATGAACAAACAGGTTTTCAAGGTCATTACACGGTGATTTGCCCAAATAATGAACGT
ATTAATGTGTTGCTCAATGTTCCTGGAAAACATAATGCATTAAATGCAACGGCTGCACTT
GCTGTAGCAAAAGAAGAGGGTATTGCTAACGAGGCAATTTTAGAAGCTCTGGCTGATTTT
CAGGGGGCTGGTCGTCGTTTTGATCAGCTAGGCGAATTTATTCGTCCAAATGGTAAAGTG
CGTTTAGTTGATGATTATGGTCATCATCCAACAGAAGTAGGCGTAACCATTAAAGCGGCG
CGAGAAGGCTGGGGAGATAAACGTATTGTAATGATTTTCCAACCGCATCGTTATTCTCGC
ACTCGTGATTTGTTTGATGATTTTGTACAAGTGCTTTCGCAAGTAGACGCTTTGATTATG
CTTGATGTGTACGCAGCGGGAGAAGCCCCTATTGTTGGCGCTGACAGTAAATCTCTTTGC
CGTTCCATTCGTAATCTTGGTAAAGTTGATCCTATTTTGGTATCAGATACTTCGCAACTA
GGCGATGTTCTCGATCAAATTATTCAAGATGGCGATTTGATTTTGGCACAAGGTGCTGGT
AGCGTAAGTAAAATTTCTCGTGGCTTGGCTGAATCTTGGAAGAATTAA

# Drug_Target_37_General_Function:
Cell wall/membrane/envelope biogenesis

# Drug_Target_37_General_References:
7542800	Fleischmann RD, Adams MD, White O, Clayton RA, Kirkness EF, Kerlavage AR, Bult CJ, Tomb JF, Dougherty BA, Merrick JM, et al.: Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science. 1995 Jul 28;269(5223):496-512.

# Drug_Target_37_HGNC_ID:
Not Available

# Drug_Target_37_HPRD_ID:
Not Available

# Drug_Target_37_ID:
2299

# Drug_Target_37_Locus:
Not Available

# Drug_Target_37_Molecular_Weight:
51995

# Drug_Target_37_Name:
UDP-N-acetylmuramate--L-alanine ligase

# Drug_Target_37_Number_of_Residues:
475

# Drug_Target_37_PDB_ID:
1GQY

# Drug_Target_37_Pathway:
Not Available

# Drug_Target_37_Pfam_Domain_Function:
PF01225	Mur_ligase
PF02875	Mur_ligase_C
PF08245	Mur_ligase_M

# Drug_Target_37_Protein_Sequence:
>UDP-N-acetylmuramate--L-alanine ligase
MKHSHEEIRKIIPEMRRVQQIHFIGIGGAGMSGIAEILLNEGYQISGSDIADGVVTQRLA
QAGAKIYIGHAEEHIEGASVVVVSSAIKDDNPELVTSKQKRIPVIQRAQMLAEIMRFRHG
IAVAGTHGKTTTTAMISMIYTQAKLDPTFVNGGLVKSAGKNAHLGASRYLIAEADESDAS
FLHLQPMVSVVTNMEPDHMDTYEGDFEKMKATYVKFLHNLPFYGLAVMCADDPVLMELVP
KVGRQVITYGFSEQADYRIEDYEQTGFQGHYTVICPNNERINVLLNVPGKHNALNATAAL
AVAKEEGIANEAILEALADFQGAGRRFDQLGEFIRPNGKVRLVDDYGHHPTEVGVTIKAA
REGWGDKRIVMIFQPHRYSRTRDLFDDFVQVLSQVDALIMLDVYAAGEAPIVGADSKSLC
RSIRNLGKVDPILVSDTSQLGDVLDQIIQDGDLILAQGAGSVSKISRGLAESWKN

# Drug_Target_37_Reaction:
ATP + UDP-N-acetylmuramate + L-alanine = ADP + phosphate + UDP-N-acetylmuramoyl-L-alanine

# Drug_Target_37_Signals:
None

# Drug_Target_37_Specific_Function:
Cell wall formation

# Drug_Target_37_SwissProt_ID:
P45066

# Drug_Target_37_SwissProt_Name:
MURC_HAEIN

# Drug_Target_37_Synonyms:
EC 6.3.2.8
UDP-N- acetylmuramoyl-L-alanine synthetase

# Drug_Target_37_Theoretical_pI:
5.97

# Drug_Target_37_Transmembrane_Regions:
None

# Drug_Target_38_Cellular_Location:
Cell inner membrane
multi-pass membrane protein

# Drug_Target_38_Chromosome_Location:
Not Available

# Drug_Target_38_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_38_Essentiality:
Non-Essential

# Drug_Target_38_GenAtlas_ID:
Not Available

# Drug_Target_38_GenBank_ID_Gene:
U18997

# Drug_Target_38_GenBank_ID_Protein:
Not Available

# Drug_Target_38_GeneCard_ID:
Not Available

# Drug_Target_38_Gene_Name:
envZ

# Drug_Target_38_Gene_Sequence:
Not Available

# Drug_Target_38_General_Function:
Signal transduction mechanisms

# Drug_Target_38_General_References:
10426948	Tomomori C, Tanaka T, Dutta R, Park H, Saha SK, Zhu Y, Ishima R, Liu D, Tong KI, Kurokawa H, Qian H, Inouye M, Ikura M: Solution structure of the homodimeric core domain of Escherichia coli histidine kinase EnvZ. Nat Struct Biol. 1999 Aug;6(8):729-34.
1323560	Tokishita S, Kojima A, Mizuno T: Transmembrane signal transduction and osmoregulation in Escherichia coli: functional importance of the transmembrane regions of membrane-located protein kinase, EnvZ. J Biochem (Tokyo). 1992 Jun;111(6):707-13.
2277041	Kanamaru K, Aiba H, Mizuno T: Transmembrane signal transduction and osmoregulation in Escherichia coli: I. Analysis by site-directed mutagenesis of the amino acid residues involved in phosphotransfer between the two regulatory components, EnvZ and OmpR. J Biochem (Tokyo). 1990 Sep;108(3):483-7.
2824492	Forst S, Comeau D, Norioka S, Inouye M: Localization and membrane topology of EnvZ, a protein involved in osmoregulation of OmpF and OmpC in Escherichia coli. J Biol Chem. 1987 Dec 5;262(34):16433-8.
2997120	Comeau DE, Ikenaka K, Tsung KL, Inouye M: Primary characterization of the protein products of the Escherichia coli ompB locus: structure and regulation of synthesis of the OmpR and EnvZ proteins. J Bacteriol. 1985 Nov;164(2):578-84.
6292200	Mizuno T, Wurtzel ET, Inouye M: Osmoregulation of gene expression. II. DNA sequence of the envZ gene of the ompB operon of Escherichia coli and characterization of its gene product. J Biol Chem. 1982 Nov 25;257(22):13692-8.
8132603	Roberts DL, Bennett DW, Forst SA: Identification of the site of phosphorylation on the osmosensor, EnvZ, of Escherichia coli. J Biol Chem. 1994 Mar 25;269(12):8728-33.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9817206	Tanaka T, Saha SK, Tomomori C, Ishima R, Liu D, Tong KI, Park H, Dutta R, Qin L, Swindells MB, Yamazaki T, Ono AM, Kainosho M, Inouye M, Ikura M: NMR structure of the histidine kinase domain of the E. coli osmosensor EnvZ. Nature. 1998 Nov 5;396(6706):88-92.

# Drug_Target_38_HGNC_ID:
Not Available

# Drug_Target_38_HPRD_ID:
Not Available

# Drug_Target_38_ID:
3794

# Drug_Target_38_Locus:
Not Available

# Drug_Target_38_Molecular_Weight:
50335

# Drug_Target_38_Name:
Osmolarity sensor protein envZ

# Drug_Target_38_Number_of_Residues:
450

# Drug_Target_38_PDB_ID:
Not Available

# Drug_Target_38_Pathway:
Not Available

# Drug_Target_38_Pfam_Domain_Function:
PF00512	HisKA
PF00672	HAMP
PF02518	HATPase_c

# Drug_Target_38_Protein_Sequence:
>Osmolarity sensor protein envZ
MRRLRFSPRSSFARTLLLIVTLLFASLVTTYLVVLNFAILPSLQQFNKVLAYEVRMLMTD
KLQLEDGTQLVVPPAFRREIYRELGISLYSNEAAEEAGLRWAQHYEFLSHQMAQQLGGPT
EVRVEVNKSSPVVWLKTWLSPNIWVRVPLTEIHQGDFSPLFRYTLAIMLLAIGGAWLFIR
IQNRPLVDLEHAALQVGKGIIPPPLREYGASEVRSVTRAFNHMAAGVKQLADDRTLLMAG
VSHDLRTPLTRIRLATEMMSEQDGYLAESINKDIEECNAIIEQFIDYLRTGQEMPMEMAD
LNAVLGEVIAAESGYEREIETALYPGSIEVKMHPLSIKRAVANMVVNAARYGNGWIKVSS
GTEPNRAWFQVEDDGPGIAPEQRKHLFQPFVRGDSARTISGTGLGLAIVQRIVDNHNGML
ELGTSERGGLSIRAWLPVPVTRAQGTTKEG

# Drug_Target_38_Reaction:
Not Available

# Drug_Target_38_Signals:
None

# Drug_Target_38_Specific_Function:
Member of the two-component regulatory system envZ/ompR involved in the regulation of osmoregulation (genes ompF and ompC). EnvZ functions as a membrane-associated protein kinase that phosphorylates ompR in response to environmental signals

# Drug_Target_38_SwissProt_ID:
P0AEJ4

# Drug_Target_38_SwissProt_Name:
ENVZ_ECOLI

# Drug_Target_38_Synonyms:
EC 2.7.13.3

# Drug_Target_38_Theoretical_pI:
6.81

# Drug_Target_38_Transmembrane_Regions:
16-35
159-179

# Drug_Target_39_Cellular_Location:
Cytoplasmic

# Drug_Target_39_Chromosome_Location:
Not Available

# Drug_Target_39_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_39_Essentiality:
Non-Essential

# Drug_Target_39_GenAtlas_ID:
Not Available

# Drug_Target_39_GenBank_ID_Gene:
X04341

# Drug_Target_39_GenBank_ID_Protein:
41646

# Drug_Target_39_GeneCard_ID:
Not Available

# Drug_Target_39_Gene_Name:
gyrB

# Drug_Target_39_Gene_Sequence:
>2415 bp
ATGTCGAATTCTTATGACTCCTCCAGTATCAAAGTCCTGAAAGGGCTGGATGCGGTGCGT
AAGCGCCCGGGTATGTATATCGGCGACACGGATGACGGCACCGGTCTGCACCACATGGTA
TTCGAGGTGGTAGATAACGCTATCGACGAAGCGCTCGCGGGTCACTGTAAAGAAATTATC
GTCACCATTCACGCCGATAACTCTGTCTCTGTACAGGATGACGGGCGCGGCATTCCGACC
GGTATTCACCCGGAAGAGGGCGTATCGGCGGCGGAAGTGATCATGACCGTTCTGCACGCA
GGCGGTAAATTTGACGATAACTCCTATAAAGTGTCCGGCGGTCTGCACGGCGTTGGTGTT
TCGGTAGTAAACGCCCTGTCGCAAAAACTGGAGCTGGTTATCCAGCGCGAGGGTAAAATT
CACCGTCAGATCTACGAACACGGTGTACCGCAGGCCCCGCTGGCGGTTACCGGCGAGACT
GAAAAAACCGGCACCATGGTGCGTTTCTGGCCCAGCCTCGAAACCTTCACCAATGTGACC
GAGTTCGAATATGAAATTCTGGCGAAACGTCTGCGTGAGTTGTCGTTCCTCAACTCCGGC
GTTTCCATTCGTCTGCGCGACAAGCGCGACGGCAAAGAAGACCACTTCCACTATGAAGGC
GGCATCAAGGCGTTCGTTGAATATCTGAACAAGAACAAAACGCCGATCCACCCGAATATC
TTCTACTTCTCCACTGAAAAAGACGGTATTGGCGTCGAAGTGGCGTTGCAGTGGAACGAT
GGCTTCCAGGAAAACATCTACTGCTTTACCAACAACATTCCGCAGCGTGACGGCGGTACT
CACCTGGCAGGCTTCCGTGCGGCGATGACCCGTACCCTGAACGCCTACATGGACAAAGAA
GGCTACAGCAAAAAAGCCAAAGTCAGCGCCACCGGTGACGATGCGCGTGAAGGCCTGATT
GCGGTCGTTTCCGTGAAAGTGCCGGACCCGAAATTCTCCTCCCAGACCAAAGACAAACTG
GTTTCTTCTGAGGTGAAATCGGCGGTTGAACAGCAGATGAACGAACTGCTGGCAGAATAC
CTGCTGGAAAACCCAACCGACGCGAAAATCGTGGTTGGCAAAATTATCGATGCTGCCCGT
GCCCGTGAAGCGGCGCGTCGCGCGCGTGAAATGACCCGCCGTAAAGGTGCGCTCGACTTA
GCGGGCCTGCCGGGCAAACTGGCAGACTGCCAGGAACGCGATCCGGCGCTTTCCGAACTG
TACCTGGTGGAAGGGGACTCCGCGGGCGGCTCTGCGAAGCAGGGGCGTAACCGCAAGAAC
CAGGCGATTCTGCCGCTGAAGGGTAAAATCCTCAACGTCGAGAAAGCGCGCTTCGATAAG
ATGCTCTCTTCTCAGGAAGTGGCGACGCTTATCACCGCGCTTGGCTGTGGTATCGGTCGT
GACGAGTACAACCCGGACAAACTGCGTTATCACAGCATCATCATCATGACCGATGCGGAC
GTCGACGGCTCGCACATTCGTACGCTGCTGTTGACCTTCTTCTATCGTCAGATGCCGGAA
ATCGTTGAACGCGGTCACGTCTATATCGCTCAGCCGCCGCTGTACAAAGTGAAGAAAGGC
AAGCAGGAACAGTACATTAAAGACGACGAAGCGATGGATCAGTACCAGATCTCTATCGCG
CTGGACGGCGCAACGCTGCACACCAACGCCAGTGCACCGGCATTGGCTGGCGAAGCGTTA
GAGAAACTGGTATCTGAGTACAACGCGACGCAGAAAATGATCAATCGTATGGAGCGTCGT
TATCCGAAAGCAATGCTGAAAGAGCTTATCTATCAGCCGACGTTGACGGAAGCTGACCTT
TCTGATGAGCAGACCGTTACCCGCTGGGTGAACGCGCTGGTCAGCGAACTGAACGACAAA
GAACAGCACGGCAGCCAGTGGAAGTTTGATGTTCACACCAATGCTGAGCAAAACCTGTTC
GAGCCGATTGTTCGCGTGCGTACCCACGGTGTGGATACTGACTATCCGCTGGATCACGAG
TTTATCACCGGTGGCGAATATCGTCGTATCTGCACGCTGGGTGAGAAACTGCGTGGCTTG
CTGGAAGAAGATGCGTTTATCGAACGTGGCGAGCGTCGTCAGCCGGTAGCCAGCTTCGAG
CAGGCGCTGGACTGGCTGGTGAAAGAGTCCCGTCGCGGCCTCTCCATCCAGCGTTATAAA
GGTCTGGGCGAGATGAACCCGGAACAGCTGTGGGAAACCACTATGGACCCGGAAAGTCGT
CGTATGCTGCGCGTTACCGTTAAAGATGCGATTGCTGCCGACCAGTTGTTCACCACGCTG
ATGGGCGACGCCGTTGAACCGCGCCGTGCGTTTATTGAAGAGAACGCCCTGAAAGCGGCG
AATATCGATATTTAA

# Drug_Target_39_General_Function:
Replication, recombination and repair

# Drug_Target_39_General_References:
1646964	Wigley DB, Davies GJ, Dodson EJ, Maxwell A, Dodson G: Crystal structure of an N-terminal fragment of the DNA gyrase B protein. Nature. 1991 Jun 20;351(6328):624-9.
1656869	Yoshida H, Bogaki M, Nakamura M, Yamanaka LM, Nakamura S: Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother. 1991 Aug;35(8):1647-50.
1846808	Vizan JL, Hernandez-Chico C, del Castillo I, Moreno F: The peptide antibiotic microcin B17 induces double-strand cleavage of DNA mediated by E. coli DNA gyrase. EMBO J. 1991 Feb;10(2):467-76.
2174443	Tamura JK, Gellert M: Characterization of the ATP binding site on Escherichia coli DNA gyrase. Affinity labeling of Lys-103 and Lys-110 of the B subunit by pyridoxal 5'-diphospho-5'-adenosine. J Biol Chem. 1990 Dec 5;265(34):21342-9.
3020376	Yamagishi J, Yoshida H, Yamayoshi M, Nakamura S: Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli. Mol Gen Genet. 1986 Sep;204(3):367-73.
3029031	Menzel R, Gellert M: Fusions of the Escherichia coli gyrA and gyrB control regions to the galactokinase gene are inducible by coumermycin treatment. J Bacteriol. 1987 Mar;169(3):1272-8.
3029692	Adachi T, Mizuuchi M, Robinson EA, Appella E, O'Dea MH, Gellert M, Mizuuchi K: DNA sequence of the E. coli gyrB gene: application of a new sequencing strategy. Nucleic Acids Res. 1987 Jan 26;15(2):771-84.
6089112	Adachi T, Mizuuchi K, Menzel R, Gellert M: DNA sequence and transcription of the region upstream of the E. coli gyrB gene. Nucleic Acids Res. 1984 Aug 24;12(16):6389-95.
7686882	Burland V, Plunkett G 3rd, Daniels DL, Blattner FR: DNA sequence and analysis of 136 kilobases of the Escherichia coli genome: organizational symmetry around the origin of replication. Genomics. 1993 Jun;16(3):551-61.
9148951	Funatsuki K, Tanaka R, Inagaki S, Konno H, Katoh K, Nakamura H: acrB mutation located at carboxyl-terminal region of gyrase B subunit reduces DNA binding of DNA gyrase. J Biol Chem. 1997 May 16;272(20):13302-8.
9245398	Holdgate GA, Tunnicliffe A, Ward WH, Weston SA, Rosenbrock G, Barth PT, Taylor IW, Pauptit RA, Timms D: The entropic penalty of ordered water accounts for weaker binding of the antibiotic novobiocin to a resistant mutant of DNA gyrase: a thermodynamic and crystallographic study. Biochemistry. 1997 Aug 12;36(32):9663-73.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_39_HGNC_ID:
Not Available

# Drug_Target_39_HPRD_ID:
Not Available

# Drug_Target_39_ID:
887

# Drug_Target_39_Locus:
Not Available

# Drug_Target_39_Molecular_Weight:
89820

# Drug_Target_39_Name:
DNA gyrase subunit B

# Drug_Target_39_Number_of_Residues:
803

# Drug_Target_39_PDB_ID:
1EI1

# Drug_Target_39_Pathway:
Not Available

# Drug_Target_39_Pfam_Domain_Function:
PF00204	DNA_gyraseB
PF00986	DNA_gyraseB_C
PF01751	Toprim
PF02518	HATPase_c

# Drug_Target_39_Protein_Sequence:
>DNA gyrase subunit B
SNSYDSSSIKVLKGLDAVRKRPGMYIGDTDDGTGLHHMVFEVVDNAIDEALAGHCKEIIV
TIHADNSVSVQDDGRGIPTGIHPEEGVSAAEVIMTVLHAGGKFDDNSYKVSGGLHGVGVS
VVNALSQKLELVIQREGKIHRQIYEHGVPQAPLAVTGETEKTGTMVRFWPSLETFTNVTE
FEYEILAKRLRELSFLNSGVSIRLRDKRDGKEDHFHYEGGIKAFVEYLNKNKTPIHPNIF
YFSTEKDGIGVEVALQWNDGFQENIYCFTNNIPQRDGGTHLAGFRAAMTRTLNAYMDKEG
YSKKAKVSATGDDAREGLIAVVSVKVPDPKFSSQTKDKLVSSEVKSAVEQQMNELLAEYL
LENPTDAKIVVGKIIDAARAREAARRAREMTRRKGALDLAGLPGKLADCQERDPALSELY
LVEGDSAGGSAKQGRNRKNQAILPLKGKILNVEKARFDKMLSSQEVATLITALGCGIGRD
EYNPDKLRYHSIIIMTDADVDGSHIRTLLLTFFYRQMPEIVERGHVYIAQPPLYKVKKGK
QEQYIKDDEAMDQYQISIALDGATLHTNASAPALAGEALEKLVSEYNATQKMINRMERRY
PKAMLKELIYQPTLTEADLSDEQTVTRWVNALVSELNDKEQHGSQWKFDVHTNAEQNLFE
PIVRVRTHGVDTDYPLDHEFITGGEYRRICTLGEKLRGLLEEDAFIERGERRQPVASFEQ
ALDWLVKESRRGLSIQRYKGLGEMNPEQLWETTMDPESRRMLRVTVKDAIAADQLFTTLM
GDAVEPRRAFIEENALKAANIDI

# Drug_Target_39_Reaction:
ATP-dependent breakage, passage and rejoining of double-stranded DNA INHIBITOR Coumermycin A1; GRI22222X; Nalidixic acid; Novobiocin; Ciprofloxacin

# Drug_Target_39_Signals:
None

# Drug_Target_39_Specific_Function:
DNA gyrase negatively supercoils closed circular double- stranded DNA in an ATP-dependent manner and also catalyzes the interconversion of other topological isomers of double-stranded DNA rings, including catenanes and knotted rings

# Drug_Target_39_SwissProt_ID:
P0AES6

# Drug_Target_39_SwissProt_Name:
GYRB_ECOLI

# Drug_Target_39_Synonyms:
EC 5.99.1.3

# Drug_Target_39_Theoretical_pI:
5.93

# Drug_Target_39_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Not Available

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
Not Available

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
Not Available

# Drug_Target_3_GenBank_ID_Gene:
X63150

# Drug_Target_3_GenBank_ID_Protein:
Not Available

# Drug_Target_3_GeneCard_ID:
Not Available

# Drug_Target_3_Gene_Name:
trwB

# Drug_Target_3_Gene_Sequence:
>1524 bp
ATGCATCCAGACGATCAAAGAAAGGTCAGCGCCGGAATCGTTATTGTCCTGCCGCTTATC
TTTTGGATTACCGCCGTTCAGAAAACGGAGGTACTCGGTTCGCCGAAACTTTTGGCGCTT
TGGGAGCTAATGAAGCTCACCCCACAGAAGCCAATTTTGTTGCTTTCTGCGCTTGGAGGT
TTGGCCGTTGGAGTGTTGTTTGTCTGGCTATTGAATAGCGTCGGACAAGGCGAATTTGGC
GGCGCTCCATTCAAGCGATTTTTGCGCGGAACTCGCATCGTCAGTGGGGGAAAACTCAAA
CGCATGACACGCGAAAAAGCCAAGCAAGTTACCGTTGCTGGTGTACCAATGCCGCGTGAT
GCAGAGCCGCGCCATTTGCTGGTAAATGGTGCCACTGGTACGGGTAAATCGGTGTTGCTT
CGTGAGCTTGCTTATACCGGACTTTTGCGCGGCGACCGCATGGTAATTGTTGACCCGAAT
GGCGATATGTTGTCGAAATTCGGCAGGGATAAAGACATTATCTTGAACCCCTACGATCAG
CGTACAAAGGGTTGGTCTTTCTTCAACGAAATCCGAAATGACTACGACTGGCAGCGTTAT
GCGTTGTCGGTTGTTCCACGCGGAAAGACAGATGAGGCCGAGGAATGGGCCAGCTACGGG
CGCTTGCTGTTACGTGAAACAGCTAAAAAATTGGCGCTTATTGGTACGCCTTCCATGCGC
GAATTGTTCCACTGGACAACCATCGCCACGTTTGACGATTTGCGGGGGTTTCTGGAAGGA
ACTTTGGCCGAATCTTTGTTTGCTGGGTCGAATGAAGCGAGCAAGGCGCTGACCTCAGCG
CGCTTTGTTCTTTCCGACAAATTACCGGAGCATGTCACCATGCCGGACGGTGATTTCAGC
ATTCGTAGTTGGCTGGAAGACCCGAACGGCGGCAATCTGTTCATTACGTGGCGCGAGGAC
ATGGGGCCAGCCTTGCGTCCGTTGATCTCCGCATGGGTTGACGTGGTGTGCACGTCTATT
CTGTCACTACCGGAAGAACCCAAGCGCCGCTTGTGGCTGTTCATCGACGAGTTGGCTTCG
CTGGAAAAGCTGGCGAGCTTGGCCGACGCACTCACCAAAGGCCGAAAGGCAGGGCTTCGG
GTTGTGGCGGGCCTGCAATCGACCTCGCAGCTTGATGACGTGTACGGCGTGAAAGAGGCG
CAGACCCTGCGGGCCAGCTTCCGCTCGCTTGTTGTCCTGGGCGGCTCGCGCACCGACCCG
AAAACCAATGAGGACATGAGTTTGAGCTTGGGCGAGCATGAAGTCGAACGCGACCGCTAC
AGCAAGAACACAGGCAAACACCACAGCACCGGGCGGGCGCTTGAGCGCGTGCGCGAGCGC
GTCGTGATGCCGGCGGAAATCGCCAACTTGCCCGACCTCACCGCCTATGTCGGCTTTGCC
GGTAATCGGCCAATTGCCAAGGTTCCGCTTGAAATCAAGCAGTTTGCAAACCGGCAACCG
GCCTTTGTTGAGGGGACTATCTAA

# Drug_Target_3_General_Function:
Intracellular trafficking, secretion, and vesicular transport

# Drug_Target_3_General_References:
11959558	Partridge SR, Brown HJ, Hall RM: Characterization and movement of the class 1 integron known as Tn2521 and Tn1405. Antimicrob Agents Chemother. 2002 May;46(5):1288-94.
12533481	Rabel C, Grahn AM, Lurz R, Lanka E: The VirB4 family of proposed traffic nucleoside triphosphatases: common motifs in plasmid RP4 TrbE are essential for conjugation and phage adsorption. J Bacteriol. 2003 Feb;185(3):1045-58.
2038309	Llosa M, Bolland S, de la Cruz F: Structural and functional analysis of the origin of conjugal transfer of the broad-host-range IncW plasmid R388 and comparison with the related IncN plasmid R46. Mol Gen Genet. 1991 May;226(3):473-83.
3054482	Sundstrom L, Radstrom P, Swedberg G, Skold O: Site-specific recombination promotes linkage between trimethoprim- and sulfonamide resistance genes. Sequence characterization of dhfrV and sulI and a recombination active locus of Tn21. Mol Gen Genet. 1988 Aug;213(2-3):191-201.
7022127	Swift G, McCarthy BJ, Heffron F: DNA sequence of a plasmid-encoded dihydrofolate reductase. Mol Gen Genet. 1981;181(4):441-7.
7929000	Hall RM, Brown HJ, Brookes DE, Stokes HW: Integrons found in different locations have identical 5' ends but variable 3' ends. J Bacteriol. 1994 Oct;176(20):6286-94.
8289274	Llosa M, Bolland S, de la Cruz F: Genetic organization of the conjugal DNA processing region of the IncW plasmid R388. J Mol Biol. 1994 Jan 14;235(2):448-64.
9325277	Rivas S, Bolland S, Cabezon E, Goni FM, de la Cruz F: TrwD, a protein encoded by the IncW plasmid R388, displays an ATP hydrolase activity essential for bacterial conjugation. J Biol Chem. 1997 Oct 10;272(41):25583-90.

# Drug_Target_3_HGNC_ID:
Not Available

# Drug_Target_3_HPRD_ID:
Not Available

# Drug_Target_3_ID:
5302

# Drug_Target_3_Locus:
Not Available

# Drug_Target_3_Molecular_Weight:
56274

# Drug_Target_3_Name:
TrwB

# Drug_Target_3_Number_of_Residues:
507

# Drug_Target_3_PDB_ID:
1GL7

# Drug_Target_3_Pathway:
Not Available

# Drug_Target_3_Pfam_Domain_Function:
Not Available

# Drug_Target_3_Protein_Sequence:
>TrwB
MHPDDQRKVSAGIVIVLPLIFWITAVQKTEVLGSPKLLALWELMKLTPQKPILLLSALGG
LAVGVLFVWLLNSVGQGEFGGAPFKRFLRGTRIVSGGKLKRMTREKAKQVTVAGVPMPRD
AEPRHLLVNGATGTGKSVLLRELAYTGLLRGDRMVIVDPNGDMLSKFGRDKDIILNPYDQ
RTKGWSFFNEIRNDYDWQRYALSVVPRGKTDEAEEWASYGRLLLRETAKKLALIGTPSMR
ELFHWTTIATFDDLRGFLEGTLAESLFAGSNEASKALTSARFVLSDKLPEHVTMPDGDFS
IRSWLEDPNGGNLFITWREDMGPALRPLISAWVDVVCTSILSLPEEPKRRLWLFIDELAS
LEKLASLADALTKGRKAGLRVVAGLQSTSQLDDVYGVKEAQTLRASFRSLVVLGGSRTDP
KTNEDMSLSLGEHEVERDRYSKNTGKHHSTGRALERVRERVVMPAEIANLPDLTAYVGFA
GNRPIAKVPLEIKQFANRQPAFVEGTI

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Not Available

# Drug_Target_3_SwissProt_ID:
Q04230

# Drug_Target_3_SwissProt_Name:
Q04230_ECOLX

# Drug_Target_3_Synonyms:
Not Available

# Drug_Target_3_Theoretical_pI:
9.87

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_40_Cellular_Location:
Not Available

# Drug_Target_40_Chromosome_Location:
Not Available

# Drug_Target_40_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_40_Essentiality:
Non-Essential

# Drug_Target_40_GenAtlas_ID:
Not Available

# Drug_Target_40_GenBank_ID_Gene:
Z11831

# Drug_Target_40_GenBank_ID_Protein:
42067

# Drug_Target_40_GeneCard_ID:
Not Available

# Drug_Target_40_Gene_Name:
mutL

# Drug_Target_40_Gene_Sequence:
>1848 bp
ATGCCAATTCAGGTCTTACCGCCACAACTGGCGAACCAGATTGCCGCAGGTGAGGTGGTC
GAGCGACCTGCGTCGGTAGTCAAAGAACTAGTGGAAAACAGCCTCGATGCAGGTGCGACG
CGTATCGATATTGATATCGAACGCGGTGGGGCGAAACTTATCCGCATTCGTGATAACGGC
TGCGGTATCAAAAAAGATGAGCTGGCGCTGGCGCTGGCTCGTCATGCCACCAGTAAAATC
GCCTCTCTGGACGATCTCGAAGCCATTATCAGCCTGGGCTTTCGCGGTGAGGCGCTGGCG
AGTATCAGTTCGGTTTCCCGCCTGACGCTCACTTCACGCACCGCAGAACAGCAGGAAGCC
TGGCAGGCCTATGCCGAAGGGCGCGATATGAACGTGACGGTAAAACCGGCGGCGCATCCT
GTGGGGACGACGCTGGAGGTGCTGGATCTGTTCTACAACACCCCGGCGCGGCGCAAATTC
CTGCGCACCGAGAAAACCGAATTTAACCACATTGATGAGATCATCCGCCGCATTGCGCTG
GCGCGTTTCGACGTCACGATCAACCTGTCGCATAACGGTAAAATTGTGCGTCAGTACCGC
GCAGTGCCGGAAGGCGGGCAAAAAGAACGGCGCTTAGGCGCGATTTGCGGCACCGCTTTT
CTTGAACAAGCGCTGGCGATTGAATGGCAACACGGCGATCTCACGCTACGCGGCTGGGTG
GCCGATCCAAATCACACCACGCCCGCACTGGCAGAAATTCAGTATTGCTACGTGAACGGT
CGCATGATGCGCGATCGCCTGATCAATCACGCGATCCGCCAGGCCTGCGAAGACAAACTG
GGGGCCGATCAGCAACCGGCATTTGTGTTGTATCTGGAGATCGACCCACATCAGGTGGAC
GTCAACGTGCACCCCGCCAAACACGAAGTGCGTTTCCATCAGTCGCGTCTGGTGCATGAT
TTTATCTATCAGGGCGTGCTGAGCGTGCTACAACAGCAACTGGAAACGCCGCTACCGCTG
GACGATGAACCCCAACCTGCACCGCGTTCCATTCCGGAAAACCGCGTGGCGGCGGGGCGC
AATCACTTTGCAGAACCGGCAGCTCGTGAGCCGGTAGCTCCGCGCTACACTCCTGCGCCA
GCATCAGGCAGTCGTCCGGCTGCCCCCTGGCCGAATGCGCAGCCAGGCTACCAGAAACAG
CAAGGTGAAGTGTATCGCCAGCTTTTGCAAACGCCCGCGCCGATGCAAAAATTAAAAGCG
CCGGAACCGCAGGAACCTGCACTTGCGGCGAACAGTCAGAGTTTTGGTCGGGTACTGACT
ATCGTCCATTCCGACTGTGCGTTGCTGGAGCGCGACGGCAACATTTCACTTTTATCCTTG
CCAGTGGCAGAACGTTGGCTGCGTCAGGCACAATTGACGCCGGGTGAAGCGCCCGTTTGC
GCCCAGCCGCTGCTGATTCCGTTGCGGCTAAAAGTTTCTGCCGAAGAAAAATCGGCATTA
GAAAAAGCGCAGTCTGCCCTGGCGGAATTGGGTATTGATTTCCAGTCAGATGCACAGCAT
GTGACCATCAGGGCAGTGCCTTTACCCTTACGCCAACAAAATTTACAAATCTTGATTCCT
GAACTGATAGGCTACCTGGCGAAGCAGTCCGTATTCGAACCTGGCAATATTGCGCAGTGG
ATTGCACGAAATCTGATGAGCGAACATGCGCAGTGGTCAATGGCACAGGCCATAACCCTG
CTGGCGGACGTGGAACGGTTATGTCCGCAACTTGTGAAAACGCCGCCGGGTGGTCTGTTA
CAATCTGTTGATTTACATCCGGCGATAAAAGCCCTGAAAGATGAGTGA

# Drug_Target_40_General_Function:
Replication, recombination and repair

# Drug_Target_40_General_References:
10199405	Ban C, Junop M, Yang W: Transformation of MutL by ATP binding and hydrolysis: a switch in DNA mismatch repair. Cell. 1999 Apr 2;97(1):85-97.
1594459	Tsui HT, Mandavilli BS, Winkler ME: Nonconserved segment of the MutL protein from Escherichia coli K-12 and Salmonella typhimurium. Nucleic Acids Res. 1992 May 11;20(9):2379.
1999389	Connolly DM, Winkler ME: Structure of Escherichia coli K-12 miaA and characterization of the mutator phenotype caused by miaA insertion mutations. J Bacteriol. 1991 Mar;173(5):1711-21.
7511774	Tsui HC, Zhao G, Feng G, Leung HC, Winkler ME: The mutL repair gene of Escherichia coli K-12 forms a superoperon with a gene encoding a new cell-wall amidase. Mol Microbiol. 1994 Jan;11(1):189-202.
7610040	Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL, Blattner FR: Analysis of the Escherichia coli genome VI: DNA sequence of the region from 92.8 through 100 minutes. Nucleic Acids Res. 1995 Jun 25;23(12):2105-19.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.
9827806	Ban C, Yang W: Crystal structure and ATPase activity of MutL: implications for DNA repair and mutagenesis. Cell. 1998 Nov 13;95(4):541-52.

# Drug_Target_40_HGNC_ID:
Not Available

# Drug_Target_40_HPRD_ID:
Not Available

# Drug_Target_40_ID:
2852

# Drug_Target_40_Locus:
Not Available

# Drug_Target_40_Molecular_Weight:
67925

# Drug_Target_40_Name:
DNA mismatch repair protein mutL

# Drug_Target_40_Number_of_Residues:
615

# Drug_Target_40_PDB_ID:
1B62

# Drug_Target_40_Pathway:
Not Available

# Drug_Target_40_Pfam_Domain_Function:
PF01119	DNA_mis_repair
PF02518	HATPase_c
PF08676	MutL_C

# Drug_Target_40_Protein_Sequence:
>DNA mismatch repair protein mutL
MPIQVLPPQLANQIAAGEVVERPASVVKELVENSLDAGATRIDIDIERGGAKLIRIRDNG
CGIKKDELALALARHATSKIASLDDLEAIISLGFRGEALASISSVSRLTLTSRTAEQQEA
WQAYAEGRDMNVTVKPAAHPVGTTLEVLDLFYNTPARRKFLRTEKTEFNHIDEIIRRIAL
ARFDVTINLSHNGKIVRQYRAVPEGGQKERRLGAICGTAFLEQALAIEWQHGDLTLRGWV
ADPNHTTPALAEIQYCYVNGRMMRDRLINHAIRQACEDKLGADQQPAFVLYLEIDPHQVD
VNVHPAKHEVRFHQSRLVHDFIYQGVLSVLQQQLETPLPLDDEPQPAPRSIPENRVAAGR
NHFAEPAAREPVAPRYTPAPASGSRPAAPWPNAQPGYQKQQGEVYRQLLQTPAPMQKLKA
PEPQEPALAANSQSFGRVLTIVHSDCALLERDGNISLLSLPVAERWLRQAQLTPGEAPVC
AQPLLIPLRLKVSAEEKSALEKAQSALAELGIDFQSDAQHVTIRAVPLPLRQQNLQILIP
ELIGYLAKQSVFEPGNIAQWIARNLMSEHAQWSMAQAITLLADVERLCPQLVKTPPGGLL
QSVDLHPAIKALKDE

# Drug_Target_40_Reaction:
Not Available

# Drug_Target_40_Signals:
None

# Drug_Target_40_Specific_Function:
This protein is involved in the repair of mismatches in DNA. It is required for dam-dependent methyl-directed DNA mismatch repair. May act as a "molecular matchmaker", a protein that promotes the formation of a stable complex between two or more DNA-binding proteins in an ATP-dependent manner without itself being part of the final effector complex. The ATPase activity of mutL is stimulated by DNA

# Drug_Target_40_SwissProt_ID:
P23367

# Drug_Target_40_SwissProt_Name:
MUTL_ECOLI

# Drug_Target_40_Synonyms:
Not Available

# Drug_Target_40_Theoretical_pI:
6.76

# Drug_Target_40_Transmembrane_Regions:
None

# Drug_Target_41_Cellular_Location:
Not Available

# Drug_Target_41_Chromosome_Location:
Not Available

# Drug_Target_41_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_41_Essentiality:
Non-Essential

# Drug_Target_41_GenAtlas_ID:
Not Available

# Drug_Target_41_GenBank_ID_Gene:
Not Available

# Drug_Target_41_GenBank_ID_Protein:
Not Available

# Drug_Target_41_GeneCard_ID:
Not Available

# Drug_Target_41_Gene_Name:
KIF2C

# Drug_Target_41_Gene_Sequence:
Not Available

# Drug_Target_41_General_Function:
Not Available

# Drug_Target_41_General_References:
Not Available

# Drug_Target_41_HGNC_ID:
Not Available

# Drug_Target_41_HPRD_ID:
Not Available

# Drug_Target_41_ID:
7132

# Drug_Target_41_Locus:
Not Available

# Drug_Target_41_Molecular_Weight:
Not Available

# Drug_Target_41_Name:
Kinesin-like protein KIF2C

# Drug_Target_41_Number_of_Residues:
0

# Drug_Target_41_PDB_ID:
Not Available

# Drug_Target_41_Pathway:
Not Available

# Drug_Target_41_Pfam_Domain_Function:
Not Available

# Drug_Target_41_Protein_Sequence:
Not Available

# Drug_Target_41_Reaction:
Not Available

# Drug_Target_41_Signals:
Not Available

# Drug_Target_41_Specific_Function:
Not Available

# Drug_Target_41_SwissProt_ID:
Q99661

# Drug_Target_41_SwissProt_Name:
KIF2C_HUMAN

# Drug_Target_41_Synonyms:
Not Available

# Drug_Target_41_Theoretical_pI:
Not Available

# Drug_Target_41_Transmembrane_Regions:
Not Available

# Drug_Target_42_Cellular_Location:
Not Available

# Drug_Target_42_Chromosome_Location:
Not Available

# Drug_Target_42_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_42_Essentiality:
Non-Essential

# Drug_Target_42_GenAtlas_ID:
ITPKA

# Drug_Target_42_GenBank_ID_Gene:
X54938

# Drug_Target_42_GenBank_ID_Protein:
32105

# Drug_Target_42_GeneCard_ID:
ITPKA

# Drug_Target_42_Gene_Name:
ITPKA

# Drug_Target_42_Gene_Sequence:
>1386 bp
ATGACCCTGCCCGGGGGCCCAACGGGCATGGCGCGGCCGGGGGGCGCGAGGCCCTGCAGC
CCGGGGCTGGAGCGGGCCCCGCGCCGGAGTGTCGGGGAGCTGCGCCTGCTCTTCGAGGCG
CGCTGTGCGGCGGTCGCTGCGGCCGCCGCCGCGGGGGAGCCCCGGGCCCGCGGGGCCAAG
CGGCGTGGGGGACAGGTCCCCAACGGGCTTCCGCGGGCTCCCCCGGCCCCGGTGATCCCT
CAGCTGACCGTGACAGCCGAGGAGCCCGACGTGCCCCCGACCAGCCCTGGGCCGCCGGAG
CGGGAGAGGGACTGCCTCCCGGCAGCGGGCTCTTCGCACCTGCAGCAGCCGCGCCGCCTT
TCCACCTCGTCGGTCTCCTCCACTGGCTCCTCGTCGCTGCTCGAGGACTCGGAGGACGAC
CTGCTGAGCGACAGTGAGAGCCGGAGCCGCGGCAACGTGCAGCTGGAAGCGGGCGAGGAC
GTGGGTCAGAAAAACCACTGGCAGAAGATCCGGACCATGGTCAATCTGCCGGTCATAAGC
CCTTTCAAGAAGCGCTACGCCTGGGTGCAGCTGGCAGGGCACACTGGGAGTTTTAAGGCG
GCGGGCACCAGCGGGCTGATCCTGAAGCGCTGCTCGGAGCCGGAGCGCTACTGCCTGGCG
CGGCTGATGGCTGACGCGCTGCGCGGCTGCGTGCCTGCCTTCCACGGCGTGGTGGAGCGC
GACGGCGAAAGCTACCTGCAGCTGCAGGACCTGCTCGATGGCTTCGACGGACCTTGTGTG
CTCGACTGCAAAATGGGCGTCAGGACTTACCTAGAGGAGGAGCTGACCAAGGCCCGTGAG
CGGCCCAAGCTGCGGAAGGACATGTACAAGAAAATGCTGGCGGTGGATCCTGAAGCTCCC
ACGGAGGAGGAGCACGCGCAGCGCGCCGTCACCAAGCCGCGCTACATGCAGTGGCGGGAA
GGCATCAGCTCCAGCACCACCCTCGGCTTCCGCATCGAGGGCATCAAGAAAGCGGACGGC
TCCTGCAGCACCGACTTCAAGACTACGCGAAGCCGAGAGCAGGTGCTTCGCGTCTTTGAA
GAGTTTGTGCAAGGAGATGAGGAAGTGCTGAGGCGGTATCTGAACCGCCTGCAGCAGATC
CGGGACACCCTGGAGGTATCCGAGTTCTTCAGGAGGCACGAGGTGATCGGCAGCTCGCTC
CTCTTTGTGCACGATCACTGCCATCGCGCCGGCGTGTGGCTCATCGACTTCGGCAAGACC
ACGCCCCTCCCCGATGGCCAGATCCTGGACCACCGGCGGCCCTGGGAGGAGGGCAACCGC
GAGGACGGCTATTTGCTGGGGCTGGACAATCTCATTGGCATCCTGGCCAGCCTGGCTGAG
AGATGA

# Drug_Target_42_General_Function:
Involved in inositol trisphosphate 3-kinase activity

# Drug_Target_42_General_References:
1847047	Takazawa K, Perret J, Dumont JE, Erneux C: Molecular cloning and expression of a human brain inositol 1,4,5-trisphosphate 3-kinase. Biochem Biophys Res Commun. 1991 Jan 31;174(2):529-35.
2175886	Takazawa K, Perret J, Dumont JE, Erneux C: Human brain inositol 1,4,5-trisphosphate 3-kinase cDNA sequence. Nucleic Acids Res. 1990 Dec 11;18(23):7141.

# Drug_Target_42_HGNC_ID:
HGNC:6178

# Drug_Target_42_HPRD_ID:
00941

# Drug_Target_42_ID:
2950

# Drug_Target_42_Locus:
15q14-q21

# Drug_Target_42_Molecular_Weight:
51009

# Drug_Target_42_Name:
Inositol-trisphosphate 3-kinase A

# Drug_Target_42_Number_of_Residues:
461

# Drug_Target_42_PDB_ID:
1W2F

# Drug_Target_42_Pathway:
Not Available

# Drug_Target_42_Pfam_Domain_Function:
PF03770	IPK

# Drug_Target_42_Protein_Sequence:
>Inositol-trisphosphate 3-kinase A
MTLPGGPTGMARPGGARPCSPGLERAPRRSVGELRLLFEARCAAVAAAAAAGEPRARGAK
RRGGQVPNGLPRAPPAPVIPQLTVTAEEPDVPPTSPGPPERERDCLPAAGSSHLQQPRRL
STSSVSSTGSSSLLEDSEDDLLSDSESRSRGNVQLEAGEDVGQKNHWQKIRTMVNLPVIS
PFKKRYAWVQLAGHTGSFKAAGTSGLILKRCSEPERYCLARLMADALRGCVPAFHGVVER
DGESYLQLQDLLDGFDGPCVLDCKMGVRTYLEEELTKARERPKLRKDMYKKMLAVDPEAP
TEEEHAQRAVTKPRYMQWREGISSSTTLGFRIEGIKKADGSCSTDFKTTRSREQVLRVFE
EFVQGDEEVLRRYLNRLQQIRDTLEVSEFFRRHEVIGSSLLFVHDHCHRAGVWLIDFGKT
TPLPDGQILDHRRPWEEGNREDGYLLGLDNLIGILASLAER

# Drug_Target_42_Reaction:
ATP + 1D-myo-inositol 1,4,5-trisphosphate = ADP + 1D-myo-inositol 1,3,4,5-tetrakisphosphate

# Drug_Target_42_Signals:
None

# Drug_Target_42_Specific_Function:
ATP + 1D-myo-inositol 1,4,5-trisphosphate = ADP + 1D-myo-inositol 1,3,4,5-tetrakisphosphate

# Drug_Target_42_SwissProt_ID:
P23677

# Drug_Target_42_SwissProt_Name:
IP3KA_HUMAN

# Drug_Target_42_Synonyms:
EC 2.7.1.127
IP3 3-kinase A
IP3K A
Inositol 1,4,5- trisphosphate 3-kinase A

# Drug_Target_42_Theoretical_pI:
7.72

# Drug_Target_42_Transmembrane_Regions:
None

# Drug_Target_43_Cellular_Location:
Cytoplasm. Nucleus

# Drug_Target_43_Chromosome_Location:
Not Available

# Drug_Target_43_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_43_Essentiality:
Non-Essential

# Drug_Target_43_GenAtlas_ID:
TOP2B

# Drug_Target_43_GenBank_ID_Gene:
X68060

# Drug_Target_43_GenBank_ID_Protein:
Not Available

# Drug_Target_43_GeneCard_ID:
Not Available

# Drug_Target_43_Gene_Name:
TOP2B

# Drug_Target_43_Gene_Sequence:
>4866 bp
ATGGCCAAGTCGGGTGGCTGCGGCGCGGGAGCCGGCGTGGGCGGCGGCAACGGGGCACTG
ACCTGGGTGAACAATGCTGCAAAAAAAGAAGAGTCAGAAACTGCCAACAAAAATGATTCT
TCAAAGAAGTTGTCTGTTGAGAGAGTGTATCAGAAGAAGACACAACTTGAACACATTCTT
CTTCGTCCTGATACATATATTGGGTCAGTGGAGCCATTGACGCAGTTCATGTGGGTGTAT
GATGAAGATGTAGGAATGAATTGCAGGGAGGTTACCTTTGTGCCAGGTTTATACAAGATC
TTTGATGAAATTTTGGTTAATGCTGCTGACAATAAACAGAGGGATAAGAACATGACTTGT
ATTAAAGTTTCTATTGATCCTGAATCTAACATTATAAGCATTTGGAATAATGGGAAAGGC
ATTCCAGTAGTAGAACACAAGGTAGAGAAAGTTTATGTTCCTGCTTTAATTTTTGGACAG
CTTTTAACATCCAGTAACTATGATGATGATGAGAAAAAAGTTACAGGTGGTCGTAATGGT
TATGGTGCAAAACTTTGTAATATTTTCAGTACAAAGTTTACAGTAGAAACAGCTTGCAAA
GAATACAAACACAGTTTTAAGCAGACATGGATGAATAATATGATGAAGACTTCTGAAGCC
AAAATTAAACATTTTGATGGTGAAGATTACACATGCATAACATTCCAACCAGATCTGTCC
AAATTTAAGATGGAAAAACTTGACAAGGATATTGTGGCCCTCATGACTAGAAGGGCATAT
GATTTGGCTGGTTCGTGTAGAGGGGTCAAGGTCATGTTTAATGGAAAGAAATTGCCTGTA
AATGGATTTCGCAGTTATGTAGATCTTTATGTGAAAGACAAATTGGATGAAACTGGGGTG
GCCCTGAAAGTTATTCATGAGCTTGCAAATGAAAGATGGGATGTTTGTCTCACATTGAGT
GAAAAAGGATTCCAGCAAATCAGCTTTGTAAATAGTATTGCAACTACAAAAGGTGGACGG
CACGTGGATTATGTGGTAGATCAAGTTGTTGGTAAACTGATTGAAGTAGTTAAGAAAAAG
AACAAAGCTGGTGTATCAGTGAAACCATTTCAAGTAAAAAACCATATATGGGTTTTTATT
AATTGCCTTATTGAAAATCCAACTTTTGATTCTCAGACTAAGGAAAACATGACTCTGCAG
CCCAAAAGTTTTGGGTCTAAATGCCAGCTGTCAGAAAAATTTTTTAAAGCAGCCTCTAAT
TGTGGCATTGTAGAAAGTATCCTGAACTGGGTGAAATTTAAGGCTCAGACTCAGCTGAAT
AAGAAGTGTTCATCAGTAAAATACAGTAAAATCAAAGGTATTCCCAAACTGGATGATGCT
AATGATGCTGGTGGTAAACATTCCCTGGAGTGTACACTGATATTAACAGAGGGAGACTCT
GCCAAATCACTGGCTGTGTCTGGATTAGGTGTGATTGGACGAGACAGATACGGAGTTTTT
CCACTCAGGGGCAAAATTCTTAATGTACGGGAAGCTTCTCATAAACAGATCATGGAAAAT
GCTGAAATAAATAATATTATTAAAATAGTTGGTCTACAATATAAGAAAAGTTACGATGAT
GCAGAATCTCTGAAAACCTTACGCTATGGAAAGATTATGATTATGACCGATCAGGATCAA
GATGGTTCTCACATAAAAGGCCTGCTTATTAATTTCATCCATCACAATTGGCCATCACTT
TTGAAGCATGGTTTTCTTGAAGAGTTCATTACTCCTATTGTAAAGGCAAGCAAAAATAAG
CAGGAACTTTCCTTCTACAGTATTCCTGAATTTGACGAATGGAAAAAACATATAGAAAAC
CAGAAAGCCTGGAAAATAAAGTACTATAAAGGATTGGGTACTAGTACAGCTAAAGAAGCA
AAGGAATATTTTGCTGATATGGAAAGGCATCGCATCTTGTTTAGATATGCTGGTCCTGAA
GATGATGCTGCCATTACCTTGGCATTTAGTAAGAAGAAGATTGATGACAGAAAAGAATGG
TTAACAAATTTTATGGAAGACCGGAGACAGCGTAGGCTACATGGCTTACCAGAGCAATTT
TTATATGGTACTGCAACAAAGCATTTGACTTATAATGATTTCATCAACAAGGAATTGATT
CTCTTCTCAAACTCAGACAATGAAAGATCTATACCATCTCTTGTTGATGGCTTTAAACCT
GGCCAGCGGAAAGTTTTATTTACCTGTTTCAAGAGGAATGATAAACGTGAAGTAAAAGTT
GCCCAGTTGGCTGGCTCTGTTGCTGAGATGTCGGCTTATCATCATGGAGAACAAGCATTG
ATGATGACTATTGTGAATTTGGCTCAGAACTTTGTGGGAAGTAACAACATTAACTTGCTT
CAGCCTATTGGTCAGTTTGGAACTCGGCTTCATGGTGGCAAAGATGCTGCAAGCCCTCGT
TATATTTTCACAATGTTAAGCACTTTAGCAAGGCTACTTTTTCCTGCTGTGGATGACAAC
CTCCTTAAGTTCCTTTATGATGATAATCAACGTGTAGAGCCTGAGTGGTATATTCCTATA
ATTCCCATGGTTTTAATAAATGGTGCTGAGGGCATTGGTACTGGATGGGCTTGTAAACTA
CCCAACTATGATGCTAGGGAAATTGTGAACAATGTCAGACGAATGCTAGATGGCCTGGAT
CCTCATCCCATGCTTCCAAACTACAAAAACTTTAAAGGCACGATTCAAGAACTTGGTCAA
AACCAGTATGCAGTCAGTGGTGAAATATTTGTAGTGGACAGAAACACAGTAGAAATTACA
GAGCTTCCAGTTAGAACTTGGACACAGGTATATAAAGAACAGGTTTTAGAACCTATGCTA
AATGGAACAGATAAAACACCAGCATTAATTTCTGATTATAAAGAATATCATACTGACACA
ACTGTGAAATTTGTGGTGAAAATGACTGAAGAGAAACTAGCACAAGCAGAAGCTGCTGGA
CTGCATAAAGTTTTTAAACTTCAAACTACTCTTACTTGTAATTCCATGGTACTTTTTGAT
CATATGGGATGTCTGAAGAAATATGAAACTGTGCAAGACATTCTGAAAGAATTCTTTGAT
TTACGATTAAGTTATTACGGTTTACGTAAGGAGTGGCTTGTGGGAATGTTGGGAGCAGAA
TCTACAAAGCTTAACAATCAAGCCCGTTTCATTTTAGAGAAGATACAAGGGAAAATTACT
ATAGAGAATAGGTCAAAGAAAGATTTGATTCAAATGTTAGTCCAGAGAGGTTATGAATCT
GACCCAGTGAAAGCCTGGAAAGAAGCACAAGAAAAGGCAGCAGAAGAGGATGAAACACAA
AACCAGCATGATGATAGTTCCTCCGATTCAGGAACTCCTTCAGGCCCAGATTTTAATTAT
ATTTTAAATATGTCTCTGTGGTCTCTTACTAAAGAAAAAGTTGAAGAACTGATTAAACAG
AGAGATGCAAAAGGGCGAGAGGTCAATGATCTTAAAAGAAAATCTCCTTCAGATCTTTGG
AAAGAGGATTTAGCGGCATTTGTTGAAGAACTGGATAAAGTGGAATCTCAAGAACGAGAA
GATGTTCTGGCTGGAATGTCTGGAAAAGCAATTAAAGGTAAAGTTGGCAAACCTAAGGTG
AAGAAACTCCAGTTGGAAGAGACAATGCCCTCACCTTATGGCAGAAGAATAATTCCTGAA
ATTACAGCTATGAAGGCAGATGCCAGCAAAAAGTTGCTGAAGAAGAAGAAGGGTGATCTT
GATACTGCAGCAGTAAAAGTGGAATTTGATGAAGAATTCAGTGGAGCACCAGTAGAAGGT
GCAGGAGAAGAGGCATTGACTCCATCAGTTCCTATAAATAAAGGTCCCAAACCTAAGAGG
GAGAAGAAGGAGCCTGGTACCAGAGTGAGAAAAACACCTACATCATCTGGTAAACCTAGT
GCAAAGAAAGTGAAGAAACGGAATCCTTGGTCAGATGATGAATCCAAGTCAGAAAGTGAT
TTGGAAGAAACAGAACCTGTGGTTATTCCAAGAGATTCTTTGCTTAGGAGAGCAGCAGCC
GAAAGACCTAAATACACATTTGATTTCTCAGAAGAAGAGGATGATGATGCTGATGATGAT
GATGATGACAATAATGATTTAGAGGAATTGAAAGTTAAAGCATCTCCCATAACAAATGAT
GGGGAAGATGAATTTGTTCCTTCAGATGGGTTAGATAAAGATGAATATACATTTTCACCA
GGCAAATCAAAAGCCACTCCAGAAAAATCTTTGCATGACAAAAAAAGTCAGGATTTTGGA
AATCTCTTCTCATTTCCTTCATATTCTCAGAAGTCAGAAGATGATTCAGCTAAATTTGAC
AGTAATGAAGAAGATTCTGCTTCTGTTTTTTCACCATCATTTGGTCTGAAACAGACAGAT
AAAGTTCCAAGTAAAACGGTAGCTGCTAAAAAGGGAAAACCGTCTTCAGATACAGTCCCT
AAGCCCAAGAGAGCCCCAAAACAGAAGAAAGTAGTAGAGGCTGTAAACTCTGACTCGGAT
TCAGAATTTGGCATTCCAAAGAAGACTACAACACCAAAAGGTAAAGGCCGAGGGGCAAAG
AAAAGGAAAGCATCTGGCTCTGAAAATGAAGGCGATTATAACCCTGGCAGGAAAACATCC
AAAACAACAAGCAAGAAACCGAAGAAGACATCTTTTGATCAGGATTCAGATGTGGACATC
TTCCCCTCAGACTTCCCTACTGAGCCACCTTCTCTGCCACGAACCGGTCGGGCTAGGAAA
GAAGTAAAATATTTTACAGAGTCTGATGAAGAAGAAGATGATGTTGATTTTGCAATGTTT
AATTAA

# Drug_Target_43_General_Function:
Involved in ATP binding

# Drug_Target_43_General_References:
10095062	Sng JH, Heaton VJ, Bell M, Maini P, Austin CA, Fisher LM: Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication. Biochim Biophys Acta. 1999 Mar 19;1444(3):395-406.
12821127	Mirski SE, Bielawski JC, Cole SP: Identification of functional nuclear export sequences in human topoisomerase IIalpha and beta. Biochem Biophys Res Commun. 2003 Jul 11;306(4):905-11.
1333583	Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D, Hickson ID: Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res. 1992 Nov 11;20(21):5587-92.
2163884	Austin CA, Fisher LM: Isolation and characterization of a human cDNA clone encoding a novel DNA topoisomerase II homologue from HeLa cells. FEBS Lett. 1990 Jun 18;266(1-2):115-7.
2556712	Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK: Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9431-5.
8383537	Austin CA, Sng JH, Patel S, Fisher LM: Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta. 1993 Mar 20;1172(3):283-91.
8396237	Davies SL, Jenkins JR, Hickson ID: Human cells express two differentially spliced forms of topoisomerase II beta mRNA. Nucleic Acids Res. 1993 Aug 11;21(16):3719-23.

# Drug_Target_43_HGNC_ID:
HGNC:11990

# Drug_Target_43_HPRD_ID:
Not Available

# Drug_Target_43_ID:
4192

# Drug_Target_43_Locus:
3p24

# Drug_Target_43_Molecular_Weight:
183269

# Drug_Target_43_Name:
DNA topoisomerase 2-beta

# Drug_Target_43_Number_of_Residues:
1626

# Drug_Target_43_PDB_ID:
Not Available

# Drug_Target_43_Pathway:
Not Available

# Drug_Target_43_Pfam_Domain_Function:
PF00204	DNA_gyraseB
PF00521	DNA_topoisoIV
PF02518	HATPase_c
PF08070	DTHCT

# Drug_Target_43_Protein_Sequence:
>DNA topoisomerase 2-beta
MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQ
LEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRD
KNMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVT
GGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNNMMKTSEAKIKHFDGEDYTCITF
QPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKL
DETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIE
VVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKENMTLQPKSFGSKCQLSEKFF
KAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLIL
TEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYK
KSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVK
ASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFR
YAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFI
NKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHH
GEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFP
AVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRM
LDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQV
LEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNS
MVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKI
QGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSG
PDFNYILNMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVE
SQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKK
KKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTS
SGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDD
DADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKK
SQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPS
SDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNP
GRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDV
DFAMFN

# Drug_Target_43_Reaction:
Not Available

# Drug_Target_43_Signals:
None

# Drug_Target_43_Specific_Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks

# Drug_Target_43_SwissProt_ID:
Q02880

# Drug_Target_43_SwissProt_Name:
TOP2B_HUMAN

# Drug_Target_43_Synonyms:
DNA topoisomerase II, beta isozyme
EC 5.99.1.3

# Drug_Target_43_Theoretical_pI:
8.16

# Drug_Target_43_Transmembrane_Regions:
None

# Drug_Target_44_Cellular_Location:
Not Available

# Drug_Target_44_Chromosome_Location:
Not Available

# Drug_Target_44_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_44_Essentiality:
Non-Essential

# Drug_Target_44_GenAtlas_ID:
GSS

# Drug_Target_44_GenBank_ID_Gene:
L42531

# Drug_Target_44_GenBank_ID_Protein:
886284

# Drug_Target_44_GeneCard_ID:
GSS

# Drug_Target_44_Gene_Name:
GSS

# Drug_Target_44_Gene_Sequence:
>1425 bp
ATGGCCACCAACTGGGGGAGCCTCTTGCAGGATAAACAGCAGCTAGAGGAGCTGGCACGG
CAGGCCGTGGACCGGGCCCTGGCTGAGGGAGTATTGCTGAGGACCTCACAGGAGCCCACT
TCCTCGGAGGTGGTGAGCTATGCCCCATTCACGCTCTTCCCCTCACTGGTCCCCAGTGCC
CTGCTGGAGCAAGCCTATGCTGTGCAGATGGACTTCAACCTGCTAGTGGATGCTGTCAGC
CAGAACGCTGCCTTCCTGGAGCAAACTCTTTCCAGCACCATCAAACAGGATGACTTTACC
GCTCGTCTCTTTGACATCCACAAGCAAGTCCTAAAAGAGGGCATTGCCCAGACTGTGTTC
CTGGGCCTGAATCGCTCAGACTACATGTTCCAGCGCAGCGCAGATGGCTCCCCAGCCCTG
AAACAGATCGAAATCAACACCATCTCTGCCAGCTTTGGGGGCCTGGCCTCCCGGACCCCA
GCTGTGCACCGACATGTTCTCAGTGTCCTGAGTAAGACCAAAGAAGCTGGCAAGATCCTC
TCTAATAATCCCAGCAAGGGACTGGCCCTGGGAATTGCCAAAGCCTGGGAGCTCTACGGC
TCACCCAATGCTCTGGTGCTACTGATTGCTCAAGAGAAGGAAAGAAACATATTTGACCAG
CGTGCCATAGAGAATGAGCTACTGGCCAGGAACATCCATGTGATCCGACGAACATTTGAA
GATATCTCTGAAAAGGGGTCTCTGGACCAAGACCGAAGGCTGTTTGTGGATGGCCAGGAA
ATTGCTGTGGTTTACTTCCGGGATGGCTACATGCCTCGTCAGTACAGTCTACAGAATTGG
GAAGCACGTCTACTGCTGGAGAGGTCACATGCTGCCAAGTGCCCAGACATTGCCACCCAG
CTGGCTGGGACTAAGAAGGTGCAGCAGGAGCTAAGCAGGCCGGGCATGCTGGAGATGTTG
CTCCCTGGCCAGCCTGAGGCTGTGGCCCGCCTCCGCGCCACCTTTGCTGGCCTCTACTCA
CTGGATGTGGGTGAAGAAGGGGACCAGGCCATCGCCGAGGCCCTTGCTGCCCCTAGCCGG
TTTGTGCTAAAGCCCCAGAGAGAGGGTGGAGGTAACAACCTATATGGGGAGGAAATGGTA
CAGGCCCTGAAACAGCTGAAGGACAGTGAGGAGAGGGCCTCCTACATCCTCATGGAGAAG
ATCGAACCTGAGCCTTTTGAGAATTGCCTGCTACGGCCTGGCAGCCCTGCCCGAGTGGTC
CAGTGCATTTCAGAGCTGGGCATCTTTGGGGTCTATGTCAGGCAGGAAAAGACACTCGTG
ATGAACAAGCACGTGGGGCATCTACTTCGAACCAAAGCCATCGAGCATGCAGATGGTGGT
GTGGCAGCGGGAGTGGCAGTCCTGGACAACCCATACCCTGTGTGA

# Drug_Target_44_General_Function:
Involved in catalytic activity

# Drug_Target_44_General_References:
11780052	Deloukas P, Matthews LH, Ashurst J, Burton J, Gilbert JG, Jones M, Stavrides G, Almeida JP, Babbage AK, Bagguley CL, Bailey J, Barlow KF, Bates KN, Beard LM, Beare DM, Beasley OP, Bird CP, Blakey SE, Bridgeman AM, Brown AJ, Buck D, Burrill W, Butler AP, Carder C, Carter NP, Chapman JC, Clamp M, Clark G, Clark LN, Clark SY, Clee CM, Clegg S, Cobley VE, Collier RE, Connor R, Corby NR, Coulson A, Coville GJ, Deadman R, Dhami P, Dunn M, Ellington AG, Frankland JA, Fraser A, French L, Garner P, Grafham DV, Griffiths C, Griffiths MN, Gwilliam R, Hall RE, Hammond S, Harley JL, Heath PD, Ho S, Holden JL, Howden PJ, Huckle E, Hunt AR, Hunt SE, Jekosch K, Johnson CM, Johnson D, Kay MP, Kimberley AM, King A, Knights A, Laird GK, Lawlor S, Lehvaslaiho MH, Leversha M, Lloyd C, Lloyd DM, Lovell JD, Marsh VL, Martin SL, McConnachie LJ, McLay K, McMurray AA, Milne S, Mistry D, Moore MJ, Mullikin JC, Nickerson T, Oliver K, Parker A, Patel R, Pearce TA, Peck AI, Phillimore BJ, Prathalingam SR, Plumb RW, Ramsay H, Rice CM, Ross MT, Scott CE, Sehra HK, Shownkeen R, Sims S, Skuce CD, Smith ML, Soderlund C, Steward CA, Sulston JE, Swann M, Sycamore N, Taylor R, Tee L, Thomas DW, Thorpe A, Tracey A, Tromans AC, Vaudin M, Wall M, Wallis JM, Whitehead SL, Whittaker P, Willey DL, Williams L, Williams SA, Wilming L, Wray PW, Hubbard T, Durbin RM, Bentley DR, Beck S, Rogers J: The DNA sequence and comparative analysis of human chromosome 20. Nature. 2001 Dec 20-27;414(6866):865-71.
7646467	Gali RR, Board PG: Sequencing and expression of a cDNA for human glutathione synthetase. Biochem J. 1995 Aug 15;310 ( Pt 1):353-8.
8896573	Shi ZZ, Habib GM, Rhead WJ, Gahl WA, He X, Sazer S, Lieberman MW: Mutations in the glutathione synthetase gene cause 5-oxoprolinuria. Nat Genet. 1996 Nov;14(3):361-5.
9215686	Dahl N, Pigg M, Ristoff E, Gali R, Carlsson B, Mannervik B, Larsson A, Board P: Missense mutations in the human glutathione synthetase gene result in severe metabolic acidosis, 5-oxoprolinuria, hemolytic anemia and neurological dysfunction. Hum Mol Genet. 1997 Jul;6(7):1147-52.

# Drug_Target_44_HGNC_ID:
HGNC:4624

# Drug_Target_44_HPRD_ID:
03000

# Drug_Target_44_ID:
207

# Drug_Target_44_Locus:
20q11.2

# Drug_Target_44_Molecular_Weight:
52385

# Drug_Target_44_Name:
Glutathione synthetase

# Drug_Target_44_Number_of_Residues:
474

# Drug_Target_44_PDB_ID:
2HGS

# Drug_Target_44_Pathway:
Cyclophosphamide Pathway	SMP00447
Ifosfamide Pathway	SMP00448

# Drug_Target_44_Pfam_Domain_Function:
PF03199	GSH_synthase
PF03917	GSH_synth_ATP

# Drug_Target_44_Protein_Sequence:
>Glutathione synthetase
MATNWGSLLQDKQQLEELARQAVDRALAEGVLLRTSQEPTSSEVVSYAPFTLFPSLVPSA
LLEQAYAVQMDFNLLVDAVSQNAAFLEQTLSSTIKQDDFTARLFDIHKQVLKEGIAQTVF
LGLNRSDYMFQRSADGSPALKQIEINTISASFGGLASRTPAVHRHVLSVLSKTKEAGKIL
SNNPSKGLALGIAKAWELYGSPNALVLLIAQEKERNIFDQRAIENELLARNIHVIRRTFE
DISEKGSLDQDRRLFVDGQEIAVVYFRDGYMPRQYSLQNWEARLLLERSHAAKCPDIATQ
LAGTKKVQQELSRPGMLEMLLPGQPEAVARLRATFAGLYSLDVGEEGDQAIAEALAAPSR
FVLKPQREGGGNNLYGEEMVQALKQLKDSEERASYILMEKIEPEPFENCLLRPGSPARVV
QCISELGIFGVYVRQEKTLVMNKHVGHLLRTKAIEHADGGVAAGVAVLDNPYPV

# Drug_Target_44_Reaction:
ATP + gamma-L-glutamyl-L-cysteine + glycine = ADP + phosphate + glutathione

# Drug_Target_44_Signals:
None

# Drug_Target_44_Specific_Function:
Not Available

# Drug_Target_44_SwissProt_ID:
P48637

# Drug_Target_44_SwissProt_Name:
GSHB_HUMAN

# Drug_Target_44_Synonyms:
EC 6.3.2.3
GSH synthetase
GSH-S
Glutathione synthase

# Drug_Target_44_Theoretical_pI:
5.73

# Drug_Target_44_Transmembrane_Regions:
None

# Drug_Target_45_Cellular_Location:
Not Available

# Drug_Target_45_Chromosome_Location:
Not Available

# Drug_Target_45_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_45_Essentiality:
Non-Essential

# Drug_Target_45_GenAtlas_ID:
Not Available

# Drug_Target_45_GenBank_ID_Gene:
AE005674

# Drug_Target_45_GenBank_ID_Protein:
24051512

# Drug_Target_45_GeneCard_ID:
Not Available

# Drug_Target_45_Gene_Name:
ispE

# Drug_Target_45_Gene_Sequence:
>852 bp
TTAAAGCATGGCTCTGTGCAATGGGGAAAGATTAACGCCTTTCGCCACAAAGCCATTGAG
CCATTCCGGGGCTTGCTCTAGCACCTGGCGGGCTTCAGACTCTGTATCAAATTCAGCAAA
GACACAGGCCCCTGTCCCAGTCAGGCGTGACGGGGCGTATTCTAACAGCCAGGAAAGCAC
CGCATCAACCTCGCGAAAACGTTTTCTTGCGATAACCTCGCAATCATTGCTGAATTCACA
TTTTAGCAACGTTTCTATTGACCTTTTTGGCGTATTGCGCGGGAGTTCAGGATCTTTAAA
AATCACCGGAGTCGGAATACTTACACCAGGGTGCGCCACCAGATACCACTTCTCTGGCGG
ATCCACCGGCGTTAGTATTTCACCAACGCCTTCGGCAAACGCGGCATGCCCCCGAACAAA
GACAGGAACATCTGCGCCCAGCGTCAGCCCCATTTCCGCCAGCTCATCCATGCTTAGCCC
GCATTGCCAGAGATGATTTAATGCCACCAGGACCGTCGCGGCATTGGATGAACCACCGCC
GAGACCGCCGCCCATCGGCAAACGCTTGTCAATGCTGATATTCGCACCGCTTCCCGTCGG
AAGACGCCCGCTGTCTGCCGCAGTTTTCATCAACAACCGCGCTGCGCGAACGATCAGGTT
ATCTTCATGTTCCACGCCTTCAACGGGCGTTAACAGACGAATATCCCCATCGTCACGAAG
CTCAATGCTGATGGTGTCGCCGTAATCAAGAAACTGAAACAGCGTTTGCAGCGTGTGGTA
ACCATCCGCACGCTGACCGGTAATGTATAAAAACAGATTAAGTTTTGCCGGAGAGGGCCA
CTGTGTCCGCAT

# Drug_Target_45_General_Function:
Lipid transport and metabolism

# Drug_Target_45_General_References:
12384590	Jin Q, Yuan Z, Xu J, Wang Y, Shen Y, Lu W, Wang J, Liu H, Yang J, Yang F, Zhang X, Zhang J, Yang G, Wu H, Qu D, Dong J, Sun L, Xue Y, Zhao A, Gao Y, Zhu J, Kan B, Ding K, Chen S, Cheng H, Yao Z, He B, Chen R, Ma D, Qiang B, Wen Y, Hou Y, Yu J: Genome sequence of Shigella flexneri 2a: insights into pathogenicity through comparison with genomes of Escherichia coli K12 and O157. Nucleic Acids Res. 2002 Oct 15;30(20):4432-41.
12704152	Wei J, Goldberg MB, Burland V, Venkatesan MM, Deng W, Fournier G, Mayhew GF, Plunkett G 3rd, Rose DJ, Darling A, Mau B, Perna NT, Payne SM, Runyen-Janecky LJ, Zhou S, Schwartz DC, Blattner FR: Complete genome sequence and comparative genomics of Shigella flexneri serotype 2a strain 2457T. Infect Immun. 2003 May;71(5):2775-86.

# Drug_Target_45_HGNC_ID:
Not Available

# Drug_Target_45_HPRD_ID:
Not Available

# Drug_Target_45_ID:
2867

# Drug_Target_45_Locus:
Not Available

# Drug_Target_45_Molecular_Weight:
30954

# Drug_Target_45_Name:
4-diphosphocytidyl-2-C-methyl-D-erythritol kinase

# Drug_Target_45_Number_of_Residues:
283

# Drug_Target_45_PDB_ID:
1OJ4

# Drug_Target_45_Pathway:
Not Available

# Drug_Target_45_Pfam_Domain_Function:
PF00288	GHMP_kinases_N
PF08544	GHMP_kinases_C

# Drug_Target_45_Protein_Sequence:
>4-diphosphocytidyl-2-C-methyl-D-erythritol kinase
MRTQWPSPAKLNLFLYITGQRADGYHTLQTLFQFLDYGDTISIELRDDGDIRLLTPVEGV
EHEDNLIVRAARLLMKTAADSGRLPTGSGANISIDKRLPMGGGLGGGSSNAATVLVALNH
LWQCGLSMDELAEMGLTLGADVPVFVRGHAAFAEGVGEILTPVDPPEKWYLVAHPGVSIP
TPVIFKDPELPRNTPKRSIETLLKCEFSNDCEVIARKRFREVDAVLSWLLEYAPSRLTGT
GACVFAEFDTESEARQVLEQAPEWLNGFVAKGVNLSPLHRAML

# Drug_Target_45_Reaction:
ATP + 4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol = ADP + 2-phospho-4-(cytidine 5'-diphospho)-2-C-methyl-D-erythritol

# Drug_Target_45_Signals:
None

# Drug_Target_45_Specific_Function:
Catalyzes the phosphorylation of the position 2 hydroxy group of 4-diphosphocytidyl-2C-methyl-D-erythritol

# Drug_Target_45_SwissProt_ID:
Q83LD8

# Drug_Target_45_SwissProt_Name:
ISPE_SHIFL

# Drug_Target_45_Synonyms:
4-(cytidine-5'-diphospho)-2-C-methyl-D-erythritol kinase
CMK
EC 2.7.1.148

# Drug_Target_45_Theoretical_pI:
4.91

# Drug_Target_45_Transmembrane_Regions:
None

# Drug_Target_46_Cellular_Location:
Not Available

# Drug_Target_46_Chromosome_Location:
3

# Drug_Target_46_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_46_Essentiality:
Non-Essential

# Drug_Target_46_GenAtlas_ID:
Not Available

# Drug_Target_46_GenBank_ID_Gene:
D49818

# Drug_Target_46_GenBank_ID_Protein:
1905761

# Drug_Target_46_GeneCard_ID:
PFKFB4

# Drug_Target_46_Gene_Name:
PFKFB4

# Drug_Target_46_Gene_Sequence:
>1410 bp
ATGGCGTCCCCACGGGAATTGACACAGAACCCCCTGAAGAAGATCTGGATGCCATACAGC
AATGGGCGGCCCGCTCTGCACGCTTGCCAGCGCGGTGTGTGCATGACCAACTGCCCAACT
CTCATTGTCATGGTGGGCCTGCCCGCCAGGGGCAAGACCTACATCTCCAAGAAGCTGACT
CGATACCTGAACTGGATTGGTGTGCCCACTCGGGAGTTCAATGTTGGCCAGTACCGCCGG
GACGTGGTCAAGACCTACAAATCTTTTGAATTTTTTCTCCCCGACAATGAAGAGGGCCTG
AAAATCAGGAAGCAGTGTGCCCTGGCAGCCCTCCGTGACGTCCGGCGGTTCCTTAGTGAG
GAGGGGGGACATGTGGCGGTTTTTGATGCCACAAACACCACCCGAGAACGGAGAGCGACC
ATCTTTAATTTTGGAGAACAGAATGGCTACAAGACCTTTTTTGTCGAGTCCATCTGTGTG
GATCCTGAGGTCATAGCTGCCAACATCGTGCAAGTGAAACTGGGCAGCCCTGACTATGTC
AACCGCGACAGTGATGAGGCTACGGAGGACTTCATGAGGCGCATTGAGTGCTATGAGAAC
TCCTACGAGTCGCTAGATGAGGACCTGGATAGGGACCTGTCCTATATCAAGATCATGGAT
GTGGGCCAGAGCTACGTGGTGAACCGTGTGGCTGACCACATCCAGAGCCGCATCGTATAT
TACCTCATGAACATCCACGTGACCCCCCGCTCCATCTACCTCTGCCGGCACGGGGAGAGC
GAGCTCAACCTCAAGGGCCGGATTGGCGGGGACCCAGGACTGTCCCCTCGGGGCAGGGAG
TTTGCCAAGAGTCTAGCCCAGTTCATCAGTGACCAAAATATCAAGGATCTGAAGGTCTGG
ACAAGCCAGATGAAGAGGACAATCCAGACGGCTGAGGCACTGGGTGTGCCCTATGAACAG
TGGAAGGTCCTCAACGAGATCGATGCGGGCGTCTGTGAGGAAATGACCTACGAGGAAATT
CAGGATAATTATCCACTGGAGTTCGCCCTGCGGGACCAGGACAAGTACCGGTACCGGTAC
CCTAAAGGGGAGTCCTACGAGGACCTGGTCCAGAGACTGGAGCCTGTCATCATGGAGCTG
GAGAGGCAAGAGAATGTGCTGGTCATCTGCCACCAGGCTGTGATGCGCTGCCTGCTGGCC
TACTTCCTCGACAAGGCAGCAGAACAGCTGCCCTACCTCAAGTGTCCGCTGCACACAGTC
CTGAAGCTGACTCCTGTGGCATATGGTTGTAAAGTGGAGTCCATATTCCTGAACGTGGCT
GCTGTGAACACGCACCGGGACAGGCCTCAGAACGTGGACATCTCAAGACCTCCAGAGGAA
GCCCTTGTCACGGTGCCTGCTCACCAGTGA

# Drug_Target_46_General_Function:
Carbohydrate transport and metabolism

# Drug_Target_46_General_References:
10095107	Manzano A, Perez JX, Nadal M, Estivill X, Lange A, Bartrons R: Cloning, expression and chromosomal localization of a human testis 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene. Gene. 1999 Mar 18;229(1-2):83-9.
15489334	Gerhard DS, Wagner L, Feingold EA, Shenmen CM, Grouse LH, Schuler G, Klein SL, Old S, Rasooly R, Good P, Guyer M, Peck AM, Derge JG, Lipman D, Collins FS, Jang W, Sherry S, Feolo M, Misquitta L, Lee E, Rotmistrovsky K, Greenhut SF, Schaefer CF, Buetow K, Bonner TI, Haussler D, Kent J, Kiekhaus M, Furey T, Brent M, Prange C, Schreiber K, Shapiro N, Bhat NK, Hopkins RF, Hsie F, Driscoll T, Soares MB, Casavant TL, Scheetz TE, Brown-stein MJ, Usdin TB, Toshiyuki S, Carninci P, Piao Y, Dudekula DB, Ko MS, Kawakami K, Suzuki Y, Sugano S, Gruber CE, Smith MR, Simmons B, Moore T, Waterman R, Johnson SL, Ruan Y, Wei CL, Mathavan S, Gunaratne PH, Wu J, Garcia AM, Hulyk SW, Fuh E, Yuan Y, Sneed A, Kowis C, Hodgson A, Muzny DM, McPherson J, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madari A, Young AC, Wetherby KD, Granite SJ, Kwong PN, Brinkley CP, Pearson RL, Bouffard GG, Blakesly RW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Griffith M, Griffith OL, Krzywinski MI, Liao N, Morin R, Palmquist D, Petrescu AS, Skalska U, Smailus DE, Stott JM, Schnerch A, Schein JE, Jones SJ, Holt RA, Baross A, Marra MA, Clifton S, Makowski KA, Bosak S, Malek J: The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC). Genome Res. 2004 Oct;14(10B):2121-7.
15642344	Gomez M, Manzano A, Navarro-Sabate A, Duran J, Obach M, Perales JC, Bartrons R: Specific expression of pfkfb4 gene in spermatogonia germ cells and analysis of its 5'-flanking region. FEBS Lett. 2005 Jan 17;579(2):357-62.
16959974	Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, Willis J, Dawson D, Willson JK, Gazdar AF, Hartigan J, Wu L, Liu C, Parmigiani G, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, Velculescu VE: The consensus coding sequences of human breast and colorectal cancers. Science. 2006 Oct 13;314(5797):268-74. Epub 2006 Sep 7.
8830046	Sakai A, Kato M, Fukasawa M, Ishiguro M, Furuya E, Sakakibara R: Cloning of cDNA encoding for a novel isozyme of fructose 6-phosphate, 2-kinase/fructose 2,6-bisphosphatase from human placenta. J Biochem. 1996 Mar;119(3):506-11.

# Drug_Target_46_HGNC_ID:
GNC:8875

# Drug_Target_46_HPRD_ID:
Not Available

# Drug_Target_46_ID:
6433

# Drug_Target_46_Locus:
3p22-p21

# Drug_Target_46_Molecular_Weight:
54039.3

# Drug_Target_46_Name:
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4

# Drug_Target_46_Number_of_Residues:
469

# Drug_Target_46_PDB_ID:
1BIF

# Drug_Target_46_Pathway:
Not Available

# Drug_Target_46_Pfam_Domain_Function:
PF00300	PGAM
PF01591	6PF2K

# Drug_Target_46_Protein_Sequence:
>6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4
MASPRELTQNPLKKIWMPYSNGRPALHACQRGVCMTNCPTLIVMVGLPARGKTYISKKLT
RYLNWIGVPTREFNVGQYRRDVVKTYKSFEFFLPDNEEGLKIRKQCALAALRDVRRFLSE
EGGHVAVFDATNTTRERRATIFNFGEQNGYKTFFVESICVDPEVIAANIVQVKLGSPDYV
NRDSDEATEDFMRRIECYENSYESLDEDLDRDLSYIKIMDVGQSYVVNRVADHIQSRIVY
YLMNIHVTPRSIYLCRHGESELNLKGRIGGDPGLSPRGREFAKSLAQFISDQNIKDLKVW
TSQMKRTIQTAEALGVPYEQWKVLNEIDAGVCEEMTYEEIQDNYPLEFALRDQDKYRYRY
PKGESYEDLVQRLEPVIMELERQENVLVICHQAVMRCLLAYFLDKAAEQLPYLKCPLHTV
LKLTPVAYGCKVESIFLNVAAVNTHRDRPQNVDISRPPEEALVTVPAHQ

# Drug_Target_46_Reaction:
Not Available

# Drug_Target_46_Signals:
None

# Drug_Target_46_Specific_Function:
Synthesis and degradation of fructose 2,6-bisphosphate

# Drug_Target_46_SwissProt_ID:
Q16877

# Drug_Target_46_SwissProt_Name:
F264_HUMAN

# Drug_Target_46_Synonyms:
6-phosphofructo-2-kinase
6PF-2-K/Fru-2,6-P2ASE testis-type isozyme
Fructose-2,6-bisphosphatase

# Drug_Target_46_Theoretical_pI:
6.60

# Drug_Target_46_Transmembrane_Regions:
None

# Drug_Target_47_Cellular_Location:
Not Available

# Drug_Target_47_Chromosome_Location:
Not Available

# Drug_Target_47_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_47_Essentiality:
Non-Essential

# Drug_Target_47_GenAtlas_ID:
Not Available

# Drug_Target_47_GenBank_ID_Gene:
V01547

# Drug_Target_47_GenBank_ID_Protein:
47034

# Drug_Target_47_GeneCard_ID:
Not Available

# Drug_Target_47_Gene_Name:
aphA

# Drug_Target_47_Gene_Sequence:
>795 bp
ATGGCTAAAATGAGAATATCACCGGAATTGAAAAAACTGATCGAAAAATACCGCTGCGTA
AAAGATACGGAAGGAATGTCTCCTGCTAAGGTATATAAGCTGGTGGGAGAAAATGAAAAC
CTATATTTAAAAATGACGGACAGCCGGTATAAAGGGACCACCTATGATGTGGAACGGGAA
AAGGACATGATGCTATGGCTGGAAGGAAAGCTGCCTGTTCCAAAGGTCCTGCACTTTGAA
CGGCATGATGGCTGGAGCAATCTGCTCATGAGTGAGGCCGATGGCGTCCTTTGCTCGGAA
GAGTATGAAGATGAACAAAGCCCTGAAAAGATTATCGAGCTGTATGCGGAGTGCATCAGG
CTCTTTCACTCCATCGACATATCGGATTGTCCCTATACGAATAGCTTAGACAGCCGCTTA
GCCGAATTGGATTACTTACTGAATAACGATCTGGCCGATGTGGATTGCGAAAACTGGGAA
GAAGACACTCCATTTAAAGATCCGCGCGAGCTGTATGATTTTTTAAAGACGGAAAAGCCC
GAAGAGGAACTTGTCTTTTCCCACGGCGACCTGGGAGACAGCAACATCTTTGTGAAAGAT
GGCAAAGTAAGTGGCTTTATTGATCTTGGGAGAAGCGGCAGGGCGGACAAGTGGTATGAC
ATTGCCTTCTGCGTCCGGTCGATCAGGGAGGATATCGGGGAAGAACAGTATGTCGAGCTA
TTTTTTGACTTACTGGGGATCAAGCCTGATTGGGAGAAAATAAAATATTATATTTTACTG
GATGAATTGTTTTAG

# Drug_Target_47_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_47_General_References:
6313476	Trieu-Cuot P, Courvalin P: Nucleotide sequence of the Streptococcus faecalis plasmid gene encoding the 3'5"-aminoglycoside phosphotransferase type III. Gene. 1983 Sep;23(3):331-41.

# Drug_Target_47_HGNC_ID:
Not Available

# Drug_Target_47_HPRD_ID:
Not Available

# Drug_Target_47_ID:
3390

# Drug_Target_47_Locus:
Not Available

# Drug_Target_47_Molecular_Weight:
30974

# Drug_Target_47_Name:
Aminoglycoside 3'-phosphotransferase

# Drug_Target_47_Number_of_Residues:
264

# Drug_Target_47_PDB_ID:
1J7U

# Drug_Target_47_Pathway:
Not Available

# Drug_Target_47_Pfam_Domain_Function:
PF01636	APH

# Drug_Target_47_Protein_Sequence:
>Aminoglycoside 3'-phosphotransferase
MAKMRISPELKKLIEKYRCVKDTEGMSPAKVYKLVGENENLYLKMTDSRYKGTTYDVERE
KDMMLWLEGKLPVPKVLHFERHDGWSNLLMSEADGVLCSEEYEDEQSPEKIIELYAECIR
LFHSIDISDCPYTNSLDSRLAELDYLLNNDLADVDCENWEEDTPFKDPRELYDFLKTEKP
EEELVFSHGDLGDSNIFVKDGKVSGFIDLGRSGRADKWYDIAFCVRSIREDIGEEQYVEL
FFDLLGIKPDWEKIKYYILLDELF

# Drug_Target_47_Reaction:
ATP + kanamycin = ADP + kanamycin 3'-phosphate ALL_REAC (other) R01888

# Drug_Target_47_Signals:
None

# Drug_Target_47_Specific_Function:
Resistance to kanamycin and structurally-related aminoglycosides, including amikacin

# Drug_Target_47_SwissProt_ID:
P0A3Y5

# Drug_Target_47_SwissProt_Name:
KKA3_ENTFA

# Drug_Target_47_Synonyms:
APH(3')III
EC 2.7.1.95
Kanamycin kinase, type III
Neomycin-kanamycin phosphotransferase type III

# Drug_Target_47_Theoretical_pI:
4.27

# Drug_Target_47_Transmembrane_Regions:
None

# Drug_Target_48_Cellular_Location:
Cytoplasm. Note=Colocalizes with the actin filament system

# Drug_Target_48_Chromosome_Location:
Not Available

# Drug_Target_48_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_48_Essentiality:
Non-Essential

# Drug_Target_48_GenAtlas_ID:
DAPK1

# Drug_Target_48_GenBank_ID_Gene:
X76104

# Drug_Target_48_GenBank_ID_Protein:
2094873

# Drug_Target_48_GeneCard_ID:
DAPK1

# Drug_Target_48_Gene_Name:
DAPK1

# Drug_Target_48_Gene_Sequence:
>4296 bp
ATGACCGTGTTCAGGCAGGAAAACGTGGATGATTACTACGACACCGGCGAGGAACTTGGC
AGTGGACAGTTTGCGGTTGTGAAGAAATGCCGTGAGAAAAGTACCGGCCTCCAGTATGCC
GCCAAATTCATCAAGAAAAGGAGGACTAAGTCCAGCCGGCGGGGTGTGAGCCGCGAGGAC
ATCGAGCGGGAGGTCAGCATCCTGAAGGAGATCCAGCACCCCAATGTCATCACCCTGCAC
GAGGTCTATGAGAACAAGACGGACGTCATCCTGATCTTGGAACTCGTTGCAGGTGGCGAG
CTGTTTGACTTCTTAGCTGAAAAGGAATCTTTAACTGAAGAGGAAGCAACTGAATTTCTC
AAACAAATTCTTAATGGTGTTTACTACCTGCACTCCCTTCAAATCGCCCACTTTGATCTT
AAGCCTGAGAACATAATGCTTTTGGATAGAAATGTCCCCAAACCTCGGATCAAGATCATT
GACTTTGGGTTGGCCCATAAAATTGACTTTGGAAATGAATTTAAAAACATATTTGGGACT
CCAGAGTTTGTCGCTCCTGAGATAGTCAACTATGAACCTCTTGGTCTTGAGGCAGATATG
TGGAGTATCGGGGTAATAACCTATATCCTCCTAAGTGGGGCCTCCCCATTTCTTGGAGAC
ACTAAGCAAGAAACGTTAGCAAATGTATCCGCTGTCAACTACGAATTTGAGGATGAATAC
TTCAGTAATACCAGTGCCCTAGCCAAAGATTTCATAAGAAGACTTCTGGTCAAGGATCCA
AAGAAGAGAATGACAATTCAAGATAGTTTGCAGCATCCCTGGATCAAGCCTAAAGATACA
CAACAGGCACTTAGTAGAAAAGCATCAGCAGTAAACATGGAGAAATTCAAGAAGTTTGCA
GCCCGGAAAAAATGGAAACAATCCGTTCGCTTGATATCACTGTGCCAAAGATTATCCAGG
TCATTCCTGTCCAGAAGTAACATGAGTGTTGCCAGAAGCGATGATACTCTGGATGAGGAA
GACTCCTTTGTGATGAAAGCCATCATCCATGCCATCAACGATGACAATGTCCCAGGCCTG
CAGCACCTTCTGGGCTCATTATCCAACTATGATGTTAACCAACCCAACAAGCACGGGACA
CCTCCATTACTCATTGCTGCTGGCTGTGGGAATATTCAAATACTACAGTTGCTCATTAAA
AGAGGCTCGAGAATCGATGTCCAGGATAAGGGCGGGTCCAATGCCGTCTACTGGGCTGCT
CGGCATGGCCACGTCGATACCTTGAAATTTCTCAGTGAGAACAAATGCCCTTTGGATGTG
AAAGACAAGTCTGGAGAGATGGCCCTCCACGTGGCAGCTCGCTATGGCCATGCTGACGTG
GCTCAAGTTACTTGTGCAGCTTCGGCTCAAATCCCAATATCCAGGACAAAGGAAGAAGAA
ACCCCCCTGCACTGTGCTGCTTGGCACGGCTATTACTCTGTGGCCAAAGCCCTTTGTGAA
GCCGGCTGTAACGTGAACATCAAGAACCGAGAAGGAGAGACGCCCCTCCTGACAGCCTCT
GCCAGGGGCTACCACGACATCGTGGAGTGTCTGGCCGAACATGGAGCCGACCTTAATGCT
TGCGACAAGGACGGACACATTGCCCTTCATCTGGCTGTAAGACGGTGTCAGATGGAGGTA
ATCAAGACTCTCCTCAGCCAAGGGTGTTTCGTCGATTATCAAGACAGGCACGGCAATACT
CCCCTCCATGTGGCATGTAAAGATGGCAACATGCCTATCGTGGTGGCCCTCTGTGAAGCA
AACTGCAATTTGGACATCTCCAACAAGTATGGGCGAACGCCTCTGCACCTTGCGGCCAAC
AACGGAATCCTAGACGTGGTCCGGTATCTCTGTCTGATGGGAGCCAGCGTTGAGGCGCTG
ACCACGGACGGAAAGACGGCAGAAGATCTTGCTAGATCGGAACAGCACGAGCACGTAGCA
GGTCTCCTTGCAAGACTTCGAAAGGATACGCACCGAGGACTCTTCATCCAGCAGCTCCGA
CCCACACAGAACCTGCAGCCAAGAATTAAGCTCAAGCTGTTTGGCCACTCGGGATCCGGG
AAAACCACCCTTGTAGAATCTCTCAAGTGTGGGCTGCTGAGGAGCTTTTTCAGAAGGCGT
CGGCCCAGACTGTCTTCCACCAACTCCAGCAGGTTCCCACCTTCACCCCTGGCTTCTAAG
CCCACAGTCTCAGTGAGCATCAACAACCTGTACCCAGGCTGCGAGAACGTGAGTGTGAGG
AGCCGCAGCATGATGTTCGAGCCGGGTCTTACCAAAGGGATGCTGGAGGTGTTTGTGGCC
CCGACCCACCACCCGCACTGCTCGGCCGATGACCAGTCCACCAAGGCCATCGACATCCAG
AACGCTTATTTGAATGGAGTTGGCGATTTCAGCGTGTGGGAGTTCTCTGGAAATCCTGTG
TATTTCTGCTGTTATGACTATTTTGCTGCAAATGATCCCACGTCAATCCATGTTGTTGTC
TTTAGTCTAGAAGAGCCCTATGAGATCCAGCTGAACCCAGTGATTTTCTGGCTCAGTTTC
CTGAAGTCCCTTGTCCCAGTTGAAGAACCCATAGCCTTCGGTGGCAAGCTGAAGAACCCA
CTCCAAGTTGTCCTGGTGGCCACCCACGCTGACATCATGAATGTTCCTCGACCGGCTGGA
GGCGAGTTTGGATATGACAAAGACACATCGTTGCTGAAAGAGATTAGGAACAGGTTTGGA
AATGATCTTCACATTTCAAATAAGCTGTTTGTTCTGGATGCTGGGGCTTCTGGGTCAAAG
GACATGAAGGTACTTCGAAATCATCTGCAAGAAATACGAAGCCAGATTGTTTCGGTCTGT
CCTCCCATGACTCACCTGTGTGAGAAAATCATCTCCACGCTGCCTTCCTGGAGGAAGCTC
AATGGACCCAACCAGCTGATGTCGCTGCAGCAGTTTGTGTACGACGTGCAGGACCAGCTG
AACCCCCTGGCCAGCGAGGAGGACCTCAGGCGCATTGCTCAGCAGCTCCACAGCACAGGC
GAGATCAACATCATGCAAAGTGAAACAGTTCAGGACGTGCTGCTCCTGGACCCCCGCTGG
CTCTGCACAAACGTCCTGGGGAAGTTGCTGTCCGTGGAGACCCCACGGGCGCTGCACCAC
TACCGGGGCCGCTACACCGTGGAGGACATCCAGCGCCTGGTGCCCGACAGCGACGTGGAG
GAGCTGCTGCAGATCCTCGATGCCATGGACATCTGCGCCCGGGACCTGAGCAGCGGGACC
ATGGTGGACGTCCCAGCCCTGATCAAGACAGACAACCTGCACCGCTCCTGGGCTGATGAG
GAGGACGAGGTGATGGTGTATGGTGGCGTGCGCATCGTGCCCGTGGAACACCTCACCCCC
TTCCCATGTGGCATCTTTCACAAGGTCCAGGTGAACCTGTGCCGGTGGATCCACCAGCAA
AGCACAGAGGGCGACGCGGACATCCGCCTGTGGGTGAATGGCTGCAAGCTGGCCAACCGT
GGGGCCGAGCTGCTGGTGCTGCTGGTCAACCACGGCCAGGGCATTGAGGTCCAGGTCCGT
GGCCTGGAGACGGAGAAGATCAAGTGCTGCCTGCTGCTGGACTCGGTGTGCAGCACCATT
GAGAACGTCATGGCCACCACGCTGCCAGGGCTCCTGACCGTGAAGCATTACCTGAGCCCC
CAGCAGCTGCGGGAGCACCATGAGCCCGTCATGATCTACCAGCCACGGGACTTCTTCCGG
GCACAGACTCTGAAGGAAACCTCACTGACCAACACCATGGGGGGGTACAAGGAAAGCTTC
AGCAGCATCATGTGCTTCGGGTGTCACGACGTCTACTCACAGGCCAGCCTCGGCATGGAC
ATCCATGCATCAGACCTGAACCTCCTCACTCGGAGGAAACTGAGTCGCCTGCTGGACCCG
CCCGACCCCCTGGGGAAGGACTGGTGCCTTCTCGCCATGAACTTAGGCCTCCCTGACCTC
GTGGCAAAGTACAACACCAATAACGGGGCTCCCAAGGATTTCCTCCCCAGCCCCCTCCAC
GCCCTGCTGCGGGAATGGACCACCTACCCTGAGAGCACAGTGGGCACCCTCATGTCCAAA
CTGAGGGAGCTGGGTCGCCGGGATGCCGCAGACCTTTTGCTGAAGGCATCCTCTGTGTTC
AAAATCAACCTGGATGGCAATGGCCAGGAGGCCTATGCCTCGAGCTGCAACAGCGGCACC
TCTTACAATTCCATTAGCTCTGTTGTATCCCGGTGA

# Drug_Target_48_General_Function:
Involved in protein binding

# Drug_Target_48_General_References:
10629061	Inbal B, Shani G, Cohen O, Kissil JL, Kimchi A: Death-associated protein kinase-related protein 1, a novel serine/threonine kinase involved in apoptosis. Mol Cell Biol. 2000 Feb;20(3):1044-54.
7828849	Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A: Identification of a novel serine/threonine kinase and a novel 15-kD protein as potential mediators of the gamma interferon-induced cell death. Genes Dev. 1995 Jan 1;9(1):15-30.

# Drug_Target_48_HGNC_ID:
HGNC:2674

# Drug_Target_48_HPRD_ID:
02902

# Drug_Target_48_ID:
3231

# Drug_Target_48_Locus:
9q34.1

# Drug_Target_48_Molecular_Weight:
160223

# Drug_Target_48_Name:
Death-associated protein kinase 1

# Drug_Target_48_Number_of_Residues:
1432

# Drug_Target_48_PDB_ID:
1JKT

# Drug_Target_48_Pathway:
Not Available

# Drug_Target_48_Pfam_Domain_Function:
PF00023	Ank
PF00069	Pkinase
PF00531	Death

# Drug_Target_48_Protein_Sequence:
>Death-associated protein kinase 1
MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSRED
IEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFL
KQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGT
PEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEY
FSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSRKASAVNMEKFKKFA
ARKKWKQSVRLISLCQRLSRSFLSRSNMSVARSDDTLDEEDSFVMKAIIHAINDDNVPGL
QHLLGSLSNYDVNQPNKHGTPPLLIAAGCGNIQILQLLIKRGSRIDVQDKGGSNAVYWAA
RHGHVDTLKFLSENKCPLDVKDKSGEMALHVAARYGHADVAQVQVLCSFGSNPNIQDKEE
ETPLHCAAWHGYYSVAKALCEAGCNVNIKNREGETPLLTASARGYHDIVECLAEHGADLN
ACDKDGHIALHLAVRRCQMEVIKTLLSQGCFVDYQDRHGNTPLHVACKDGNMPIVVALCE
ANCNLDISNKYGRTPLHLAANNGILDVVRYLCLMGASVEALTTDGKTAEDLARSEQHEHV
AGLLARLRKDTHRGLFIQQLRPTQNLQPRIKLKLFGHSGSGKTTLVESLKCGLLRSFFRR
RRPRLSSTNSSRFPPSPLASKPTVSVSINNLYPGCENVSVRSRSMMFEPGLTKGMLEVFV
APTHHPHCSADDQSTKAIDIQNAYLNGVGDFSVWEFSGNPVYFCCYDYFAANDPTSIHVV
VFSLEEPYEIQLNPVIFWLSFLKSLVPVEEPIAFGGKLKNPLQVVLVATHADIMNVPRPA
GGEFGYDKDTSLLKEIRNRFGNDLHISNKLFVLDAGASGSKDMKVLRNHLQEIRSQIVSV
CPPMTHLCEKIISTLPSWRKLNGPNQLMSLQQFVYDVQDQLNPLASEEDLRRIAQQLHST
GEINIMQSETVQDVLLLDPRWLCTNVLGKLLSVETPRALHHYRGRYTVEDIQRLVPDSDV
EELLQILDAMDICARDLSSGTMVDVPALIKTDNLHRSWADEEDEVMVYGGVRIVPVEHLT
PFPCGIFHKVQVNLCRWIHQQSTEGDADIRLWVNGCKLANRGAELLVLLVNHGQGIEVQV
RGLETEKIKCCLLLDSVCSTIENVMATTLPGLLTVKHYLSPQQLREHHEPVMIYQPRDFF
RAQTLKETSLTNTMGGYKESFSSIMCFGCHDVYSQASLGMDIHASDLNLLTRRKLSRLLD
PPDPLGKDWCLLAMNLGLPDLVAKYNTNNGAPKDFLPSPLHALLREWTTYPESTVGTLMS
KLRELGRRDAADLLLKASSVFKINLDGNGQEAYASSCNSGTSYNSISSVVSR

# Drug_Target_48_Reaction:
ATP + a protein = ADP + a phosphoprotein

# Drug_Target_48_Signals:
None

# Drug_Target_48_Specific_Function:
Calcium/calmodulin-dependent serine/threonine kinase which acts as a positive regulator of apoptosis

# Drug_Target_48_SwissProt_ID:
P53355

# Drug_Target_48_SwissProt_Name:
DAPK1_HUMAN

# Drug_Target_48_Synonyms:
DAP kinase 1
EC 2.7.11.1

# Drug_Target_48_Theoretical_pI:
6.82

# Drug_Target_48_Transmembrane_Regions:
None

# Drug_Target_49_Cellular_Location:
Cytoplasmic

# Drug_Target_49_Chromosome_Location:
Not Available

# Drug_Target_49_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_49_Essentiality:
Non-Essential

# Drug_Target_49_GenAtlas_ID:
Not Available

# Drug_Target_49_GenBank_ID_Gene:
J02591

# Drug_Target_49_GenBank_ID_Protein:
151857

# Drug_Target_49_GeneCard_ID:
Not Available

# Drug_Target_49_Gene_Name:
arsA

# Drug_Target_49_Gene_Sequence:
>1752 bp
ATGCAATTCTTACAGAATATCCCCCCTTATCTGTTTTTTACGGGTAAAGGAGGCGTGGGT
AAAACCTCTATTTCCTGCGCCACGGCGATCCGTCTGGCAGAACAGGGGAAACGGGTGCTG
CTGGTCAGTACCGATCCGGCCTCAAACGTAGGCCAGGTGTTTAGCCAGACGATTGGCATT
ACCATTCAGGCAATAGCCTCTGTTCCTGGATTGTCGGCTCTTGAGATTGATCCTCAGGCT
GCTGCACAACAGTACCGGGCCAGAATCGTTGACCCTATTAAAGGCGTCCTGCCTGATGAC
GTTGTTTCCAGCATCAACGAACAACTGTCAGGTGCATGCACAACAGAGATTGCGGCTTTT
GATGAATTTACCGGATTACTGACAGATGCCTCTCTGCTGACGCGGTTTGACCATATCATT
TTTGATACCGCGCCGACGGGTCACACCATTCGCCTTCTGCAGTTGCCGGGCGCCTGGAGT
AGCTTTATTGACAGCAATCCCGAGGGCGCGTCCTGTCTCGGCCCAATGGCGGGGCTGGAA
AAGCAGCGTGAACAGTATGCCTATGCTGTTGAAGCGTTGTCTGATCCAAAGCGTACCCGA
CTGGTATTAGTTGCTCGTCTGCAAAAATCCACGTTGCAGGAAGTCGCCCGGACTCATCTG
GAACTTGCCGCCATCGGCCTTAAAAATCAGTACCTGGTTATTAATGGCGTTCTGCCCAAA
ACTGAAGCGGCAAACGATACACTGGCTGCTGCAATATGGGAGCGTGAACAGGAGGCGCTG
GCCAATCTTCCCGCTGATCTTGCAGGTTTGCCAACTGACACATTATTTCTCCAGCCGGTC
AATATGGTCGGTGTGTCTGCGCTCAGCAGGCTTCTCTCCACTCAGCCTGTAGCGTCGCCA
TCCTCGGATGAATACCTGCAACAGCGGCCTGATATTCCGTCACTTTCTGCGTTGGTTGAT
GATATTGCCCGTAATGAACATGGCCTGATTATGCTGATGGGTAAAGGTGGCGTGGGGAAA
ACCACGATGGCTGCTGCCATTGCTGTCAGGCTGGCCGACATGGGATTTGATGTCCATCTG
ACAACATCTGATCCTGCGGCGCATCTCAGCATGACCCTGAACGGTAGCCTTAACAACCTG
CAGGTCAGCAGGATCGATCCTCACGAGGAAACGGAACGCTATCGTCAGCATGTTCTTGAA
ACAAAGGGAAAAGAACTGGACGAAGCGGGAAAACGCCTGCTGGAAGAGGACTTACGCTCA
CCTTGCACTGAGGAAATTGCTGTTTTCCAGGCCTTTTCACGGGTGATTCGTGAAGCGGGT
AAACGTTTCGTGGTGATGGATACGGCTCCGACCGGACACACGCTGTTGCTGCTGGATGCT
ACAGGCGCGTACCACCGCGAAATTGCGAAGAAAATGGGAGAAAAAGGCCATTTCACCACA
CCGATGATGCTGCTTCAGGATCCGGAGCGCACTAAAGTGTTACTGGTCACGCTGCCGGAA
ACCACGCCCGTGCTTGAAGCGGCAAATTTACAGGCCGACCTTGAGCGTGCAGGCATTCAC
CCCTGGGGCTGGATTATCAATAACAGCCTTTCCATTGCGGATACCCGTTCGCCACTGCTT
CGTATGCGGGCACAACAGGAACTTCCGCAGATAGAGAGCGTTAAACGCCAGCACGCCAGC
CGTGTCGCTCTTGTTCCCGTACTGGCGTCAGAACCAACCGGCATCGACAAACTCAAACAA
CTTGCTGGGTAA

# Drug_Target_49_General_Function:
Inorganic ion transport and metabolism

# Drug_Target_49_General_References:
1704144	Rosen BP: The plasmid-encoded arsenical resistance pump: an anion-translocating ATPase. Res Microbiol. 1990 Mar-Apr;141(3):336-41.
3021763	Chen CM, Misra TK, Silver S, Rosen BP: Nucleotide sequence of the structural genes for an anion pump. The plasmid-encoded arsenical resistance operon. J Biol Chem. 1986 Nov 15;261(32):15030-8.

# Drug_Target_49_HGNC_ID:
Not Available

# Drug_Target_49_HPRD_ID:
Not Available

# Drug_Target_49_ID:
3435

# Drug_Target_49_Locus:
Not Available

# Drug_Target_49_Molecular_Weight:
63189

# Drug_Target_49_Name:
Arsenical pump-driving ATPase

# Drug_Target_49_Number_of_Residues:
583

# Drug_Target_49_PDB_ID:
1II9

# Drug_Target_49_Pathway:
Not Available

# Drug_Target_49_Pfam_Domain_Function:
PF02374	ArsA_ATPase

# Drug_Target_49_Protein_Sequence:
>Arsenical pump-driving ATPase
MQFLQNIPPYLFFTGKGGVGKTSISCATAIRLAEQGKRVLLVSTDPASNVGQVFSQTIGI
TIQAIASVPGLSALEIDPQAAAQQYRARIVDPIKGVLPDDVVSSINEQLSGACTTEIAAF
DEFTGLLTDASLLTRFDHIIFDTAPTGHTIRLLQLPGAWSSFIDSNPEGASCLGPMAGLE
KQREQYAYAVEALSDPKRTRLVLVARLQKSTLQEVARTHLELAAIGLKNQYLVINGVLPK
TEAANDTLAAAIWEREQEALANLPADLAGLPTDTLFLQPVNMVGVSALSRLLSTQPVASP
SSDEYLQQRPDIPSLSALVDDIARNEHGLIMLMGKGGVGKTTMAAAIAVRLADMGFDVHL
TTSDPAAHLSMTLNGSLNNLQVSRIDPHEETERYRQHVLETKGKELDEAGKRLLEEDLRS
PCTEEIAVFQAFSRVIREAGKRFVVMDTAPTGHTLLLLDATGAYHREIAKKMGEKGHFTT
PMMLLQDPERTKVLLVTLPETTPVLEAANLQADLERAGIHPWGWIINNSLSIADTRSPLL
RMRAQQELPQIESVKRQHASRVALVPVLASEPTGIDKLKQLAG

# Drug_Target_49_Reaction:
ATP + H2O + arsenitein = ADP + phosphate + arseniteout

# Drug_Target_49_Signals:
None

# Drug_Target_49_Specific_Function:
Anion-transporting ATPase. Catalyzes the extrusion of the oxyanions arsenite, antimonite and arsenate. Maintenance of a low intracellular concentration of oxyanion produces resistance to the toxic agents

# Drug_Target_49_SwissProt_ID:
P08690

# Drug_Target_49_SwissProt_Name:
ARSA1_ECOLX

# Drug_Target_49_Synonyms:
Arsenical resistance ATPase
Arsenite-translocating ATPase
Arsenite-transporting ATPase
EC 3.6.3.16

# Drug_Target_49_Theoretical_pI:
5.64

# Drug_Target_49_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Cytoplasmic

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
Not Available

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
Not Available

# Drug_Target_4_GenBank_ID_Gene:
AB032368

# Drug_Target_4_GenBank_ID_Protein:
Not Available

# Drug_Target_4_GeneCard_ID:
Not Available

# Drug_Target_4_Gene_Name:
ftsH

# Drug_Target_4_Gene_Sequence:
>1875 bp
ATGCCTCGAGCCCCCTTTAGCCTTCTCGCCCTGGTCCTGGGCCTCGCCTTCCTGGCCTGG
CCTTCAGCCTCGCGGGGCACCGTGGGCGCCCCAAGCGGGACGGTGAACTACACGACCTTC
CTGGAGGACCTCAAGGCGGGCCGGGTCAAGGAGGTGGTGGTGCGCGCCGGGGACACCCGG
ATCCAGGGGGTCCTGGAGGACGGCTCCGCCTTCACCACCTACGCGGCGAGCCCTCCGGAC
AACGCCACCCTCGAGGGCTGGATGGCCCGGGGGGTGAGCGTCCGGGTGGAGCCCCCCCAG
GGCCAAAACGCCCTCGGCTTCCTCTGGCCCCTCCTCCTCGTGGGCCTCCTCATCGGCGCC
CTCTACTACTTCTCCCGCAACGGCCGGGCCGGGCCTTCGGACTCCGCCTTCAGCTTCACC
AAAAGCCGGGCCCGGGTCCTCACCGAGGCCCCCAAGGTCACCTTCAAGGACGTGGCCGGG
GCGGAGGAGGCCAAGGAGGAACTCAAGGAGATCGTGGAGTTCCTCAAAAACCCCAGCCGC
TTCCACGAGATGGGCGCCCGCATCCCCAAGGGTGTCCTCCTGGTGGGGCCCCCGGGGGTG
GGCAAGACCCACCTGGCCCGGGCCGTGGCCGGGGAGGCCCGGGTGCCCTTCATCACCGCC
TCGGGCTCCGACTTCGTGGAGATGTTCGTGGGGGTAGGGGCGGCGAGGGTCCGGGACCTC
TTTGAGACCGCCAAGCGCCACGCCCCCTGCATCGTCTTCATTGACGAGATTGACGCCGTG
GGGAGGAAGCGGGGAAGCGGGGTGGGGGGCGGGAACGACGAGCGGGAGCAGACCCTGAAC
CAGCTCCTCGTGGAGATGGACGGCTTTGAGAAGGACACGGCCATCGTGGTCATGGCCGCC
ACCAACCGCCCCGACATCCTGGACCCCGCCCTGCTCCGCCCCGGGCGCTTTGACCGGCAG
ATCGCCATAGACGCCCCCGACGTCAAGGGCCGGGAGCAGATCCTCAGGATCCACGCCCGG
GGCAAGCCCCTGGCGGAGGACGTGGACCTGGCCCTCCTCGCCAAGCGCACCCCGGGCTTC
GTGGGGGCGGACCTGGAGAACCTCCTGAACGAAGCCGCCCTCCTCGCCGCCCGGGAGGGG
CGGAGGAAGATCACCATGAAGGACCTGGAGGAGGCCGCCGACCGGGTGATGATGGGCCCG
GCCAAGAAAAGCCTCGTCCTCTCCCCCCGCGACCGCAGGATCACCGCCTACCACGAGGCG
GGGCACGCCCTGGCGGCCCACTTCCTGGAGCACGCCGACGGGGTGCACAAGGTGACCATC
GTGCCCCGGGGAAGGGCCTTGGGCTTCATGATGCCCAGGCGGGAGGACATGCTCCACTGG
TCCAGAAAGCGCCTTTTGGACCAGATCGCCGTGGCCCTGGCGGGGCGGGCGGCGGAGGAG
ATCGTCTTTGACGACGTGACCACGGGGGCGGAGAACGACTTCCGCCAGGCCACGGAGCTC
GCCCGCCGCATGATCACCGAGTGGGGGATGCACCCCGAGTTCGGCCCCGTGGCCTACGCG
GTGCGGGAGGACACCTACCTGGGCGGCTACGACGTGCGCCAGTACTCGGAGGAGACCGCC
AAGCGCATTGACGAGGCGGTGCGCCGCCTCATTGAGGAGCAGTACCAGAGGGTGAAGGCC
CTTCTCCTGGAAAAGCGGGAGGTCCTGGAGCGGGTGGCGGAGACCCTCCTGGAGCGGGAG
ACCCTCACCGCCGAGGAGTTCCAACGGGTGGTGGAGGGGCTCCCCTTGGAGGCCCCCGAG
GAGGCCCGGGAGGAGCGGGAGCCCCCCCGGGTGGTGCCCAAGGTGAAGCCGGGGGGCGCC
CTGGGCGGGGCCTGA

# Drug_Target_4_General_Function:
Involved in nucleotide binding

# Drug_Target_4_General_References:
10377389	Motohashi K, Watanabe Y, Yohda M, Yoshida M: Heat-inactivated proteins are rescued by the DnaK.J-GrpE set and ClpB chaperones. Proc Natl Acad Sci U S A. 1999 Jun 22;96(13):7184-9.
10788805	Asahara Y, Atsuta K, Motohashi K, Taguchi H, Yohda M, Yoshida M: FtsH recognizes proteins with unfolded structure and hydrolyzes the carboxyl side of hydrophobic residues. J Biochem. 2000 May;127(5):931-7.
12377127	Niwa H, Tsuchiya D, Makyio H, Yoshida M, Morikawa K: Hexameric ring structure of the ATPase domain of the membrane-integrated metalloprotease FtsH from Thermus thermophilus HB8. Structure. 2002 Oct;10(10):1415-23.

# Drug_Target_4_HGNC_ID:
Not Available

# Drug_Target_4_HPRD_ID:
Not Available

# Drug_Target_4_ID:
5265

# Drug_Target_4_Locus:
Not Available

# Drug_Target_4_Molecular_Weight:
68462

# Drug_Target_4_Name:
FtsH

# Drug_Target_4_Number_of_Residues:
624

# Drug_Target_4_PDB_ID:
1IY2

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00004	AAA
PF01434	Peptidase_M41
PF06480	FtsH_ext

# Drug_Target_4_Protein_Sequence:
>FtsH
MPRAPFSLLALVLGLAFLAWPSASRGTVGAPSGTVNYTTFLEDLKAGRVKEVVVRAGDTR
IQGVLEDGSAFTTYAASPPDNATLEGWMARGVSVRVEPPQGQNALGFLWPLLLVGLLIGA
LYYFSRNGRAGPSDSAFSFTKSRARVLTEAPKVTFKDVAGAEEAKEELKEIVEFLKNPSR
FHEMGARIPKGVLLVGPPGVGKTHLARAVAGEARVPFITASGSDFVEMFVGVGAARVRDL
FETAKRHAPCIVFIDEIDAVGRKRGSGVGGGNDEREQTLNQLLVEMDGFEKDTAIVVMAA
TNRPDILDPALLRPGRFDRQIAIDAPDVKGREQILRIHARGKPLAEDVDLALLAKRTPGF
VGADLENLLNEAALLAAREGRRKITMKDLEEAADRVMMGPAKKSLVLSPRDRRITAYHEA
GHALAAHFLEHADGVHKVTIVPRGRALGFMMPRREDMLHWSRKRLLDQIAVALAGRAAEE
IVFDDVTTGAENDFRQATELARRMITEWGMHPEFGPVAYAVREDTYLGGYDVRQYSEETA
KRIDEAVRRLIEEQYQRVKALLLEKREVLERVAETLLERETLTAEEFQRVVEGLPLEAPE
EAREEREPPRVVPKVKPGGALGGA

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Seems to act as an ATP-dependent zinc metallopeptidase (By similarity)

# Drug_Target_4_SwissProt_ID:
Q9LCZ4

# Drug_Target_4_SwissProt_Name:
FTSH_THET8

# Drug_Target_4_Synonyms:
Not Available

# Drug_Target_4_Theoretical_pI:
6.61

# Drug_Target_4_Transmembrane_Regions:
None

# Drug_Target_50_Cellular_Location:
Cytoplasm

# Drug_Target_50_Chromosome_Location:
Not Available

# Drug_Target_50_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_50_Essentiality:
Non-Essential

# Drug_Target_50_GenAtlas_ID:
ACTA1

# Drug_Target_50_GenBank_ID_Gene:
J00068

# Drug_Target_50_GenBank_ID_Protein:
178029

# Drug_Target_50_GeneCard_ID:
ACTA1

# Drug_Target_50_Gene_Name:
ACTA1

# Drug_Target_50_Gene_Sequence:
>1134 bp
ATGTGCGACGAAGACGAGACCACCGCCCTCGTGTGCGACAATGGCTCCGGCCTGGTGAAA
GCCGGCTTCGCCGGGGATGACGCCCCTAGGGCCGTGTTCCCGTCCATCGTGGGCCGCCCC
CGACACCAGGGCGTCATGGTCGGTATGGGTCAGAAAGATTCCTACGTGGGCGACGAGGCT
CAGAGCAAGAGAGGTATCCTGACCCTGAAGTACCCTATCGAGCACGGCATCATCACCAAC
TGGGATGACATGGAGAAGATCTGGCACCACACCTTCTACAACGAGCTTCGCGTGGCTCCC
GAGGAGCACCCCACCCTGCTCACCGAAGCCCCCCTCAATCCCAAGGCCAACCGCGAGAAG
ATGACCCAGATCATGTTTGAGACCTTCAACGTGCCCGCCATGTACGTGGCCATCCAGGCC
GTGCTGTCCCTCTACGCCTCCGGCAGGACCACCGGCATCGTGCTGGACTCCGGCGACGGC
GTCACCCACAACGTGCCCATTTATGAGGGCTACGCGCTGCCGCACGCCATCATGCGCCTG
GACCTGGCGGGCCGCGATCTTACCGACTACCTGATGAAGATCCTCACTGAGCGTGGCTAC
TCCTTCGTGACCACAGCTGAGCGCGAGATCGTGCGCGACATCAAGGAGAAGCTGTGCTAC
GTGGCCCTGGACTTCGAGAACGAGATGGCGACGGCCGCCTCCTCCTCCTCCCTGGAAAAG
AGCTACGAGCTGCCAGACGGGCAGGTCATCACCATCGGCAACGAGCGCTTCCGCTGCCCG
GAGACGCTCTTCCAGCCCTCCTTCATCGGTATGGAGTCGGCGGGCATTCACGAGACCACC
TACAACAGCATCATGAAGTGTGACATCGACATCAGGAAGGACCTGTATGCCAACAACGTC
ATGTCGGGGGGCACCACGATGTACCCTGGGATCGCTGACCGCATGCAGAAAGAGATCACC
GCGCTGGCACCCAGCACCATGAAGATCAAGATCATCGCCCCGCCGGAGCGCAAATACTCG
GTGTGGATCGGCGGCTCCATCCTGGCCTCGCTGTCCACCTTCCAGCAGATGTGGATCACC
AAGCAGGAGTACGACGAGGCCGGCCCTTCCATCGTCCACCGCAAATGCTTCTAG

# Drug_Target_50_General_Function:
Cytoskeleton

# Drug_Target_50_General_References:
10508519	Nowak KJ, Wattanasirichaigoon D, Goebel HH, Wilce M, Pelin K, Donner K, Jacob RL, Hubner C, Oexle K, Anderson JR, Verity CM, North KN, Iannaccone ST, Muller CR, Nurnberg P, Muntoni F, Sewry C, Hughes I, Sutphen R, Lacson AG, Swoboda KJ, Vigneron J, Wallgren-Pettersson C, Beggs AH, Laing NG: Mutations in the skeletal muscle alpha-actin gene in patients with actin myopathy and nemaline myopathy. Nat Genet. 1999 Oct;23(2):208-12.
11166164	Jungbluth H, Sewry CA, Brown SC, Nowak KJ, Laing NG, Wallgren-Pettersson C, Pelin K, Manzur AY, Mercuri E, Dubowitz V, Muntoni F: Mild phenotype of nemaline myopathy with sleep hypoventilation due to a mutation in the skeletal muscle alpha-actin (ACTA1) gene. Neuromuscul Disord. 2001 Jan;11(1):35-40.
11333380	Ilkovski B, Cooper ST, Nowak K, Ryan MM, Yang N, Schnell C, Durling HJ, Roddick LG, Wilkinson I, Kornberg AJ, Collins KJ, Wallace G, Gunning P, Hardeman EC, Laing NG, North KN: Nemaline myopathy caused by mutations in the muscle alpha-skeletal-actin gene. Am J Hum Genet. 2001 Jun;68(6):1333-43. Epub 2001 Apr 27.
2907503	Taylor A, Erba HP, Muscat GE, Kedes L: Nucleotide sequence and expression of the human skeletal alpha-actin gene: evolution of functional regulatory domains. Genomics. 1988 Nov;3(4):323-36.
6190133	Hanauer A, Levin M, Heilig R, Daegelen D, Kahn A, Mandel JL: Isolation and characterization of cDNA clones for human skeletal muscle alpha actin. Nucleic Acids Res. 1983 Jun 11;11(11):3503-16.

# Drug_Target_50_HGNC_ID:
HGNC:129

# Drug_Target_50_HPRD_ID:
Not Available

# Drug_Target_50_ID:
3822

# Drug_Target_50_Locus:
1q42.13-q42.2

# Drug_Target_50_Molecular_Weight:
42052

# Drug_Target_50_Name:
Actin, alpha skeletal muscle

# Drug_Target_50_Number_of_Residues:
377

# Drug_Target_50_PDB_ID:
1IJJ

# Drug_Target_50_Pathway:
Not Available

# Drug_Target_50_Pfam_Domain_Function:
PF00022	Actin

# Drug_Target_50_Protein_Sequence:
>Actin, alpha skeletal muscle
MCDEDETTALVCDNGSGLVKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEA
QSKRGILTLKYPIEHGIITNWDDMEKIWHHTFYNELRVAPEEHPTLLTEAPLNPKANREK
MTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRL
DLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEK
SYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNV
MSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWIT
KQEYDEAGPSIVHRKCF

# Drug_Target_50_Reaction:
Not Available

# Drug_Target_50_Signals:
None

# Drug_Target_50_Specific_Function:
Actins are highly conserved proteins that are involved in various types of cell motility and are ubiquitously expressed in all eukaryotic cells

# Drug_Target_50_SwissProt_ID:
P68133

# Drug_Target_50_SwissProt_Name:
ACTS_HUMAN

# Drug_Target_50_Synonyms:
Alpha-actin-1

# Drug_Target_50_Theoretical_pI:
5.05

# Drug_Target_50_Transmembrane_Regions:
None

# Drug_Target_51_Cellular_Location:
Cytoplasm (Probable)

# Drug_Target_51_Chromosome_Location:
Not Available

# Drug_Target_51_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_51_Essentiality:
Non-Essential

# Drug_Target_51_GenAtlas_ID:
Not Available

# Drug_Target_51_GenBank_ID_Gene:
M21446

# Drug_Target_51_GenBank_ID_Protein:
145334

# Drug_Target_51_GeneCard_ID:
Not Available

# Drug_Target_51_Gene_Name:
argB

# Drug_Target_51_Gene_Sequence:
>777 bp
ATGATGAATCCATTAATTATCAAACTGGGCGGCGTACTGCTGGATAGTGAAGAGGCGCTG
GAACGTCTGTTTAGCGCACTGGTGAATTATCGTGAGTCACATCAGCGTCCGCTGGTGATT
GTGCACGGCGGCGGTTGCGTGGTGGATGAGCTGATGAAAGGGCTGAATCTGCCGGTGAAA
AAGAAAAACGGCCTGCGGGTGACGCCTGCTGATCAGATAGACATTATCACCGGAGCACTG
GCGGGAACGGCAAATAAAACCCTGTTGGCATGGGCGAAGAAACATCAGATTGCGGCCGTA
GGTTTGTTTCTCGGTGACGGCGACAGCGTCAAAGTGACCCAGCTTGATGAAGAGTTAGGT
CATGTTGGACTGGCGCAGCCAGGTTCGCCTAAGCTTATCAACTCCTTGCTGGAGAACGGT
TATCTGCCGGTGGTCAGCTCCATTGGCGTAACAGACGAAGGGCAACTGATGAACGTCAAT
GCCGACCAGGCGGCAACGGCGCTGGCGGCAACGCTGGGCGCGGATCTGATTTTGCTCTCC
GACGTCAGCGGCATTCTCGACGGCAAAGGGCAACGCATTGCCGAAATGACCGCCGCGAAA
GCAGAACAACTGATTGAGCAGGGCATTATTACTGACGGCATGATAGTGAAAGTGAACGCG
GCGCTGGATGCGGCCCGCACGCTGGGCCGTCCGGTAGATATCGCCTCCTGGCGTCATGCG
GAGCAGCTTCCGGCACTGTTTAACGGTATGCCGATGGGTACGCGGATTTTAGCTTAA

# Drug_Target_51_General_Function:
Amino acid transport and metabolism

# Drug_Target_51_General_References:
10393305	Gil F, Ramon-Maiques S, Marina A, Fita I, Rubio V: N-Acetyl-L-glutamate kinase from Escherichia coli: cloning of the gene, purification and crystallization of the recombinant enzyme and preliminary X-ray analysis of the free and ligand-bound forms. Acta Crystallogr D Biol Crystallogr. 1999 Jul;55(Pt 7):1350-2.
12005432	Ramon-Maiques S, Marina A, Gil-Ortiz F, Fita I, Rubio V: Structure of acetylglutamate kinase, a key enzyme for arginine biosynthesis and a prototype for the amino acid kinase enzyme family, during catalysis. Structure. 2002 Mar;10(3):329-42.
2851495	Parsot C, Boyen A, Cohen GN, Glansdorff N: Nucleotide sequence of Escherichia coli argB and argC genes: comparison of N-acetylglutamate kinase and N-acetylglutamate-gamma-semialdehyde dehydrogenase with homologous and analogous enzymes. Gene. 1988 Sep 7;68(2):275-83.
8265357	Blattner FR, Burland V, Plunkett G 3rd, Sofia HJ, Daniels DL: Analysis of the Escherichia coli genome. IV. DNA sequence of the region from 89.2 to 92.8 minutes. Nucleic Acids Res. 1993 Nov 25;21(23):5408-17.
9278503	Blattner FR, Plunkett G 3rd, Bloch CA, Perna NT, Burland V, Riley M, Collado-Vides J, Glasner JD, Rode CK, Mayhew GF, Gregor J, Davis NW, Kirkpatrick HA, Goeden MA, Rose DJ, Mau B, Shao Y: The complete genome sequence of Escherichia coli K-12. Science. 1997 Sep 5;277(5331):1453-74.

# Drug_Target_51_HGNC_ID:
Not Available

# Drug_Target_51_HPRD_ID:
Not Available

# Drug_Target_51_ID:
2892

# Drug_Target_51_Locus:
Not Available

# Drug_Target_51_Molecular_Weight:
27160

# Drug_Target_51_Name:
Acetylglutamate kinase

# Drug_Target_51_Number_of_Residues:
258

# Drug_Target_51_PDB_ID:
1OHB

# Drug_Target_51_Pathway:
Not Available

# Drug_Target_51_Pfam_Domain_Function:
PF00696	AA_kinase

# Drug_Target_51_Protein_Sequence:
>Acetylglutamate kinase
MMNPLIIKLGGVLLDSEEALERLFSALVNYRESHQRPLVIVHGGGCVVDELMKGLNLPVK
KKNGLRVTPADQIDIITGALAGTANKTLLAWAKKHQIAAVGLFLGDGDSVKVTQLDEELG
HVGLAQPGSPKLINSLLENGYLPVVSSIGVTDEGQLMNVNADQAATALAATLGADLILLS
DVSGILDGKGQRIAEMTAAKAEQLIEQGIITDGMIVKVNAALDAARTLGRPVDIASWRHA
EQLPALFNGMPMGTRILA

# Drug_Target_51_Reaction:
ATP + N-acetyl-L-glutamate = ADP + N-acetyl-L-glutamyl 5-phosphate

# Drug_Target_51_Signals:
None

# Drug_Target_51_Specific_Function:
ATP + N-acetyl-L-glutamate = ADP + N-acetyl-L- glutamate 5-phosphate

# Drug_Target_51_SwissProt_ID:
P0A6C8

# Drug_Target_51_SwissProt_Name:
ARGB_ECOLI

# Drug_Target_51_Synonyms:
AGK
EC 2.7.2.8
N-acetyl-L- glutamate 5-phosphotransferase
NAG kinase

# Drug_Target_51_Theoretical_pI:
5.32

# Drug_Target_51_Transmembrane_Regions:
None

# Drug_Target_5_Cellular_Location:
Membrane
multi-pass membrane protein

# Drug_Target_5_Chromosome_Location:
Not Available

# Drug_Target_5_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_5_Essentiality:
Non-Essential

# Drug_Target_5_GenAtlas_ID:
CFTR

# Drug_Target_5_GenBank_ID_Gene:
M28668

# Drug_Target_5_GenBank_ID_Protein:
180332

# Drug_Target_5_GeneCard_ID:
CFTR

# Drug_Target_5_Gene_Name:
CFTR

# Drug_Target_5_Gene_Sequence:
>4443 bp
ATGCAGAGGTCGCCTCTGGAAAAGGCCAGCGTTGTCTCCAAACTTTTTTTCAGCTGGACC
AGACCAATTTTGAGGAAAGGATACAGACAGCGCCTGGAATTGTCAGACATATACCAAATC
CCTTCTGTTGATTCTGCTGACAATCTATCTGAAAAATTGGAAAGAGAATGGGATAGAGAG
CTGGCTTCAAAGAAAAATCCTAAACTCATTAATGCCCTTCGGCGATGTTTTTTCTGGAGA
TTTATGTTCTATGGAATCTTTTTATATTTAGGGGAAGTCACCAAAGCAGTACAGCCTCTC
TTACTGGGAAGAATCATAGCTTCCTATGACCCGGATAACAAGGAGGAACGCTCTATCGCG
ATTTATCTAGGCATAGGCTTATGCCTTCTCTTTATTGTGAGGACACTGCTCCTACACCCA
GCCATTTTTGGCCTTCATCACATTGGAATGCAGATGAGAATAGCTATGTTTAGTTTGATT
TATAAGAAGACTTTAAAGCTGTCAAGCCGTGTTCTAGATAAAATAAGTATTGGACAACTT
GTTAGTCTCCTTTCCAACAACCTGAACAAATTTGATGAAGGACTTGCATTGGCACATTTC
GTGTGGATCGCTCCTTTGCAAGTGGCACTCCTCATGGGGCTAATCTGGGAGTTGTTACAG
GCGTCTGCCTTCTGTGGACTTGGTTTCCTGATAGTCCTTGCCCTTTTTCAGGCTGGGCTA
GGGAGAATGATGATGAAGTACAGAGATCAGAGAGCTGGGAAGATCAGTGAAAGACTTGTG
ATTACCTCAGAAATGATTGAAAATATCCAATCTGTTAAGGCATACTGCTGGGAAGAAGCA
ATGGAAAAAATGATTGAAAACTTAAGACAAACAGAACTGAAACTGACTCGGAAGGCAGCC
TATGTGAGATACTTCAATAGCTCAGCCTTCTTCTTCTCAGGGTTCTTTGTGGTGTTTTTA
TCTGTGCTTCCCTATGCACTAATCAAAGGAATCATCCTCCGGAAAATATTCACCACCATC
TCATTCTGCATTGTTCTGCGCATGGCGGTCACTCGGCAATTTCCCTGGGCTGTACAAACA
TGGTATGACTCTCTTGGAGCAATAAACAAAATACAGGATTTCTTACAAAAGCAAGAATAT
AAGACATTGGAATATAACTTAACGACTACAGAAGTAGTGATGGAGAATGTAACAGCCTTC
TGGGAGGAGGGATTTGGGGAATTATTTGAGAAAGCAAAACAAAACAATAACAATAGAAAA
ACTTCTAATGGTGATGACAGCCTCTTCTTCAGTAATTTCTCACTTCTTGGTACTCCTGTC
CTGAAAGATATTAATTTCAAGATAGAAAGAGGACAGTTGTTGGCGGTTGCTGGATCCACT
GGAGCAGGCAAGACTTCACTTCTAATGATGATTATGGGAGAACTGGAGCCTTCAGAGGGT
AAAATTAAGCACAGTGGAAGAATTTCATTCTGTTCTCAGTTTTCCTGGATTATGCCTGGC
ACCATTAAAGAAAATATCATCTTTGGTGTTTCCTATGATGAATATAGATACAGAAGCGTC
ATCAAAGCATGCCAACTAGAAGAGGACATCTCCAAGTTTGCAGAGAAAGACAATATAGTT
CTTGGAGAAGGTGGAATCACACTGAGTGGAGGTCAACGAGCAAGAATTTCTTTAGCAAGA
GCAGTATACAAAGATGCTGATTTGTATTTATTAGACTCTCCTTTTGGATACCTAGATGTT
TTAACAGAAAAAGAAATATTTGAAAGCTGTGTCTGTAAACTGATGGCTAACAAAACTAGG
ATTTTGGTCACTTCTAAAATGGAACATTTAAAGAAAGCTGACAAAATATTAATTTTGAAT
GAAGGTAGCAGCTATTTTTATGGGACATTTTCAGAACTCCAAAATCTACAGCCAGACTTT
AGCTCAAAACTCATGGGATGTGATTCTTTCGACCAATTTAGTGCAGAAAGAAGAAATTCA
ATCCTAACTGAGACCTTACACCGTTTCTCATTAGAAGGAGATGCTCCTGTCTCCTGGACA
GAAACAAAAAAACAATCTTTTAAACAGACTGGAGAGTTTGGGGAAAAAAGGAAGAATTCT
ATTCTCAATCCAATCAACTCTATACGAAAATTTTCCATTGTGCAAAAGACTCCCTTACAA
ATGAATGGCATCGAAGAGGATTCTGATGAGCCTTTAGAGAGAAGGCTGTCCTTAGTACCA
GATTCTGAGCAGGGAGAGGCGATACTGCCTCGCATCAGCGTGATCAGCACTGGCCCCACG
CTTCAGGCACGAAGGAGGCAGTCTGTCCTGAACCTGATGACACACTCAGTTAACCAAGGT
CAGAACATTCACCGAAAGACAACAGCATCCACACGAAAAGTGTCACTGGCCCCTCAGGCA
AACTTGACTGAACTGGATATATATTCAAGAAGGTTATCTCAAGAAACTGGCTTGGAAATA
AGTGAAGAAATTAACGAAGAAGACTTAAAGGAGTGCCTTTTTGATGATATGGAGAGCATA
CCAGCAGTGACTACATGGAACACATACCTTCGATATATTACTGTCCACAAGAGCTTAATT
TTTGTGCTAATTTGGTGCTTAGTAATTTTTCTGGCAGAGGTGGCTGCTTCTTTGGTTGTG
CTGTGGCTCCTTGGAAACACTCCTCTTCAAGACAAAGGGAATAGTACTCATAGTAGAAAT
AACAGCTATGCAGTGATTATCACCAGCACCAGTTCGTATTATGTGTTTTACATTTACGTG
GGAGTAGCCGACACTTTGCTTGCTATGGGATTCTTCAGAGGTCTACCACTGGTGCATACT
CTAATCACAGTGTCGAAAATTTTACACCACAAAATGTTACATTCTGTTCTTCAAGCACCT
ATGTCAACCCTCAACACGTTGAAAGCAGGTGGGATTCTTAATAGATTCTCCAAAGATATA
GCAATTTTGGATGACCTTCTGCCTCTTACCATATTTGACTTCATCCAGTTGTTATTAATT
GTGATTGGAGCTATAGCAGTTGTCGCAGTTTTACAACCCTACATCTTTGTTGCAACAGTG
CCAGTGATAGTGGCTTTTATTATGTTGAGAGCATATTTCCTCCAAACCTCACAGCAACTC
AAACAACTGGAATCTGAAGGCAGGAGTCCAATTTTCACTCATCTTGTTACAAGCTTAAAA
GGACTATGGACACTTCGTGCCTTCGGACGGCAGCCTTACTTTGAAACTCTGTTCCACAAA
GCTCTGAATTTACATACTGCCAACTGGTTCTTGTACCTGTCAACACTGCGCTGGTTCCAA
ATGAGAATAGAAATGATTTTTGTCATCTTCTTCATTGCTGTTACCTTCATTTCCATTTTA
ACAACAGGAGAAGGAGAAGGAAGAGTTGGTATTATCCTGACTTTAGCCATGAATATCATG
AGTACATTGCAGTGGGCTGTAAACTCCAGCATAGATGTGGATAGCTTGATGCGATCTGTG
AGCCGAGTCTTTAAGTTCATTGACATGCCAACAGAAGGTAAACCTACCAAGTCAACCAAA
CCATACAAGAATGGCCAACTCTCGAAAGTTATGATTATTGAGAATTCACACGTGAAGAAA
GATGACATCTGGCCCTCAGGGGGCCAAATGACTGTCAAAGATCTCACAGCAAAATACACA
GAAGGTGGAAATGCCATATTAGAGAACATTTCCTTCTCAATAAGTCCTGGCCAGAGGGTG
GGCCTCTTGGGAAGAACTGGATCAGGGAAGAGTACTTTGTTATCAGCTTTTTTGAGACTA
CTGAACACTGAAGGAGAAATCCAGATCGATGGTGTGTCTTGGGATTCAATAACTTTGCAA
CAGTGGAGGAAAGCCTTTGGAGTGATACCACAGAAAGTATTTATTTTTTCTGGAACATTT
AGAAAAAACTTGGATCCCTATGAACAGTGGAGTGATCAAGAAATATGGAAAGTTGCAGAT
GAGGTTGGGCTCAGATCTGTGATAGAACAGTTTCCTGGGAAGCTTGACTTTGTCCTTGTG
GATGGGGGCTGTGTCCTAAGCCATGGCCACAAGCAGTTGATGTGCTTGGCTAGATCTGTT
CTCAGTAAGGCGAAGATCTTGCTGCTTGATGAACCCAGTGCTCATTTGGATCCAGTAACA
TACCAAATAATTAGAAGAACTCTAAAACAAGCATTTGCTGATTGCACAGTAATTCTCTGT
GAACACAGGATAGAAGCAATGCTGGAATGCCAACAATTTTTGGTCATAGAAGAGAACAAA
GTGCGGCAGTACGATTCCATCCAGAAACTGCTGAACGAGAGGAGCCTCTTCCGGCAAGCC
ATCAGCCCCTCCGACAGGGTGAAGCTCTTTCCCCACCGGAACTCAAGCAAGTGCAAGTCT
AAGCCCCAGATTGCTGCTCTGAAAGAGGAGACAGAAGAAGAGGTGCAAGATACAAGGCTT
TAG

# Drug_Target_5_General_Function:
Involved in chloride ion transport

# Drug_Target_5_General_References:
10094564	Picci L, Cameran M, Olante P, Zacchello F, Scarpa M: Identification of a D579G homozygote cystic fibrosis patient with pancreatic sufficiency and minor lung involvement. Mutations in brief no. 221. Online. Hum Mutat. 1999;13(2):173.
11304524	Karthikeyan S, Leung T, Ladias JA: Structural basis of the Na+/H+ exchanger regulatory factor PDZ1 interaction with the carboxyl-terminal region of the cystic fibrosis transmembrane conductance regulator. J Biol Chem. 2001 Jun 8;276(23):19683-6. Epub 2001 Apr 13.
11707463	Cheng J, Moyer BD, Milewski M, Loffing J, Ikeda M, Mickle JE, Cutting GR, Li M, Stanton BA, Guggino WB: A Golgi-associated PDZ domain protein modulates cystic fibrosis transmembrane regulator plasma membrane expression. J Biol Chem. 2002 Feb 1;277(5):3520-9. Epub 2001 Nov 13.
12690205	Scherer SW, Cheung J, MacDonald JR, Osborne LR, Nakabayashi K, Herbrick JA, Carson AR, Parker-Katiraee L, Skaug J, Khaja R, Zhang J, Hudek AK, Li M, Haddad M, Duggan GE, Fernandez BA, Kanematsu E, Gentles S, Christopoulos CC, Choufani S, Kwasnicka D, Zheng XH, Lai Z, Nusskern D, Zhang Q, Gu Z, Lu F, Zeesman S, Nowaczyk MJ, Teshima I, Chitayat D, Shuman C, Weksberg R, Zackai EH, Grebe TA, Cox SR, Kirkpatrick SJ, Rahman N, Friedman JM, Heng HH, Pelicci PG, Lo-Coco F, Belloni E, Shaffer LG, Pober B, Morton CC, Gusella JF, Bruns GA, Korf BR, Quade BJ, Ligon AH, Ferguson H, Higgins AW, Leach NT, Herrick SR, Lemyre E, Farra CG, Kim HG, Summers AM, Gripp KW, Roberts W, Szatmari P, Winsor EJ, Grzeschik KH, Teebi A, Minassian BA, Kere J, Armengol L, Pujana MA, Estivill X, Wilson MD, Koop BF, Tosi S, Moore GE, Boright AP, Zlotorynski E, Kerem B, Kroisel PM, Petek E, Oscier DG, Mould SJ, Dohner H, Dohner K, Rommens JM, Vincent JB, Venter JC, Li PW, Mural RJ, Adams MD, Tsui LC: Human chromosome 7: DNA sequence and biology. Science. 2003 May 2;300(5620):767-72. Epub 2003 Apr 10.
1284466	Jones CT, McIntosh I, Keston M, Ferguson A, Brock DJ: Three novel mutations in the cystic fibrosis gene detected by chemical cleavage: analysis of variant splicing and a nonsense mutation. Hum Mol Genet. 1992 Apr;1(1):11-7.
1284468	Cheadle JP, Meredith AL, al-Jader LN: A new missense mutation (R1283M) in exon 20 of the cystic fibrosis transmembrane conductance regulator gene. Hum Mol Genet. 1992 May;1(2):123-5.
1284529	Shackleton S, Beards F, Harris A: Detection of novel and rare mutations in exon 4 of the cystic fibrosis gene by SSCP. Hum Mol Genet. 1992 Sep;1(6):439-40.
1284530	Lissens W, Bonduelle M, Malfroot A, Dab I, Liebaers I: A serine to proline substitution (S1255P) in the second nucleotide binding fold of the cystic fibrosis gene. Hum Mol Genet. 1992 Sep;1(6):441-2.
1284534	Tsui LC: Mutations and sequence variations detected in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: a report from the Cystic Fibrosis Genetic Analysis Consortium. Hum Mutat. 1992;1(3):197-203.
12853948	Hillier LW, Fulton RS, Fulton LA, Graves TA, Pepin KH, Wagner-McPherson C, Layman D, Maas J, Jaeger S, Walker R, Wylie K, Sekhon M, Becker MC, O'Laughlin MD, Schaller ME, Fewell GA, Delehaunty KD, Miner TL, Nash WE, Cordes M, Du H, Sun H, Edwards J, Bradshaw-Cordum H, Ali J, Andrews S, Isak A, Vanbrunt A, Nguyen C, Du F, Lamar B, Courtney L, Kalicki J, Ozersky P, Bielicki L, Scott K, Holmes A, Harkins R, Harris A, Strong CM, Hou S, Tomlinson C, Dauphin-Kohlberg S, Kozlowicz-Reilly A, Leonard S, Rohlfing T, Rock SM, Tin-Wollam AM, Abbott A, Minx P, Maupin R, Strowmatt C, Latreille P, Miller N, Johnson D, Murray J, Woessner JP, Wendl MC, Yang SP, Schultz BR, Wallis JW, Spieth J, Bieri TA, Nelson JO, Berkowicz N, Wohldmann PE, Cook LL, Hickenbotham MT, Eldred J, Williams D, Bedell JA, Mardis ER, Clifton SW, Chissoe SL, Marra MA, Raymond C, Haugen E, Gillett W, Zhou Y, James R, Phelps K, Iadanoto S, Bubb K, Simms E, Levy R, Clendenning J, Kaul R, Kent WJ, Furey TS, Baertsch RA, Brent MR, Keibler E, Flicek P, Bork P, Suyama M, Bailey JA, Portnoy ME, Torrents D, Chinwalla AT, Gish WR, Eddy SR, McPherson JD, Olson MV, Eichler EE, Green ED, Waterston RH, Wilson RK: The DNA sequence of human chromosome 7. Nature. 2003 Jul 10;424(6945):157-64.
1377674	Picciotto MR, Cohn JA, Bertuzzi G, Greengard P, Nairn AC: Phosphorylation of the cystic fibrosis transmembrane conductance regulator. J Biol Chem. 1992 Jun 25;267(18):12742-52.
1378801	McIntosh I, Cutting GR: Cystic fibrosis transmembrane conductance regulator and the etiology and pathogenesis of cystic fibrosis. FASEB J. 1992 Jul;6(10):2775-82.
1695717	Cutting GR, Kasch LM, Rosenstein BJ, Zielenski J, Tsui LC, Antonarakis SE, Kazazian HH Jr: A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature. 1990 Jul 26;346(6282):366-9.
1710598	Zielenski J, Rozmahel R, Bozon D, Kerem B, Grzelczak Z, Riordan JR, Rommens J, Tsui LC: Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics. 1991 May;10(1):214-28.
1710600	White MB, Krueger LJ, Holsclaw DS Jr, Gerrard BC, Stewart C, Quittell L, Dolganov G, Baranov V, Ivaschenko T, Kapronov NI, et al.: Detection of three rare frameshift mutations in the cystic fibrosis gene in an African-American (CF444delA), an Italian (CF2522insC), and a Soviet (CF3821delT). Genomics. 1991 May;10(1):266-9.
2236053	Kerem BS, Zielenski J, Markiewicz D, Bozon D, Gazit E, Yahav J, Kennedy D, Riordan JR, Collins FS, Rommens JM, et al.: Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. Proc Natl Acad Sci U S A. 1990 Nov;87(21):8447-51.
2475911	Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, Zielenski J, Lok S, Plavsic N, Chou JL, et al.: Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989 Sep 8;245(4922):1066-73.
7504969	Gasparini P, Marigo C, Bisceglia G, Nicolis E, Zelante L, Bombieri C, Borgo G, Pignatti PF, Cabrini G: Screening of 62 mutations in a cohort of cystic fibrosis patients from north eastern Italy: their incidence and clinical features of defined genotypes. Hum Mutat. 1993;2(5):389-94.
7505694	Chillon M, Casals T, Nunes V, Gimenez J, Perez Ruiz E, Estivill X: Identification of a new missense mutation (P205S) in the first transmembrane domain of the CFTR gene associated with a mild cystic fibrosis phenotype. Hum Mol Genet. 1993 Oct;2(10):1741-2.
7513296	Boteva K, Papageorgiou E, Georgiou C, Angastiniotis M, Middleton LT, Constantinou-Deltas CD: Novel cystic fibrosis mutation associated with mild disease in Cypriot patients. Hum Genet. 1994 May;93(5):529-32.
7517264	Chillon M, Casals T, Gimenez J, Nunes V, Estivill X: Analysis of the CFTR gene in the Spanish population: SSCP-screening for 60 known mutations and identification of four new mutations (Q30X, A120T, 1812-1 G-->A, and 3667del4). Hum Mutat. 1994;3(3):223-30.
7520022	Greil I, Wagner K, Rosenkranz W: A new missense mutation G1249E in exon 20 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Hum Hered. 1994 Jul-Aug;44(4):238-40.
7522211	Ghanem N, Costes B, Girodon E, Martin J, Fanen P, Goossens M: Identification of eight mutations and three sequence variations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics. 1994 May 15;21(2):434-6.
7524909	Schaedel C, Kristoffersson AC, Kornfalt R, Holmberg L: A novel cystic fibrosis mutation, Y109C, in the first transmembrane domain of CFTR. Hum Mol Genet. 1994 Jun;3(6):1001-2.
7524913	Petreska L, Koceva S, Gordova-Muratovska A, Nestorov R, Efremov GD: Identification of two new mutations (711 +3A-->G and V1397E) in CF chromosomes of Albanian and Macedonian origin. Hum Mol Genet. 1994 Jun;3(6):999-1000.
7525450	Dork T, Mekus F, Schmidt K, Bosshammer J, Fislage R, Heuer T, Dziadek V, Neumann T, Kalin N, Wulbrand U, et al.: Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. Hum Genet. 1994 Nov;94(5):533-42.
7529962	Mercier B, Verlingue C, Lissens W, Silber SJ, Novelli G, Bonduelle M, Audrezet MP, Ferec C: Is congenital bilateral absence of vas deferens a primary form of cystic fibrosis? Analyses of the CFTR gene in 67 patients. Am J Hum Genet. 1995 Jan;56(1):272-7.
7537150	Zielenski J, Markiewicz D, Chen HS, Schappert K, Seller A, Durie P, Corey M, Tsui LC: Identification of six mutations (R31L, 441delA, 681delC, 1461ins4, W1089R, E1104X) in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Hum Mutat. 1995;5(1):43-7.
7539342	Jezequel P, Dorval I, Fergelot P, Chauvel B, Le Treut A, Le Gall JY, Le Lannou D, Blayau M: Structural analysis of CFTR gene in congenital bilateral absence of vas deferens. Clin Chem. 1995 Jun;41(6 Pt 1):833-5.
7541273	Verlingue C, Kapranov NI, Mercier B, Ginter EK, Petrova NV, Audrezet MP, Ferec C: Complete screening of mutations in the coding sequence of the CFTR gene in a sample of CF patients from Russia: identification of three novel alleles. Hum Mutat. 1995;5(3):205-9.
7541510	Ferec C, Novelli G, Verlingue C, Quere I, Dallapiccola B, Audrezet MP, Mercier B: Identification of six novel CFTR mutations in a sample of Italian cystic fibrosis patients. Mol Cell Probes. 1995 Apr;9(2):135-7.
7543567	Leoni GB, Pitzalis S, Podda R, Zanda M, Silvetti M, Caocci L, Cao A, Rosatelli MC: A specific cystic fibrosis mutation (T3381) associated with the phenotype of isolated hypotonic dehydration. J Pediatr. 1995 Aug;127(2):281-3.
7544319	Brancolini V, Cremonesi L, Belloni E, Pappalardo E, Bordoni R, Seia M, Russo S, Padoan R, Giunta A, Ferrari M: Search for mutations in pancreatic sufficient cystic fibrosis Italian patients: detection of 90% of molecular defects and identification of three novel mutations. Hum Genet. 1995 Sep;96(3):312-8.
7581407	Romey MC, Desgeorges M, Ray P, Godard P, Demaille J, Claustres M: Novel missense mutation in the first transmembrane segment of the CFTR gene (Q98R) identified in a male adult. Hum Mutat. 1995;6(2):190-1.
7680525	Zielenski J, Fujiwara TM, Markiewicz D, Paradis AJ, Anacleto AI, Richards B, Schwartz RH, Klinger KW, Tsui LC, Morgan K: Identification of the M1101K mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and complete detection of cystic fibrosis mutations in the Hutterite population. Am J Hum Genet. 1993 Mar;52(3):609-15.
7683628	Mercier B, Lissens W, Novelli G, Kalaydjieva L, De Arce M, Kapranov N, Klain NC, Lenoir G, Chauveau P, Lenaerts C, et al.: Identification of eight novel mutations in a collaborative analysis of a part of the second transmembrane domain of the CFTR gene. Genomics. 1993 Apr;16(1):296-7.
7683954	Nunes V, Chillon M, Dork T, Tummler B, Casals T, Estivill X: A new missense mutation (E92K) in the first transmembrane domain of the CFTR gene causes a benign cystic fibrosis phenotype. Hum Mol Genet. 1993 Jan;2(1):79-80.
8081395	Bienvenu T, Petitpretz P, Beldjord C, Kaplan JC: A missense mutation (F87L) in exon 3 of the cystic fibrosis transmembrane conductance regulator gene. Hum Mutat. 1994;3(4):395-6.
8522333	Desgeorges M, Rodier M, Piot M, Demaille J, Claustres M: Four adult patients with the missense mutation L206W and a mild cystic fibrosis phenotype. Hum Genet. 1995 Dec;96(6):717-20.
8723693	Petreska L, Plaseska D, Koceva S, Stavljenic-Rukavina A, Efremov GD: A novel mutation in exon 12 (Y569C) of the CFTR gene identified in a patient of Croatian origin. Hum Mutat. 1996;7(4):374-5.
8723695	Bienvenu T, Chertkoff L, Beldjord C, Segal E, Carniglia L, Barreiro C, Kaplan JC: Identification of three novel mutations in the cystic fibrosis transmembrane conductance regulator gene in Argentinian CF patients. Hum Mutat. 1996;7(4):376-7.
8800923	Messaoud T, Verlingue C, Denamur E, Pascaud O, Quere I, Fattoum S, Elion J, Ferec C: Distribution of CFTR mutations in cystic fibrosis patients of Tunisian origin: identification of two novel mutations. Eur J Hum Genet. 1996;4(1):20-4.
8829633	Nasr SZ, Strong TV, Mansoura MK, Dawson DC, Collins FS: Novel missense mutation (G314R) in a cystic fibrosis patient with hepatic failure. Hum Mutat. 1996;7(2):151-4.
8956039	Hughes DJ, Hill AJ, Macek M Jr, Redmond AO, Nevin NC, Graham CA: Mutation characterization of CFTR gene in 206 Northern Irish CF families: thirty mutations, including two novel, account for approximately 94% of CF chromosomes. Hum Mutat. 1996;8(4):340-7.
9067761	Zielenski J, Patrizio P, Markiewicz D, Asch RH, Tsui LC: Identification of two mutations (S50Y and 4173delC) in the CFTR gene from patients with congenital bilateral absence of vas deferens (CBAVD). Hum Mutat. 1997;9(2):183-4.
9101301	Clavel C, Pennaforte F, Pigeon F, Verlingue C, Birembaut P, Ferec C: Identification of four novel mutations in the cystic fibrosis transmembrane conductance regulator gene: E664X, 2113delA, 306delTAGA, and delta M1140. Hum Mutat. 1997;9(4):368-9.
9222768	Gouya L, Pascaud O, Munck A, Elion J, Denamur E: Novel mutation (A141D) in exon 4 of the CFTR gene identified in an Algerian patient. Hum Mutat. 1997;10(1):86-7.
9375855	Casals T, Pacheco P, Barreto C, Gimenez J, Ramos MD, Pereira S, Pinheiro JA, Cobos N, Curvelo A, Vazquez C, Rocha H, Seculi JL, Perez E, Dapena J, Carrilho E, Duarte A, Palacio AM, Nunes V, Lavinha J, Estivill X: Missense mutation R1066C in the second transmembrane domain of CFTR causes a severe cystic fibrosis phenotype: study of 19 heterozygous and 2 homozygous patients. Hum Mutat. 1997;10(5):387-92.
9385646	Neville DC, Rozanas CR, Price EM, Gruis DB, Verkman AS, Townsend RR: Evidence for phosphorylation of serine 753 in CFTR using a novel metal-ion affinity resin and matrix-assisted laser desorption mass spectrometry. Protein Sci. 1997 Nov;6(11):2436-45.
9401006	Shrimpton AE, Borowitz D, Swender P: Cystic fibrosis mutation frequencies in upstate New York. Hum Mutat. 1997;10(6):436-42.
9443874	Friedman KJ, Leigh MW, Czarnecki P, Feldman GL: Cystic fibrosis transmembrane-conductance regulator mutations among African Americans. Am J Hum Genet. 1998 Jan;62(1):195-6.
9452048	Feldmann D, Sardet A, Cougoureux E, Plouvier E, Fontaine JL, Tournier G, Aymard P: Identification of three novel mutations in the CFTR gene, R117P, deltaD192, and 3121-1G-->A in four French patients. Hum Mutat. 1998;Suppl 1:S78-80.
9452054	Casals T, Ramos MD, Gimenez J, Nadal M, Nunes V, Estivill X: Paternal origin of a de novo novel CFTR mutation (L1065R) causing cystic fibrosis. Hum Mutat. 1998;Suppl 1:S99-102.
9452073	Shackleton S, Harris A: A 2-amino acid insertion mutation (1243insACAAAA) in exon 7 of the CFTR gene. Hum Mutat. 1998;Suppl 1:S156-7.
9482579	Malone G, Haworth A, Schwarz MJ, Cuppens H, Super M: Detection of five novel mutations of the cystic fibrosis transmembrane regulator (CFTR) gene in Pakistani patients with cystic fibrosis: Y569D, Q98X, 296+12(T>C), 1161delC and 621+2(T>C). Hum Mutat. 1998;11(2):152-7.
9517543	Hoedemaeker FJ, Davidson AR, Rose DR: A model for the nucleotide-binding domains of ABC transporters based on the large domain of aspartate aminotransferase. Proteins. 1998 Feb 15;30(3):275-86.
9521595	Onay T, Topaloglu O, Zielenski J, Gokgoz N, Kayserili H, Camcioglu Y, Cokugras H, Akcakaya N, Apak M, Tsui LC, Kirdar B: Analysis of the CFTR gene in Turkish cystic fibrosis patients: identification of three novel mutations (3172delAC, P1013L and M1028I). Hum Genet. 1998 Feb;102(2):224-30.
9554753	Leoni GB, Pitzalis S, Tonelli R, Cao A: Identification of a novel mutation (S13F) in the CFTR gene in a CF patient of Sardinian origin. Hum Mutat. 1998;11(4):337.
9736778	Vankeerberghen A, Wei L, Jaspers M, Cassiman JJ, Nilius B, Cuppens H: Characterization of 19 disease-associated missense mutations in the regulatory domain of the cystic fibrosis transmembrane conductance regulator. Hum Mol Genet. 1998 Oct;7(11):1761-9.
9921909	Bombieri C, Benetazzo M, Saccomani A, Belpinati F, Gile LS, Luisetti M, Pignatti PF: Complete mutational screening of the CFTR gene in 120 patients with pulmonary disease. Hum Genet. 1998 Dec;103(6):718-22.

# Drug_Target_5_HGNC_ID:
HGNC:1884

# Drug_Target_5_HPRD_ID:
03883

# Drug_Target_5_ID:
2184

# Drug_Target_5_Locus:
7q31.2

# Drug_Target_5_Molecular_Weight:
168144

# Drug_Target_5_Name:
Cystic fibrosis transmembrane conductance regulator

# Drug_Target_5_Number_of_Residues:
1480

# Drug_Target_5_PDB_ID:
1XMI

# Drug_Target_5_Pathway:
Not Available

# Drug_Target_5_Pfam_Domain_Function:
PF00005	ABC_tran
PF00664	ABC_membrane

# Drug_Target_5_Protein_Sequence:
>Cystic fibrosis transmembrane conductance regulator
MQRSPLEKASVVSKLFFSWTRPILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRE
LASKKNPKLINALRRCFFWRFMFYGIFLYLGEVTKAVQPLLLGRIIASYDPDNKEERSIA
IYLGIGLCLLFIVRTLLLHPAIFGLHHIGMQMRIAMFSLIYKKTLKLSSRVLDKISIGQL
VSLLSNNLNKFDEGLALAHFVWIAPLQVALLMGLIWELLQASAFCGLGFLIVLALFQAGL
GRMMMKYRDQRAGKISERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTELKLTRKAA
YVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILRKIFTTISFCIVLRMAVTRQFPWAVQT
WYDSLGAINKIQDFLQKQEYKTLEYNLTTTEVVMENVTAFWEEGFGELFEKAKQNNNNRK
TSNGDDSLFFSNFSLLGTPVLKDINFKIERGQLLAVAGSTGAGKTSLLMVIMGELEPSEG
KIKHSGRISFCSQFSWIMPGTIKENIIFGVSYDEYRYRSVIKACQLEEDISKFAEKDNIV
LGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGYLDVLTEKEIFESCVCKLMANKTR
ILVTSKMEHLKKADKILILHEGSSYFYGTFSELQNLQPDFSSKLMGCDSFDQFSAERRNS
ILTETLHRFSLEGDAPVSWTETKKQSFKQTGEFGEKRKNSILNPINSIRKFSIVQKTPLQ
MNGIEEDSDEPLERRLSLVPDSEQGEAILPRISVISTGPTLQARRRQSVLNLMTHSVNQG
QNIHRKTTASTRKVSLAPQANLTELDIYSRRLSQETGLEISEEINEEDLKECFFDDMESI
PAVTTWNTYLRYITVHKSLIFVLIWCLVIFLAEVAASLVVLWLLGNTPLQDKGNSTHSRN
NSYAVIITSTSSYYVFYIYVGVADTLLAMGFFRGLPLVHTLITVSKILHHKMLHSVLQAP
MSTLNTLKAGGILNRFSKDIAILDDLLPLTIFDFIQLLLIVIGAIAVVAVLQPYIFVATV
PVIVAFIMLRAYFLQTSQQLKQLESEGRSPIFTHLVTSLKGLWTLRAFGRQPYFETLFHK
ALNLHTANWFLYLSTLRWFQMRIEMIFVIFFIAVTFISILTTGEGEGRVGIILTLAMNIM
STLQWAVNSSIDVDSLMRSVSRVFKFIDMPTEGKPTKSTKPYKNGQLSKVMIIENSHVKK
DDIWPSGGQMTVKDLTAKYTEGGNAILENISFSISPGQRVGLLGRTGSGKSTLLSAFLRL
LNTEGEIQIDGVSWDSITLQQWRKAFGVIPQKVFIFSGTFRKNLDPYEQWSDQEIWKVAD
EVGLRSVIEQFPGKLDFVLVDGGCVLSHGHKQLMCLARSVLSKAKILLLDEPSAHLDPVT
YQIIRRTLKQAFADCTVILCEHRIEAMLECQQFLVIEENKVRQYDSIQKLLNERSLFRQA
ISPSDRVKLFPHRNSSKCKSKPQIAALKEETEEEVQDTRL

# Drug_Target_5_Reaction:
Not Available

# Drug_Target_5_Signals:
None

# Drug_Target_5_Specific_Function:
Involved in the transport of chloride ions. May regulate bicarbonate secretion and salvage in epithelial cells by regulating the SLC4A7 transporter

# Drug_Target_5_SwissProt_ID:
P13569

# Drug_Target_5_SwissProt_Name:
CFTR_HUMAN

# Drug_Target_5_Synonyms:
ATP-binding cassette transporter sub- family C member 7
CFTR
cAMP- dependent chloride channel

# Drug_Target_5_Theoretical_pI:
9.02

# Drug_Target_5_Transmembrane_Regions:
81-103
118-138
195-215
221-241
308-328
331-350
860-880
912-932
991-1011
1014-1034
1103-1123
1129-1149

# Drug_Target_6_Cellular_Location:
Not Available

# Drug_Target_6_Chromosome_Location:
Not Available

# Drug_Target_6_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_6_Essentiality:
Non-Essential

# Drug_Target_6_GenAtlas_ID:
Not Available

# Drug_Target_6_GenBank_ID_Gene:
Not Available

# Drug_Target_6_GenBank_ID_Protein:
Not Available

# Drug_Target_6_GeneCard_ID:
Not Available

# Drug_Target_6_Gene_Name:
VCP

# Drug_Target_6_Gene_Sequence:
Not Available

# Drug_Target_6_General_Function:
Not Available

# Drug_Target_6_General_References:
Not Available

# Drug_Target_6_HGNC_ID:
Not Available

# Drug_Target_6_HPRD_ID:
Not Available

# Drug_Target_6_ID:
7082

# Drug_Target_6_Locus:
Not Available

# Drug_Target_6_Molecular_Weight:
Not Available

# Drug_Target_6_Name:
Transitional endoplasmic reticulum ATPase

# Drug_Target_6_Number_of_Residues:
0

# Drug_Target_6_PDB_ID:
Not Available

# Drug_Target_6_Pathway:
Not Available

# Drug_Target_6_Pfam_Domain_Function:
Not Available

# Drug_Target_6_Protein_Sequence:
Not Available

# Drug_Target_6_Reaction:
Not Available

# Drug_Target_6_Signals:
Not Available

# Drug_Target_6_Specific_Function:
Not Available

# Drug_Target_6_SwissProt_ID:
P55072

# Drug_Target_6_SwissProt_Name:
TERA_HUMAN

# Drug_Target_6_Synonyms:
Not Available

# Drug_Target_6_Theoretical_pI:
Not Available

# Drug_Target_6_Transmembrane_Regions:
Not Available

# Drug_Target_7_Cellular_Location:
Not Available

# Drug_Target_7_Chromosome_Location:
Not Available

# Drug_Target_7_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_7_Essentiality:
Non-Essential

# Drug_Target_7_GenAtlas_ID:
Not Available

# Drug_Target_7_GenBank_ID_Gene:
Not Available

# Drug_Target_7_GenBank_ID_Protein:
Not Available

# Drug_Target_7_GeneCard_ID:
Not Available

# Drug_Target_7_Gene_Name:
TRPM7

# Drug_Target_7_Gene_Sequence:
Not Available

# Drug_Target_7_General_Function:
Not Available

# Drug_Target_7_General_References:
Not Available

# Drug_Target_7_HGNC_ID:
Not Available

# Drug_Target_7_HPRD_ID:
Not Available

# Drug_Target_7_ID:
7134

# Drug_Target_7_Locus:
Not Available

# Drug_Target_7_Molecular_Weight:
Not Available

# Drug_Target_7_Name:
Transient receptor potential cation channel subfamily M member 7

# Drug_Target_7_Number_of_Residues:
0

# Drug_Target_7_PDB_ID:
Not Available

# Drug_Target_7_Pathway:
Not Available

# Drug_Target_7_Pfam_Domain_Function:
Not Available

# Drug_Target_7_Protein_Sequence:
Not Available

# Drug_Target_7_Reaction:
Not Available

# Drug_Target_7_Signals:
Not Available

# Drug_Target_7_Specific_Function:
Not Available

# Drug_Target_7_SwissProt_ID:
Q96QT4

# Drug_Target_7_SwissProt_Name:
TRPM7_HUMAN

# Drug_Target_7_Synonyms:
Not Available

# Drug_Target_7_Theoretical_pI:
Not Available

# Drug_Target_7_Transmembrane_Regions:
Not Available

# Drug_Target_8_Cellular_Location:
Not Available

# Drug_Target_8_Chromosome_Location:
Not Available

# Drug_Target_8_Drug_References:
Not Available

# Drug_Target_8_Essentiality:
Non-Essential

# Drug_Target_8_GenAtlas_ID:
Not Available

# Drug_Target_8_GenBank_ID_Gene:
AB126656

# Drug_Target_8_GenBank_ID_Protein:
Not Available

# Drug_Target_8_GeneCard_ID:
Not Available

# Drug_Target_8_Gene_Name:
Not Available

# Drug_Target_8_Gene_Sequence:
>1626 bp
ATGGAGGGGGAAAGGATGAACGCGTTCCCAAGCACCATGATGGACGAGGAGCTGAACCTC
TGGGACTTTTTGGAGCGGGCGGCGGCGCTTTTCGGTAGGAAGGAGGTGGTCTCCCGCCTC
CACACCGGGGAGGTCCACCGCACCACCTACGCCGAGGTCTACCAAAGGGCCAGGAGGCTC
ATGGGGGGGCTTAGGGCCCTCGGGGTGGGCGTGGGGGACCGGGTGGCCACCCTGGGCTTC
AACCACTTCCGCCACCTCGAGGCCTACTTCGCCGTCCCCGGCATGGGGGCGGTGCTCCAC
ACCGCCAACCCCCGCCTCTCCCCCAAGGAGATCGCCTACATCCTGAACCACGCCGAGGAC
AAGGTCCTCCTCTTTGACCCCAACCTCCTGCCCCTGGTGGAGGCCATACGGGGCGAGCTC
AAGACGGTGCAGCACTTCGTGGTCATGGACGAGAAGGCCCCGGAGGGCTACCTGGCCTAC
GAGGAGGCCCTGGGGGAGGAGGCGGACCCCGTGCGGGTGCCGGAGCGGGCCGCCTGCGGC
ATGGCCTACACCACGGGGACCACGGGCCTCCCCAAGGGGGTGGTCTACAGCCACCGGGCT
TTGGTCCTCCACTCCCTGGCGGCAAGCCTCGTTGACGGCACCGCCCTCTCGGAGAAGGAC
GTGGTCTTGCCGGTGGTCCCCATGTTCCACGTGAACGCCTGGTGCCTGCCCTACGCCGCC
ACCCTGGTGGGGGCCAAACAGGTCCTGCCCGGGCCCAGGCTGGACCCCGCCTCCCTGGTG
GAGCTCTTTGACGGGGAGGGGGTGACCTTCACCGCCGGGGTGCCCACGGTCTGGCTCGCC
CTGGCGGACTACCTGGAAAGCACGGGCCACCGCCTGAAGACCCTGAGGCGGCTCGTGGTG
GGGGGCTCGGCCGCGCCCAGGAGCCTCATCGCCCGCTTTGAGCGGATGGGCGTGGAGGTG
CGCCAGGGCTACGGCCTCACCGAGACCTCCCCGGTGGTGGTGCAGAACTTCGTAAAAAGC
CACCTGGAGTCCCTCTCCGAGGAGGAGAAGCTCACCCTCAAGGCCAAGACGGGCCTCCCC
ATCCCCCTGGTGCGCCTAAGGGTGGCGGACGAGGAGGGCCGCCCCGTGCCCAAGGACGGG
AAGGCCCTGGGGGAGGTCCAGCTCAAGGGCCCCTGGATCACCGGGGGCTACTACGGAAAC
GAGGAGGCCACGCGGAGCGCCCTCACCCCGGACGGCTTCTTCCGCACCGGGGACATCGCC
GTCTGGGACGAGGAGGGGTACGTTGAGATCAAGGACCGGCTCAAGGACCTGATCAAGTCG
GGCGGGGAGTGGATCTCCAGCGTGGACCTGGAGAACGCCCTCATGGGCCACCCCAAGGTG
AAGGAGGCGGCGGTGGTGGCCATCCCCCACCCCAAGTGGCAGGAGAGGCCCCTGGCGGTG
GTGGTGCCCAGGGGCGAGAAGCCCACCCCGGAGGAGCTGAACGAGCACCTCCTAAAGGCC
GGCTTCGCCAAGTGGCAGCTCCCCGACGCCTACGTCTTCGCGGAGGAGATCCCGAGGACA
TCCGCGGGCAAGTTCCTCAAGCGGGCCTTAAGGGAGCAGTACAAGAACTACTACGGAGGC
GCCTGA

# Drug_Target_8_General_Function:
Involved in catalytic activity

# Drug_Target_8_General_References:
Not Available

# Drug_Target_8_HGNC_ID:
Not Available

# Drug_Target_8_HPRD_ID:
Not Available

# Drug_Target_8_ID:
4373

# Drug_Target_8_Locus:
Not Available

# Drug_Target_8_Molecular_Weight:
59572

# Drug_Target_8_Name:
Medium-chain-fatty-acid--CoA ligase

# Drug_Target_8_Number_of_Residues:
541

# Drug_Target_8_PDB_ID:
1V26

# Drug_Target_8_Pathway:
Not Available

# Drug_Target_8_Pfam_Domain_Function:
PF00501	AMP-binding

# Drug_Target_8_Protein_Sequence:
>Medium-chain-fatty-acid--CoA ligase
MEGERMNAFPSTMMDEELNLWDFLERAAALFGRKEVVSRLHTGEVHRTTYAEVYQRARRL
MGGLRALGVGVGDRVATLGFNHFRHLEAYFAVPGMGAVLHTANPRLSPKEIAYILNHAED
KVLLFDPNLLPLVEAIRGELKTVQHFVVMDEKAPEGYLAYEEALGEEADPVRVPERAACG
MAYTTGTTGLPKGVVYSHRALVLHSLAASLVDGTALSEKDVVLPVVPMFHVNAWCLPYAA
TLVGAKQVLPGPRLDPASLVELFDGEGVTFTAGVPTVWLALADYLESTGHRLKTLRRLVV
GGSAAPRSLIARFERMGVEVRQGYGLTETSPVVVQNFVKSHLESLSEEEKLTLKAKTGLP
IPLVRLRVADEEGRPVPKDGKALGEVQLKGPWITGGYYGNEEATRSALTPDGFFRTGDIA
VWDEEGYVEIKDRLKDLIKSGGEWISSVDLENALMGHPKVKEAAVVAIPHPKWQERPLAV
VVPRGEKPTPEELNEHLLKAGFAKWQLPDAYVFAEEIPRTSAGKFLKRALREQYKNYYGG
A

# Drug_Target_8_Reaction:
Not Available

# Drug_Target_8_Signals:
None

# Drug_Target_8_Specific_Function:
Not Available

# Drug_Target_8_SwissProt_ID:
Q6L8F0

# Drug_Target_8_SwissProt_Name:
Q6L8F0_THETH

# Drug_Target_8_Synonyms:
Not Available

# Drug_Target_8_Theoretical_pI:
6.47

# Drug_Target_8_Transmembrane_Regions:
None

# Drug_Target_9_Cellular_Location:
Not Available

# Drug_Target_9_Chromosome_Location:
Not Available

# Drug_Target_9_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_9_Essentiality:
Non-Essential

# Drug_Target_9_GenAtlas_ID:
KIF1A

# Drug_Target_9_GenBank_ID_Gene:
X90840

# Drug_Target_9_GenBank_ID_Protein:
Not Available

# Drug_Target_9_GeneCard_ID:
Not Available

# Drug_Target_9_Gene_Name:
KIF1A

# Drug_Target_9_Gene_Sequence:
>5073 bp
ATGGCCGGGGCTTCGGTGAAGGTGGCGGTGCGGGTCCGCCCCTTCAATTCCCGGGAAATG
AGCCGTGACTCCAAGTGCATCATTCAGATGTCTGGAAGCACCACCACCATTGTTAACCCC
AAACAGCCCAAGGAGACGCCCAAAAGCTTCAGCTTTGACTACTCCTACTGGTCGCACACC
TCACCTGAGGACATCAACTACGCGTCGCAGAAGCAGGTGTACCGGGACATCGGCGAGGAG
ATGCTGCAGCATGCCTTTGAGGGATACAACGTGTGCATCTTCGCCTATGGGCAGACGGGT
GCCGGCAAGTCCTACACCATGATGGGCAAGCAGGAGAAGGACCAGCAGGGCATCATCCCA
CAGCTCTGCGAGGACCTCTTCTCTCGGATCAACGACACGACCAACGACAACATGTCCTAC
TCCGTGGAGGTCAGCTACATGGAGATTTACTGTGAGCGCGTCCGTGACCTCCTGAACCCC
AAGAACAAGGGCAACCTTCGCGTGAGGGAGCACCCACTGCTGGGGCCCTACGTGGAGGAC
CTCTCCAAGCTGGCTGTCACCTCCTACAATGACATCCAGGACCTCATGGACTCAGGGAAC
AAGGCCAGGACCGTGGCGGCCACCAACATGAATGAGACCAGCAGTCGCTCCCACGCCGTC
TTCAACATCATCTTCACCCAGAAGCGCCATGACGCAGAGACCAATATCACCACGGAGAAG
GTGAGCAAAATCAGCCTGGTGGACCTGGCTGGGAGCGAGCGGGCTGACTCCACGGGAGCC
AAGGGCACGCGCCTCAAGGAGGGGGCCAACATCAACAAGTCGCTGACCACCCTGGGCAAG
GTCATCTCCGCCCTGGCTGAAATGGACTCCGGACCCAACAAGAACAAGAAAAAGAAGAAG
ACAGATTTCATTCCGTACCGAGATTCCGTGTTGACCTGGCTCCTCCGGGAAAACCTGGGC
GGTAACTCAAGGACAGCTATGGTGGCAGCCCTGAGTCCTGCAGACATCAACTACGATGAG
ACCCTTAGCACGCTGAGGTATGCTGACCGGGCCAAGCAGATCCGCTGCAATGCTGTCATC
AATGAGGACCCCAACAACAAGCTGATCCGCGAGCTGAAGGATGAGGTGACCCGGCTGCGG
GACCTTCTGTACGCCCAGGGTCTTGGCGACATCACTGACATGACCAATGCCCTGGTGGGT
ATGAGCCCCTCATCCTCGCTCTCAGCCCTGTCCAGCCGCGCGGCCTCCGTGTCCAGCCTC
CACGAGCGCATCTTGTTTGCCCCGGGCAGCGAGGAGGCCATTGAAAGACTGAAGGAAACA
GAGAAGATCATAGCTGAGCTCAATGAGACCTGGGAGGAGAAGCTGCGGCGGACAGAAGCC
ATCCGGATGGAGAGGGAAGCCCTGCTGGCCGAGATGGGTGTGGCCATGAGGGAGGATGGC
GGCACCTTGGGCGTATTCTCTCCCAAAAAGACACCACACCTCGTCAACCTGAACGAGGAC
CCGCTGATGTCTGAGTGCCTGCTCTACTACATCAAGGATGGGATCACCAGAGTGGGCAGG
GAGGATGGCGAGAGGCGGCAGGACATTGTTCTGAGTGGGCACTTCATCAAGGAGGAGCAC
TGCGTCTTCCGGAGCGACTCCAGGGGAGGCAGCGAAGCTGTGGTGACCTTGGAGCCCTGT
GAGGGGGCAGACACCTACGTCAATGGCAAGAAAGTCACAGAGCCCAGCATCCTGCGTTCA
GGAAACCGCATCATCATGGGTAAGAGCCATGTGTTCCGGTTCACCCACCCCGAGCAGGCC
CGGCAGGAGCGTGAGCGCACGCCTTGTGCGGAGACGCCAGCTGAGCCTGTGGACTGGGCC
TTCGCCCAGCGTGAGCTGCTGGAGAAGCAGGGCATCGACATGAAGCAGGAGATGGAGCAG
AGGCTCCAGGAACTGGAGGACCAGTACCGCCGCGAGCGGGAGGAGGCCACCTACCTGCTG
GAGCAGCAGCGGCTGGACTATGAGAGCAAGCTGGAGGCTCTGCAGAAGCAGATGGACTCC
AGGTACTACCCGGAGGTGAACGAGGAGGAGGAGGAGCCCGAGGATGAAGTCCAGTGGACA
GAGCGGGAGTGTGAGCTGGCGCTCTGGGCCTTCCGGAAGTGGAAGTGGTACCAGTTCACG
TCTCTGCGGGACCTGCTGTGGGGCAACGCCATCTTCCTCAAGGAGGCCAATGCCATCAGC
GTGGAGCTGAAAAAGAAGGTACAATTCCAGTTTGTCCTCCTGACGGACACACTCTACTCC
CCTCTGCCACCCGACCTGCTGCCCCCAGAGGCCGCCAAAGACCGAGAGAAGCGGCCCTTC
CCCCGCACCATTGTGGCCGTGGAGGTCCAGGACCAGAAGAACGGGGCCACCCACTACTGG
ACGCTGGAGAAGCTCAGGCAGCGTCTGGACCTGATGCGGGAGATGTACGACCGCGCTGCA
GAGGTGCCCTCCAGTGTCATCGAGGACTGTGACAACGTGGTGACCGGCGGAGACCCCTTC
TATGACCGCTTCCCCTGGTTCCGGCTGGTGGGCAGGGCCTTCGTGTACCTGAGCAACCTG
CTGTACCCCGTTCCCCTGGTACACCGTGTGGCAATCGTCAGCGAGAAGGGCGAGGTGAAG
GGCTTCCTCCGCGTGGCCGTCCAGGCCATCTCAGCCGATGAAGAGGCCCCTGATTATGGC
TCTGGCGTCCGCCAGTCGGGAACTGCTAAAATCTCCTTTGATGACCAGCATTTTGAAAAG
TTCCAGTCCGAGTCTTGCCCCGTGGTGGGGATGTCCCGCTCGGGAACCTCCCAGGAAGAG
CTTCGCATCGTGGAGGGCCAGGGCCAGGGTGCAGACGTGGGGCCCTCAGCCGATGAAGTC
AACAACAACACCTGTTCAGCAGTGCCCCCAGAAGGCCTCCTCCTAGACAGCTCTGAGAAA
GCCGCCCTGGATGGGCCCCTGGATGCTGCCCTGGACCACCTCCGCCTGGGCAACACCTTC
ACCTTCCGTGTGACAGTCCTGCAGGCGTCCAGCATCTCTGCCGAATATGCCGACATCTTC
TGCCAGTTCAACTTCATCCACCGCCACGACGAGGCCTTCTCCACAGAGCCCCTGAAGAAC
ACAGGCAGAGGCCCCCCACTTGGCTTCTACCACGTCCAGAACATCGCAGTGGAGGTGACC
AAGTCCTTCATTGAGTACATCAAGAGCCAGCCCATTGTTTTCGAGGTCTTTGGCCACTAC
CAGCAGCACCCGTTCCCGCCCCTCTGCAAGGACGTGCTCAGCCCCCTGAGGCCCTCGCGC
CGCCACTTCCCTCGGGTCATGCCACTGTCCAAGCCAGTGCCCGCCACCAAGCTCAGCACA
CTGACGCGGCCCTGTCCGGGACCCTGCCACTGCAAGTACGACCTGCTGGTCTACTTCGAG
ATCTGTGAGCTGGAGGCCAACGGCGATTACATCCCGGCCGTGGTGGACCACCGTGGGGGC
ATGCCATGCATGGGGACCTTCCTCCTCCACCAGGGCATCCAGCGACGGATTACGGTGACA
CTACTGCATGAGACAGGCAGCCATATCCGCTGGAAGGAAGTGCGCGAGCTGGTCGTGGGC
CGCATCCGAAACACTCCAGAGACCGACGAGTCCCTGATCGACCCCAACATCTTGTCTCTC
AACATCCTCTCTGCCGGATACATCCACCCAGCCCATGATGACCGGACCTTTTACCAATTT
GAGGCTGCGTGGAACAGCTCCATGCACAACTCTCTCCTGCTGAACCGGATCACCCCTTAT
CGAGAGAAAATCTACATGACACTCTCCGCTTATATCGAGATGGAGAACTGCACCCAGCCG
GCTGTTGTCACCAAGGACTTCTGCATGGTCTTCTATTCCCGTGATGCCAAGCTGCCAGCC
TCGCGCTCCATCCGCAACCTCTTTGGCAGTGGGAGCCTTCGGGCCTCAGAGAGTAACCGT
GTGACTGGTGTGTACGAGCTCAGCCTGTGCCACGTGGCTGACGCGGGCAGCCCAGGGATG
CAGCGCCGGCGCCGACGAGTCCTGGACACATCTGTGGCCTATGTCCGGGGCGAGGAGAAC
CTGGCAGGCTGGAGGCCCCGGAGTGACAGTCTCATTCTGGACCACCAGTGGGAGCTGGAG
AAGCTGAGCCTCCTGCAGGAGGTGGAGAAGACTAGGCACTACCTGCTCCTGCGGGAGAAG
CTGGAGACCGCCCAGCGGCCTGTCCCGGAGGCACTGTCCCCGGCCTTCAGCGAGGACTCT
GAGTCCCATGGCTCCTCCAGCGCCTCCTCCCCGCTCTCGGCTGAGGGCCGCCCATCACCC
CTGGAGGCTCCCAACGAGAGGCAGCGGGAGCTGGCCGTCAAGTGCTTGCGCCTGCTCACG
CACACATTCAACAGAGAGTACACACACAGCCACGTCTGCGTCAGTGCCAGCGAGAGCAAG
CTCTCCGAGATGTCTGTCACCCTGCTCCGGGACCCGTCGATGTCCCCTCTAGGGGTGGCC
ACTCTCACCCCCTCCTCCACTTGCCCCTCTCTGGTTGAAGGGCGGTACGGTGCCACTGAC
CTGAGGACCCCGCAGCCCTGCTCCCGGCCAGCCAGCCCAGAGCCCGAGCTGCTGCCAGAG
GCCGACTCCAAGAAGCTCCCTTCCCCTGCCCGGGCAACAGAGACAGACAAGGAGCCCCAG
CGCCTGCTGGTCCCTGACATCCAGGAGATCCGAGTCAGCCCGATCGTTTCCAAGAAGGGG
TACCTGCACTTCCTGGAGCCGCACACGTCAGGCTGGGCCAGGCGCTTCGTGGTGGTGCGG
CGCCCCTATGCCTACATGTACAACAGCGACAAGGACACCGTGGAGCGGTTCGTGCTCAAC
CTGGCCACTGCCCAGGTGGAGTACAGTGAGGACCAGCAGGCTATGCTCAAGACACCCAAC
ACATTCGCGGTGTGCACGGAACACCGCGGCATCCTGCTGCAGGCCGCCAGCGACAAGGAC
ATGCATGACTGGCTGTACGCCTTCAACCCCCTCCTGGCCGGGACCATACGGTCCAAGCTC
TCCAGAAGGAGGTCTGCCCAGATGCGGGTCTGA

# Drug_Target_9_General_Function:
Involved in microtubule motor activity

# Drug_Target_9_General_References:
8661001	Furlong RA, Zhou CY, Ferguson-Smith MA, Affara NA: Characterization of a kinesin-related gene ATSV, within the tuberous sclerosis locus (TSC1) candidate region on chromosome 9Q34. Genomics. 1996 May 1;33(3):421-9.

# Drug_Target_9_HGNC_ID:
HGNC:888

# Drug_Target_9_HPRD_ID:
Not Available

# Drug_Target_9_ID:
5312

# Drug_Target_9_Locus:
2q37.3

# Drug_Target_9_Molecular_Weight:
191066

# Drug_Target_9_Name:
Kinesin-like protein KIF1A

# Drug_Target_9_Number_of_Residues:
1690

# Drug_Target_9_PDB_ID:
1I6I

# Drug_Target_9_Pathway:
Not Available

# Drug_Target_9_Pfam_Domain_Function:
PF00169	PH
PF00225	Kinesin
PF00498	FHA

# Drug_Target_9_Protein_Sequence:
>Kinesin-like protein KIF1A
MAGASVKVAVRVRPFNSREMSRDSKCIIQMSGSTTTIVNPKQPKETPKSFSFDYSYWSHT
SPEDINYASQKQVYRDIGEEMLQHAFEGYNVCIFAYGQTGAGKSYTMMGKQEKDQQGIIP
QLCEDLFSRINDTTNDNMSYSVEVSYMEIYCERVRDLLNPKNKGNLRVREHPLLGPYVED
LSKLAVTSYNDIQDLMDSGNKARTVAATNMNETSSRSHAVFNIIFTQKRHDAETNITTEK
VSKISLVDLAGSERADSTGAKGTRLKEGANINKSLTTLGKVISALAEMDSGPNKNKKKKK
TDFIPYRDSVLTWLLRENLGGNSRTAMVAALSPADINYDETLSTLRYADRAKQIRCNAVI
NEDPNNKLIRELKDEVTRLRDLLYAQGLGDITDMTNALVGMSPSSSLSALSSRAASVSSL
HERILFAPGSEEAIERLKETEKIIAELNETWEEKLRRTEAIRMEREALLAEMGVAMREDG
GTLGVFSPKKTPHLVNLNEDPLMSECLLYYIKDGITRVGREDGERRQDIVLSGHFIKEEH
CVFRSDSRGGSEAVVTLEPCEGADTYVNGKKVTEPSILRSGNRIIMGKSHVFRFNHPEQA
RQERERTPCAETPAEPVDWAFAQRELLEKQGIDMKQEMEQRLQELEDQYRREREEATYLL
EQQRLDYESKLEALQKQMDSRYYPEVNEEEEEPEDEVQWTERECELALWAFRKWKWYQFT
SLRDLLWGNAIFLKEANAISVELKKKVQFQFVLLTDTLYSPLPPDLLPPEAAKDRETRPF
PRTIVAVEVQDQKNGATHYWTLEKLRQRLDLMREMYDRAAEVPSSVIEDCDNVVTGGDPF
YDRFPWFRLVGRAFVYLSNLLYPVPLVHRVAIVSEKGEVKGFLRVAVQAISADEEAPDYG
SGVRQSGTAKISFDDQHFEKFQSESCPVVGMSRSGTSQEELRIVEGQGQGADVGPSADEV
NNNTCSAVPPEGLLLDSSEKAALDGPLDAALDHLRLGNTFTFRVTVLQASSISAEYADIF
CQFNFIHRHDEAFSTEPLKNTGRGPPLGFYHVQNIAVEVTKSFIEYIKSQPIVFEVFGHY
QQHPFPPLCKDVLSPLRPSRRHFPRVMPLSKPVPATKLSTLTRPCPGPCHCKYDLLVYFE
ICELEANGDYIPAVVDHRGGMPCMGTFLLHQGIQRRITVTLLHETGSHIRWKEVRELVVG
RIRNTPETDESLIDPNILSLNILSSGYIHPAQDDRTFYQFEAAWDSSMHNSLLLNRVTPY
REKIYMTLSAYIEMENCTQPAVVTKDFCMVFYSRDAKLPASRSIRNLFGSGSLRASESNR
VTGVYELSLCHVADAGSPGMQRRRRRVLDTSVAYVRGEENLAGWRPRSDSLILDHQWELE
KLSLLQEVEKTRHYLLLREKLETAQRPVPEALSPAFSEDSESHGSSSASSPLSAEGRPSP
LEAPNERQRELAVKCLRLLTHTFNREYTHSHVCVSASESKLSEMSVTLLRDPSMSPLGVA
TLTPSSTCPSLVEGRYGATDLRTPQPCSRPASPEPELLPEADSKKLPSPARATETDKEPQ
RLLVPDIQEIRVSPIVSKKGYLHFLEPHTSGWARRFVVVRRPYAYMYNSDKDTVERFVLN
LATAQVEYSEDQQAMLKTPNTFAVCTEHRGILLQAASDKDMHDWLYAFNPLLAGTIRSKL
SRRRSAQMRV

# Drug_Target_9_Reaction:
Not Available

# Drug_Target_9_Signals:
None

# Drug_Target_9_Specific_Function:
Motor for anterograde axonal transport of synaptic vesicle precursors (By similarity)

# Drug_Target_9_SwissProt_ID:
Q12756

# Drug_Target_9_SwissProt_Name:
KIF1A_HUMAN

# Drug_Target_9_Synonyms:
Axonal transporter of synaptic vesicles
Microtubule-based motor KIF1A
UNC-104-and KIF1A-related protein
hUNC-104

# Drug_Target_9_Theoretical_pI:
6.13

# Drug_Target_9_Transmembrane_Regions:
None

#END_DRUGCARD DB04395
